U.S. patent number 9,006,264 [Application Number 14/021,197] was granted by the patent office on 2015-04-14 for substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines.
This patent grant is currently assigned to 3M Innovative Properties Company. The grantee listed for this patent is 3M Innovative Properties Company. Invention is credited to David T. Amos, Jason D. Bonk, Joseph F. Dellaria, Jr., Luke T. Dressel, Doris Stoermer, Bernhard M. Zimmermann.
United States Patent |
9,006,264 |
Stoermer , et al. |
April 14, 2015 |
Substituted imidazoquinolines, imidazopyridines, and
imidazonaphthyridines
Abstract
Imidazo-quinoline, -pyridine, and -naphthyridine ring systems
(particularly quinolines, tetrahydroquinolines, pyridines,
[1,5]naphthyridines, [1,5]tetrahydronaphthyridines) substituted at
the 1-position with a cyclic substituent, pharmaceutical
compositions containing the compounds, methods of making these
compounds, and methods of use of these compounds as
immunomodulators, for inducing cytokine biosynthesis in animals and
in the treatment of diseases including viral and neoplastic
diseases are disclosed.
Inventors: |
Stoermer; Doris (Newbury Park,
CA), Dellaria, Jr.; Joseph F. (Woodbury, MN), Amos; David
T. (St. Paul, MN), Zimmermann; Bernhard M. (Apple
Valley, MN), Dressel; Luke T. (Somerset, WI), Bonk; Jason
D. (Hudson, WI) |
Applicant: |
Name |
City |
State |
Country |
Type |
3M Innovative Properties Company |
St. Paul |
MN |
US |
|
|
Assignee: |
3M Innovative Properties
Company (St. Paul, MN)
|
Family
ID: |
43879767 |
Appl.
No.: |
14/021,197 |
Filed: |
September 9, 2013 |
Prior Publication Data
|
|
|
|
Document
Identifier |
Publication Date |
|
US 20140011777 A1 |
Jan 9, 2014 |
|
Related U.S. Patent Documents
|
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
Issue Date |
|
|
12974459 |
Dec 21, 2010 |
8541438 |
|
|
|
11570707 |
Feb 8, 2011 |
7884207 |
|
|
|
PCT/US2005/021445 |
Jun 17, 2005 |
|
|
|
|
60581274 |
Jun 18, 2004 |
|
|
|
|
Current U.S.
Class: |
514/293; 546/82;
546/83 |
Current CPC
Class: |
A61P
35/00 (20180101); C07D 471/14 (20130101); C07D
471/04 (20130101); A61P 31/12 (20180101); A61K
31/445 (20130101); A61K 31/435 (20130101); A61K
31/351 (20130101); A61K 31/341 (20130101); A61K
31/437 (20130101) |
Current International
Class: |
C07D
471/04 (20060101) |
Field of
Search: |
;546/82,84 ;514/293 |
References Cited
[Referenced By]
U.S. Patent Documents
Foreign Patent Documents
|
|
|
|
|
|
|
0 394 026 |
|
Oct 1990 |
|
EP |
|
1 104 764 |
|
Jun 2001 |
|
EP |
|
9-176116 |
|
Jul 1997 |
|
JP |
|
9-208584 |
|
Aug 1997 |
|
JP |
|
11-080156 |
|
Mar 1999 |
|
JP |
|
11-222432 |
|
Aug 1999 |
|
JP |
|
2000-247884 |
|
Sep 2000 |
|
JP |
|
WO 02/36592 |
|
May 2002 |
|
WO |
|
WO 2005/003064 |
|
Jan 2005 |
|
WO |
|
WO 2006/028451 |
|
Mar 2006 |
|
WO |
|
WO 2006/063072 |
|
Jun 2006 |
|
WO |
|
WO 2006/121528 |
|
Nov 2006 |
|
WO |
|
WO 2007/030775 |
|
Mar 2007 |
|
WO |
|
Other References
Wozniak et al., "The Amination of 3-nitro-1, 5-naphthyridines by
Liquid Ammonia/Potassium Permanganate.sup.1,2. A New and Convenient
Amination Method.", Journal of the Royal Netherlands Chemical
Society, 102, pp. 511-513, Dec. 12, 1983. cited by applicant .
Brennan et al., "Automated Bioassay of Interferons in Micro-test
Plates.", Biotechniques, Jun./Jul., 78, 1983. cited by applicant
.
Testerman et al., "Cytokine Induction by the Immunomodulators
Imiquimod and S-27609.", Journal of Leukocyte Biology, vol. 58, pp.
365-372, Sep. 1995. cited by applicant .
Bachman et al., "Synthesis of Substituted Quinolylamines.
Derivatives of 4-Amino-7-Chloroquinoline.", J. Org. Chem. 15, pp.
1278-1284 (1950). cited by applicant .
Jain et al., "Chemical and Pharmacological Investigations of Some
.omega.-Substituted Alkylamino-3-aminopyridines.", J. Med. Chem.,
11, pp. 87-92 (1968). cited by applicant .
Baranov et al., "Pyrazoles, Imidazoles, and Other 5-Membered
Rings.", Chem. Abs. 85, 94362, (1976). cited by applicant .
Berenyi et al., "Ring Transformation of Condensed
Dihydro-as-triazines.", J. Heterocyclic Chem., 18, pp. 1537-1540
(1981). cited by applicant .
Chollet et al., "Development of a Topically Active Imiquimod
Formulation.",Pharmaceutical Development and Technology, 4(1), pp.
35-43 (1999). cited by applicant .
Izumi et al., "1H-Imidazo[4,5-c]quinoline Derivatives as Novel
Potent TNF-.alpha. Suppressors: Synthesis and Structure-Activity
Relationship of 1-, 2- and 4-Substituted
1H-imidazo[4,5-c]pyridines.", Bioorganic & Medicinal Chemistry,
11, pp. 2541-2550 (2003). cited by applicant .
Gerster et al. "Synthesis and Structure" J. Med Chem. 2005, 48,
3481-3491. cited by applicant.
|
Primary Examiner: Desai; Rita
Parent Case Text
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a continuation of U.S. patent application Ser.
No. 12/974,459, filed Dec. 21, 2010, now U.S. Pat. No. 8,541,438,
which is a divisional of U.S. patent application Ser. No.
11/570,707, filed Dec. 15, 2006, now U.S. Pat. No. 7,884,207, which
is a National Stage Filing of International Application No.
PCT/US2005/021445, filed Jun. 17, 2005, which claims priority to
U.S. Provisional Application Ser. No. 60/581,274, filed Jun. 18,
2004, all of which are incorporated herein by reference.
Claims
What is claimed is:
1. A compound of the formula: ##STR00470## wherein: m is 1, 2, or
3; R.sub.2 is selected from the group consisting of hydrogen,
C.sub.1-4 alkyl, HO--C.sub.1-4 alkylenyl and C.sub.1-4
alkyl-O--C.sub.1-4 alkylenyl; Z is selected from the group
consisting of: a bond, C.sub.1-3 alkylene, and ##STR00471## A' is
selected from the group consisting of: --O--, --N(Q-R.sub.4)--, and
--S(O).sub.0-2--; Q is selected from the group consisting of a
bond, --C(O)--, --S(O).sub.2--, and --C(O)--NH--; R.sub.4 is
selected from the group consisting of alkyl, aryl, arylalkylene,
heteroaryl, and heterocyclyl, wherein aryl is unsubstituted or
substituted by acetylamino, alkyl, alkoxy, cyano, or halogen; and x
and y are each independently 0, 1, or 2 with the proviso that x+y
is .ltoreq.2; or a pharmaceutically acceptable salt thereof.
2. A pharmaceutical composition comprising a therapeutically
effective amount of a compound or salt of claim 1 in combination
with a pharmaceutically acceptable carrier.
3. The compound or salt of claim 1 selected from the group
consisting of:
1-[(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclobutanol;
1-[(4-amino-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclobutanol;
1-[4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclobutanol;
1-[(4-amino-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclobutanol;
1-[4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclobutanol;
1-{[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cyclob-
utanol;
1-[(4-amino-2-hydroxymethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]-
cyclobutanol; and
1-{[4-amino-2-(2-hydroxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cycl-
obutanol.
4. The compound or salt of claim 1 selected from the group
consisting of:
1-[(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclohexanol;
1-[(4-amino-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclohexanol;
1-[(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclohexanol;
1-[(4-amino-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclohexanol;
1-[(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclohexanol;
1-{[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cycl-
ohexanol;
1-{[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]meth-
yl}cyclohexanol; 1-{[4-amino-2-(hydroxymethyl)-1H-imidazo[4,5
-c]quinolin-1-yl]methyl}cyclohexanol;
1-[2-(4-amino-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)ethyl]cyclohexanol;
1-[2-(4-amino-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)ethyl]cyclohexanol;
1-{2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethyl}cyclo-
hexanol; and
1-{3-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]propyl}cycl-
ohexanol.
5. The compound or salt of claim 1 selected from the group
consisting of:
4-[(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetrahydro-2H-pyran-4-o-
l;
4-[(4-amino-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetrahydro-2-
H-pyran-4-ol;
4-[(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetrahydro-2H-p-
yran-4-ol;
4-[(4-amino-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetr-
ahydro-2H-pyran-4-ol; 4-[(4-amino-2-butyl-1H-imidazo[4,5
-c]quinolin-1-yl)methyl]tetrahydro-2H-pyran-4-ol;
4-{[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}tetr-
ahydro-2H -pyran-4-ol;
4-{[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}tetrah-
ydro-2H -pyran-4-ol; 4-{[4-amino-2-(hydroxymethyl)-1H-imidazo[4,5
-c]quinolin-1-yl]methyl}tetrahydro-2H -pyran-4-ol;
4-{[4-amino-2-(2-hydroxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}tetr-
ahydro-2H -pyran-4-ol;
4-[2-(4-amino-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)ethyl]tetrahydro-2H-
-pyran-4-ol; 4-[2-(4-amino-2-ethyl-1H-imidazo[4,5
-c]quinolin-1-yl)ethyl]tetrahydro-2H-pyran-4-ol; and
4-[2-(4-amino-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)ethyl]tetrahydro-2H-
-pyran-4-ol.
6. The compound or salt of claim 1 selected from the group
consisting of:
1-{[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cyclop-
ropanol;
1-[2-(4-amino-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)ethyl]cyclo-
propanol;
1-[2-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)ethyl]cyclo-
propanol;
1-[2-(4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl)et-
hyl]cyclopropanol;
1-[3-(4-amino-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)propyl]cyclopropano-
l; 1-[(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclopentanol;
1-[(4-amino-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclopentanol;
1-[(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclopentanol;
1-[(4-amino-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclopentanol;
and
1-{[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cy-
clopentanol.
7. A method of inducing biosynthesis of at least one of
interferon-.alpha. or tumor necrosis factor-.alpha. in an animal
comprising administering an effective amount of a compound or salt
of claim 1 to the animal.
8. A compound of the Formula VII: ##STR00472## wherein: R.sub.2 is
selected from the group consisting of hydrogen, C.sub.1-4 alkyl,
HO--C.sub.1-4 alkylenyl and C.sub.1-4 alkyl-O--C.sub.1-4 alkylenyl;
Z is selected from the group consisting of: a bond, C.sub.1-3
alkylene, and ##STR00473## A' is selected from the group consisting
of: --O--, --N(Q-R.sub.4)--, and --S(O).sub.0-2--; Q is selected
from the group consisting of a bond, --C(O)--, --S(O).sub.2--, and
--C(O)--NH--; R.sub.4 is selected from the group consisting of
alkyl, aryl, arylalkylene, heteroaryl, and heterocyclyl, wherein
aryl is unsubstituted or substituted by acetylamino, alkyl, alkoxy,
cyano, or halogen; and x and y are each independently 0, 1, or 2
with the proviso that x+y is .ltoreq.2; or a pharmaceutically
acceptable salt thereof.
9. The compound or salt of claim 8 wherein R.sub.4 is alkyl.
10. The compound or salt of claim 8 wherein R.sub.4 is selected
from the group consisting of methyl, ethyl, isopropyl, and
phenyl.
11. The compound or salt of claim 8 wherein R.sub.2 is selected
from the group consisting of hydrogen, methyl, ethyl, n-propyl,
n-butyl, ethoxymethyl, and 2-methoxyethyl.
12. The compound or salt of claim 8 wherein R.sub.2 is selected
from the group consisting of hydroxymethyl, 2-hydroxyethyl,
ethoxymethyl, and 2-methoxyethyl.
13. The compound or salt of claim 8 wherein Q is
--S(O).sub.2--.
14. The compound or salt of claim 8 wherein Z is a
--(CH.sub.2)-A'--(CH.sub.2)-- and R.sub.2 is selected from the
group consisting of hydrogen, methyl, ethyl, n-propyl, n-butyl,
ethoxymethyl, and 2-methoxyethyl.
15. The compound or salt of claim 8 wherein Z is
--CH.sub.2CH.sub.2CH.sub.2-- or --CH.sub.2--O--CH.sub.2--; and
R.sub.2 is selected from the group consisting of hydrogen, methyl,
ethyl, n-propyl, n-butyl, ethoxymethyl, and 2-methoxyethyl.
16. A pharmaceutical composition comprising a therapeutically
effective amount of a compound or salt of claim 8 in combination
with a pharmaceutically acceptable carrier.
17. A compound selected from the group consisting of:
4-{[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}piperi-
din-4-ol;
4-[(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]-1-met-
hylpiperidin-4-ol;
4-[(4-amino-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]-1-methylpiper-
idin-4-ol; 4-[(4-amino-2-ethoxymethyl-1H-imidazo[4,5
-c]quinolin-1-yl)methyl]-1 -methylpiperidin-4-ol; ethyl
4-{[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}-4-hyd-
roxypiperidine-1-carboxylate;
4-[4-amino-1H-imidazo[4,5-c]quinolin-1-yl)methyl]-1-(methylsulfonyl)piper-
idin-4-ol;
4-[4-amino-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]-1-(m-
ethylsulfonyl)piperidin-4-ol;
4-[4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]-1-(methylsulfon-
yl)piperidin-4-ol;
4-[4-amino-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]-1-(methylsulfo-
nyl)piperidin-4-ol;
4-[4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]-1-(methylsulfon-
yl)piperidin-4-ol;
4-{[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}-1-(me-
thylsulfonyl)piperidin-4-ol;
4-[4-amino-2-ethoxymethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]-1-(cyclo-
propylcarbonyl)piperidin-4-ol;
4-[(4-amino-2-ethoxymethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]-4-hydro-
xy-N -phenylpiperidine-1-carboxamide; and
4-[4-amino-2-ethoxymethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]-4-hydrox-
y-N,N -dimethylpiperidine-1-carboxamide; or a pharmaceutically
acceptable salt thereof.
18. A pharmaceutical composition comprising a therapeutically
effective amount of the compound or salt of claim 17 in combination
with a pharmaceutically acceptable carrier.
19. A method of inducing biosynthesis of at least one of
interferon-.alpha. or tumor necrosis factor-.alpha. in an animal
comprising administering an effective amount of a compound or salt
of claim 17 to the animal.
20. A method of inducing biosynthesis of at least one of
interferon-.alpha. or tumor necrosis factor-.alpha. in an animal
comprising administering an effective amount of a compound or salt
of claim 8 to the animal.
Description
BACKGROUND
In the 1950's the 1H-imidazo[4,5-c]quinoline ring system was
developed and
1-(6-methoxy-8-quinolinyl)-2-methyl-1H-imidazo[4,5-c]quinoline was
synthesized for possible use as an antimalarial agent.
Subsequently, syntheses of various substituted
1H-imidazo[4,5-c]quinolines were reported. For example,
1-[2-(4-piperidyl)ethyl]-1H-imidazo[4,5-c]quinoline was synthesized
as a possible anticonvulsant and cardiovascular agent. Also,
several 2-oxoimidazo[4,5-c]quinolines have been reported.
Certain 1H-imidazo[4,5-c]quinolin-4-amines and 1- and 2-substituted
derivatives thereof were later found to be useful as antiviral
agents, bronchodilators and immunomodulators. Subsequently, certain
substituted 1H-imidazo[4,5-c]pyridin-4-amine, quinolin-4-amine,
tetrahydroquinolin-4-amine, naphthyridin-4-amine, and
tetrahydronaphthyridin-4-amine compounds as well as certain
analogous thiazolo and oxazolo compounds were synthesized and found
to be useful as immune response modifiers, rendering them useful in
the treatment of a variety of disorders.
There continues to be interest in the imidazoquinoline ring system,
as well as other imidazo ring systems, and there is a continuing
need for compounds that have the ability to modulate the immune
response, by induction of cytokine biosynthesis or other
mechanisms.
SUMMARY
The present invention provides a new class of compounds that are
useful in inducing cytokine biosynthesis in animals. Such compounds
are of the following Formula (I):
##STR00001## wherein R.sub.A, R.sub.B, R.sub.2, R', Z, and m are as
defined below.
Compounds of Formula (I) include imidazo-quinoline, -pyridine, and
-naphthyridine ring systems, particularly quinolines,
tetrahydroquinolines, pyridines, 1,5-naphthyridines, and
1,5-tetrahydronaphthyridines, substituted at the 1-position with a
cyclic substituent.
The compounds of Formula I are useful as immune response modifiers
due to their ability to induce cytokine biosynthesis (e.g., induces
the synthesis of at least one cytokine) and otherwise modulate the
immune response when administered to animals. This makes the
compounds useful in the treatment of a variety of conditions such
as viral diseases and tumors that are responsive to such changes in
the immune response.
The invention further provides pharmaceutical compositions
containing an effective amount of a compound of Formula I and
methods of inducing cytokine biosynthesis in an animal, treating a
viral infection and/or treating a neoplastic disease in an animal
by administering an effective amount of a compound of Formula I to
the animal.
In addition, methods of synthesizing compounds of Formula I useful
in the synthesis of these compounds are provided.
As used herein, "a," "an," "the," "at least one," and "one or more"
are used interchangeably.
The terms "comprises" and variations thereof do not have a limiting
meaning where these terms appear in the description and claims.
The above summary of the present invention is not intended to
describe each disclosed embodiment or every implementation of the
present invention. The description that follows more particularly
exemplifies illustrative embodiments. In several places throughout
the application, guidance is provided through lists of examples,
which examples can be used in various combinations. In each
instance, the recited list serves only as a representative group
and should not be interpreted as an exclusive list.
DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS OF THE
INVENTION
The present invention provides compounds of the following Formula
(I):
##STR00002## as well as more specific compounds of the following
Formulas (II, III, IV, V, VI, VII, VIII, IX, and X):
##STR00003## ##STR00004## as well as intermediates of the following
Formulas (XI) and (XII):
##STR00005## and pharmaceutically acceptable salts thereof.
In one embodiment, there is provided a compound of the Formula
(I):
##STR00006## wherein:
m is an integer from 1 to 5;
R' is selected from the group consisting of: hydroxy, thiol,
--S(O).sub.0-2-alkyl, --S(O).sub.2--NH--R.sub.9, alkoxy,
--O--C.sub.1-3 alkylene-S(O).sub.2-alkyl, --N(R.sub.9).sub.2, and
--NH-Q-R.sub.4;
Z is selected from the group consisting of: a bond, C.sub.1-5
alkylene,
##STR00007##
A' is selected from the group consisting of: --O--, --C(O)--,
--N(R.sub.8)--, --N(Q-R.sub.4)--, --N(C.sub.1-5
alkylene-NH-Q-R.sub.4)--, --N(C.sub.1-5 alkylene-W--NH--R.sub.8)--,
and --S(O).sub.0-2--;
R.sub.2 is selected from the group consisting of: --R.sub.4,
--X--R.sub.4, --X--Y--R.sub.4, and --X--R.sub.5;
R.sub.A and R.sub.B are each independently selected from the group
consisting of: hydrogen, halogen, alkyl, alkenyl, alkoxy,
alkylthio, and --N(R.sub.9).sub.2;
or when taken together, R.sub.A and R.sub.B form a fused aryl ring
or heteroaryl ring containing one heteroatom selected from the
group consisting of N and S wherein the aryl or heteroaryl ring is
unsubstituted or substituted by one or more R groups;
or when taken together, R.sub.A and R.sub.B form a fused 5 to 7
membered saturated ring, optionally containing one heteroatom
selected from the group consisting of N and S, and unsubstituted or
substituted by one or more R groups;
R is selected from the group consisting of: halogen, hydroxy,
alkyl, alkenyl, haloalkyl, alkoxy, alkylthio, and
--N(R.sub.9).sub.2;
X is selected from the group consisting of alkylene, alkenylene,
alkynylene, arylene, heteroarylene, and heterocyclylene wherein the
alkylene, alkenylene, and alkynylene groups can be optionally
interrupted or terminated with arylene, heteroarylene, or
heterocyclylene, and optionally interrupted by one or more --O--
groups;
Y is selected from the group consisting of: --S(O).sub.0-2--,
--S(O).sub.2--N(R.sub.8)--, --C(R.sub.6)--, --C(R.sub.6)--O--,
--O--C(R.sub.6)--, --O--C(O)--O--, --N(R.sub.8)-Q-,
--C(R.sub.6)--N(R.sub.8)--, --O--C(R.sub.6)--N(R.sub.8)--,
--C(R.sub.6)--N(OR.sub.9)--,
##STR00008##
R.sub.4 is selected from the group consisting of hydrogen, alkyl,
alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl,
alkylarylenyl, heteroaryl, heteroarylalkylenyl,
heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl,
wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl,
aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl,
heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl
groups can be unsubstituted or substituted by one or more
substituents independently selected from the group consisting of
alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro,
hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy,
heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl,
amino, acetylamino, alkylamino, dialkylamino,
(dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl,
alkynyl, and heterocyclyl, oxo;
R.sub.5 is selected from the group consisting of:
##STR00009##
R.sub.6 is selected from the group consisting of .dbd.O and
.dbd.S;
R.sub.7 is C.sub.2-7 alkylene;
R.sub.8 is selected from the group consisting of hydrogen, alkyl,
alkoxyalkylenyl, and arylalkylenyl;
R.sub.9 is selected from the group consisting of hydrogen and
alkyl;
R.sub.10 is C.sub.3-8 alkylene;
R.sub.11 is selected from the group consisting of hydrogen, alkyl,
halogen, and trifluoromethyl;
R.sub.12 is selected from the group consisting of hydrogen, alkyl,
phenyl, 2-pyridyl, 3-pyridyl, and 4-pyridyl;
A is selected from the group consisting of --O--, --C(O)--,
--S(O).sub.0-2--, --CH.sub.2--, and --N(R.sub.4)--;
Q is selected from the group consisting of a bond, --C(R.sub.6)--,
--C(R.sub.6)--C(R.sub.6), --S(O).sub.2--,
--C(R.sub.6)--N(R.sub.8)--W--, --S(O).sub.2--N(R.sub.8)--,
--C(R.sub.6)--O--, and --C(R.sub.6)--N(OR.sub.9)--;
V is selected from the group consisting of --C(R.sub.6)--,
--O--C(R.sub.6)--, --N(R.sub.8)--C(R.sub.6)--, and
--S(O).sub.2--;
W is selected from the group consisting of a bond, --C(O)--, and
--S(O).sub.2--; and
a and b are independently integers from 1 to 6 with the proviso
that a+b is.ltoreq.7;
with the proviso that when Z is a bond or C.sub.1-5 alkylene then
R' is other than --O--C.sub.1-3 alkylene-S(O).sub.2-alkyl, and with
the further proviso that when Z is a bond or C.sub.1-5 alkylene and
R.sub.2 is --X--Y--R.sub.4 and Y is --N(R.sub.8)-Q-, then Q is
other than --C(R.sub.6)--N(R.sub.8)--W--;
or a pharmaceutically acceptable salt thereof.
In another embodiment, there is provided a compound of the Formula
(II):
##STR00010## wherein:
m is an integer from 1 to 5;
n is an integer from 0 to 4;
R' is selected from the group consisting of: hydroxy, thiol,
--S(O).sub.0-2-alkyl, --S(O).sub.2--NH--R.sub.9, alkoxy,
--O--C.sub.1-3 alkylene-S(O).sub.2-alkyl, --N(R.sub.9).sub.2, and
--NH-Q-R.sub.4;
Z is selected from the group consisting of: a bond, C.sub.1-5
alkylene,
##STR00011##
A' is selected from the group consisting of: --O--, --C(O)--,
--N(R.sub.8)--, --N(Q-R.sub.4)--, --N(C.sub.1-5
alkylene-NH-Q-R.sub.4)--, --N(C.sub.1-5 alkylene-W--NH--R.sub.8)--,
and --S(O).sub.0-2--;
R.sub.2 is selected from the group consisting of: --R.sub.4,
--X--R.sub.4, --X--Y--R.sub.4, and --X--R.sub.5;
R is selected from the group consisting of: halogen, hydroxy,
alkyl, alkenyl, haloalkyl, alkoxy, alkylthio, and
--N(R.sub.9).sub.2;
X is selected from the group consisting of alkylene, alkenylene,
alkynylene, arylene, heteroarylene, and heterocyclylene wherein the
alkylene, alkenylene, and alkynylene groups can be optionally
interrupted or terminated with arylene, heteroarylene, or
heterocyclylene, and optionally interrupted by one or more --O--
groups;
Y is selected from the group consisting of: --S(O).sub.0-2--,
--S(O).sub.2--N(R.sub.8)--, --C(R.sub.6)--, --C(R.sub.6)--O--,
--O--C(R.sub.6)--, --O--C(O)--O--, --N(R.sub.8)-Q-,
--C(R.sub.6)--N(R.sub.8)--, --O--C(R.sub.6)--N(R.sub.8)--,
--C(R.sub.6)--N(OR.sub.9)--,
##STR00012##
R.sub.4 is selected from the group consisting of hydrogen, alkyl,
alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl,
alkylarylenyl, heteroaryl, heteroarylalkylenyl,
heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl,
wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl,
aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl,
heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl
groups can be unsubstituted or substituted by one or more
substituents independently selected from the group consisting of
alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro,
hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy,
heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl,
amino, acetylamino, alkylamino, dialkylamino,
(dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl,
alkynyl, and heterocyclyl, oxo;
R.sub.5 is selected from the group consisting of:
##STR00013##
R.sub.6 is selected from the group consisting of .dbd.O and
.dbd.S;
R.sub.7 is C.sub.2-7 alkylene;
R.sub.8 is selected from the group consisting of hydrogen, alkyl,
alkoxyalkylenyl, and arylalkylenyl;
R.sub.9 is selected from the group consisting of hydrogen and
alkyl;
R.sub.10 is C.sub.3-8 alkylene;
R.sub.11 is selected from the group consisting of hydrogen, alkyl,
halogen, and trifluoromethyl;
R.sub.12 is selected from the group consisting of hydrogen, alkyl,
phenyl, 2-pyridyl, 3-pyridyl, and 4-pyridyl;
A is selected from the group consisting of --O--, --C(O)--,
--S(O).sub.0-2--, --CH.sub.2--, and --N(R.sub.4)--;
Q is selected from the group consisting of a bond, --C(R.sub.6)--,
--C(R.sub.6)--C(R.sub.6), --S(O).sub.2--,
--C(R.sub.6)--N(R.sub.8)--W--, --S(O).sub.2--N(R.sub.8)--,
--C(R.sub.6)--O--, and --C(R.sub.6)--N(OR.sub.9)--;
V is selected from the group consisting of --C(R.sub.6)--,
--O--C(R.sub.6)--, --N(R.sub.8)--C(R.sub.6)--, and
--S(O).sub.2--;
W is selected from the group consisting of a bond, --C(O)--, and
--S(O).sub.2--; and
a and b are independently integers from 1 to 6 with the proviso
that a+b is.ltoreq.7;
with the proviso that when Z is a bond or C.sub.1-5 alkylene then
R' is other than --O--C.sub.1-3 alkylene-S(O).sub.2-alkyl, and with
the further proviso that when Z is a bond or C.sub.1-5 alkylene and
R.sub.2 is --X--Y--R.sub.4 and Y is --N(R.sub.8)-Q-, then Q is
other than --C(R.sub.6)--N(R.sub.8)--W--;
or a pharmaceutically acceptable salt thereof.
In another embodiment, there is provided a compound of the Formula
(III):
##STR00014## wherein:
m is an integer from 1 to 5;
n is an integer from 0 to 4;
R' is selected from the group consisting of: hydroxy, thiol,
--S(O).sub.0-2-alkyl, --S(O).sub.2--NH--R.sub.9, alkoxy,
--O--C.sub.1-3 alkylene-S(O).sub.2-alkyl, --N(R.sub.9).sub.2, and
--NH-Q-R.sub.4;
Z is selected from the group consisting of: a bond, C.sub.1-5
alkylene,
##STR00015##
A' is selected from the group consisting of: --O--, --C(O)--,
--N(R.sub.8)--, --N(Q-R.sub.4)--, --N(C.sub.1-5
alkylene-NH-Q-R.sub.4)--, --N(C.sub.1-5 alkylene-W--NH--R.sub.8)--,
and --S(O).sub.0-2--;
R.sub.2 is selected from the group consisting of: --R.sub.4,
--X--R.sub.4, --X--Y--R.sub.4, and --X--R.sub.5;
R is selected from the group consisting of: halogen, hydroxy,
alkyl, alkenyl, haloalkyl, alkoxy, alkylthio, and
--N(R.sub.9).sub.2;
X is selected from the group consisting of alkylene, alkenylene,
alkynylene, arylene, heteroarylene, and heterocyclylene wherein the
alkylene, alkenylene, and alkynylene groups can be optionally
interrupted or terminated with arylene, heteroarylene, or
heterocyclylene, and optionally interrupted by one or more --O--
groups;
Y is selected from the group consisting of: --S(O).sub.0-2--,
--S(O).sub.2--N(R.sub.8)--, --C(R.sub.6)--, --C(R.sub.6)--O--,
--O--C(R.sub.6)--, --O--C(O)--O--, --N(R.sub.8)-Q-,
--C(R.sub.6)--N(R.sub.8)--, --O--C(R.sub.6)--N(R.sub.8)--,
--C(R.sub.6)--N(OR.sub.9)--,
##STR00016##
R.sub.4 is selected from the group consisting of hydrogen, alkyl,
alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl,
alkylarylenyl, heteroaryl, heteroarylalkylenyl,
heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl,
wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl,
aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl,
heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl
groups can be unsubstituted or substituted by one or more
substituents independently selected from the group consisting of
alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro,
hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy,
heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl,
amino, acetylamino, alkylamino, dialkylamino,
(dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl,
alkynyl, and heterocyclyl, oxo;
R.sub.5 is selected from the group consisting of:
##STR00017##
R.sub.6 is selected from the group consisting of .dbd.O and
.dbd.S;
R.sub.7 is C.sub.2-7 alkylene;
R.sub.8 is selected from the group consisting of hydrogen, alkyl,
alkoxyalkylenyl, and arylalkylenyl;
R.sub.9 is selected from the group consisting of hydrogen and
alkyl;
R.sub.10 is C.sub.3-8 alkylene;
R.sub.11 is selected from the group consisting of hydrogen, alkyl,
halogen, and trifluoromethyl;
R.sub.12 is selected from the group consisting of hydrogen, alkyl,
phenyl, 2-pyridyl, 3-pyridyl, and 4-pyridyl;
A is selected from the group consisting of --O--, --C(O)--,
--S(O).sub.0-2--, --CH.sub.2--, and --N(R.sub.4)--;
Q is selected from the group consisting of a bond, --C(R.sub.6)--,
--C(R.sub.6)--C(R.sub.6), --S(O).sub.2--,
--C(R.sub.6)--N(R.sub.8)--W--, --S(O).sub.2--N(R.sub.8)--,
--C(R.sub.6)--O--, and --C(R.sub.6)--N(OR.sub.9)--;
V is selected from the group consisting of --C(R.sub.6)--,
--O--C(R.sub.6)--, --N(R.sub.8)--C(R.sub.6)--, and
--S(O).sub.2--;
W is selected from the group consisting of a bond, --C(O)--, and
--S(O).sub.2--; and
a and b are independently integers from 1 to 6 with the proviso
that a+b is.ltoreq.7;
with the proviso that when Z is a bond or C.sub.1-5 alkylene then
R' is other than --O--C.sub.1-3 alkylene-S(O).sub.2-alkyl, and with
the further proviso that when Z is a bond or C.sub.1-5 alkylene and
R.sub.2 is --X--Y--R.sub.4 and Y is --N(R.sub.8)-Q-, then Q is
other than --C(R.sub.6)--N(R.sub.8)--W--;
or a pharmaceutically acceptable salt thereof.
In another embodiment, the present invention provides a compound of
the Formula (IV):
##STR00018## wherein:
m is an integer from 1 to 5;
R' is selected from the group consisting of: hydroxy, thiol,
--S(O).sub.0-2-alkyl, --S(O).sub.2--NH--R.sub.9, alkoxy,
--O--C.sub.1-3 alkylene-S(O).sub.2-alkyl, --N(R.sub.9).sub.2, and
--NH-Q-R.sub.4;
Z is selected from the group consisting of: a bond, C.sub.1-5
alkylene,
##STR00019##
A' is selected from the group consisting of: --O--, --C(O)--,
--N(R.sub.8)--, --N(Q-R.sub.4)--, --N(C.sub.1-5
alkylene-NH-Q-R.sub.4)--, --N(C.sub.1-5 alkylene-W--NH--R.sub.8)--,
and --S(O).sub.0-2--;
R.sub.2 is selected from the group consisting of: --R.sub.4,
--X--R.sub.4, --X--Y--R.sub.4, and --X--R.sub.5;
R.sub.A', and R.sub.B' are each independently selected from the
group consisting of: hydrogen, halogen, alkyl, alkenyl, alkoxy,
alkylthio, and --N(R.sub.9).sub.2;
X is selected from the group consisting of alkylene, alkenylene,
alkynylene, arylene, heteroarylene, and heterocyclylene wherein the
alkylene, alkenylene, and alkynylene groups can be optionally
interrupted or terminated with arylene, heteroarylene, or
heterocyclylene, and optionally interrupted by one or more --O--
groups;
Y is selected from the group consisting of: --S(O).sub.0-2--,
--S(O).sub.2--N(R.sub.8)--, --C(R.sub.6)--, --C(R.sub.6)--O--,
--O--C(R.sub.6)--, --O--C(O)--O--, --N(R.sub.8)-Q-,
--C(R.sub.6)--N(R.sub.8)--, --O--C(R.sub.6)--N(R.sub.8)--,
--C(R.sub.6)--N(OR.sub.9)--,
##STR00020##
R.sub.4 is selected from the group consisting of hydrogen, alkyl,
alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl,
alkylarylenyl, heteroaryl, heteroarylalkylenyl,
heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl,
wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl,
aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl,
heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl
groups can be unsubstituted or substituted by one or more
substituents independently selected from the group consisting of
alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro,
hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy,
heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl,
amino, acetylamino, alkylamino, dialkylamino,
(dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl,
alkynyl, and heterocyclyl, oxo;
R.sub.5 is selected from the group consisting of:
##STR00021##
R.sub.6 is selected from the group consisting of .dbd.O and
.dbd.S;
R.sub.7 is C.sub.2-7 alkylene;
R.sub.8 is selected from the group consisting of hydrogen, alkyl,
alkoxyalkylenyl, and arylalkylenyl;
R.sub.9 is selected from the group consisting of hydrogen and
alkyl;
R.sub.10 is C.sub.3-8 alkylene;
R.sub.11 is selected from the group consisting of hydrogen, alkyl,
halogen, and trifluoromethyl;
R.sub.12 is selected from the group consisting of hydrogen, alkyl,
phenyl, 2-pyridyl, 3-pyridyl, and 4-pyridyl;
A is selected from the group consisting of --O--, --C(O)--,
--S(O).sub.0-2--, --CH.sub.2--, and --N(R.sub.4)--;
Q is selected from the group consisting of a bond, --C(R.sub.6)--,
--C(R.sub.6)--C(R.sub.6), --S(O).sub.2--,
--C(R.sub.6)--N(R.sub.8)--W--, --S(O).sub.2--N(R.sub.8)--,
--C(R.sub.6)--O--, and --C(R.sub.6)--N(OR.sub.9)--;
V is selected from the group consisting of --C(R.sub.6)--,
--O--C(R.sub.6)--, --N(R.sub.8)--C(R.sub.6)--, and
--S(O).sub.2--;
W is selected from the group consisting of a bond, --C(O)--, and
--S(O).sub.2--; and
a and b are independently integers from 1 to 6 with the proviso
that a+b is.ltoreq.7;
with the proviso that when Z is a bond or C.sub.1-5 alkylene and
R.sub.2 is --X--Y--R.sub.4 and Y is --N(R.sub.8)-Q-, then Q is
other than --C(R.sub.6)--N(R.sub.8)--W--;
or a pharmaceutically acceptable salt thereof.
In another embodiment, there is provided a compound of the Formula
(V):
##STR00022## wherein:
m is an integer from 1 to 5;
p is an integer from 0 to 3;
R' is selected from the group consisting of: hydroxy, thiol,
--S(O).sub.0-2-alkyl, --S(O).sub.2--NH--R.sub.9, alkoxy,
--O--C.sub.1-3 alkylene-S(O).sub.2-alkyl, --N(R.sub.9).sub.2, and
--NH-Q-R.sub.4;
Z is selected from the group consisting of: a bond, C.sub.1-5
alkylene,
##STR00023##
A' is selected from the group consisting of: --O--, --C(O)--,
--N(R.sub.8)--, --N(Q-R.sub.4)--, --N(C.sub.1-5
alkylene-NH-Q-R.sub.4)--, --N(C.sub.1-5 alkylene-W--NH--R.sub.8)--,
and --S(O).sub.0-2--;
R.sub.2 is selected from the group consisting of: --R.sub.4,
--X--R.sub.4, --X--Y--R.sub.4, and --X--R.sub.5;
R is selected from the group consisting of: halogen, hydroxy,
alkyl, alkenyl, haloalkyl, alkoxy, alkylthio, and
--N(R.sub.9).sub.2;
X is selected from the group consisting of alkylene, alkenylene,
alkynylene, arylene, heteroarylene, and heterocyclylene wherein the
alkylene, alkenylene, and alkynylene groups can be optionally
interrupted or terminated with arylene, heteroarylene, or
heterocyclylene, and optionally interrupted by one or more --O--
groups;
Y is selected from the group consisting of: --S(O).sub.0-2--,
--S(O).sub.2--N(R.sub.8)--, --C(R.sub.6)--, --C(R.sub.6)--O--,
--O--C(R.sub.6)--, --O--C(O)--O--, --N(R.sub.8)-Q-,
--C(R.sub.6)--N(R.sub.8)--, --O--C(R.sub.6)--N(R.sub.8)--,
--C(R.sub.6)--N(OR.sub.9)--,
##STR00024##
R.sub.4 is selected from the group consisting of hydrogen, alkyl,
alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl,
alkylarylenyl, heteroaryl, heteroarylalkylenyl,
heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl,
wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl,
aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl,
heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl
groups can be unsubstituted or substituted by one or more
substituents independently selected from the group consisting of
alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro,
hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy,
heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl,
amino, acetylamino, alkylamino, dialkylamino,
(dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl,
alkynyl, and heterocyclyl, oxo;
R.sub.5 is selected from the group consisting of:
##STR00025##
R.sub.6 is selected from the group consisting of .dbd.O and
.dbd.S;
R.sub.7 is C.sub.2-7 alkylene;
R.sub.8 is selected from the group consisting of hydrogen, alkyl,
alkoxyalkylenyl, and arylalkylenyl;
R.sub.9 is selected from the group consisting of hydrogen and
alkyl;
R.sub.10 is C.sub.3-8 alkylene;
R.sub.11 is selected from the group consisting of hydrogen, alkyl,
halogen, and trifluoromethyl;
R.sub.12 is selected from the group consisting of hydrogen, alkyl,
phenyl, 2-pyridyl, 3-pyridyl, and 4-pyridyl;
A is selected from the group consisting of --O--, --C(O)--,
--S(O).sub.0-2--, --CH.sub.2--, and --N(R.sub.4)--;
Q is selected from the group consisting of a bond, --C(R.sub.6)--,
--C(R.sub.6)--C(R.sub.6), --S(O).sub.2--,
--C(R.sub.6)--N(R.sub.8)--W--, --S(O).sub.2--N(R.sub.8)--,
--C(R.sub.6)--O--, and --C(R.sub.6)--N(OR.sub.9)--;
V is selected from the group consisting of --C(R.sub.6)--,
--O--C(R.sub.6)--, --N(R.sub.8)--C(R.sub.6)--, and
--S(O).sub.2--;
W is selected from the group consisting of a bond, --C(O)--, and
--S(O).sub.2--; and
a and b are independently integers from 1 to 6 with the proviso
that a+b is.ltoreq.7;
with the proviso that when Z is a bond or C.sub.1-5 alkylene then
R' is other than --O--C.sub.1-3 alkylene-S(O).sub.2-alkyl, and with
the further proviso that when Z is a bond or C.sub.1-5 alkylene and
R.sub.2 is --X--Y--R.sub.4 and Y is --N(R.sub.8)-Q-, then Q is
other than --C(R.sub.6)--N(R.sub.8)--W--;
or a pharmaceutically acceptable salt thereof.
In another embodiment, there is provided a compound of the Formula
(VI):
##STR00026## wherein:
m is an integer from 1 to 5;
p is an integer from 0 to 3;
R' is selected from the group consisting of: hydroxy, thiol,
--S(O).sub.0-2-alkyl, --S(O).sub.2--NH--R.sub.9, alkoxy,
--O--C.sub.1-3 alkylene-S(O).sub.2-alkyl, --N(R.sub.9).sub.2, and
--NH-Q-R.sub.4;
Z is selected from the group consisting of: a bond, C.sub.1-5
alkylene,
##STR00027##
A' is selected from the group consisting of: --O--, --C(O)--,
--N(R.sub.8)--, --N(Q-R.sub.4)--, --N(C.sub.1-5
alkylene-NH-Q-R.sub.4)--, --N(C.sub.1-5 alkylene-W--NH--R.sub.8)--,
and --S(O).sub.0-2--;
R.sub.2 is selected from the group consisting of: --R.sub.4,
--X--R.sub.4, --X--Y--R.sub.4, and --X--R.sub.5;
R is selected from the group consisting of: halogen, hydroxy,
alkyl, alkenyl, haloalkyl, alkoxy, alkylthio, and
--N(R.sub.9).sub.2;
X is selected from the group consisting of alkylene, alkenylene,
alkynylene, arylene, heteroarylene, and heterocyclylene wherein the
alkylene, alkenylene, and alkynylene groups can be optionally
interrupted or terminated with arylene, heteroarylene, or
heterocyclylene, and optionally interrupted by one or more --O--
groups;
Y is selected from the group consisting of: --S(O).sub.0-2--,
--S(O).sub.2--N(R.sub.8)--, --C(R.sub.6)--, --C(R.sub.6)--O--,
--O--C(R.sub.6)--, --O--C(O)--O--, --N(R.sub.8)-Q-,
--C(R.sub.6)--N(R.sub.8)--, --O--C(R.sub.6)--N(R.sub.8)--,
--C(R.sub.6)--N(OR.sub.9)--,
##STR00028##
R.sub.4 is selected from the group consisting of hydrogen, alkyl,
alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl,
alkylarylenyl, heteroaryl, heteroarylalkylenyl,
heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl,
wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl,
aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl,
heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl
groups can be unsubstituted or substituted by one or more
substituents independently selected from the group consisting of
alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro,
hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy,
heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl,
amino, acetylamino, alkylamino, dialkylamino,
(dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl,
alkynyl, and heterocyclyl, oxo;
R.sub.5 is selected from the group consisting of:
##STR00029##
R.sub.6 is selected from the group consisting of .dbd.O and
.dbd.S;
R.sub.7 is C.sub.2-7 alkylene;
R.sub.8 is selected from the group consisting of hydrogen, alkyl,
alkoxyalkylenyl, and arylalkylenyl;
R.sub.9 is selected from the group consisting of hydrogen and
alkyl;
R.sub.10 is C.sub.3-8 alkylene;
R.sub.11 is selected from the group consisting of hydrogen, alkyl,
halogen, and trifluoromethyl;
R.sub.12 is selected from the group consisting of hydrogen, alkyl,
phenyl, 2-pyridyl, 3-pyridyl, and 4-pyridyl;
A is selected from the group consisting of --O--, --C(O)--,
--S(O).sub.0-2--, --CH.sub.2--, and --N(R.sub.4)--;
Q is selected from the group consisting of a bond, --C(R.sub.6)--,
--C(R.sub.6)--C(R.sub.6), --S(O).sub.2--,
--C(R.sub.6)--N(R.sub.8)--W--, --S(O).sub.2--N(R.sub.8)--,
--C(R.sub.6)--O--, and --C(R.sub.6)--N(OR.sub.9)--;
V is selected from the group consisting of --C(R.sub.6)--,
--O--C(R.sub.6)--, --N(R.sub.8)--C(R.sub.6)--, and
--S(O).sub.2--;
W is selected from the group consisting of a bond, --C(O)--, and
--S(O).sub.2--; and
a and b are independently integers from 1 to 6 with the proviso
that a+b is.ltoreq.7;
with the proviso that when Z is a bond or C.sub.1-5 alkylene then
R' is other than --O--C.sub.1-3 alkylene-S(O).sub.2-alkyl, and with
the further proviso that when Z is a bond or C.sub.1-5 alkylene and
R.sub.2 is --X--Y--R.sub.4 and Y is --N(R.sub.8)-Q-, then Q is
other than --C(R.sub.6)--N(R.sub.8)--W--;
or a pharmaceutically acceptable salt thereof.
In another embodiment, there is provided a compound of the Formula
(VII):
##STR00030## wherein:
Z is a bond or C.sub.1-3 alkylene; and
R.sub.2 is selected from the group consisting of hydrogen,
C.sub.1-4 alkyl, HO--C.sub.1-4 alkylenyl and C.sub.1-4
alkyl-O--C.sub.1-4 alkylenyl;
or a pharmaceutically acceptable salt thereof.
In another embodiment, there is provided a compound of the Formula
(VIII):
##STR00031## wherein R.sub.2 is selected from the group consisting
of hydrogen, C.sub.1-4 alkyl, HO--C.sub.1-4 alkylenyl and C.sub.1-4
alkyl-O--C.sub.1-4 alkylenyl; or a pharmaceutically acceptable salt
thereof.
In another embodiment, there is provided a compound of the Formula
(IX):
##STR00032## wherein R.sub.2 is selected from the group consisting
of hydrogen, C.sub.1-4 alkyl, HO--C.sub.1-4 alkylenyl and C.sub.1-4
alkyl-O--C.sub.1-4 alkylenyl; or a pharmaceutically acceptable salt
thereof.
In another embodiment, there is provided a compound (which is a
prodrug) of the Formula (X):
##STR00033## wherein:
m is an integer from 1 to 5;
R' is selected from the group consisting of: hydroxy, thiol,
--S(O).sub.0-2-alkyl, --S(O).sub.2--NH--R.sub.9, alkoxy,
--O--C.sub.1-3 alkylene-S(O).sub.2-alkyl, --N(R.sub.9).sub.2, and
--NH-Q-R.sub.4;
Z is selected from the group consisting of: a bond, C.sub.1-5
alkylene,
##STR00034##
A' is selected from the group consisting of: --O--, --C(O)--,
--N(R.sub.8)--, --N(Q-R.sub.4)--, --N(C.sub.1-5
alkylene-NH-Q-R.sub.4)--, --N(C.sub.1-5 alkylene-W--NH--R.sub.8)--,
and --S(O).sub.0-2--;
R.sub.2 is selected from the group consisting of: --R.sub.4,
--X--R.sub.4, --X--Y--R.sub.4, and --X--R.sub.5;
R.sub.A and R.sub.B are each independently selected from the group
consisting of: hydrogen, halogen, alkyl, alkenyl, alkoxy,
alkylthio, and --N(R.sub.9).sub.2;
or when taken together, R.sub.A and R.sub.B form a fused aryl ring
or heteroaryl ring containing one heteroatom selected from the
group consisting of N and S wherein the aryl or heteroaryl ring is
unsubstituted or substituted by one or more R groups;
or when taken together, R.sub.A and R.sub.B form a fused 5 to 7
membered saturated ring, optionally containing one heteroatom
selected from the group consisting of N and S, and unsubstituted or
substituted by one or more R groups;
R is selected from the group consisting of: halogen, hydroxy,
alkyl, alkenyl, haloalkyl, alkoxy, alkylthio, and
--N(R.sub.9).sub.2;
X is selected from the group consisting of alkylene, alkenylene,
alkynylene, arylene, heteroarylene, and heterocyclylene wherein the
alkylene, alkenylene, and alkynylene groups can be optionally
interrupted or terminated with arylene, heteroarylene, or
heterocyclylene, and optionally interrupted by one or more --O--
groups;
Y is selected from the group consisting of: --S(O).sub.0-2--,
--S(O).sub.2--N(R.sub.8)--, --C(R.sub.6)--, --C(R.sub.6)--O--,
--O--C(R.sub.6)--, --O--C(O)--O--, --N(R.sub.8)-Q-,
--C(R.sub.6)--N(R.sub.8)--, --O--C(R.sub.6)--N(R.sub.8)--,
--C(R.sub.6)--N(OR.sub.9)--,
##STR00035##
R.sub.4 is selected from the group consisting of hydrogen, alkyl,
alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl,
alkylarylenyl, heteroaryl, heteroarylalkylenyl,
heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl,
wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl,
aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl,
heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl
groups can be unsubstituted or substituted by one or more
substituents independently selected from the group consisting of
alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro,
hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy,
heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl,
amino, acetylamino, alkylamino, dialkylamino,
(dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl,
alkynyl, and heterocyclyl, oxo;
R.sub.5 is selected from the group consisting of:
##STR00036##
R.sub.6 is selected from the group consisting of .dbd.O and
.dbd.S;
R.sub.7 is C.sub.2-7 alkylene;
R.sub.8 is selected from the group consisting of hydrogen, alkyl,
alkoxyalkylenyl, and arylalkylenyl;
R.sub.9 is selected from the group consisting of hydrogen and
alkyl;
R.sub.10 is C.sub.3-8 alkylene;
R.sub.11 is selected from the group consisting of hydrogen, alkyl,
halogen, and trifluoromethyl;
R.sub.12 is selected from the group consisting of hydrogen, alkyl,
phenyl, 2-pyridyl, 3-pyridyl, and 4-pyridyl;
A is selected from the group consisting of --O--, --C(O)--,
--S(O).sub.0-2--, --CH.sub.2--, and --N(R.sub.4)--;
Q is selected from the group consisting of a bond, --C(R.sub.6)--,
--C(R.sub.6)--C(R.sub.6), --S(O).sub.2--,
--C(R.sub.6)--N(R.sub.8)--W--, --S(O).sub.2--N(R.sub.8)--,
--C(R.sub.6)--O--, and --C(R.sub.6)--N(OR.sub.9)--;
V is selected from the group consisting of --C(R.sub.6)--,
--O--C(R.sub.6)--, --N(R.sub.8)--C(R.sub.6)--, and
--S(O).sub.2--;
W is selected from the group consisting of a bond, --C(O)--, and
--S(O).sub.2--; and
a and b are independently integers from 1 to 6 with the proviso
that a+b is.ltoreq.7;
G is selected from the group consisting of: --C(O)--R'',
.alpha.-aminoacyl, .alpha.-aminoacyl-.alpha.-aminoacyl,
--C(O)--O--R'', --C(O)--N(R''')R'', --C(.dbd.NY')--R'',
--CH(OH)--C(O)--OY', --CH(OC.sub.1-4 alkyl)Y.sub.0,
--CH.sub.2Y.sub.1, and --CH(CH.sub.3)Y.sub.1;
R'' and R''' are independently selected from the group consisting
of C.sub.1-10 alkyl, C.sub.3-7 cycloalkyl, and benzyl, each of
which may be unsubstituted or substituted by one or more
substitutents selected from the group consisting of halogen,
hydroxy, nitro, cyano, carboxy, C.sub.1-6 alkyl, C.sub.1-4 alkoxy,
aryl, heteroaryl, arylC.sub.1-4 alkylenyl, heteroarylC.sub.1-4
alkylenyl, haloC.sub.1-4 alkylenyl, haloC.sub.1-4 alkoxy,
--O--C(O)--CH.sub.3, --C(O)--O--CH.sub.3, --C(O)--NH.sub.2,
--O--CH.sub.2--C(O)--NH.sub.2, --NH.sub.2, and
--S(O).sub.2--NH.sub.2, with the proviso that R''' can also be
hydrogen;
.alpha.-aminoacyl is an acyl group derived from an amino acid
selected from the group consisting of racemic, D-, and L-amino
acids;
Y' is selected from the group consisting of hydrogen, C.sub.1-6
alkyl, and benzyl;
Y.sub.0 is selected from the group consisting of C.sub.1-6 alkyl,
carboxyC.sub.1-6 alkylenyl, aminoC.sub.1-4 alkylenyl,
mono-N--C.sub.1-6 alkylaminoC.sub.1-4 alkylenyl, and
di-N,N--C.sub.1-6 alkylaminoC.sub.1-4 alkylenyl;
Y.sub.1 is selected from the group consisting of mono-N--C.sub.1-6
alkylamino, di-N,N--C.sub.1-6 alkylamino, morpholin-4-yl,
piperidin-1-yl, pyrrolidin-1-yl, and 4-C.sub.1-4
alkylpiperazin-1-yl;
with the proviso that when Z is a bond or C.sub.1-5 alkylene then
R' is other than --O--C.sub.1-3 alkylene-S(O).sub.2-alkyl, and with
the further proviso that when Z is a bond or C.sub.1-5 alkylene and
R.sub.2 is --X--Y--R.sub.4 and Y is --N(R.sub.8)-Q-, then Q is
other than --C(R.sub.6)--N(R.sub.8)--W--;
or a pharmaceutically acceptable salt thereof.
In another embodiment, there is provided a compound of the Formula
(XI):
##STR00037## wherein:
R' is selected from the group consisting of: hydroxy, thiol,
--S(O).sub.0-2-alkyl, --S(O).sub.2--NH--R.sub.9, alkoxy,
--O--C.sub.1-3 alkylene-S(O).sub.2-alkyl, --N(R.sub.9).sub.2, and
--NH-Q-R.sub.4;
R.sub.2 is selected from the group consisting of: --R.sub.4,
--X--R.sub.4, --X--Y--R.sub.4, and --X--R.sub.5;
R.sub.A and R.sub.B are each independently selected from the group
consisting of: hydrogen, halogen, alkyl, alkenyl, alkoxy,
alkylthio, and --N(R.sub.9).sub.2;
or when taken together, R.sub.A and R.sub.B form a fused aryl ring
or heteroaryl ring containing one heteroatom selected from the
group consisting of N and S wherein the aryl or heteroaryl ring is
unsubstituted or substituted by one or more R groups;
or when taken together, R.sub.A and R.sub.B form a fused 5 to 7
membered saturated ring, optionally containing one heteroatom
selected from the group consisting of N and S, and unsubstituted or
substituted by one or more R groups;
R is selected from the group consisting of: halogen, hydroxy,
alkyl, alkenyl, haloalkyl, alkoxy, alkylthio, and
--N(R.sub.9).sub.2;
X is selected from the group consisting of alkylene, alkenylene,
alkynylene, arylene, heteroarylene, and heterocyclylene wherein the
alkylene, alkenylene, and alkynylene groups can be optionally
interrupted or terminated with arylene, heteroarylene, or
heterocyclylene, and optionally interrupted by one or more --O--
groups;
Y is selected from the group consisting of: --S(O).sub.0-2--,
--S(O).sub.2--N(R.sub.8)--, --C(R.sub.6)--, --C(R.sub.6)--O--,
--O--C(R.sub.6)--, --O--C(O)--O--, --N(R.sub.8)-Q-,
--C(R.sub.6)--N(R.sub.8)--, --O--C(R.sub.6)--N(R.sub.8)--,
--C(R.sub.6)--N(OR.sub.9)--,
##STR00038##
R.sub.4 is selected from the group consisting of hydrogen, alkyl,
alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl,
alkylarylenyl, heteroaryl, heteroarylalkylenyl,
heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl,
wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl,
aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl,
heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl
groups can be unsubstituted or substituted by one or more
substituents independently selected from the group consisting of
alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro,
hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy,
heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl,
amino, acetylamino, alkylamino, dialkylamino,
(dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl,
alkynyl, and heterocyclyl, oxo;
R.sub.5 is selected from the group consisting of:
##STR00039##
R.sub.6 is selected from the group consisting of .dbd.O and
.dbd.S;
R.sub.7 is C.sub.2-7 alkylene;
R.sub.8 is selected from the group consisting of hydrogen, alkyl,
alkoxyalkylenyl, and arylalkylenyl;
R.sub.9 is selected from the group consisting of hydrogen and
alkyl;
R.sub.10 is C.sub.3-8 alkylene;
A is selected from the group consisting of --O--, --C(O)--,
--S(O).sub.0-2--, --CH.sub.2--, and --N(R.sub.4)--;
Q is selected from the group consisting of a bond, --C(R.sub.6)--,
--C(R.sub.6)--C(R.sub.6), --S(O).sub.2--,
--C(R.sub.6)--N(R.sub.8)--W--, --S(O).sub.2--N(R.sub.8)--,
--C(R.sub.6)--O--, and --C(R.sub.6)--N(OR.sub.9)--;
V is selected from the group consisting of --C(R.sub.6)--,
--O--C(R.sub.6)--, --N(R.sub.8)--C(R.sub.6)--, and
--S(O).sub.2--;
W is selected from the group consisting of a bond, --C(O)--, and
--S(O).sub.2--; and
a and b are independently integers from 1 to 6 with the proviso
that a+b is.ltoreq.7;
or a pharmaceutically acceptable salt thereof.
In another embodiment, there is provided a compound of the Formula
(XII):
##STR00040## wherein:
R' is selected from the group consisting of: hydroxy, thiol,
--S(O).sub.0-2-alkyl, --S(O).sub.2--NH--R.sub.9, alkoxy,
--O--C.sub.1-3 alkylene-S(O).sub.2-alkyl, --N(R.sub.9).sub.2, and
--NH-Q-R.sub.4;
R.sub.2 is selected from the group consisting of: --R.sub.4,
--X--R.sub.4, --X--Y--R.sub.4, and --X--R.sub.5;
R.sub.A and R.sub.B are each independently selected from the group
consisting of: hydrogen, halogen, alkyl, alkenyl, alkoxy,
alkylthio, and --N(R.sub.9).sub.2;
or when taken together, R.sub.A and R.sub.B form a fused aryl ring
or heteroaryl ring containing one heteroatom selected from the
group consisting of N and S wherein the aryl or heteroaryl ring is
unsubstituted or substituted by one or more R groups;
or when taken together, R.sub.A and R.sub.B form a fused 5 to 7
membered saturated ring, optionally containing one heteroatom
selected from the group consisting of N and S, and unsubstituted or
substituted by one or more R groups;
R is selected from the group consisting of: halogen, hydroxy,
alkyl, alkenyl, haloalkyl, alkoxy, alkylthio, and
--N(R.sub.9).sub.2;
X is selected from the group consisting of alkylene, alkenylene,
alkynylene, arylene, heteroarylene, and heterocyclylene wherein the
alkylene, alkenylene, and alkynylene groups can be optionally
interrupted or terminated with arylene, heteroarylene, or
heterocyclylene, and optionally interrupted by one or more --O--
groups;
Y is selected from the group consisting of: --S(O).sub.0-2--,
--S(O).sub.2--N(R.sub.8)--, --C(R.sub.6)--, --C(R.sub.6)--O--,
--O--C(R.sub.6)--,
--O--C(O)--O--, --N(R.sub.8)-Q-, --C(R.sub.6)--N(R.sub.8)--,
--O--C(R.sub.6)--N(R.sub.8)--, --C(R.sub.6)--N(OR.sub.9)--,
##STR00041##
R.sub.4 is selected from the group consisting of hydrogen, alkyl,
alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl,
alkylarylenyl, heteroaryl, heteroarylalkylenyl,
heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl,
wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl,
aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl,
heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl
groups can be unsubstituted or substituted by one or more
substituents independently selected from the group consisting of
alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen, nitro,
hydroxy, mercapto, cyano, aryl, aryloxy, arylalkyleneoxy,
heteroaryl, heteroaryloxy, heteroarylalkyleneoxy, heterocyclyl,
amino, acetylamino, alkylamino, dialkylamino,
(dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl,
alkynyl, and heterocyclyl, oxo;
R.sub.5 is selected from the group consisting of:
##STR00042##
R.sub.6 is selected from the group consisting of .dbd.O and
.dbd.S;
R.sub.7 is C.sub.2-7 alkylene;
R.sub.8 is selected from the group consisting of hydrogen, alkyl,
alkoxyalkylenyl, and arylalkylenyl;
R.sub.9 is selected from the group consisting of hydrogen and
alkyl;
R.sub.10 is C.sub.3-8 alkylene;
A is selected from the group consisting of --O--, --C(O)--,
--S(O).sub.0-2--, --CH.sub.2--, and --N(R.sub.4)--;
Q is selected from the group consisting of a bond, --C(R.sub.6)--,
--C(R.sub.6)--C(R.sub.6), --S(O).sub.2--,
--C(R.sub.6)--N(R.sub.8)--W--, --S(O).sub.2--N(R.sub.8)--,
--C(R.sub.6)--O--, and --C(R.sub.6)--N(OR.sub.9)--;
V is selected from the group consisting of --C(R.sub.6)--,
--O--C(R.sub.6)--, --N(R.sub.8)--C(R.sub.6)--, and
--S(O).sub.2--;
W is selected from the group consisting of a bond, --C(O)--, and
--S(O).sub.2--; and
a and b are independently integers from 1 to 6 with the proviso
that a+b is.ltoreq.7;
or a pharmaceutically acceptable salt thereof.
For any of the compounds presented herein, each one of the
following variables (e.g., Z, X, Y, R, R', R.sub.A, R.sub.B,
R.sub.A', R.sub.B', R.sub.2, Q, W, m, n, p, G, and so on) in any of
its embodiments can be combined with any one or more of the other
variables in any of their embodiments and associated with any one
of the formulas described herein, as would be understood by one of
skill in the art. Each of the resulting combinations of variables
is an embodiment of the present invention.
For certain embodiments, m is an integer from 1 to 5. For certain
embodiments, m is 1, 2, or 3. For certain embodiments, m is 1 or 2.
Preferably, m is 1.
For certain embodiments, n is an integer from 0 to 4. Preferably, n
is 0.
For certain embodiments, p is an integer from 0 to 3. Preferably, p
is 0.
For certain embodiments, R' is selected from the group consisting
of hydroxy, thiol, --S(O).sub.0-2-alkyl, --S(O).sub.2--NH--R.sub.9,
alkoxy, --O--C.sub.1-3 alkylene-S(O).sub.2-alkyl,
--N(R.sub.9).sub.2, and --NH-Q-R.sub.4. For certain embodiments,
particularly when Z is a bond or C.sub.1-5 alkylene, R' is other
than --O--C.sub.1-3 alkylene-S(O).sub.2-alkyl.
For certain embodiments, R' is selected from the group consisting
of hydroxy, methoxy, and amino. For certain embodiments, R' is
selected from the group consisting of hydroxy and methoxy. For
certain embodiments R' is hydroxy. For certain embodiments, R' is
--O--C.sub.1-3 alkylene-S(O).sub.2-alkyl. For certain alternative
embodiments, R' is selected from the group consisting of --NH.sub.2
and --NH-Q-R.sub.4. In such embodiments, preferably Q is selected
from the group consisting of --C(O)--, --S(O).sub.2--, --C(O)--O--,
and --C(O)--NH--, and R.sub.4 is selected from the group consisting
of alkyl and alkoxyalkylene. Alternatively, in such embodiments,
preferably Q is selected from the group consisting of --C(O)--,
--C(O)--O--, --S(O).sub.2--, and --C(R.sub.6)--N(R.sub.8)--,
R.sub.8 is selected from hydrogen and C.sub.1-4 alkyl, and R.sub.4
is alkyl, aryl, arylalkylene, heteroaryl, and heterocyclyl, wherein
the aryl group can be unsubstituted or substituted by acetylamino,
alkyl, alkoxy, cyano, and halogen. More preferably, Q is selected
from the group consisting of --C(O)--, --S(O).sub.2--, --C(O)--O--,
and --C(O)--NH--, and R.sub.4 is selected from the group consisting
of alkyl and alkoxyalkylene.
For certain embodiments, Z is selected from the group consisting of
a bond, C.sub.1-5 alkylene,
##STR00043##
For certain embodiments, Z is selected from the group consisting of
a bond and C.sub.1-5 alkylene. In such embodiments, preferably R'
is other than --O--C.sub.1-3 alkylene-S(O).sub.2-alkyl.
Alternatively or additionally, in such embodiments, preferably,
when Z is a bond or C.sub.1-5 alkylene and R.sub.2 is
--X--Y--R.sub.4 and Y is --N(R.sub.8)-Q-, then Q is other than
--C(R.sub.6)--N(R.sub.8)--W--
For certain embodiments, Z is selected from the group consisting of
a bond and C.sub.1-3 alkylene.
For certain alternative embodiments, Z is
--(CH.sub.2).sub.0-1-A'-(CH.sub.2).sub.0-1--. In some of these
embodiments Z is --(CH.sub.2)-A'-(CH.sub.2)--. In some embodiments,
preferably, A' is --O--. In some embodiments, preferably, A' is
--S(O).sub.2--. In some embodiments, preferably, A' is selected
from the group consisting of --N(R.sub.8)-- and --N(Q-R.sub.4)--.
In some embodiments, In some embodiments, preferably, A' is
selected from the group consisting of --O--, --N(R.sub.8)--, and
--N(Q-R.sub.4)--. In such embodiments, preferably, Q is selected
from the group consisting of --C(O)--, --C(O)--O--, --S(O).sub.2--,
and --C(R.sub.6)--N(R.sub.8)--, wherein, preferably, R.sub.8 is
selected from hydrogen and C.sub.1-4 alkyl. In such embodiments,
preferably, R.sub.4 is selected from the group consisting of alkyl,
aryl, arylalkylene, heteroaryl, and heterocyclyl, wherein the aryl
group can be unsubstituted or substituted by acetylamino, alkyl,
alkoxy, cyano, and halogen. In such embodiments, more preferably, Q
is --S(O).sub.2-- and R.sub.4 is C.sub.1-4 alkyl.
For certain embodiments, Z is selected from the group consisting of
a bond, --CH.sub.2--, --CH.sub.2CH.sub.2--,
--CH.sub.2CH.sub.2CH.sub.2--, and --CH.sub.2--O--CH.sub.2--. For
certain embodiments Z is --CH.sub.2CH.sub.2CH.sub.2-- or
--CH.sub.2--O--CH.sub.2--.
For certain embodiments, R.sub.2 is selected from the group
consisting of --R.sub.4, --X--R.sub.4, --X--Y--R.sub.4, and
--X--R.sub.5. For certain embodiments, R.sub.2 is
--X--Y--R.sub.4.
For certain embodiments, R.sub.2 is selected from the group
consisting of hydrogen, alkyl, alkoxyalkylenyl, hydroxyalkylenyl,
and --X--Y--R.sub.4 wherein X is C.sub.1-2 alkylene; Y is selected
from the group consisting of --S(O).sub.0-2--,
--S(O).sub.2--N(R.sub.8)--, --C(R.sub.6)--, --C(R.sub.6)--O--,
--O--C(R.sub.6)--, --O--C(O)--O--, --N(R.sub.8)-Q-,
--C(R.sub.6)--N(R.sub.8)--, --O--C(R.sub.6)--N(R.sub.8)--, and
--C(R.sub.6)--N(OR.sub.9)--; and R.sub.4 is alkyl.
For certain embodiments, R.sub.2 is selected from the group
consisting of hydrogen, alkyl, alkoxyalkylenyl, and --X--Y--R.sub.4
wherein X is C.sub.1-2 alkylene; Y is selected from the group
consisting of --S(O).sub.0-2--, --S(O).sub.2--N(R.sub.8)--,
--C(R.sub.6)--, --C(R.sub.6)--O--, --O--C(R.sub.6)--,
--O--C(O)--O--, --N(R.sub.8)-Q-, --C(R.sub.6)--N(R.sub.8)--,
--O--C(R.sub.6)--N(R.sub.8)--, and --C(R.sub.6)--N(OR.sub.9)--; and
R.sub.4 is alkyl. Preferably, R.sub.2 is selected from the group
consisting of hydrogen, C.sub.1-4 alkyl, and C.sub.1-4
alkyl-O--C.sub.1-4 alkylenyl. For certain embodiments, R.sub.2 is
hydrogen or C.sub.1-4 alkyl. For certain embodiments, R.sub.2 is
C.sub.1-4 alkyl. More preferably, R.sub.2 is selected from the
group consisting of hydrogen, methyl, ethyl, n-propyl, n-butyl,
ethoxymethyl, and 2-methoxyethyl. For certain embodiments, R.sub.2
is selected from the group consisting of hydrogen, methyl, ethyl,
n-propyl, and n-butyl.
For certain embodiments, R.sub.2 is HO--C.sub.1-4 alkylenyl or
C.sub.1-4 alkyl-O--C.sub.1-4 alkylenyl. For certain embodiments,
R.sub.2 is selected from the group consisting of hydroxymethyl,
2-hydroxyethyl, ethoxymethyl, and 2-methoxyethyl. For certain
embodiments, R.sub.2 is selected from the group consisting of
hydrogen, C.sub.1-4 alkyl, HO--C.sub.1-4 alkylenyl and C.sub.1-4
alkyl-O--C.sub.1-4 alkylenyl.
For certain embodiments, R.sub.A' and R.sub.B' are each
independently selected from the group consisting of hydrogen,
halogen, alkyl, alkenyl, alkoxy, alkylthio, and
--N(R.sub.9).sub.2.
For certain embodiments, R.sub.A' and R.sub.B' are independently
hydrogen or alkyl. Preferably, R.sub.A' and R.sub.B' are both
methyl.
For certain embodiments, X is selected from the group consisting of
alkylene, alkenylene, alkynylene, arylene, heteroarylene, and
heterocyclylene wherein the alkylene, alkenylene, and alkynylene
groups can be optionally interrupted or terminated with arylene,
heteroarylene, or heterocyclylene, and optionally interrupted by
one or more --O--groups. For certain embodiments, particularly in
--X--Y--R.sub.4, X is C.sub.1-2 alkylene.
For certain embodiments, Y is selected from the group consisting of
--S(O).sub.0-2--, --S(O).sub.2--N(R.sub.8)--, --C(R.sub.6)--,
--C(R.sub.6)--O--, --O--C(R.sub.6)--, --O--C(O)--O--,
--N(R.sub.8)-Q-, --C(R.sub.6)--N(R.sub.8)--,
--O--C(R.sub.6)--N(R.sub.8)--, --C(R.sub.6)--N(OR.sub.9)--,
##STR00044##
For certain embodiments, Y is selected from the group consisting of
--S(O).sub.0-2--, --S(O).sub.2--N(R.sub.8)--, --C(R.sub.6)--,
--C(R.sub.6)--O--, --O--C(R.sub.6)--, --O--C(O)--O--,
--N(R.sub.8)-Q-, --C(R.sub.6)--N(R.sub.8)--,
--O--C(R.sub.6)--N(R.sub.8)--, and --C(R.sub.6)--N(OR.sub.9)--. For
certain embodiments, Y is --N(R.sub.8)-Q-.
For certain embodiments, R.sub.A and R.sub.B are each independently
selected from the group consisting of hydrogen, halogen, alkyl,
alkenyl, alkoxy, alkylthio, and --N(R.sub.9).sub.2. Alternatively,
for certain embodiments, when taken together, R.sub.A and R.sub.B
form a fused aryl ring or heteroaryl ring containing one heteroatom
selected from the group consisting of N and S wherein the aryl or
heteroaryl ring is unsubstituted or substituted by one or more R
groups. Alternatively, when taken together, R.sub.A and R.sub.B
form a fused 5 to 7 membered saturated ring, optionally containing
one heteroatom selected from the group consisting of N and S, and
unsubstituted or substituted by one or more R groups. For certain
embodiments, R.sub.A and R.sub.B join to form a fused benzene ring.
For certain embodiments, R.sub.A and R.sub.B join to form a fused
pyridine ring.
For certain embodiments, R is selected from the group consisting of
halogen, hydroxy, alkyl, alkenyl, haloalkyl, alkoxy, alkylthio, and
--N(R.sub.9).sub.2.
For certain embodiments, R.sub.4 is selected from the group
consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl,
arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl,
heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl,
and heterocyclyl, wherein the alkyl, alkenyl, alkynyl, aryl,
arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl,
heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl,
and heterocyclyl groups can be unsubstituted or substituted by one
or more substituents independently selected from the group
consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy,
halogen, nitro, hydroxy, mercapto, cyano, aryl, aryloxy,
arylalkyleneoxy, heteroaryl, heteroaryloxy, heteroarylalkyleneoxy,
heterocyclyl, amino, acetylamino, alkylamino, dialkylamino,
(dialkylamino)alkyleneoxy, and in the case of alkyl, alkenyl,
alkynyl, and heterocyclyl, oxo.
For certain embodiments, R.sub.4 is alkyl, aryl, arylalkylene,
heteroaryl, and heterocyclyl, wherein the aryl group can be
unsubstituted or substituted by acetylamino, alkyl, alkoxy, cyano,
and halogen. For certain embodiments, R.sub.4 is selected from the
group consisting of alkyl and alkoxyalkylene.
For certain embodiments, R.sub.4 is alkyl. For certain embodiments,
R.sub.4 is methyl, ethyl, isopropyl, or phenyl. For certain
embodiments, R.sub.4 is methyl or ethyl.
For certain embodiments, R.sub.5 is selected from the group
consisting of
##STR00045##
For certain embodiments, R.sub.6 is selected from the group
consisting of .dbd.O and .dbd.S. For certain embodiments, R.sub.6
is .dbd.O.
For certain embodiments, R.sub.7 is C.sub.2-7 alkylene. For certain
embodiments, particularly embodiments where Y is
##STR00046## R.sub.7 is selected such that the total number of ring
atoms is from 6 to 8.
For certain embodiments, R.sub.8 is selected from the group
consisting of hydrogen, alkyl, alkoxyalkylenyl, and arylalkylenyl.
For certain embodiments, R.sub.8 is hydrogen or alkyl. For certain
embodiments, R.sub.8 is selected from hydrogen and C.sub.1-4
alkyl.
For certain embodiments, R.sub.9 is hydrogen or alkyl. For certain
embodiments, R.sub.9 is hydrogen.
For certain embodiments, R.sub.10 is C.sub.3-8 alkylene.
For certain embodiments, R.sub.11 is selected from the group
consisting of hydrogen, alkyl, halogen, and trifluoromethyl.
For certain embodiments, R.sub.12 is selected from the group
consisting of hydrogen, alkyl, phenyl, 2-pyridyl, 3-pyridyl, and
4-pyridyl.
For certain embodiments, A is selected from the group consisting of
--O--, --C(O)--, --S(O).sub.0-2--, --CH.sub.2--, and
--N(R.sub.4)--.
For certain embodiments, A' is selected from the group consisting
of --O--, --C(O)--, --N(R.sub.8)--, --N(Q-R.sub.4)--, --N(C.sub.1-5
alkylene-NH-Q-R.sub.4)--, --N(C.sub.1-5 alkylene-W--NH--R.sub.8)--,
and --S(O).sub.0-2--. For certain embodiments, A' is --O--,
--N(R.sub.8)--, or --N(Q-R.sub.4)--. For certain embodiments, A' is
--O--. For certain embodiments, A' is --S(O).sub.2--.
For certain embodiments, A' is --N(R.sub.8)-- or --N(Q-R.sub.4)--.
In such embodiments, preferably, Q is selected from the group
consisting of --C(O)--, --C(O)--O--, --S(O).sub.2--, and
--C(R.sub.6)--N(R.sub.8)--, R.sub.8 is selected from hydrogen and
C.sub.1-4 alkyl, and R.sub.4 is selected from the group consisting
of alkyl, aryl, arylalkylene, heteroaryl, and heterocyclyl, wherein
the aryl group can be unsubstituted or substituted by acetylamino,
alkyl, alkoxy, cyano, and halogen. In such embodiments, more
preferably, Q is --S(O).sub.2-- and R.sub.4 is C.sub.1-4 alkyl.
For certain embodiments, Q is selected from the group consisting of
a bond, --C(R.sub.6)--, --C(R.sub.6)--C(R.sub.6), --S(O).sub.2--,
--C(R.sub.6)--N(R.sub.8)--W--, --S(O).sub.2--N(R.sub.8)--,
--C(R.sub.6)--O--, and --C(R.sub.6)--N(OR.sub.9)--. For certain
embodiments, Q is --C(O)--, --C(O)--O--, --S(O).sub.2--, or
--C(R.sub.6)--N(R.sub.8)--. For certain embodiments, Q is selected
from the group consisting of --C(O)--, --S(O).sub.2--, --C(O)--O--,
and --C(O)--NH--. For certain embodiments, Q is a bond, --C(O)--,
--S(O).sub.2--, or --C(O)--NH--. For certain embodiments, Q is
--S(O).sub.2--.
For certain embodiments, particularly when Z is a bond or C.sub.1-5
alkylene and R.sub.2 is --X--Y--R.sub.4 and Y is --N(R.sub.8)-Q-,
then Q is other than --C(R.sub.6)--N(R.sub.8)--W--.
For certain embodiments, V is selected from the group consisting of
--C(R.sub.6)--, --O--C(R.sub.6)--, --N(R.sub.8)--C(R.sub.6)--, and
--S(O).sub.2--.
For certain embodiments, W is selected from the group consisting of
a bond, --C(O)--, and --S(O).sub.2--. For certain embodiments, W is
a bond.
For certain embodiments, a and b are independently integers from 1
to 6 with the proviso that a+b is.ltoreq.7.
For certain embodiments of the compounds of Formulas (I) through
(IX), the --NH.sub.2 group can be replaced by an --NH-G group to
form prodrugs. In such embodiments, G is selected from the group
consisting of: --C(O)--R'', .alpha.-aminoacyl,
.alpha.-aminoacyl-.alpha.-aminoacyl, --C(O)--O--R'',
--C(O)--N(R''')R'', --C(.dbd.NY')--R'', --CH(OH)--C(O)--OY',
--CH(OC.sub.1-4 alkyl)Y.sub.0, --CH.sub.2Y.sub.1, and
--CH(CH.sub.3)Y.sub.1. In some of these embodiments G is
--C(O)--R'', .alpha.-aminoacyl,
.alpha.-aminoacyl-.alpha.-aminoacyl, or --C(O)--O--R''. Preferably,
R'' and R''' are independently selected from the group consisting
of C.sub.1-10 alkyl, C.sub.3-7 cycloalkyl, and benzyl, each of
which may be unsubstituted or substituted by one or more
substitutents selected from the group consisting of halogen,
hydroxy, nitro, cyano, carboxy, C.sub.1-6 alkyl, C.sub.1-4 alkoxy,
aryl, heteroaryl, arylC.sub.1-4 alkylenyl, heteroarylC.sub.1-4
alkylenyl, haloC.sub.1-4 alkylenyl, haloC.sub.1-4 alkoxy,
--O--C(O)--CH.sub.3, --C(O)--O--CH.sub.3, --C(O)--NH.sub.2,
--O--CH.sub.2--C(O)--NH.sub.2, --NH.sub.2, and
--S(O).sub.2--NH.sub.2. R''' can also be hydrogen. Preferably,
.alpha.-aminoacyl is an acyl group derived from an amino acid
selected from the group consisting of racemic, D-, and L-amino
acids. Preferably, Y' is selected from the group consisting of
hydrogen, C.sub.1-6 alkyl, and benzyl. Preferably, Y.sub.0 is
selected from the group consisting of C.sub.1-6 alkyl,
carboxyC.sub.1-6 alkylenyl, aminoC.sub.1-4 alkylenyl,
mono-N--C.sub.1-6 alkylaminoC.sub.1-4 alkylenyl, and
di-N,N--C.sub.1-6 alkylaminoC.sub.1-4 alkylenyl. Preferably,
Y.sub.1 is selected from the group consisting of mono-N--C.sub.1-6
alkylamino, di-N,N--C.sub.1-6 alkylamino, morpholin-4-yl,
piperidin-1-yl, pyrrolidin-1-yl, and 4-C.sub.1-4
alkylpiperazin-1-yl.
As used herein, the terms "alkyl, "alkenyl," "alkynyl" and the
prefix "alk-" are inclusive of both straight chain and branched
chain groups and of cyclic groups, e.g., cycloalkyl and
cycloalkenyl. Unless otherwise specified, these groups contain from
1 to 20 carbon atoms, with alkenyl groups containing from 2 to 20
carbon atoms, and alkynyl groups containing from 2 to 20 carbon
atoms. In some embodiments, these groups have a total of up to 10
carbon atoms, up to 8 carbon atoms, up to 6 carbon atoms, up to 5
carbon atoms, or up to 4 carbon atoms. Cyclic groups can be
monocyclic or polycyclic and preferably have from 3 to 10 ring
carbon atoms. Exemplary cyclic groups include cyclopropyl,
cyclopropylmethyl, cyclopentyl, cyclohexyl, adamantyl, and
substituted and unsubstituted bornyl, norbornyl, and
norbornenyl.
Unless otherwise specified, "alkylene," "alkenylene," and
"alkynylene" are the divalent forms of the "alkyl," "alkenyl," and
"alkynyl" groups defined above. Likewise, "alkylenyl,"
"alkenylenyl," and "alkynylenyl" are the divalent forms of the
"alkyl," "alkenyl," and "alkynyl" groups defined above. For
example, an arylalkylenyl group comprises an alkylene moiety to
which an aryl group is attached.
The term "haloalkyl" is inclusive of groups that are substituted by
one or more halogen atoms, including perfluorinated groups. This is
also true of other groups that include the prefix "halo-". Examples
of suitable haloalkyl groups are chloromethyl, trifluoromethyl, and
the like.
The term "aryl" as used herein includes carbocyclic aromatic rings
or ring systems. Examples of aryl groups include phenyl, naphthyl,
biphenyl, fluorenyl and indenyl.
The term "heteroatom" refers to the atoms O, S, or N.
The term "heteroaryl" includes aromatic rings or ring systems that
contain at least one ring heteroatom (e.g., O, S, N). In some
embodiments, the term "heteroaryl" includes a ring or ring system
that contains 2 to 12 carbon atoms, 1 to 3 rings, 1 to 4
heteroatoms, and O, S, and/or N as the heteroatoms. Suitable
heteroaryl groups include furyl, thienyl, pyridyl, quinolinyl,
isoquinolinyl, indolyl, isoindolyl, triazolyl, pyrrolyl,
tetrazolyl, imidazolyl, pyrazolyl, oxazolyl, thiazolyl,
benzofuranyl, benzothiophenyl, carbazolyl, benzoxazolyl,
pyrimidinyl, benzimidazolyl, quinoxalinyl, benzothiazolyl,
naphthyridinyl, isoxazolyl, isothiazolyl, purinyl, quinazolinyl,
pyrazinyl, 1-oxidopyridyl, pyridazinyl, triazinyl, tetrazinyl,
oxadiazolyl, thiadiazolyl, and so on.
The term "heterocyclyl" includes non-aromatic rings or ring systems
that contain at least one ring heteroatom (e.g., O, S, N) and
includes all of the fully saturated and partially unsaturated
derivatives of the above mentioned heteroaryl groups. In some
embodiments, the term "heterocyclyl" includes a ring or ring system
that contains 2 to 12 carbon atoms, 1 to 3 rings, 1 to 4
heteroatoms, and O, S, and N as the heteroatoms. Exemplary
heterocyclic groups include pyrrolidinyl, tetrahydrofuranyl,
morpholinyl, thiomorpholinyl, 1,1-dioxothiomorpholinyl,
piperidinyl, piperazinyl, thiazolidinyl, imidazolidinyl,
isothiazolidinyl, tetrahydropyranyl, quinuclidinyl, homopiperidinyl
(azepanyl), 1,4-oxazepanyl, homopiperazinyl (diazepanyl),
1,3-dioxolanyl, aziridinyl, azetidinyl, dihydroisoquinolin-(1H)-yl,
octahydroisoquinolin-(1H)-yl, dihydroquinolin-(2H)-yl,
octahydroquinolin-(2H)-yl, dihydro-1H-imidazolyl,
3-azabicyclo[3.2.2]non-3-yl, and the like.
The term "heterocyclyl" includes bicylic and tricyclic heterocyclic
ring systems. Such ring systems include fused and/or bridged rings
and spiro rings. Fused rings can include, in addition to a
saturated or partially saturated ring, an aromatic ring, for
example, a benzene ring. Spiro rings include two rings joined by
one spiro atom and three rings joined by two spiro atoms.
When "heterocyclyl" contains a nitrogen atom, the point of
attachment of the heterocyclyl group may be the nitrogen atom.
The terms "arylene," "heteroarylene," and "heterocyclylene" are the
divalent forms of the "aryl," "heteroaryl," and "heterocyclyl"
groups defined above. Likewise, "arylenyl," "heteroarylenyl," and
"heterocyclylenyl" are the divalent forms of the "aryl,"
"heteroaryl," and "heterocyclyl" groups defined above. For example,
an alkylarylenyl group comprises an arylene moiety to which an
alkyl group is attached.
The term "fused aryl ring" includes fused carbocyclic aromatic
rings or ring systems. Examples of fused aryl rings include benzo,
naphtho, fluoreno, and indeno.
The term "fused heteroaryl ring" includes the fused forms of 5 or 6
membered aromatic rings that contain one heteroatom selected from S
and N.
The term "fused 5 to 7 membered saturated ring" includes rings
which are fully saturated except for the bond where the ring is
fused.
When a group (or substituent or variable) is present more than once
in any Formula described herein, each group (or substituent or
variable) is independently selected, whether explicitly stated or
not. For example, for the formula --N(R.sub.9).sub.2 each R.sub.9
group is independently selected. In another example, when an R' and
an A' group both contain an R.sub.4 group, each R.sub.4 group is
independently selected.
The invention is inclusive of the compounds described herein in any
of their pharmaceutically acceptable forms, including isomers
(e.g., diastereomers and enantiomers), salts, solvates, polymorphs,
prodrugs, and the like. In particular, if a compound is optically
active, the invention specifically includes each of the compound's
enantiomers as well as racemic mixtures of the enantiomers. It
should be understood that the term "compound" includes any or all
of such forms, whether explicitly stated or not (although at times,
"salts" are explicitly stated).
The term "prodrug" means a compound that can be transformed in vivo
to yield an immune response modifying compound in any of the salt,
solvated, polymorphic, or isomeric forms described above. The
prodrug, itself, may be an immune response modifying compound in
any of the salt, solvated, polymorphic, or isomeric forms described
above. The transformation may occur by various mechanisms, such as
through a chemical (e.g., solvolysis or hydrolysis, for example, in
the blood) or enzymatic biotransformation. A discussion of the use
of prodrugs is provided by T. Higuchi and W. Stella, "Pro-drugs as
Novel Delivery Systems," Vol. 14 of the A. C. S. Symposium Series,
and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche,
American Pharmaceutical Association and Pergamon Press, 1987.
Preparation of the Compounds
Compounds of the invention may be synthesized by synthetic routes
that include processes analogous to those well known in the
chemical arts, particularly in light of the description contained
herein. The starting materials are generally available from
commercial sources such as Aldrich Chemicals (Milwaukee, Wis., USA)
or are readily prepared using methods well known to those skilled
in the art (e.g., prepared by methods generally described in Louis
F. Fieser and Mary Fieser, Reagents for Organic Synthesis, v. 1-19,
Wiley, N.Y., (1967-1999 ed.); Alan R. Katritsky, Otto Meth-Cohn,
Charles W. Rees, Comprehensive Organic Functional Group
Transformations, v 1-6, Pergamon Press, Oxford, England, (1995);
Barry M. Trost and Ian Fleming, Comprehensive Organic Synthesis, v.
1-8, Pergamon Press, Oxford, England, (1991); or Beilsteins
Handbuch der organischen Chemie, 4, Aufl. Ed. Springer-Verlag,
Berlin, Germany, including supplements (also available via the
Beilstein online database)).
For illustrative purposes, the reaction schemes depicted below
provide potential routes for synthesizing the compounds of the
present invention as well as key intermediates. For more detailed
description of the individual reaction steps, see the EXAMPLES
section below. Those skilled in the art will appreciate that other
synthetic routes may be used to synthesize the compounds of the
invention. Although specific starting materials and reagents are
depicted in the reaction schemes and discussed below, other
starting materials and reagents can be easily substituted to
provide a variety of derivatives and/or reaction conditions. In
addition, many of the compounds prepared by the methods described
below can be further modified in light of this disclosure using
conventional methods well known to those skilled in the art.
In the preparation of compounds of the invention it may sometimes
be necessary to protect a particular functionality while reacting
other functional groups on an intermediate. The need for such
protection will vary depending on the nature of the particular
functional group and the conditions of the reaction step. Suitable
amino protecting groups include acetyl, trifluoroacetyl,
tert-butoxycarbonyl (Boc), benzyloxycarbonyl, and
9-fluorenylmethoxycarbonyl (Fmoc). Suitable hydroxy protecting
groups include acetyl and silyl groups such as the
tert-butyldimethylsilyl group. For a general description of
protecting groups and their use, see T. W. Greene and P. G. M.
Wuts, Protective Groups in Organic Synthesis, John Wiley &
Sons, New York, USA, 1991.
Conventional methods and techniques of separation and purification
can be used to isolate compounds of the invention, as well as
various intermediates related thereto. Such techniques may include,
for example, all types of chromatography (high performance liquid
chromatography (HPLC), column chromatography using common
absorbents such as silica gel, and thin layer chromatography),
recrystallization, and differential (i.e., liquid-liquid)
extraction techniques.
Compounds of the Formula II where R, R', R.sub.2, n, m, and Z are
as defined above can be prepared starting from
2,4-dichloro-3-nitroquinoline XV as shown in Reaction Scheme I. The
route shown in Reaction Scheme I is especially useful when Z, R',
and R.sub.2 contain functional groups that are easily oxidized by
reagents used in step (4) of Reaction Scheme II. Easily oxidizable
groups include --S--, heteroaryl groups, and amines. In step (1) of
Reaction Scheme I, a 2,4-dichloro-3-nitroquinoline of Formula XV is
reacted with an amine of the Formula XVI or hydrochloride salt
thereof to form a compound of Formula XVII. This reaction is
carried out by adding a compound of Formula XVI or a salt thereof
to a solution of 2,4-dichloro-3-nitroquinoline of Formula XV in the
presence of a base such as triethylamine. The reaction is carried
out in a suitable solvent, such as dichloromethane or chloroform.
Amines of the Formula XVI and hydrochloride salts thereof can be
obtained commercially or prepared according to published procedures
or modified versions thereof, and according to Schemes III-V and
XI. Compounds of Formula XV are known or can be prepared using
known synthetic methods, see for example, U.S. Pat. No. 4,988,815
and the documents cited therein.
The resultant compound of Formula XVII is reduced in step (2) of
Reaction Scheme I to provide a quinoline-3,4-diamine of Formula
XVIII. The reaction can be carried out by hydrogenation using a
heterogeneous hydrogenation catalyst such as platinum on carbon or
palladium on carbon. The hydrogenation is conveniently carried out
in a Parr apparatus in a suitable solvent such as acetonitrile,
ethyl acetate, or ethanol. The reaction can be carried out at
ambient temperature, and the product can be isolated using
conventional methods.
Alternatively step (2) can be carried out using a one- or two-phase
sodium dithionite reduction. The reaction is conveniently carried
out using the conditions described by K. K. Park et al., W. K.;
Tetrahedron Lett., 34, 7445-7446 (1993) by adding sodium dithionite
to a compound of Formula XVII in a mixture of dichloromethane and
water at ambient temperature in the presence of potassium carbonate
and ethyl viologen dibromide, ethyl viologen diiodide, or
1,1'-di-n-octyl-4,4'-bipyridinium dibromide. The product can be
isolated using conventional methods.
In step (3) of Reaction Scheme I, a quinoline-3,4-diamine of
Formula XVIII is treated with a carboxylic acid equivalent to
provide a 1H-imidazo[4,5-c]quinoline of Formula XIX. Suitable
carboxylic acid equivalents include orthoesters of Formula
R.sub.2C(O-alkyl).sub.3, 1,1-dialkoxyalkyl alkanoates of Formula
R.sub.2C(O-alkyl).sub.2(O--C(O)-alkyl), and acid chlorides of
Formula R.sub.2C(O)Cl. The selection of the carboxylic acid
equivalent is determined by the desired substituent at R.sub.2. For
example, ethoxyacetyl chloride will provide a compound where
R.sub.2 is an ethoxymethyl group, and acetyl chloride will provide
a compound where R.sub.2 is a methyl group. Step (3) can be carried
out in two steps when an acid chloride of Formula R.sub.2C(O)Cl is
used as the carboxylic acid equivalent. The first step is
conveniently carried out by adding the acid chloride to a solution
of a quinoline-3,4-diamine of Formula XVIII in a suitable solvent
such as dichloromethane in the presence of a base such as
triethylamine, pyridine, or 4-dimethylaminopyridine to afford an
amide. Optionally, the reaction can be performed without a tertiary
amine. The reaction can be carried out starting at a sub-ambient
temperature, such as 0.degree. C., with warming to ambient
temperature or at ambient temperature. The amide product can be
isolated and optionally purified using conventional techniques
before it is heated and cyclized to provide a
1H-imidazo[4,5-c]quinoline of Formula XIX. The cyclization reaction
is conveniently carried out in a solvent such as ethanol or
methanol in the presence of a base such as triethylamine and may be
carried out at an elevated temperature, such as the reflux
temperature of the solvent. The 1H-imidazo[4,5-c]quinoline of
Formula XIX can be isolated using conventional methods.
Alternatively, step (3) can be carried out in one step when
orthoesters of Formula R.sub.2C(O-alkyl).sub.3 or 1,1-dialkoxyalkyl
alkanoates of Formula R.sub.2C(O-alkyl).sub.2(O--C(O)-alkyl) are
used. For example, triethyl orthoformate will provide a compound
where R.sub.2 is hydrogen, and trimethyl orthovalerate will provide
a compound where R.sub.2 is a butyl group. The reaction is
conveniently carried out by adding the carboxylic acid equivalent
to a quinoline-3,4-diamine of Formula XVIII in a suitable solvent
such as toluene. Optionally, catalytic pyridine hydrochloride or
pyridium p-toluenesulfonate can be added. The reaction is carried
out at an elevated temperature, such as at reflux.
In step (4) of Reaction Scheme I, a compound of Formula XIX is
reacted with ammonia in a suitable solvent at elevated temperature
and pressure. The product of Formula II or a pharmaceutically
acceptable salt thereof can be isolated by conventional
methods.
##STR00047##
Compounds of Formula IIa can be prepared according to Reaction
Scheme II, wherein R, n, and m are as defined above, and Z.sub.a
and R.sub.2a are subsets of Z and R.sub.2 as defined above that do
not include those substitutents that one skilled in the art would
recognize as being susceptible to the oxidation in step (4) or
incompatible with other functional groups present. Those
substitutents include --S--, heteroaryl groups, and alkyl amines.
One exception is that --S-- is included in the set of Z.sub.a and
is oxidized to a sulfone during step (4). Therefore, Z.sub.b is a
subset of Z that contains --S(O).sub.2-- and all of Z.sub.a except
for --S--. In step (1) of Reaction Scheme II, a
4-chloro-3-nitroquinoline of Formula XX is reacted with an amine of
the Formula XVIa or hydrochloride salt thereof to form a compound
of Formula XXI. Amines of the Formula XVIa and hydrochloride salts
thereof can be obtained commercially or prepared according to
published procedures or modified versions thereof, and according to
Schemes III-V. Many compounds of Formula XX are known or can be
prepared using known synthetic methods, see for example, U.S. Pat.
Nos. 4,689,338; 5,175,296; 5,367,076; and 5,389,640; and the
documents cited therein. Step (1) of Reaction Scheme II is carried
out as described for step (1) of Reaction Scheme I, as are steps
(2) and (3).
In step (4) of Reaction Scheme II, a 1H-imidazo[4,5-c]quinoline of
Formula XXIII is oxidized to provide a
1H-imidazo[4,5-c]quinoline-5N-oxide of Formula XXIV using a
conventional oxidizing agent capable of forming N-oxides. The
reaction is conveniently carried out by adding
3-chloroperoxybenzoic acid to a solution of a compound of Formula
XXIII in a solvent such as dichloromethane or chloroform. The
reaction can be carried out at ambient temperature, and the product
can be isolated using conventional methods.
In step (5) of Reaction Scheme II, a
1H-imidazo[4,5-c]quinoline-5N-oxide of Formula XXIV is aminated to
provide a 1H-imidazo[4,5-c]quinolin-4-amine of Formula IIa. Step
(5) can be carried out by the activation of an N-oxide of Formula
XXIV by conversion to an ester and then reacting the ester with an
aminating agent. Suitable activating agents include alkyl- or
arylsulfonyl chlorides such as benzenesulfonyl chloride,
methanesulfonyl chloride, or p-toluenesulfonyl chloride. Suitable
aminating agents include ammonia, in the form of ammonium
hydroxide, for example, and ammonium salts such as ammonium
carbonate, ammonium bicarbonate, and ammonium phosphate. The
reaction is conveniently carried out by adding ammonium hydroxide
to a solution of the N-oxide of Formula XXIV in a suitable solvent
such as dichloromethane or chloroform and then adding
p-toluenesulfonyl chloride. The reaction can be carried out at
ambient temperature. The product or pharmaceutically acceptable
salt thereof can be isolated using conventional methods.
Alternatively step (5) can be carried out by the reaction of a
1H-imidazo[4,5-c]quinoline-5N-oxide of Formula XXIV with
trichloroacetyl isocyanate followed by base-promoted hydrolysis of
the resulting intermediate to provide a
1H-imidazo[4,5-c]quinolin-4-amine of Formula IIa. The reaction is
conveniently carried out in two steps by (i) adding trichloroacetyl
isocyanate to a solution of the N-oxide of Formula XXIV in a
solvent such as dichloromethane and stirring at ambient temperature
to provide an amide intermediate which may be isolated. In step
(ii), a solution of the intermediate in methanol is treated with a
base such as sodium methoxide or ammonium hydroxide at ambient
temperature. The product or a pharmaceutically acceptable salt
thereof can be isolated using conventional methods.
Steps (4) and (5) of Reaction Scheme II may be carried out as a
one-pot procedure by adding 3-chloroperoxybenzoic acid to a
solution of a compound of Formula XXIII in a solvent such as
dichloromethane or chloroform and then adding ammonium hydroxide
and p-toluenesulfonyl chloride without isolating the N-oxide
compound of Formula XXIV. The product of Formula IIa or
pharmaceutically acceptable salt thereof can be isolated by
conventional methods.
##STR00048##
The amine of the Formula XVI where m is 1, R' is --OH, and Z is
--CH.sub.2CH.sub.2CH.sub.2-- can be obtained commercially as the
hydrochloride salt. Some amines of the Formula XVI can be prepared
according to published procedures or modified versions thereof. For
example, the amine of Formula XVI where m is 2, R' is --OH, and Z
is --CH.sub.2CH.sub.2CH.sub.2-- has been prepared previously by J.
Bicking et al., J. Med. Chem., 26, 342-348 (1983). The route
described by J. Bicking et al. may also be applied toward the
synthesis of many amines of Formula XVI where m is 2 and R' is
--OH. In a publication by I. L. Lysenko et al., Russ. J. Org.
Chem., 37, 1238-1243 (2001), the synthesis of the amine of Formula
XVI where m is 1, R' is --OH, and Z is a bond has been described.
The synthesis of the amine of Formula XVI where m is 3, R' is --OH,
and Z is a bond from butyrolactone has been published by A.
Esposito et al., J. Org. Chem., 65, 9245-9248 (2000). The method
described by A. Esposito et al. may be applied toward the synthesis
of amines of Formula XVI where m is 2, 4, and 5, R' is --OH, and Z
is a bond starting from the appropriate commercially available
lactones. Other amines of Formula XVI where R' is --OH may be
prepared according to Schemes III-V.
Amines of the Formula XVIb where Z is defined as above and
hydrochloride salts thereof can be prepared according to Reaction
Scheme III. In step (1) of Reaction Scheme III, a ketone of Formula
XXV can be treated with excess nitromethane in a suitable solvent
such as ethanol or methanol in the presence of a catalytic amount
of base such as sodium ethoxide or sodium hydroxide to provide a
compound of Formula XXVI. A wide variety of ketones of Formula XXV
can be obtained from commercial sources or can be synthesized using
known synthetic methods. The reaction can be carried out at ambient
temperature. The product of Formula XXVI can be isolated using
conventional methods.
Step (2) of Reaction Scheme III can be carried out by hydrogenation
using a heterogeneous hydrogenation catalyst such as palladium
hydroxide on carbon or palladium on carbon or Raney nickel. The
hydrogenation is conveniently carried out in a Parr apparatus in a
suitable solvent such as ethanol or methanol. The reaction can be
carried out at ambient temperature, and the product amino alcohol
of Formula XVIb can be isolated using conventional methods.
Alternatively, amino alcohols of Formula XVIb can be prepared by
treating a ketone of Formula XXV with a cyanide source, such as
trimethylsilylcyanide, in the presence of a catalytic amount of a
crown ether, such as 18-crown-6, and a catalytic amount of a
cyanide source, such as potassium cyanide. The intermediate
cyanohydrin is then reduced with a hydride reducing agent, such as
lithium aluminum hydride. The reduction may be carried out at a
sub-ambient temperature, such as 0.degree. C., in a suitable
solvent such as THF, and the amino alcohol of Formula XVIb can be
isolated by conventional methods.
##STR00049##
Reaction Scheme IV shows the synthesis of amines of Formula XVIc
where m' may equal 0-3, Z is defined as above, and TBS- is a
tert-butyldimethylsilyl group. In step (1), a ketone of Formula XXV
is treated with an organometallic reagent of the Formula
H.sub.2C.dbd.CH.sub.2(CH.sub.2).sub.m'M where M is MgCl, MgBr, MgI,
ZnBr, ZnI, or Li, or the product of such reagent with CeCl.sub.3.
The organometallic reagents are commercially available or can be
prepared from H.sub.2C.dbd.CH.sub.2(CH.sub.2).sup.m'X, where X is a
chloride or preferably a bromide or iodide. The reaction can be
carried out in an appropriate solvent such as tetrahydrofuran or
diethyl ether. The resulting tertiary alcohol of Formula XXVII can
be isolated using conventional methods.
In step (2) of Reaction Scheme IV, the newly formed tertiary
alcohol of Formula XXVII is protected as a tert-butyldimethylsilyl
(TBS) ether to yield the product of Formula XXVIII. The tertiary
alcohol of Formula XXVII can be reacted with
tert-butyldimethylsilyl chloride or tert-butyldimethylsilyl
triflate with a base such as pyridine, 2,6-lutidine, triethylamine,
or ethyldiisopropylamine in an appropriate solvent such as
acetonitrile or dichloromethane optionally with a catalytic amount
of dimethylaminopyridine. The resulting compound of Formula XXVIII
can be isolated using conventional methods.
In step (3) of Reaction Scheme IV, the terminal olefin of Formula
XXVIII undergoes hydroboration and subsequent oxidation to provide
a primary alcohol of Formula XXIX. The two step procedure is
carried out by first adding a reagent such as borane,
catecholborane or 9-borabicyclo(3.3.1)nonane with or without
(PPh.sub.3).sub.3RhCl present in an appropriate solvent such as
tetrahydrofuran to generate an alkyl borane intermediate. Sodium
hydroxide and an aqueous solution of hydrogen peroxide are added to
convert the intermediate to the product of Formula XXIX, which can
be isolated using conventional methods.
In step (4) of Reaction Scheme IV, the primary alcohol of Formula
XXIX is reacted with methanesulfonyl chloride to yield a compound
of Formula XXX. The reaction is conveniently carried out in a
solvent such as dichloromethane in the presence of a base such as
triethylamine. The reaction may be carried out starting at a
sub-ambient temperature, such as 0.degree. C., with warming to
ambient temperature. The resulting compound of Formula XXX can be
isolated using conventional methods.
In step (5) of Reaction Scheme IV, the compound of Formula XXX may
be reacted with sodium azide in a suitable solvent such as
dimethylformamide. The reaction may be carried out at ambient
temperature or at elevated temperature. The resulting compound of
Formula XXXI can be isolated using conventional methods.
In step (6) of Reaction Scheme IV, the tert-butyldimethylsilyl
(TBS) group is removed from the compound of Formula XXXI to
generate the alcohol in a compound of Formula XXXII. Typically, a
compound of Formula XXXI is treated with a fluoride source such as
tetrabutylammonium fluoride in a suitable solvent such as
tetrahydrofuran with or without acetic acid added. Alternatively,
hydrogen fluoride-pyridine may be used in a suitable solvent such
as tetrahydrofuran optionally with pyridine added to the reaction.
The reaction can be carried out at ambient temperature. The
resulting compound of Formula XXXII can be isolated using
conventional methods.
In step (7) of Reaction Scheme IV, a compound of Formula XXXII can
be reduced to provide a amino alcohol of Formula XVIc. The reaction
can be carried out by hydrogenation using a heterogeneous
hydrogenation catalyst such as palladium on carbon. The
hydrogenation is conveniently carried out in a Parr apparatus in a
suitable solvent such as ethanol. The reaction can be carried out
at ambient temperature, and the product of Formula XVIc where
R'.sub.a is --OH can be isolated using conventional methods.
In step (7a) of Reaction Scheme IV, an azide of Formula XXXI may be
reduced using the conditions described in step (7) of Reaction
Scheme IV to yield the corresponding amine of Formula XVIc where
R'.sub.a is --OTBS, which may be used in place of an amine of
Formula XVIa in Reaction Scheme II. Subsequent removal of the
tert-butyldimethylsilyl protecting group after completion of step
(4) of Reaction Scheme II using aqueous hydrogen chloride in a
suitable solvent such as methanol or using the conditions described
for step (6) in Reaction Scheme IV ultimately provides a compound
of Formula XXIII, which can be converted to a compound of Formula
IIa.
##STR00050##
Reaction Scheme V shows a general synthesis of amines of Formula
XVId where m equals 1-5 and Bz is a benzyl group. Compounds of the
Formula XXXIII are used as the starting material and can be
obtained from commercial sources or can be readily synthesized as
described by R. K. Olsen et al., J. Org. Chem., 47, 4605-4611
(1982), S. Kobayashi et al., Syn. Lett., 909-912 (1999), and C. F.
Garcia et al., J. Chem. Soc. Chem. Commun., 12, 1465-1466 (1996).
In step (1) of Reaction Scheme V, a cyclopropane of Formula XXXIV
is formed upon treatment of the starting material of Formula XXXIII
with ethylmagnesium bromide in the presence of titanium(IV)
isopropoxide in a suitable solvent such as tetrahydrofuran at
sub-ambient temperature. The product of Formula XXXIV can be
isolated using conventional methods.
In step (2) of reaction Scheme V, a compound of Formula XVId is
prepared by the reduction of compound of Formula XXXIV. The
reaction can be carried out by hydrogenation using a heterogeneous
hydrogenation catalyst such as palladium on carbon. The
hydrogenation is conveniently carried out in a Parr apparatus using
a suitable solvent such as ethanol, methanol, or ethyl acetate. The
reaction can be performed at ambient temperature, and the product
of Formula XVId can be isolated using conventional methods.
##STR00051##
Functional group transformations in a compound of Formula XXIII are
possible using known synthetic methods. For example, as shown in
step (1) of Reaction Scheme VI, a compound of Formula XXIII where
Z.sub.a=--(CH.sub.2).sub.0-3--NBoc-(CH.sub.2).sub.0-3-- (Boc is
defined as tert-butyloxycarbonyl) can be treated with acid to
remove the Boc group to yield an amine of Formula XXXV. In step (2)
of Reaction Scheme VI, an amine of Formula XXXV can react with an
acid chloride of Formula R.sub.4C(O)Cl, an alkyl chloroformate of
Formula R.sub.4OC(O)Cl, a sulfonyl chloride of Formula
R.sub.4S(O).sub.2Cl, a sulfonic anydride of Formula
(R.sub.4S(O).sub.2).sub.2O, or an acid anhydride of the Formula
(R.sub.4C(O)).sub.2O to provide compound of Formula XXIII in which
Z.sub.a is --CH.sub.2-A'-CH.sub.2-- and A' is --N(Q-R.sub.4) where
R.sub.4 is defined as above and Q is --C(O)--, --C(O)O--,
--S(O).sub.2--. Numerous acid chlorides, alkyl chloroformates,
sulfonyl chlorides, and sulfonic anhydrides are commercially
available; others can be prepared readily using known synthetic
methods. The reaction can be conveniently carried out by adding the
acid chloride, alkyl chloroformate, sulfonyl chloride, sulfonic
anhydride, or acid anhydride to a solution of amine of Formula XXXV
in a suitable solvent such as pyridine. The reaction can be carried
out at ambient temperature and the product can be isolated using
conventional methods. In step (3) of Reaction Scheme VI, the
tertiary hydroxy group of a 1H-imidazo[4,5-c]quinoline of Formula
XXIII can be alkylated to produce an ether of Formula XXXVI. The
reaction is conventionally carried out in a suitable solvent such
as tetrahydrofuran using a base such as sodium hydride or potassium
hydride to first deprotonate the alcohol, followed by addition of
an alkyl iodide or alkyl triflate. The reaction can be carried out
at elevated temperature. Alternatively, the hydroxy group can be
reacted with methyl vinyl sulfone after treatment with a
sub-stoichiometric amount of sodium hydride in a suitable solvent
such as tetrahydrofuran at ambient temperature. The product of
Formula XXXVI can be isolated using conventional methods. Steps (4)
and (5) can be carried out as described for steps (4) and (5) of
Reaction Scheme II to provide a compound of Formula IIb.
##STR00052##
For some embodiments, compounds shown in Reaction Schemes I and II
can be further elaborated using conventional synthetic methods. For
example, as shown in Scheme VII, a compound of Formula IIa, where Z
is --(CH.sub.2).sub.0-3--NBoc-(CH.sub.2).sub.0-3-- and Boc is
defined as tert-butyloxycarbonyl, can undergo acid mediated
cleavage of the Boc group in step (1) to give a secondary amine
that can be functionalized in step (2) with an acid chloride of
Formula R.sub.4C(O)Cl, an alkyl chloroformate of Formula
R.sub.4OC(O)Cl, a sulfonyl chloride of Formula R.sub.4S(O).sub.2Cl,
a sulfonic anydride of Formula (R.sub.4S(O).sub.2).sub.2O, an
isocyanate of formula R.sub.4NCO, or an isothiocyanate of formula
R.sub.4NCS to provide a compound of Formula IId in which Z is
--(CH.sub.2).sub.0-3-A'-(CH.sub.2).sub.0-3-- and A' is
--N(Q-R.sub.4) where R.sub.4 is defined as above and Q is --C(O)--,
--C(O)O--, --S(O).sub.2--, --C(O)NH--, or --C(S)NH--.
Alternatively, a compound of Formula XXIII in Reaction Scheme II,
where Z.sub.a=--(CH.sub.2).sub.0-3--NBoc-(CH.sub.2).sub.0-3-- for
example, can be treated with acid to remove the Boc group. The
resulting amine can react further with an acid chloride of Formula
R.sub.4C(O)Cl, an alkyl chloroformate of Formula R.sub.4OC(O)Cl, a
sulfonyl chloride of Formula R.sub.4S(O).sub.2Cl, a sulfonic
anydride of Formula (R.sub.4S(O).sub.2).sub.2O, or an isocyanate of
formula R.sub.4NCO before step (4) of Reaction Scheme II. The
product can then be treated according to steps (4) and (5) of
Reaction Scheme II to provide compound of Formula IId in which Z is
--(CH.sub.2).sub.0-3-A'-(CH.sub.2).sub.0-3-- and A' is
--N(Q-R.sub.4) where R.sub.4 is defined as above and Q is --C(O)--,
--C(O)O--, --S(O).sub.2--, or --C(O)NH--. Numerous acid chlorides,
alkyl chloroformates, sulfonyl chlorides, sulfonic anhydrides,
isocyanates, and isothiocyanates are commercially available; others
can be prepared readily using known synthetic methods. The reaction
can be conveniently carried out by adding the acid chloride, alkyl
chloroformate, sulfonyl chloride, sulfonic anhydride, isocyanate,
or isothiocyanate to a solution of amine of Formula IIc or XXIII,
in which Z or Z.sub.a contains a secondary amine in a suitable
solvent such as pyridine. The reaction can be carried out at
ambient temperature.
In addition, a compound of Formula IIc in Reaction Scheme VII can
undergo alkylation of the secondary amine. In step (3) the compound
of Formula IIc may react with aldehydes, alkyl halides or triflates
to provide a compound Formula IIe in which R.sub.8 is defined as
above. For example, treatment of a compound of Formula IIc with
aqueous formaldehyde and a reducing agent such as sodium
cyanoborohydride in an appropriate solvent such as methanol yields
a compound of Formula IIe, where R.sub.8 is a methyl group.
##STR00053##
Compounds of the invention of Formula IIf and IIg can be prepared
according to Reaction Scheme VIII, wherein R, n, Z.sub.a, Z.sub.b,
and R.sub.2a are defined as above. In step (1) of Reaction Scheme
VIII, a 4-chloro-3-nitroquinoline of Formula XX is reacted with an
amine of the Formula XVIe or a salt thereof to form a compound of
Formula XXXVIII. This reaction is carried out as described for step
(1) in Reaction Scheme I. Amines of the Formula XVIe and salts
thereof can be prepared according to published procedures or
modified versions thereof, or by using conventional synthetic
methods. For example, the synthesis of amines of the Formula XVI
where m is one, R'.dbd.NH.sub.2 and Z is --(CH.sub.2).sub.2-4--,
and --CH.sub.2(NCH.sub.3)CH.sub.2-- has been published by M. A.
Fernandez et al., Anales de la Real Academia de Farmacia, 54,
502-510 (1988). The starting materials used by M. A. Fernandez et
al. were ketones of Formula XXV. A wide variety of ketones of
Formula XXV can be obtained from commercial sources or can be
synthesized. Those ketones of Formula XXV may be used in the
synthesis of amines of Formula XVI where m is one, R'.dbd.NH.sub.2
and Z is as described above. Similar chemistry to that published by
Fernandez et al. that is also relevant has been published by S. L.
Deng et al., Synthesis, 2445-2449 (2001), A. A. Cordi et al., J.
Med. Chem., 44, 787-805 (2001), and M. Freifelder et al., J. Amer.
Chem. Soc., 82, 696-698 (1960). In addition, the amine of Formula
XVIe wherein m is one and Z.sub.a is a bond has been synthesized
previously by F. Vergne et al., J. Org. Chem., 57, 6071-6075
(1992). Many compounds of Formula XX are known or can be prepared
using known synthetic methods, see for example, U.S. Pat. Nos.
4,689,338; 5,175,296; 5,367,076; and 5,389,640; and the documents
cited therein.
In step (2) of Reaction Scheme VIII, the primary amine in a
compound of Formula XXXVIII is converted into a tert-butyl
carbamate to provide a compound of Formula XXXIX. The reaction is
conveniently carried out using di-tert-butyldicarbonate in the
presence of a base such as aqueous sodium hydroxide in a solvent
such as tetrahydrofuran. The compound of Formula XXXIX can be
isolated using conventional methods.
Steps (3), (4), (5), and (6) of Reaction Scheme VIII can be carried
out as described for steps (2), (3), (4), and (5), respectively, of
Reaction Scheme II to provide a compound of Formula IIf.
In step (7) of Reaction Scheme VIII, the tert-butyl carbamate in a
compound of Formula IIf is converted to a primary amine of Formula
IIg. The reaction is conveniently performed in the presence of an
acid such as hydrogen chloride in a suitable solvent such as
ethanol. The reaction is performed at elevated temperature and the
product of Formula IIg or a pharmaceutically acceptable salt
thereof is isolated using conventional methods.
##STR00054##
For some embodiments, compounds shown in Reaction Scheme VIII can
be further elaborated using conventional synthetic methods. For
example, as shown in Scheme IX, a compound of Formula XLI can
undergo acid mediated cleavage of the Boc group in step (1) to give
a primary amine of Formula XLIII that can be functionalized with
the reagents described in step (2) of Reaction Scheme VII to
provide a compound of Formula XLIV in which where R.sub.4 is
defined as above and Q is --C(O)--, --C(O)O--, --S(O).sub.2--,
--C(O)NH--, or --C(S)NH--. The reaction can be carried out in an
appropriate solvent such as dichloromethane in the presence of a
tertiary amine such as triethylamine, or can be performed in
pyridine. Optionally, dimethylaminopyridine may be used in the
reaction. The reaction is carried out at ambient temperature. Steps
(3) and (4) of Reaction Scheme IX can be carried out as described
for steps (4) and (5) in Reaction Scheme II to yield a compound of
Formula IIh. If Z.sub.b in a compound of Formula IIh contains an
appropriately protected amine, deprotection will provide a free
amine that may be functionalized with the reagents described in
step (2) of Reaction Scheme VII.
##STR00055##
Compounds of the Formula IIi can be prepared according to Reaction
Scheme X, wherein R, n, and m are as defined above, and Z.sub.a,
Z.sub.b and R.sub.2a are subsets of Z and R.sub.2 as defined above.
In step (1) of Reaction Scheme X, 4-chloro-3-nitroquinoline of
Formula XX is reacted with an amine of the Formula XVIf or
hydrochloride salt thereof to form a compound of Formula XLV. Step
(1) of Reaction Scheme X is carried out as described for step (1)
in Reaction Scheme II. Steps (2), (3), (4), and (5) of Reaction
Scheme X can be carried out as described for steps (2), (3), (4),
and (5), respectively, of Reaction Scheme II to provide a compound
of Formula IIi or a pharmaceutically active salt thereof
##STR00056##
Some amines of the Formula XVIf and hydrochloride salts thereof can
be prepared according to Reaction Scheme XI and by conventional
synthetic methods. In step (1) of Reaction Scheme XI, a ketone of
Formula XXV is treated nitromethane and an alkyl thiol in the
presence of a base in an appropriate solvent by modifying the
procedure of W. W. Lin et al., J. Org. Chem., 66, 1984-1991 (2001)
to yield a compound of Formula XLIX.
In step (2) of Reaction Scheme XI, a compound of Formula XLIX is
reduced using lithium aluminum hydride or hydrogenated using a
heterogeneous hydrogenation catalyst palladium on carbon. The
product of Formula XVIf or salt thereof can be isolated using
conventional methods.
Compounds of Formula II where R' is a sulfide and R, R.sub.2, n, m,
and Z are as defined above can be prepared according to the route
shown in Reaction Scheme I using an amine of Formula XVIf as the
starting material.
##STR00057##
As shown in Reaction Scheme XII, an 1H-imidazo[4,5-c]quinoline of
Formula IIj can be reduced to a
6,7,8,9-tetrahydro-1H-imidazo[4,5-d]quinolin-4-amine of Formula
IIIa where Z and R' are as defined above and R.sub.2b and R.sub.b
are subsets of R.sub.2 and R as defined above that do not include
substituents that one skilled in the art would recognize as being
susceptible to reduction under the acidic hydrogenation conditions
of step (1). Those susceptible groups include, for example,
alkenyl, alkynyl, aryl groups, and groups bearing nitro
substituents. The reaction is conveniently carried out under
heterogeneous hydrogenation conditions by adding platinum (IV)
oxide to a solution of the compound of Formula IIj in
trifluoroacetic acid and placing the reaction under hydrogen
pressure. The reaction can be carried out on a Parr apparatus at
ambient temperature. The product or pharmaceutically acceptable
salt thereof can be isolated by conventional methods.
##STR00058##
For some embodiments, compounds of the invention are prepared
according to Reaction Scheme XIII, where Z, R', R.sub.2, R.sub.A,
and R.sub.B are as defined above. In step (1) of Reaction Scheme
XIII, a 2,4-dichloro-3-nitropyridine of Formula LI is reacted with
an amine of Formula XVI or a hydrochloride salt thereof to form a
2-chloro-3-nitropyridine of Formula LII. The reaction is
conveniently carried out by combining an amine of Formula XVI or a
hydrochloride salt thereof and 2,4-dichloro-3-nitropyridine of
Formula LI in the presence of a base such as triethylamine in a
solvent such as N,N-dimethylformamide (DMF). The reaction can be
carried out at ambient temperature or above, and the product can be
isolated from the reaction mixture using conventional methods. Many
2,4-dichloro-3-nitropyridines of Formula LI are known and can be
readily prepared using known synthetic methods. (See, for example,
U.S. Pat. No. 6,525,064(Dellaria et al.) and the references cited
therein.)
In step (2) of Reaction Scheme XIII, a 2-chloro-3-nitropyridine of
Formula LII is reacted with dibenzylamine to provide a compound of
Formula LIII. The reaction can be carried out by combining the
compound of Formula LII with dibenzylamine and a tertiary amine
such as triethylamine in a suitable solvent such as toluene. The
reaction can be carried out at elevated temperature and the product
of Formula LIII is isolated from the reaction mixture using
conventional methods.
In step (3) of Reaction Scheme XIII, a compound of formula LIII is
reduced to provide a compound of Formula LIV. The reduction can be
carried out by hydrogenation using a conventional heterogeneous
catalyst, for example, platinum on carbon or palladium on carbon.
The reaction can conveniently be carried out on a Parr apparatus in
a suitable solvent such as acetonitrile or ethyl acetate. The
product of Formula LIV can be isolated from the reaction mixture
using conventional methods.
In step (4) of reaction Scheme XIII, a compound of Formula LIV is
reacted with a carboxylic acid equivalent to provide a compound of
Formula LV. The reaction can be carried out as described in step
(3) of Reaction Scheme I, and the product can be isolated from the
reaction mixture using conventional methods.
A compound of Formula LV may also be prepared by subjecting a
compound of Formula LII to the reaction conditions in described in
steps (3) and (4) to provide a 4-chloroimidazopyridine which may
then be treated with dibenzylamine in a microwave to provide a
compound of Formula LV.
In step (5) of reaction Scheme XIII, the benzyl groups of a
compound of Formula LV are cleaved to provide a compound of Formula
III. The reaction can be carried out by transfer hydrogenation in
the presence of a suitable hydrogenation catalyst. The transfer
hydrogenation is conveniently carried out by adding ammonium
formate to a solution of a compound of Formula LV in a suitable
solvent such as ethanol or methanol in the presence of a catalyst
such as palladium on carbon. The reaction is carried out at an
elevated temperature, for example, the reflux temperature of the
solvent. The product of Formula III or pharmaceutically acceptable
salt thereof can be isolated using conventional methods.
##STR00059##
Compounds of the invention can be prepared according to Reaction
Scheme XIV, wherein R, Z.sub.a, Z.sub.b, R.sub.2a and m are as
defined above. Reaction Scheme XIV begins with a
4-chloro-3-nitro[1,5]naphthyridine of Formula LVI. Compounds of
Formula LVI and their preparation are known; see, for example, U.S.
Pat. Nos. 6,194,425 (Gerster) and 6,518,280 (Gerster). Steps (1)
through (5) of Reaction Scheme XIV can be carried out as described
for the corresponding steps (1) through (5) of Reaction Scheme II
to provide a substituted 1H-imidazo[4,5-c]-1,5-naphthyridin-4-amine
of Formula IVa. The product or pharmaceutically acceptable salt
thereof can be isolated by conventional methods.
##STR00060##
For some embodiments, naphthyridines of the invention are prepared
from tetrazolo compounds of Formulas LVIII and LXI according to
Reaction Scheme XV, wherein R, R', R.sub.2, m, and Z are as defined
above and --OTf is a trifluoromethanesulfonate group. Compounds of
Formula LVIII and LXI and synthetic routes to these compounds are
known; see, for example, U.S. Pat. Nos. 6,194,425 (Gerster) and
6,518,280 (Gerster).
In steps (1) and (1a) of Reaction Scheme XV, a
tetrazolonaphthyridine of Formula LVIII or LXI is reacted with an
amine of Formula XVI or a hydrochloride salt thereof to form a
compound of Formula LIX or LXII. The reaction can be carried out as
described in step (1) of Reaction Scheme I. A compound of Formula
LIX or LXII is converted to a compound of Formula LX or LXIII
according to the methods of steps (2) and (3) of Reaction Scheme I.
The tetrazolo group of a compound of Formula LX or LXIII can then
be removed to provide a 1H-imidazo[4,5-c]naphthyridin-4-amine of
Formula VII or VIII. The removal of the tetrazolo group can be
carried out by methods described in U.S. Pat. Nos. 6,194,425
(Gerster) and 6,518,280 (Gerster). The product or pharmaceutically
acceptable salt thereof can be isolated by conventional
methods.
##STR00061## ##STR00062##
Compounds of the invention can also be prepared using variations of
the synthetic routes shown in Reaction Schemes I through XV. For
example, tetrahydronapthyridines can be prepared using the method
described in Reaction Scheme XII for the preparation of
tetrahydroquinolines. Compounds of the invention can also be
prepared using the synthetic routes described in the EXAMPLES
below.
Prodrugs can be prepared in a variety of ways. For example, a
compound wherein R.sub.2 is --X--OH can be converted into a prodrug
wherein R.sub.2 is, for example, --X--O--C(R.sub.6)--R.sub.4,
--X--O--C(R.sub.6)--O--R.sub.4, or
--X--O--C(R.sub.6)--N(R.sub.8)--R.sub.4, wherein R.sub.4, R.sub.6,
and R.sub.8 are as defined above, using methods known to one
skilled in the art. In addition, a compound wherein R' or R is
hydroxy may also be converted to an ester, an ether, a carbonate,
or a carbamate. For any of these compounds containing an alcohol
functional group, a prodrug can be formed by the replacement of the
hydrogen atom of the alcohol group with a group such as C.sub.1-6
alkanoyloxymethyl, 1-(C.sub.1-6 alkanoyloxy)ethyl,
1-methyl-1-(C.sub.1-6 alkanoyloxy)ethyl, C.sub.1-6
alkoxycarbonyloxymethyl, N--(C.sub.1-6 alkoxycarbonyl)aminomethyl,
succinoyl, C.sub.1-6 alkanoyl, .alpha.-aminoC.sub.1-4 alkanoyl,
arylacyl, --P(O)(OH).sub.2, --P(O)(O--C.sub.1-6 alkyl).sub.2,
C.sub.1-6 alkoxycarbonyl, C.sub.1-6 alkylcarbamoyl, and
.alpha.-aminoacyl or .alpha.-aminoacyl-.alpha.-aminoacyl, where
each .alpha.-aminoacyl group is independently selected from
racemic, D-, and L-amino acids. For compounds containing an alcohol
functional group, particularly useful prodrugs are esters made from
carboxylic acids containing one to six carbon atoms, unsubstituted
or substituted benzoic acid esters, or esters made from racemic,
D-, or L-amino acids.
Prodrugs can also be made from a compound containing an amino group
by conversion of the amino group to a functional group such as an
amide, carbamate, urea, amidine, or another hydrolysable group
using conventional methods. A prodrug of this type can be made by
the replacement of a hydrogen atom in an amino group, particularly
the amino group at the 4-position, with a group such as
--C(O)--R'', .alpha.-aminoacyl,
.alpha.-aminoacyl-.alpha.-aminoacyl, --C(O)--O--R'',
--C(O)--N(R''')--R'', --C(.dbd.NY')--R'', --CH(OH)--C(O)--OY',
--CH(OC.sub.1-4 alkyl)Y.sub.0, --CH.sub.2Y.sub.1, or
--CH(CH.sub.3)Y.sub.1; wherein R'' and R''' are each independently
C.sub.1-10 alkyl, C.sub.3-7 cycloalkyl, or benzyl, each of which
may be unsubstituted or substituted by one or more substituents
selected from the group consisting of halogen, hydroxy, nitro,
cyano, carboxy, C.sub.1-6 alkyl, C.sub.1-4 alkoxy, aryl,
heteroaryl, arylC.sub.1-4 alkylenyl, heteroarylC.sub.1-4 alkylenyl,
haloC.sub.1-4 alkylenyl, haloC.sub.1-4 alkoxy, --O--C(O)--CH.sub.3,
--C(O)--O--CH.sub.3, --C(O)--NH.sub.2,
--O--CH.sub.2--C(O)--NH.sub.2, --NH.sub.2, and
--S(O).sub.2--NH.sub.2, with the proviso that R''' can also be
hydrogen; each .alpha.-aminoacyl group is independently selected
from racemic, D-, and L-amino acids; Y' is hydrogen, C.sub.1-6
alkyl, or benzyl; Y.sub.0 is C.sub.1-6 alkyl, carboxyC.sub.1-6
alkylenyl, aminoC.sub.1-4 alkylenyl, mono-N--C.sub.1-6
alkylaminoC.sub.1-4 alkylenyl, or di-N,N--C.sub.1-6
alkylaminoC.sub.1-4 alkylenyl; and Y.sub.1 is mono-N--C.sub.1-6
alkylamino, di-N,N--C.sub.1-6 alkylamino, morpholin-4-yl,
piperidin-1-yl, pyrrolidin-1-yl, or 4-C.sub.1-4
alkylpiperazin-1-yl.
Pharmaceutical Compositions and Biological Activity
Pharmaceutical compositions of the invention contain a
therapeutically effective amount of a compound or salt of the
invention as described above in combination with a pharmaceutically
acceptable carrier.
The terms "a therapeutically effective amount" and "effective
amount" mean an amount of the compound or salt sufficient to induce
a therapeutic or prophylactic effect, such as cytokine induction,
immunomodulation, antitumor activity, and/or antiviral activity.
Although the exact amount of active compound or salt used in a
pharmaceutical composition of the invention will vary according to
factors known to those of skill in the art, such as the physical
and chemical nature of the compound or salt, the nature of the
carrier, and the intended dosing regimen, it is anticipated that
the compositions of the invention will contain sufficient active
ingredient to provide a dose of about 100 nanograms per kilogram
(ng/kg) to about 50 milligrams per kilogram (mg/kg), preferably
about 10 micrograms per kilogram (.mu.g/kg) to about 5 mg/kg, of
the compound or salt to the subject. A variety of dosage forms may
be used, such as tablets, lozenges, capsules, parenteral
formulations, syrups, creams, ointments, aerosol formulations,
transdermal patches, transmucosal patches and the like.
The compounds or salts of the invention can be administered as the
single therapeutic agent in the treatment regimen, or the compounds
or salts of the invention may be administered in combination with
one another or with other active agents, including additional
immune response modifiers, antivirals, antibiotics, antibodies,
proteins, peptides, oligonucleotides, etc.
Compounds or salts of the invention have been shown to induce the
production of certain cytokines in experiments performed according
to the test set forth below. These results indicate that the
compounds or salts are useful as immune response modifiers that can
modulate the immune response in a number of different ways,
rendering them useful in the treatment of a variety of
disorders.
Cytokines whose production may be induced by the administration of
compounds or salts of the invention generally include
interferon-.alpha. (IFN-.alpha.) and/or tumor necrosis
factor-.alpha. (TNF-.alpha.) as well as certain interleukins (IL).
Cytokines whose biosynthesis may be induced by compounds or salts
of the invention include IFN-.alpha., TNF-.alpha., IL-1, IL-6,
IL-10 and IL-12, and a variety of other cytokines. Among other
effects, these and other cytokines can inhibit virus production and
tumor cell growth, making the compounds or salts useful in the
treatment of viral diseases and neoplastic diseases. Accordingly,
the invention provides a method of inducing cytokine biosynthesis
in an animal comprising administering an effective amount of a
compound or salt or composition of the invention to the animal. The
animal to which the compound or salt or composition is administered
for induction of cytokine biosynthesis may have a disease as
described infra, for example a viral disease or a neoplastic
disease, and administration of the compound or salt may provide
therapeutic treatment. Alternatively, the compound or salt may be
administered to the animal prior to the animal acquiring the
disease so that administration of the compound or salt may provide
a prophylactic treatment.
In addition to the ability to induce the production of cytokines,
compounds or salts of the invention can affect other aspects of the
innate immune response. For example, natural killer cell activity
may be stimulated, an effect that may be due to cytokine induction.
The compounds or salts may also activate macrophages, which in turn
stimulate secretion of nitric oxide and the production of
additional cytokines. Further, the compounds or salts may cause
proliferation and differentiation of B-lymphocytes.
Compounds or salts of the invention can also have an effect on the
acquired immune response. For example, the production of the T
helper type 1 (T.sub.H1) cytokine IFN-.gamma. may be induced
indirectly and the production of the T helper type 2 (T.sub.H2)
cytokines IL-4, IL-5 and IL-13 may be inhibited upon administration
of the compounds or salts.
Whether for prophylaxis or therapeutic treatment of a disease, and
whether for effecting innate or acquired immunity, the compound or
salt or composition may be administered alone or in combination
with one or more active components as in, for example, a vaccine
adjuvant. When administered with other components, the compound or
salt and other component or components may be administered
separately; together but independently such as in a solution; or
together and associated with one another such as (a) covalently
linked or (b) non-covalently associated, e.g., in a colloidal
suspension.
Conditions for which compounds or salts identified herein may be
used as treatments include, but are not limited to:
(a) viral diseases such as, for example, diseases resulting from
infection by an adenovirus, a herpesvirus (e.g., HSV-I, HSV-II,
CMV, or VZV), a poxvirus (e.g., an orthopoxvirus such as variola or
vaccinia, or molluscum contagiosum), a picornavirus (e.g.,
rhinovirus or enterovirus), an orthomyxovirus (e.g.,
influenzavirus), a paramyxovirus (e.g., parainfluenzavirus, mumps
virus, measles virus, and respiratory syncytial virus (RSV)), a
coronavirus (e.g., SARS), a papovavirus (e.g., papillomaviruses,
such as those that cause genital warts, common warts, or plantar
warts), a hepadnavirus (e.g., hepatitis B virus), a flavivirus
(e.g., hepatitis C virus or Dengue virus), or a retrovirus (e.g., a
lentivirus such as HIV);
(b) bacterial diseases such as, for example, diseases resulting
from infection by bacteria of, for example, the genus Escherichia,
Enterobacter, Salmonella, Staphylococcus, Shigella, Listeria,
Aerobacter, Helicobacter, Klebsiella, Proteus, Pseudomonas,
Streptococcus, Chlamydia, Mycoplasma, Pneumococcus, Neisseria,
Clostridium, Bacillus, Corynebacterium, Mycobacterium,
Campylobacter, Vibrio, Serratia, Providencia, Chromobacterium,
Brucella, Yersinia, Haemophilus, or Bordetella;
(c) other infectious diseases, such chlamydia, fungal diseases
including but not limited to candidiasis, aspergillosis,
histoplasmosis, cryptococcal meningitis, or parasitic diseases
including but not limited to malaria, pneumocystis carnii
pneumonia, leishmaniasis, cryptosporidiosis, toxoplasmosis, and
trypanosome infection;
(d) neoplastic diseases, such as intraepithelial neoplasias,
cervical dysplasia, actinic keratosis, basal cell carcinoma,
squamous cell carcinoma, renal cell carcinoma, Kaposi's sarcoma,
melanoma, leukemias including but not limited to myelogeous
leukemia, chronic lymphocytic leukemia, multiple myeloma,
non-Hodgkin's lymphoma, cutaneous T-cell lymphoma, B-cell lymphoma,
and hairy cell leukemia, and other cancers;
(e) T.sub.H2-mediated, atopic diseases, such as atopic dermatitis
or eczema, eosinophilia, asthma, allergy, allergic rhinitis, and
Ommen's syndrome;
(f) certain autoimmune diseases such as systemic lupus
erythematosus, essential thrombocythaemia, multiple sclerosis,
discoid lupus, alopecia greata; and
(g) diseases associated with wound repair such as, for example,
inhibition of keloid formation and other types of scarring (e.g.,
enhancing wound healing, including chronic wounds).
Additionally, a compound or salt of the present invention may be
useful as a vaccine adjuvant for use in conjunction with any
material that raises either humoral and/or cell mediated immune
response, such as, for example, live viral, bacterial, or parasitic
immunogens; inactivated viral, tumor-derived, protozoal,
organism-derived, fungal, or bacterial immunogens; toxoids; toxins;
self-antigens; polysaccharides; proteins; glycoproteins; peptides;
cellular vaccines; DNA vaccines; autologous vaccines; recombinant
proteins; and the like, for use in connection with, for example,
BCG, cholera, plague, typhoid, hepatitis A, hepatitis B, hepatitis
C, influenza A, influenza B, parainfluenza, polio, rabies, measles,
mumps, rubella, yellow fever, tetanus, diphtheria, hemophilus
influenza b, tuberculosis, meningococcal and pneumococcal vaccines,
adenovirus, HIV, chicken pox, cytomegalovirus, dengue, feline
leukemia, fowl plague, HSV-1 and HSV-2, hog cholera, Japanese
encephalitis, respiratory syncytial virus, rotavirus, papilloma
virus, yellow fever, and Alzheimer's Disease.
Compounds or salts of the present invention may be particularly
helpful in individuals having compromised immune function. For
example, compounds or salts may be used for treating the
opportunistic infections and tumors that occur after suppression of
cell mediated immunity in, for example, transplant patients, cancer
patients and HIV patients.
Thus, one or more of the above diseases or types of diseases, for
example, a viral disease or a neoplastic disease may be treated in
an animal in need thereof (having the disease) by administering a
therapeutically effective amount of a compound or salt of the
invention to the animal.
An amount of a compound or salt effective to induce cytokine
biosynthesis is an amount sufficient to cause one or more cell
types, such as monocytes, macrophages, dendritic cells and B-cells
to produce an amount of one or more cytokines such as, for example,
IFN-.alpha., TNF-.alpha., IL-1, IL-6, IL-10 and IL-12 that is
increased (induced) over a background level of such cytokines. The
precise amount will vary according to factors known in the art but
is expected to be a dose of about 100 ng/kg to about 50 mg/kg,
preferably about 10 .mu.g/kg to about 5 mg/kg. The invention also
provides a method of treating a viral infection in an animal and a
method of treating a neoplastic disease in an animal comprising
administering an effective amount of a compound or salt or
composition of the invention to the animal. An amount effective to
treat or inhibit a viral infection is an amount that will cause a
reduction in one or more of the manifestations of viral infection,
such as viral lesions, viral load, rate of virus production, and
mortality as compared to untreated control animals. The precise
amount that is effective for such treatment will vary according to
factors known in the art but is expected to be a dose of about 100
ng/kg to about 50 mg/kg, preferably about 10 .mu.g/kg to about 5
mg/kg. An amount of a compound or salt effective to treat a
neoplastic condition is an amount that will cause a reduction in
tumor size or in the number of tumor foci. Again, the precise
amount will vary according to factors known in the art but is
expected to be a dose of about 100 ng/kg to about 50 mg/kg,
preferably about 10 .mu.g/kg to about 5 mg/kg.
In addition to the formulations and uses described specifically
herein, other formulations, uses, and administration devices
suitable for compounds of the present invention are described in,
for example, International Publication Nos. WO 03/077944 and WO
02/036592, U.S. Pat. No. 6,245,776, and U.S. Publication Nos.
2003/0139364, 2003/185835, 2004/0258698, 2004/0265351, 2004/076633,
and 2005/0009858.
EXAMPLES
Objects and advantages of this invention are further illustrated by
the following examples, but the particular materials and amounts
thereof recited in these examples, as well as other conditions and
details, should not be construed to unduly limit this
invention.
Example 1
1-{[4-Amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cyclohe-
xanol
##STR00063## Part A
To a mixture of 4-chloro-3-nitroquinoline (6.30 g, 30.2 mmol) in
dichloromethane (100 mL) at 0.degree. C. was added triethylamine
(0.1 mL). To the resulting solution was added
1-aminomethyl-1-cyclohexanol hydrochloride (5.00 g, 30.2 mmol),
then triethylamine (4.1 mL) and tetrahydrofuran (THF, 20 mL). The
mixture was allowed to warm to room temperature (rt) and more
triethylamine (4.2 mL) was added. The yellow mixture was stirred
overnight, then was concentrated to about half the volume and
heated at reflux for 1 hour (h). The mixture was concentrated and
the solid was partitioned between 1 M aqueous NaOH (100 mL) and
CH.sub.2Cl.sub.2 (200 mL). The organic layer was washed with water
(2.times.50 mL) and brine (50 mL), dried over MgSO.sub.4, filtered,
and concentrated to a yellow solid that was crystallized from hot
isopropanol to yield yellow crystals (9.04 g).
.sup.1H NMR analysis of the yellow crystals showed a 1:1.4 mixture
of isopropyl alcohol to
1-{[(3-nitroquinolin-4-yl)amino]methyl}cyclohexanol. Based on the
.sup.1H NMR result, the mass of the
1-{[(3-nitroquinolin-4-yl)amino]methyl}cyclohexanol in the mixture
was calculated (7.88 g, 87%). The product was used without further
purification in the next step.
Part B
A mixture of the
1-{[(3-nitroquinolin-4-yl)amino]methyl}cyclohexanol prepared above
(87%, 7.00 g, 20.3 mmol) and 5% platinum on carbon (0.60 g) in
toluene (160 mL) and ethanol (20 mL) was hydrogenated at 20-30 psi
(1.4.times.10.sup.5 to 2.1.times.10.sup.5 Pa) on a Parr apparatus
for 2 h. The mixture was filtered through CELITE filter agent,
which was rinsed with toluene. The filtrate was concentrated to a
golden oil. The oil was concentrated twice from toluene. To the oil
was added CH.sub.2Cl.sub.2 (200 mL) and the resulting solution was
cooled in an ice bath. Triethylamine (3.11 mL, 22.3 mmol) was added
followed by dropwise addition of ethoxyacetyl chloride (88%, 2.96
g, 21.3 mmol). The solution was allowed to warm to rt and stir for
1 h, during which time a precipitate formed. The reaction mixture
was concentrated to a yellow foam to which ethanol (200 mL) and
triethylamine (11 mL) were added. The resulting solution was heated
at reflux for 13 h. The solution was concentrated to a yellow
solid, which was dissolved in CH.sub.2Cl.sub.2 (150 mL) and washed
with water (50 mL) and brine (75 mL). The organic layer was dried
over MgSO.sub.4, filtered, and concentrated to a solid that was
crystallized from CDCl.sub.3/CH.sub.2Cl.sub.2 to yield
1-{[2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cyclohexanol
as pale orange crystals after drying (1.94 g, 28%).
Part C
To a solution of
1-{[2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cyclohexanol
(1.90 g, 5.60 mmol) in CHCl.sub.3 (43 mL) was added
m-chloroperoxybenzoic acid (m-CPBA, 77% w/w, 1.26 g, 5.60 mmol)
over 15 min. The reaction was monitored by thin layer
chromatography (TLC) and more m-CPBA was added over 1 h until the
starting material was consumed. Water (40 mL) and solid
K.sub.2CO.sub.3 were added to the reaction mixture until the pH=10.
The mixture was poured into a separatory funnel and extracted with
chloroform, resulting in an emulsion. The aqueous layer was
extracted with chloroform three times. The combined organic layers
were washed with water and brine, dried over MgSO.sub.4, filtered,
and concentrated to yield a crude white solid (1.51 g). The white
solid (1.51 g, 4.24 mmol) was dissolved in dichloromethane (25 mL)
at rt and concentrated ammonium hydroxide (16 mL) was added,
followed by p-toluenesulfonyl chloride (TsCl, 0.81 g, 4.24 mmol).
The mixture was stirred 1 day (d). Water (25 mL) was added and the
aqueous layer was extracted with dichloromethane (2.times.30 mL).
The combined organic layers were washed with brine (25 mL) and were
dried over MgSO.sub.4, filtered, and concentrated. The crude
product was purified by flash chromatography (silica gel, gradient
elution with 98:1:1 CH.sub.2Cl.sub.2/MeOH/NH.sub.4OH to 94:5:1
CH.sub.2Cl.sub.2/MeOH/NH.sub.4OH) then crystallized from
acetonitrile to yield
1-{[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}-
cyclohexanol as pale orange crystals that were dried under high
vacuum (0.32 g, 16% over two steps), mp 186-188.degree. C. .sup.1H
NMR (300 MHz, CDCl.sub.3) .delta. 8.15 (dm, J=8.4 Hz, 1H), 7.81
(dm, J=8.4 Hz, 1H), 7.52 (m, 1H), 7.32 (m, 1H), 5.38 (br s, 2H),
4.90 (br s, 2H), 4.74 (br s, 2H), 3.66 (q, J=7.0 Hz, 2H), 3.00 (s,
1H), 1.71-1.52 (m, 10), 1.25 (t, J=7.0 Hz, 3H). MS (APCI) m/z 355
(M+H.sup.+). Anal. calcd for C.sub.20H.sub.26O.sub.2N.sub.4: C,
67.77; H, 7.39; N, 15.81. Found: C, 67.52; H, 7.57; N, 15.78
Example 2
Ethyl
4-{[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}--
4-hydroxypiperidine-1-carboxylate
##STR00064## Part A
To a solution of N-carbethoxy-4-piperidone (11.34 g, 66.24 mmol) in
nitromethane (5.3 mL) and ethanol (2 mL) was added a solution of
sodium ethoxide in ethanol (2.67 M, 1.24 mL, 3.31 mmol). The
mixture was stirred for 5 min and a solution formed from which a
solid precipitated. After 1.5 h, water (100 mL) was added and the
solid was isolated by filtration, washed with water (100 mL), and
dried under vacuum with heat to yield the product ethyl
4-hydroxy-4-(nitromethyl)piperidine-1-carboxylate as an off white
solid, 9.58 g (62%).
Part B
A mixture of ethyl
4-hydroxy-4-(nitromethyl)piperidine-1-carboxylate (5.2 g, 22.4
mmol) and 20% palladium hydroxide on carbon (0.50 g) in ethanol
(190 mL) was hydrogenated at 35 psi (2.4.times.10.sup.5 Pa) on a
Parr apparatus for 5 h. The mixture was filtered through CELITE
filter agent and the filtrate was concentrated. By .sup.1H NMR
analysis, the reaction was incomplete and the crude material was
subjected to the reaction conditions again with fresh 20% palladium
hydroxide on carbon (0.50 g) for another 24 h. The mixture was
filtered through CELITE filter agent and the filtrate was
concentrated to provide ethyl
4-(aminomethyl)-4-hydroxypiperidine-1-carboxylate, which was
concentrated from chloroform to remove residual ethanol before
using in the next reaction.
Part C
To a solution of ethyl
4-(aminomethyl)-4-hydroxypiperidine-1-carboxylate (22.4 mmol,
prepared as described above) in dichloromethane (90 mL) was added
triethylamine (3.12 mL, 22.4 mmol) and 4-chloro-3-nitroquinoline
(3.71 g, 17.8 mmol). The mixture was sonicated and more
dichloromethane (10 mL) was added in order to dissolve the
4-chloro-3-nitroquinoline. The solution was allowed to stand at rt
for 18 h, then was poured into a separatory funnel and washed with
1 M NaOH (25 mL), water (2.times.30 mL), and brine (30 mL). The
organic layer was dried over MgSO.sub.4, filtered, and concentrated
to yield a yellow foam that was crystallized from isopropanol. The
solid was isolated by filtration and dried to afford ethyl
4-hydroxy-4-{[(3-nitroquinolin-4-yl)amino]methyl}piperidine-1-carboxylate
as yellow crystals (4.53 g, 54%).
Part D
A mixture of ethyl
4-hydroxy-4-{[(3-nitroquinolin-4-yl)amino]methyl}piperidine-1-carboxylate
(4.53 g, 12.1 mmol) and 5% platinum on carbon (0.50 g) in ethanol
was hydrogenated on a Parr apparatus at 40 psi (2.8.times.10.sup.5
Pa) for 2.5 h. The mixture was filtered through CELITE filter agent
and the filtrate was concentrated. The residue was concentrated
twice from toluene and once from chloroform to remove the ethanol,
then was dissolved in dichloromethane (100 mL). To the solution at
0.degree. C. was added triethylamine (1.86 mL, 13.3 mmol) and
ethoxyacetyl chloride (88%, 1.77 g, 12.7 mmol).
After 1 h at rt, the solution was concentrated to a yellow foam and
ethanol (120 mL) and triethylamine (6 mL) were added. The resulting
solution was heated at reflux for 16 h and then concentrated in
vacuo. The residue was partitioned between dichloromethane and
water. The organic layer was washed twice with brine, dried over
MgSO.sub.4, filtered, and concentrated to a crude yellow oil. The
oil was purified by flash chromatography (silica gel, gradient
elution with 2-7% methanol/dichloromethane) to provide ethyl
4-{[2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}-4-hydroxypipe-
ridine-1-carboxylate as a yellow foam (3.04 g, 61%).
Part E
To a solution of ethyl
4-{[2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}-4-hydroxypipe-
ridine-1-carboxylate (2.43 g, 5.90 mmol) in dichloromethane (40 mL)
at rt was added m-CPBA (55%, 1.85 g, 5.90 mmol). After 1 h,
concentrated ammonium hydroxide (40 mL) was added, followed by TsCl
(1.18 g, 6.20). The reaction was stirred rapidly overnight. Water
(40 mL) was added and the mixture was extracted three times with
dichloromethane. The combined organic phases were washed with brine
and dried over MgSO.sub.4, filtered, and concentrated. The crude
product was purified by flash chromatography (silica gel, 4%
methanol/dichloromethane with 0.1% conc. NH.sub.4OH). The
appropriate fractions were concentrated to afford a yellow oil that
was concentrated twice from toluene to yield the product as a
yellow foam, which crystallized from acetonitrile. The fine
off-white crystals were dried under vacuum at 65.degree. C. to
yield 0.71 g (28%) of ethyl
4-{[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}-4-hyd-
roxypiperidine-1-carboxylate, mp 165-167.degree. C. .sup.1H NMR
(CDCl.sub.3, 300 MHz) .delta. 8.03 (dd, J=8.3, 0.8 Hz, 1H), 7.80
(dm, J=8.3 Hz, 1H), 7.52 (m, 1H), 7.32 (m, 1H), 5.42 (br s, 2H),
4.84 (s, 2H), 4.74 (br s, 2H), 4.10 (q, J=7.1 Hz, 2H), 4.00 (br s,
3H), 3.71 (q, J=7.0 Hz, 2H), 3.08 (m, 2H), 1.85-1.30 (m, 4H), 1.26
(t, J=7.0 Hz, 3H), 1.22 (t, J=7.2 Hz, 3H); MS (APCI) m/z 428
(M+H.sup.+); Anal. calcd for C.sub.22H.sub.29N.sub.5O.sub.4: C,
61.81; H, 6.84; N, 16.38. Found: C, 61.77; H, 6.99; N, 16.44.
Example 3
1-{[4-Amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cyclope-
ntanol
##STR00065## Part A
To a solution of cyclopentanone (40.0 mL, 452 mmol) in nitromethane
(36 mL) and ethanol (14 mL) was added a solution of sodium ethoxide
in ethanol (2.67 M, 8.5 mL, 23 mmol). The solution was stirred for
5 d at rt. Water (400 mL) was added and the mixture was extracted
with ethyl acetate (2.times.350 mL). The combined organic extracts
were washed with water (2.times.200) and brine (200 mL), dried over
MgSO.sub.4, filtered, and concentrated. The starting materials and
solvent were removed from the product by distillation under reduced
pressure to yield 1-(nitromethyl)cyclopentanol as a yellow liquid,
8.3 g (13%).
Part B
A mixture of 1-(nitromethyl)cyclopentanol (8.3 g, 57.2 mmol) and
20% palladium hydroxide on carbon (0.6 g) in ethanol (150 mL) was
hydrogenated at 35 psi (2.4.times.10.sup.5 Pa) on a Parr apparatus
for 1 d. After workup, the reaction was not complete and was
subjected to the reaction conditions again for 8 d with fresh
catalyst. The mixture was filtered through CELITE filter agent and
the filtrate was concentrated to yield an oil that contained a 13:1
ratio of the desired amine product, 1-(aminomethyl)cyclopentanol,
to the corresponding hydroxylamine. The oil was concentrated from
toluene to remove the ethanol and used in the next experiment
without further purification.
Part C
To a solution of 1-(aminomethyl)cyclopentanol (approximately 55.2
mmol, prepared as described above) in dichloromethane (280 mL) was
added triethylamine (7.76 mL, 55.7 mmol) and
4-chloro-3-nitroquinoline (9.22 g, 44.3 mmol). The mixture was
allowed to stand at rt over the weekend. A solid formed that was
isolated by filtration. Two more crops of solid were isolated from
the mother liquor. The yellow solid was stirred in water and
filtered. The solid was washed with water multiple times and was
dried under vacuum with heat to give
1-{[(3-nitroquinolin-4-yl)amino]methyl}cyclopentanol as yellow
crystals (8.29 g, 52%).
Part D
A mixture of 1-{[(3-nitroquinolin-4-yl)amino]methyl}cyclopentanol
(8.26 g, 28.8 mmol) and 5% platinum on carbon (0.9 g) in ethanol
(200 mL) was hydrogenated on a Parr apparatus overnight. The
mixture was filtered through CELITE filter agent and the filtrate
was concentrated. The product
1-{[(3-aminoquinolin-4-yl)amino]methyl}-1-cyclopentanol was
concentrated from toluene and dichloromethane
1-{[(3-aminoquinolin-4-yl)amino]methyl}cyclopentanol to remove
ethanol, then used immediately in the next step.
Part E
To a solution of
1-{[(3-aminoquinolin-4-yl)amino]methyl}cyclopentanol (approximately
28.8 mmol, prepared as described above) in dichloromethane (200 mL)
at 0.degree. C. was added triethylamine (4.41 mL, 31.6 mmol) and
ethoxyacetyl chloride (88%, 3.96 g, 30.2 mmol). After 3 h at rt,
the solution was concentrated and ethanol (260 mL) and
triethylamine (14 mL) were added. The resulting solution was heated
at reflux for 18 h and then concentrated in vacuo. The residue was
partitioned between dichloromethane and water. The organic layer
was washed with brine twice and dried over MgSO.sub.4, filtered,
and concentrated to an oil that formed a white solid when
acetonitrile was added. The mixture was sonicated briefly and
filtered. The white powder was dried under vacuum to provide pure
1-{[2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cyclopentanol
(4.55 g, 49% for three steps).
Part F
To a solution of
1-{[2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cyclopentanol
(3.00 g, 9.22 mmol) in dichloromethane (60 mL) at rt was added
m-CPBA (2.89 g, 9.22 mmol). After 1 h, concentrated ammonium
hydroxide (60 mL) was added and the mixture was cooled in an ice
bath. To the mixture was added TsCl (1.85 g, 9.68 mmol). The
reaction was stirred rapidly overnight at rt. Additional TsCl (0.21
g) was added in the morning and the mixture was stirred 45 min.
Water (75 mL) was added and the mixture was extracted with
dichloromethane (3.times.100 mL). The combined organic phases were
washed with brine and dried over MgSO.sub.4, filtered, and
concentrated. The resulting foam was treated with acetonitrile and
a white solid formed. The solid was recrystallized from
acetonitrile and dried under vacuum to yield
1-{[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cyclop-
entanol as fine tan crystals (1.57 g, 50%), mp 156.5-158.0.degree.
C. .sup.1H NMR (300 MHz, d.sub.6-DMSO) .delta. 8.27 (dm, J=8.4 Hz,
1H), 7.59 (dd, J=8.4, 1.2 Hz, 1H), 7.40 (m, 1H), 7.20 (m, 1H), 6.54
(br s, 2H), 4.89 (br s, 2H), 4.82 (br s, 2H), 4.78 (s, 1H), 3.52
(q, J=7.0 Hz, 2H), 1.75-1.43 (m, 8H), 1.14 (t, J=7.0 Hz, 3H). MS
(APCI) m/z 341 (M+H.sup.+). Anal. calcd for
C.sub.19H.sub.24N.sub.4O.sub.2: C, 67.04; H, 7.11; N, 16.46. Found:
C, 67.12; H, 6.94; N, 16.36.
Example 4
tert-Butyl
4-{[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]met-
hyl}-4-hydroxypiperidine-1-carboxylate
##STR00066## Part A
To a solution of tert-butyl 4-oxopiperidine-1-carboxylate (52.65 g,
264 mmol) in nitromethane (21 mL) and ethanol (8 mL) was added a
solution of sodium ethoxide in ethanol (2.67 M, 5.0 mL, 13.4 mmol).
The mixture was stirred at rt and more ethanol (30 mL) was added.
The mixture was sonicated for 15 min, stirred overnight, then
sonicated again. To the mixture was added water (400 mL). The solid
was isolated by filtration, washed with water (300 mL), and dried
to yield tert-butyl
4-hydroxy-4-(nitromethyl)piperidine-1-carboxylate as a white solid,
67.60 g (98%).
Part B
A mixture of tert-butyl
4-hydroxy-4-(nitromethyl)piperidine-1-carboxylate (20.42 g, 78.4
mmol) and 20% palladium hydroxide on carbon (1.21 g) in ethanol
(250 mL) was hydrogenated at 40 psi (2.8.times.10.sup.5 Pa) for 3 d
on a Parr apparatus. More 20% palladium hydroxide on carbon (1.0 g)
was added and the hydrogenation was continued for 2 more days. The
mixture was filtered through CELITE filter agent and the filtrate
was concentrated to provide tert-butyl
4-(aminomethyl)-4-hydroxypiperidine-1-carboxylate, which was
concentrated from toluene (200 mL) to remove residual ethanol
before use in the next reaction.
Part C
To a solution of tert-butyl
4-(aminomethyl)-4-hydroxypiperidine-1-carboxylate (78.4 mmol,
prepared as described above) in dichloromethane (300 mL) was added
triethylamine (11 mL, 79 mmol) and 4-chloro-3-nitroquinoline (12.7
g, 61.2 mmol). The mixture was stirred at rt for 1 h, then heated
at reflux for 1 h. The solution was transferred to a separatory
funnel and extracted with water (100 mL). The organic layer was
isolated and upon standing a precipitate formed. The solid was
isolated by filtration and washed with dichloromethane and water
and dried. Additional solid precipitated from the mother liquor and
was isolated. The two yellow solids were combined and dried to
yield tert-butyl
4-hydroxy-4-{[(3-nitroquinolin-4-yl)amino]methyl}piperidine-1-carboxylate
(20.23 g, 82%).
Part D
The starting material tert-butyl
4-hydroxy-4-{[(3-nitroquinolin-4-yl)amino]methyl}piperidine-1-carboxylate
(20.23 g, 50.3 mmol) was divided into two portions. To each portion
was added ethanol (220 mL) and 5% platinum on carbon (1.1 g). Both
portions were hydrogenated on a Parr apparatus at 40 psi
(2.8.times.10.sup.5 Pa) overnight. The mixtures were filtered
through CELITE filter agent. The filtrates were combined and
concentrated to provide the product tert-butyl
4-{[(3-aminoquinolin-4-yl)amino]methyl}-4-hydroxypiperidine-1-carboxylate
as a brown oil. The product was concentrated twice from toluene and
once from chloroform and used in the subsequent experiment.
Part E
To a solution of tert-butyl
4-{[(3-aminoquinolin-4-yl)amino]methyl}-4-hydroxypiperidine-1-carboxylate
(50.3 mmol, prepared as described above) in dichloromethane (330
mL) at 0.degree. C. was added triethylamine (8 mL, 57.4 mmol)
followed by dropwise addition of ethoxyacetyl chloride (88%, 6.59
g, 50.3 mmol). After 3 h at rt, more triethylamine (4 mL) and acid
chloride (1.70 g) were added. The solution was stirred 1 h, then
concentrated in vacuo to a foam and ethanol (400 mL) and
triethylamine (24 mL) were added. The resulting solution was heated
at reflux for 20 h and then concentrated in vacuo. The residue was
dissolved in dichloromethane (600 mL) and washed with water
(2.times.200 mL) and brine (2.times.250 mL). The organic layer was
dried twice over MgSO.sub.4, filtered, and concentrated to an oil.
The oil was purified twice by flash chromatography (silica gel,
gradient elution with 3-5% methanol/dichloromethane) to provide
tert-butyl
4-{[2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}-4-hydroxypipe-
ridine-1-carboxylate as a yellow foam containing dichloromethane
(13.13 g). Based on .sup.1H NMR integration, the calculated amount
of product was 12.59 g (57%).
Part F
To a solution of tert-butyl
4-{[2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}-4-hydroxypipe-
ridine-1-carboxylate (96%, 10.0 g, 22.7 mmol) in dichloromethane
(150 mL) at rt was added m-CPBA (55%, 7.12 g, 22.7 mmol). After 1.5
h, the mixture was cooled to 0.degree. C. and concentrated ammonium
hydroxide (150 mL) was added, followed by TsCl (4.54 g, 23.8 mmol).
The reaction was stirred rapidly overnight. More TsCl (1.00 g and
0.47 g) was added as the mixture was stirred an additional 6 h.
Water (200 mL) was added and the mixture was extracted with
dichloromethane (3.times.200 mL). The combined organic phases were
washed with brine (3.times.250 mL) and dried over MgSO.sub.4,
filtered, and concentrated to a foam, which was crystallized from
acetonitrile twice. The fine yellow crystals were dried under
vacuum to yield 1.60 g (15%) of tert-butyl
4-{[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}-4-hyd-
roxypiperidine-1-carboxylate, mp 195-197.degree. C. .sup.1H NMR
(CDCl.sub.3, 300 MHz) .delta. 8.04 (dm, J=8.3 Hz, 1H), 7.82 (dm,
J=8.3 Hz, 1H), 7.53 (m, 1H), 7.31 (m, 1H), 5.40 (br s, 2H), 4.85
(s, 2H), 4.75 (br s, 2H), 3.93 (br s, 3H), 3.72 (q, J=7.0 Hz, 2H),
3.03 (m, 2H), 1.76 (m, 2H), 1.49-1.40 (m, 2H), 1.42 (s, 9H), 1.27
(t, J=7.0 Hz, 3H); MS (APCI) m/z 456 (M+H.sup.+); Anal. calcd for
C.sub.24H.sub.33N.sub.5O.sub.4: C, 63.28; H, 7.30; N, 15.37. Found:
C, 63.32; H, 7.53; N, 15.39.
Example 5
4-{[4-Amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}piperid-
in-4-ol dihydrochloride
##STR00067##
To a solution of tert-butyl
4-{[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}-4-hyd-
roxypiperidine-1-carboxylate (0.720 g, 1.62 mmol, prepared as
described in Example 4) in ethanol (10 mL) was added 4.3 M HCl in
ethanol (2 mL). The solution was heated at 65.degree. C. for 1.5 h.
After the mixture cooled to rt, a solid was isolated by filtration.
The solid was washed with diethyl ether and dried under reduced
pressure at 100.degree. C. to afford
4-{[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl-
}piperidin-4-ol dihydrochloride as a 0.5 hydrate and as a white
solid, mp>260.degree. C. MS (APCI) m/z 356 (M+H).sup.+; Anal.
calcd for C.sub.19H.sub.25N.sub.5O.sub.2.2HCl.0.5 H.sub.20: C,
52.18; H, 6.45; N, 16.01. Found: C, 52.32; H, 6.40; N, 15.90.
Example 6
4-{[4-Amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}-1-(met-
hylsulfonyl)piperidin-4-ol
##STR00068##
To the 1.5 hydrate of
4-{[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}piperi-
din-4-ol dihydrochloride (1.00 g, 2.20 mmol, prepared in a similar
manner as described in Example 5) was added chloroform (150 mL) and
triethylamine (1.1 mL, 7.7 mmol). The starting material did not
completely dissolve. To the mixture was added methanesulfonyl
chloride (MeSO.sub.2Cl, 0.19 mL, 2.42 mmol) and more triethylamine
(0.3 mL). After 4 h at rt, more MeSO.sub.2Cl (0.06 mL) and
triethylamine (0.3 mL) were added and the mixture was stirred
overnight. Pyridine (20 mL) and dimethylformamide (DMF, 20 mL) were
added, followed by MeSO.sub.2Cl (0.06 mL). To the mixture was added
methanesulfonyl anhydride (115 mg) and the mixture was allowed to
stand for 2 d. The mixture was filtered, and the filtrate was
concentrated to approximately 25 mL, which was diluted with
chloroform (400 mL) and extracted with 1 M NaOH (2.times.150 mL),
water (150 mL), and brine (200 mL). The organic phase was dried
over Na.sub.2SO.sub.4, filtered, and concentrated to a yellow oil.
The crude product was purified by flash chromatography (silica gel,
eluted with 1% CMA/CHCl.sub.3 where CMA is a solution comprised of
80:18:2 chloroform/methanol/concentrated ammonium hydroxide) to
afford
4-{[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}-1-(me-
thylsulfonyl)piperidin-4-ol as a white solid (0.34 g, 36%) after
drying at 60.degree. C. under reduced pressure, mp 254-256.degree.
C. .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 8.35 (dm, J=8.4 Hz,
1H), 7.59 (dd, J=8.4, 1.4 Hz, 1H), 7.41 (m, 1H), 7.23 (m, 1H), 6.57
(br s, 2H), 5.16-4.60 (br m, 4H), 5.05 (s, 1H), 3.53 (q, J=7.0 Hz,
2H), 3.37-3.27 (br s, 2H), 2.89-2.79 (m, 2H), 2.81 (s, 3H),
1.93-1.78 (m, 2H), 1.62-1.29 (br s, 2H), 1.14 (t, J=7.0 Hz, 3H); MS
(APCI) m/z 434 (M+H).sup.+; Anal. calcd for
C.sub.20H.sub.27N.sub.5O.sub.4S: C, 55.41; H, 6.28; N, 16.15; S,
7.40. Found: C, 55.21; H, 6.11; N, 16.35; S, 7.37.
Example 7
2-(Ethoxymethyl)-1-[(1-methoxycyclopentyl)methyl]-1H-imidazo[4,5-c]quinoli-
n-4-amine
##STR00069## Part A
To a solution of
1-{[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cyclop-
entanol (1.19 g, 3.66 mmol, prepared as described in Example 3) in
THF (18 mL) at rt was added sodium hydride (60% dispersion in oil,
161 mg, 4.03 mmol). The mixture was stirred for 1 h and iodomethane
(0.25 mL, 4.03 mmol) was added. The mixture was heated to
50.degree. C. for 3 h and then was left to stand at rt overnight.
More sodium hydride (60% dispersion in oil, 80 mg) and iodomethane
(0.13 mL) were added. The mixture was heated for 2 h, then water
was added and the mixture was extracted three times with ethyl
acetate. The combined organic extracts were washed with brine and
dried over Na.sub.2SO.sub.4, filtered and concentrated to an oil.
The crude product was purified by flash chromatography (silica gel,
eluted with ethyl acetate) to yield
2-(ethoxymethyl)-1-[(1-methoxycyclopentyl)methyl]-1H-imidazo[4,5-c]quinol-
ine as a yellow oil (0.30 g, 24%).
Part B
To a solution of
2-(ethoxymethyl)-1-[(1-methoxycyclopentyl)methyl]-1H-imidazo[4,5-c]quinol-
ine (0.30 g, 0.88 mmol) in dichloromethane at rt was added m-CPBA
(278 mg, 0.88 mmol). The solution was stirred for 1.5 h and
concentrated ammonium hydroxide (5.73 mL) was added and the mixture
was cooled in an ice bath. To the mixture was added TsCl (176 mg,
0.924 mmol). The mixture was stirred 3 h at rt. Water (10 mL) was
added and the mixture was extracted with dichloromethane
(3.times.20 mL). The combined organics were washed twice with
brine, dried over Na.sub.2SO.sub.4, filtered, and concentrated to a
yellow oil. The crude product was purified by flash chromatography
(silica gel, gradient elution with 1-10% CMA/CHCl.sub.3). The
purified product was crystallized from acetonitrile to provide
2-(ethoxymethyl)-1-[(1-methoxycyclopentyl)methyl]-1H-imidazo[4,5-c]quinol-
in-4-amine as off white crystals (0.122 g, 39%) after vacuum drying
at 80.degree. C., mp 148.0-150.0.degree. C.
.sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 8.13 (dd, J=8.4, 1.4 Hz,
1H), 7.81 (dd, J=8.4, 1.4 Hz, 1H), 7.51 (ddd, J=8.4, 7.0, 1.4 Hz,
1H), 7.30 (ddd, J=8.4, 7.0, 1.4 Hz, 1H), 5.39 (br s, 2H), 4.94 (s,
2H), 4.92 (s, 2H), 3.57 (q, J=7.0 Hz, 2H), 3.17 (s, 3H), 1.92-1.56
(m, 8H), 1.23 (t, J=7.0 Hz, 3H); MS (APCI) m/z 355 (M+H.sup.+);
Anal. calcd for C.sub.20H.sub.26N.sub.4O.sub.2: C, 67.77; H, 7.39;
N, 15.81. Found: C, 67.76; H, 7.45; N, 15.76.
Example 8
1-{[4-Amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cyclobu-
tanol
##STR00070## Part A
To a solution of cyclobutanone (10.0 g, 143 mmol) and nitromethane
(12 mL) in ethanol (10 mL) was added sodium ethoxide in ethanol
(2.67 M, 2.7 mL, 7.2 mmol). The mixture was stirred for 6 d at rt.
Water was added and the mixture was extracted thrice with ethyl
acetate. The organic phases were combined, washed with water and
brine, dried over Na.sub.2SO.sub.4, filtered, and concentrated. The
volatiles were removed by distillation under vacuum to provide
1-(nitromethyl)cyclobutanol as a yellow liquid (8.51 g, 45%).
Part B
A mixture of 1-(nitromethyl)cyclobutanol (8.2 g, 62.5 mmol) and 20%
palladium hydroxide on carbon (1.0 g) in ethanol (200 mL) was
hydrogenated at 40 psi (2.8.times.10.sup.5 Pa) on a Parr apparatus
for 6 d. More 20% palladium hydroxide on carbon (1.2 g) was added
and the mixture was hydrogenated at 40 psi (2.8.times.10.sup.5 Pa)
for an additional 5 d. The mixture was filtered through CELITE
filter agent, which was rinsed with ethanol. The filtrate was
concentrated to an oil that was concentrated from dichloromethane
and chloroform to remove residual ethanol.
1-(Aminomethyl)cyclobutanol was obtained as an off white solid
(6.15 g) that was used without further purification in the next
step.
Part C
To a solution of 1-(aminomethyl)cyclobutanol (62.5 mmol) in
dichloromethane (312 mL) was added triethylamine (8.71 mL, 62.5
mmol) and 4-chloro-3-nitroquinoline (13.04 g, 62.5 mmol). More
triethylamine (3 mL) was added almost immediately. The reaction was
stirred under N.sub.2 for 10 d at rt, then was diluted with
dichloromethane and washed with 1 M aqueous NaOH. A solid formed
and was isolated by filtration. The organic layer was washed with
water and brine, dried over Na.sub.2SO.sub.4, filtered, and
concentrated to a solid that was crystallized from isopropanol. The
resulting crystals were combined with the solid that was isolated
from the extraction and the mixture was triturated with hot
isopropanol. The solid was isolated by filtration, washed with
diethyl ether, and air dried to yield
1-{[(3-nitroquinolin-4-yl)amino]methyl}cyclobutanol as yellow
crystals. (12.83 g, 75%).
Part D
A mixture of 1-{[(3-nitroquinolin-4-yl)amino]methyl}cyclobutanol
(6.32 g, 23.1 mmol) and 20% palladium hydroxide on carbon (0.60 g)
in EtOH (100 mL) was hydrogenated overnight on a Parr apparatus at
40 psi (2.8.times.10.sup.5 Pa). The mixture was filtered through
CELITE filter agent, which was rinsed several times with EtOH, and
the filtrate was concentrated to provide
1-{[(3-aminoquinolin-4-yl)amino]methyl}cyclobutanol as a pale
yellow solid (5.66 g). The solid was concentrated from toluene and
chloroform to remove ethanol before using directly in the next
reaction.
Part E
To a mixture of 1-{[(3-aminoquinolin-4-yl)amino]methyl}cyclobutanol
(23.1 mmol, prepared as described in Part D) in dichloromethane
(154 mL) and triethylamine (3.54 mL, 25.4 mmol) at 0.degree. C. was
added chloroform (100 mL). The mixture was allowed to warm to rt
and approximately two thirds of the starting material dissolved. To
the mixture was slowly added ethoxyacetyl chloride (88%, 3.1 g,
24.3 mmol). The solution was stirred at rt for 2 h. More
triethylamine (2 mL) and ethoxyacetyl chloride (88%, 1.0 g) were
added. After an additional 16 h, the reaction solution was
concentrated in vacuo. To the residue was added ethanol (190 mL)
and triethylamine (13 mL). The resulting solution was heated at
reflux for 20 h and then concentrated in vacuo to a yellow solid.
The solid was partitioned between dichloromethane (400 mL) and
water (100 mL). The organic layer was washed with water (100 mL)
and brine (100 mL). The organic layer was dried over MgSO.sub.4,
filtered, and concentrated. The crude product was crystallized from
acetonitrile and the crystals were isolated by filtration to
provide
1-{[2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cyclobutanol
(4.52 g, 63%).
Part F
To a solution of
1-{[2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cyclobutanol
(4.05 g, 13.0 mmol) in dichloromethane (85 mL) at rt was added
m-CPBA (55%, 4.08 g, 13.0 mmol). After 1 h, concentrated ammonium
hydroxide (85 mL) was added, followed by TsCl (2.73 g, 14.3 mmol).
The reaction was stirred rapidly for 2 d. More TsCl (0.25 g) was
added and the mixture was stirred one day more. The layers were
separated. Water was added to the aqueous layer, which was
extracted twice with dichloromethane. The combined organic layers
were washed with water and brine, dried over Na.sub.2SO.sub.4,
filtered, and concentrated to a pale yellow foam. Acetonitrile was
added to the foam, causing a solid to form. The solid was
triturated with hot acetonitrile to yield an off white solid that
was crystallized from acetonitrile/dichloromethane. Pale yellow
crystals were isolated by filtration and dried under vacuum
80.degree. C. to yield 1.81 g (43%) of
1-{[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cyclob-
utanol, mp 174-175.degree. C. .sup.1H NMR (CDCl.sub.3, 300 MHz)
.delta. 8.23 (dd, J=8.3, 1.4 Hz, 1H), 7.78 (dd, J=8.4, 1.4 Hz, 1H),
7.50 (ddd, J=8.4, 7.0, 1.4 Hz, 1H), 7.31 (ddd, J=8.4, 7.0, 1.4 Hz,
1H), 5.41 (br s, 2H), 4.893 (s, 2H), 4.886 (s, 2H), 3.64 (q, J=7.0
Hz, 2H), 3.50 (br s, 1H), 2.35-2.27 (m, 2H), 2.10-1.78 (m, 4 H),
1.25 (t, J=7.0 Hz, 3H); MS (APCI) m/z 327 (M+H.sup.+); Anal. calcd
for C.sub.18H.sub.22N.sub.4O.sub.2: C, 66.24; H, 6.79; N, 17.16.
Found: C, 66.02; H, 6.87; N, 17.09.
Example 9
8-{[4-Amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}-1,4-di-
oxaspiro[4.5]decan-8-ol
##STR00071## Part A
To a solution of 1,4-cyclohexanedione mono-ethylene ketal (30.0 g,
192 mmol) and nitromethane (15.6 mL, 288 mmol) in ethanol (18 mL)
was added a solution of sodium ethoxide in ethanol (2.67 M, 3.4 mL,
9.6 mmol). The solution was stirred at room temperature (rt) for 5
days (d), then was concentrated under reduced pressure to a brown
oil that was partitioned between water (100 mL) and dichloromethane
(100 mL). The aqueous layer was extracted with dichloromethane
(3.times.100 mL). The organic layers were combined, dried over
Na.sub.2SO.sub.4, filtered, and concentrated to a light brown oil.
Purification by flash chromatography (silica gel, 40% ethyl
acetate/hexanes) provided the product
8-(nitromethyl)-1,4-dioxaspiro[4.5]decan-8-ol as a clear oil (16.7
g, 40%) that slowly formed clear crystals overnight.
Part B
A mixture of 8-(nitromethyl)-1,4-dioxaspiro[4.5]decan-8-ol (16.0 g,
13.8 mmol) and 20% palladium hydroxide on carbon (3.2 g) in ethanol
(160 mL) was hydrogenated at 50 psi (3.5.times.10.sup.5 Pa) for 5 d
on a Parr apparatus. The reaction mixture was filtered through
CELITE filter agent and the filtrate was concentrated to give
8-(aminomethyl)-1,4-dioxaspiro[4.5]decan-8-ol as a clear oil (13.7
g, 99%) that solidified upon standing overnight.
Part C
To a 0.degree. C. solution of 4-chloro-3-nitroquinoline (7.50 g,
36.0 mmol) and triethylamine (7.5 mL, 54 mmol) in dichloromethane
(150 mL) was added 8-(aminomethyl)-1,4-dioxaspiro[4.5]decan-8-ol
(8.10 g, 43.1 mmol). The reaction was allowed to warm to rt and
stir overnight, then was concentrated under reduced pressure to
yield a yellow solid. The solid was stirred in water (500 mL) and
was isolated by filtration, dried under vacuum, and recrystallized
from toluene (280 mL) to yield
8-{[(3-nitroquinolin-4-yl)amino]methyl}-1,4-dioxaspiro[4.5]decan-8-ol
as bright yellow crystals (12.3 g, 72%).
Part D
A mixture of
8-{[(3-nitroquinolin-4-yl)amino]methyl}-1,4-dioxaspiro[4.5]decan-8-ol
(12.0 g, 33.4 mmol) and 5% platinum on carbon (1.2 g) in
acetonitrile (120 mL) was hydrogenated at 50 psi
(3.5.times.10.sup.5 Pa) for 4 hours (h) on a Parr apparatus. The
reaction mixture was filtered through CELITE filter agent with
dichloromethane and ethanol. The filtrate was concentrated to give
8-{[(3-aminoquinolin-4-yl)amino]methyl}-1,4-dioxaspiro[4.5]decan-8-ol
as a orange solid (10.9 g, 99%).
Part E
A solution of ethoxyacetyl chloride (4.38 g, 35.7 mmol) in
dichloromethane (50 mL) was added to a 0.degree. C. solution of
8-{[(3-aminoquinolin-4-yl)amino]methyl}-1,4-dioxaspiro[4.5]decan-8-ol
(10.7 g, 32.5 mmol) and triethylamine (4.98 mL, 35.7 mmol) in
dichloromethane (250 mL). After one hour, the solution was allowed
to warm to rt and stir for 2 d. More ethoxyacetyl chloride (0.15
equivalent) was added. After two hours, the solution was
transferred to a separatory funnel and washed with water (200 mL).
The organic layer was dried with Na.sub.2SO.sub.4, filtered, and
concentrated under reduced pressure to yield an orange solid. The
solid was dissolved in ethanol (150 mL) and triethylamine (13.6 mL,
97.4 mmol) was added. The solution was heated at reflux for 16 h.
The volatiles were removed under reduced pressure to yield a brown
oil that was crystallized from isopropanol to yield
8-{[2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}-1,4-dioxaspir-
o[4.5]decan-8-ol as off-white crystals (2.50 g) and a second crop
(1.50 g) of crystals. A third crop (4.91 g) was isolated after
recrystallization of the mother liquor from ethyl acetate. A total
of 8.91 g (69%) of
8-{[2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}-1,4-dioxaspir-
o[4.5]decan-8-ol was isolated.
Part F
To a solution of
8-{[2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}-1,4-dioxaspir-
o[4.5]decan-8-ol (3.0 g, 10.1 mmol) in chloroform at rt was added
m-chloroperbenzoic acid (m-CPBA, 3.6 g, 12.1 mmol). After 2 h, the
solution was transferred to a separatory funnel and washed with 10%
Na.sub.2CO.sub.3 (100 mL). The aqueous layer was back-extracted
with chloroform. The organic layers were combined, dried over
MgSO.sub.4, filtered, and concentrated under reduced pressure to an
off-white solid. To the solid was added dichloromethane (30 mL) and
concentrated ammonium hydroxide (10 mL). p-Toluenesulfonyl chloride
(TsCl, 1.69 g, 8.85 mmol) was added over 5 minutes (min). After 3
h, the reaction mixture was diluted with water (100 mL) and
extracted with dichlormethane (3.times.100 mL). The organic layers
were combined, dried over MgSO.sub.4, filtered, and concentrated
under reduced pressure. The crude product was purified by flash
chromatography (silica gel, 20% methanol in ethyl acetate) and was
recrystallized from isopropanol (20 mL). The crystals were
dissolved in methanol and concentrated under reduced pressure and
dried in a vacuum oven at 80.degree. C. to provide
8-{[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}-1,4-d-
ioxaspiro[4.5]decan-8-ol (1.03 g, 33%) as a light tan frothy solid,
mp 207-209.degree. C. .sup.1H NMR (300 MHz, CDCl.sub.3) .delta.
8.12 (m, 1H), 7.79 (m, 1H), 7.49 (m, 1H), 7.31 (m, 1H), 5.39 (br s,
2H), 4.85 (s, 2H), 4.74 (s, 2H), 3.90 (m, 4H), 3.65 (q, J=7.0 Hz,
2H), 3.21 (br s, 1H), 2.01-1.45 (m, 8H), 1.24 (t, J=6.9 Hz, 3H); MS
(APCI) m/z 413 (M+H).sup.+; Anal. Calcd for
C.sub.22H.sub.28N.sub.4O.sub.4.0.25H.sub.2O: C, 63.37; H, 6.89; N,
13.44. Found: C, 63.32; H, 6.85; N, 13.41.
Example 10
4-{[4-Amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}tetrahy-
dro-2H-pyran-4-ol
##STR00072## Part A
A solution of tetrahydro-4H-pyran-4-one (45.0 g, 449 mmol) and
nitromethane (36.5 mL, 674 mmol) in ethanol (27 mL) was treated
with a solution of sodium ethoxide in ethanol (2.67 M, 8.40 mL,
22.5 mmol) using the method described in Part A of Example 9. The
reaction mixture was transferred to a reparatory funnel and water
(450 mL) was added. The mixture was extracted with ethyl acetate
(3.times.900 mL). The organic layers were combined, dried over
MgSO.sub.4, filtered, and concentrated to a light brown oil. Ethyl
acetate/hexanes was added and pale brown crystals formed that were
isolated by filtration and dried to provide
4-(nitromethyl)tetrahydro-2H-pyran-4-ol (24.4 g, 34%).
Part B
4-(Nitromethyl)tetrahydro-2H-pyran-4-ol (23.3 g, 145 mmol) was
hydrogenated according to the method described in Part B of Example
9 to provide 4-(aminomethyl)tetrahydro-2H-pyran-4-ol as a clear oil
(19.0 g, 100%).
Part C
4-Chloro-3-nitroquinoline (12.0 g, 57.5 mmol) and was reacted with
4-(aminomethyl)tetrahydro-2H-pyran-4-ol (11.3 g, 86.3 mmol)
according to the method described in Part C of Example 9. The crude
yellow solid was stirred in water (100 mL) and was isolated by
filtration, dried under vacuum, and recrystallized from
1,2-dichloroethane to yield
4-{[(3-nitroquinolin-4-yl)amino]methyl}tetrahydro-2H-pyran-4-ol as
bright yellow crystals (15.6 g, 90%).
Part D
A mixture of
4-{[(3-nitroquinolin-4-yl)amino]methyl}tetrahydro-2H-pyran-4-ol
(9.00 g, 29.7 mmol) and 5% platinum on carbon (0.90 g) in
acetonitrle (180 mL) was hydrogenated according to the method
described in Part D of Example 9 to yield
4-{[(3-aminoquinolin-4-yl)amino]methyl}tetrahydro-2H-pyran-4-ol as
a brown solid (7.60 g, 94%).
Part E
4-{[(3-Aminoquinolin-4-yl)amino]methyl}tetrahydro-2H-pyran-4-ol
(7.50 g, 27.4 mmol) was reacted with ethoxyacetyl chloride (3.70 g,
30.1 mmol) and the resulting product was cyclized according to the
method described in Part E of Example 9 to provide
4-{[2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}tetrahydro-2H--
pyran-4-ol as pale tan crystals (7.50 g, 76%) after crystallization
from ethanol.
Part F
To a solution of
4-{[2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}tetrahydro-2H--
pyran-4-ol (3.0 g, 8.79 mmol) in chloroform (60 mL) at rt was added
m-chloroperbenzoic acid (m-CPBA, 3.2 g, 10.5 mmol). After 2 h, the
solution was transferred to a separatory funnel and washed with 10%
Na.sub.2CO.sub.3 (100 mL). The aqueous layer was back-extracted
with chloroform. The organic layers were combined, dried over
MgSO.sub.4, filtered, and concentrated under reduced pressure to
yield a light orange solid. To the solid was added dichloromethane
(30 mL). Trichloroacetyl isocyanate (1.05 mL, 8.79 mL) was added
dropwise. After 1 h, additional trichloroacetyl isocyanate (0.3
equivalent) was added. After 1 h, the volatiles were removed under
reduced pressure and the residue was dissolved in methanol (30 mL).
A solution of sodium methoxide in methanol (25%, 5.0 mL) was added
and the solution stirred overnight at rt and concentrated under
reduced pressure. The residue was partitioned between
dichloromethane (100 mL) and water (100 mL). The aqueous layer was
extracted with dichlormethane (2.times.100 mL). The organic layers
were combined, dried over MgSO.sub.4, filtered, and concentrated
under reduced pressure. The crude product was purified by flash
chromatography (silica gel, eluted with 10%
methanol/dichloromethane) to afford a clear oil that was triturated
with isopropanol (50 mL) to afford white crystals. The crystals
were dissolved in methanol, concentrated under reduced pressure,
and dried in a vacuum oven at 80.degree. C. to provide
4-{[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}tetrah-
ydro-2H-pyran-4-ol (1.27 g, 41%) as a white frothy solid, mp
212-214.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 8.33
(dd, J=8.3, 1.1 Hz, 1H), 7.60 (dd, J=8.3, 1.2 Hz, 1H), 7.40 (ddd,
J=8.3, 7.0, 1.4 Hz, 1H), 7.22 (ddd, J=8.3, 7.0, 1.4 Hz, 1H), 6.37
(br s, 2H), 4.90 (br s, 2H), 4.88 (s, 1H), 4.70 (br s, 2H),
3.62-3.47 (m, 6H), 1.87-1.74 (m, 2H), 1.28 (m, 2H), 1.14 (t, J=7.0
Hz, 3H); MS (APCI) m/z 357 (M+H).sup.+; Anal. Calcd for
C.sub.19H.sub.24N.sub.4O.sub.3: C, 64.03; H, 6.79; N, 15.72. Found:
C, 63.75; H, 7.06; N, 15.71.
Example 11
4-[(4-Amino-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetrahydro-2H-p-
yran-4-ol
##STR00073## Part A
A solution of
4-{[(3-aminoquinolin-4-yl)amino]methyl}tetrahydro-2H-pyran-4-ol
(prepared as described in Part D of Example 10, 8.0 g, 29.3 mmol),
triethylorthoacetate (5.6 mL, 30.7 mmol), and pyridine
hydrochloride (1.0 g) in toluene (160 mL) was heated at reflux for
2 h, then was stirred at rt for 2 d. More triethylorthoacetate was
added and the solution was heated at reflux. The solution was
allowed to cool to rt and was washed with 10% aqueous
Na.sub.2CO.sub.3 (100 mL). The aqueous layer was back-extracted
with a solution of 10% methanol in dichloromethane (10.times.100
mL). The organic layers were combined, dried with MgSO.sub.4,
filtered, and concentrated under reduced pressure to afford a brown
solid (8.7 g). The solid was dissolved in dichloromethane (50 mL).
To the solution was added triethylamine (4.00 mL, 28.5 mmol). The
solution was cooled to 0.degree. C. and acetyl chloride (0.68 mL,
9.5 mmol) was added dropwise. After three days at rt, the reaction
was concentrated under reduced pressure. The residue was dissolved
in pyridine (80 mL) and pyridine hydrochloride (5.0 g) was added.
The reaction was heated to reflux for 4 h and concentrated under
reduced pressure. The resulting brown oil was dissolved in 10%
Na.sub.2CO.sub.3 (200 mL) and was extracted overnight with
chloroform in a continuous extractor. The chloroform layer was
reduced to a light brown solid that was purified by flash
chromatography (silica gel, eluted with 15% methanol in
dichloromethane) to afford
4-[(2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetrahydro-2H-pyran-4--
ol (6.2 g, 71%) as a tan solid.
Part B
4-[(2-Methyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetrahydro-2H-pyran-4--
ol (3.0 g, 10.1 mmol) was converted to
4-[(4-amino-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetrahydro-2H--
pyran-4-ol (0.28 g, 9%) according to the method described in Part F
of Example 10. The product
4-[(4-amino-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetrahydro-2H--
pyran-4-ol was purified by flash chromatography (silica gel, eluted
with 30% methanol/ethyl acetate) and crystallized from
methanol/water to afford white crystals, mp>250.degree. C.
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 8.32 (m, 1H), 7.58 (dd,
J=8.3, 1.2 Hz, 1H), 7.37 (ddd, J=8.3, 7.0, 1.2 Hz, 1H), 7.20 (ddd,
J=8.3, 7.0, 1.3 Hz, 1H), 6.44 (br s, 2H), 4.90 (s, 1H), 4.55 (br s,
2H), 3.65-3.46 (m, 4H), 2.66 (s, 3H), 1.88-1.74 (m, 2H), 1.40-1.24
(m, 2H); MS (APCI) m/z 313 (M+H).sup.+; Anal. Calcd for
C.sub.17H.sub.20N.sub.4O.sub.2.0.40H.sub.2O: C, 63.89; H, 6.56; N,
17.53. Found: C, 63.96; H, 6.69; N, 17.61.
Example 12
1-{3-[4-Amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]propyl}cyclo-
hexanol
##STR00074## Part A
A solution of allyl magnesium bromide in diethyl ether (1 M, 53 mL,
53 mmol) was added dropwise to a solution of cyclohexanone (5.00
mL, 48.2 mmol) in diethyl ether at 0.degree. C. The cloudy white
reaction mixture was allowed to stir at rt overnight. The reaction
was quenched with saturated aqueous NH.sub.4Cl (100 mL) and diluted
with water (20 mL) and diethyl ether (50 mL). The mixture was
transferred to a separatory funnel and the layers were separated.
The aqueous layer was extracted with diethyl ether (2.times.50 mL).
The combined organic layers were washed with brine (100 mL), dried
over MgSO.sub.4, filtered, and concentrated to afford a
1-allylcyclohexanol as a colorless oil (6.97, 103%) that contained
a small amount of diethyl ether.
Part B
Pyridine (11.7 mL, 145 mmol), 4-dimethylaminopyridine (DMAP, 0.59
g, 4.82 mmol) and tert-butyldimethylsilyl chloride (8.71 g, 57.8
mmol) were added to a solution of 1-allylcyclohexanol (48.2 mmol)
in acetonitrile (120 mL). The reaction was heated at reflux
overnight, then cooled to rt and concentrated to about 50 mL under
reduced pressure. The solution was cooled to 0.degree. C. and
tert-butyldimethylsilyl triflate (13.3 mL, 57.8 mmol) was added.
After the solution had stirred overnight at rt, additional
tert-butyldimethylsilyl triflate (5.00 mL) was added and the
solution was stirred for 6 h longer. The reaction was quenched with
saturated aqueous sodium bicarbonate (120 mL) and extracted with
dichloromethane (100 mL, then 2.times.75 mL). The combined organic
layers were dried over MgSO.sub.4, filtered, and concentrated to
give a colorless oil that was purified on a on a HORIZON
High-Performance Flash Chromatography (HPFC) instrument (available
from Biotage, Inc, Charlottesville, Va., USA) (silica gel, gradient
elution with 0-5% ethyl acetate/hexanes) to afford
[(1-allylcyclohexyl)oxy](tert-butyl)dimethylsilane as a colorless
oil (11.96 g, 97%).
Part C
A solution of borane in tetrahydrofuran (1 M, 15.7 mL, 15.7 mmol)
was added to a solution of
[(1-allylcyclohexyl)oxy](tert-butyl)dimethylsilane (8.00 g, 31.4
mmol) in tetrahydrofuran. After 2 h, water (5 mL) was added
dropwise, followed by 3 M NaOH (6 mL), followed by dropwise
addition of 30% aqueous hydrogen peroxide (6 mL). The mixture was
stirred at rt for 1 h, then was diluted with diethyl ether (100 mL)
and water (70 mL). The layers were separated and the aqueous layer
was extracted with diethyl ether (2.times.35 mL). The combined
organic layers were washed with brine (90 mL), dried over
MgSO.sub.4, filtered, and concentrated to yield a colorless oil
that was purified using HPFC (silica gel, gradient elution with
2-30% ethyl acetate/hexanes) to afford pure
3-(1-{[tert-butyl(dimethyl)silyl]oxy}cyclohexyl)propan-1-ol (6.80
g, 79%).
Part D
Methanesulfonyl chloride (2.1 mL, 27.4 mmol) was added dropwise to
a solution of
3-(1-{[tert-butyl(dimethyl)silyl]oxy}cyclohexyl)propan-1-ol (6.80
g, 24.9 mmol) and triethylamine (4.20 mL, 29.9 mmol) in
dichloromethane (100 mL) at 0.degree. C. The solution was stirred
for 2 h at 0.degree. C., then was diluted with dichloromethane
(20-25 mL) and saturated aqueous sodium bicarbonate (70 mL). The
layers were separated and the aqueous layer was extracted with
dichloromethane (40 mL). The combined organic layers were dried
over MgSO.sub.4, filtered, and concentrated to afford
341-{[tert-butyl(dimethyl)silyl]oxy}cyclohexyl)propyl
methanesulfonate as a pale oil that was used directly in the next
step.
Part E
Sodium azide (1.78 g, 27.4 mmol) was added to a solution of
3-(1-{[tert-butyl(dimethyl)silyl]oxy}cyclohexyl)propyl
methanesulfonate (prepared as described in Part D, 24.9 mmol) in
dimethylformamide (100 mL). The reaction mixture was stirred for
2.5 d and additional sodium azide (160 mg) was added. The mixture
was stirred an additional 1 d, then was diluted with diethyl ether
(250 mL) and washed with water (3.times.75 mL). The combined
aqueous layers were back-extracted with diethyl ether (50 mL).
The combined organic layers were washed with brine (100 mL), dried
over MgSO.sub.4, filtered, and concentrated to afford
{[1-(3-azidopropyl)cyclohexyl]oxy}(tert-butyl)dimethylsilane (7.05
g, 95% over two steps) as a pale yellow oil. A mixture of the
{[1-(3-azidopropyl)cyclohexyl]oxy}(tert-butyl)dimethylsilane (7.05
g, 23.7 mmol) and 5% palladium on carbon (0.71 g) in ethanol (100
mL) was hydrogenated at 30 psi (2.1.times.10.sup.5 Pa) for 4 h on a
Parr apparatus. The reaction mixture was filtered through CELITE
filter agent, which was rinsed afterwards with dichloromethane, and
the filtrate was concentrated to give
3-(1-{[tert-butyl(dimethyl)silyl]oxy}cyclohexyl)propan-1-amine as a
pale yellow oil (6.57 g, 102%) that contained a trace amount of
solvent.
Part F
4-Chloro-3-nitroquinoline (0.700 g, 3.37 mmol) was added in two
portions to a solution of
3-(1-{[tert-butyl(dimethyl)silyl]oxy}cyclohexyl)propan-1-amine
(0.960 g, 3.54 mmol) and triethylamine (0.610 mL, 4.38 mmol) in
dichloromethane (15 mL) at 0.degree. C. After 30 min, the reaction
was allowed to warm to rt and stir overnight. The mixture was
diluted with dichloromethane (40 mL) and was washed with saturated
aqueous sodium bicarbonate (30 mL). The aqueous layer was extracted
with dichloromethane (20 mL). The combined organic layers were
dried over MgSO.sub.4, filtered, and concentrated to afford a
yellow solid. The crude product was purified using HPFC (silica
gel, gradient elution with 0-2% ethyl acetate/hexanes) to yield
N-[3-(1-{[tert-butyl(dimethyl)silyl]oxy}cyclohexyl)propyl]-3-nitroquinoli-
n-4-amine as a bright yellow solid (1.40 g, 93%).
Part G
A mixture of
N-[3-(1-{[tert-butyl(dimethyl)silyl]oxy}cyclohexyl)propyl]-3-nitroquinoli-
n-4-amine (1.40 g, 3.16 mmol) and 5% platinum on carbon (0.14 g) in
ethyl acetate (15 mL) was hydrogenated at 30 psi
(2.1.times.10.sup.5 Pa) for 2 h on a Parr apparatus. The reaction
mixture was filtered through CELITE filter agent, which was rinsed
with ethyl acetate afterwards, and the filtrate was concentrated to
give
N.sup.4-[3-(1-{[tert-butyl(dimethyl)silyl]oxy}cyclohexyl)propyl]quinoline-
-3,4-diamine as an orange colored gum. The gum was dissolved in
dichloromethane (15 mL) and the solution was cooled to 0.degree. C.
Ethoxyacetyl chloride (0.350 mL, 3.48 mmol) was added dropwise over
2 min. The reaction was allowed to stir at 0.degree. C. for 1 h,
then was concentrated in vacuo to yield
N-(4-{[3-(1-{[tert-butyl(dimethyl)silyl]oxy}cyclohexyl)propyl]amino}quino-
lin-3-yl)-2-ethoxyacetamide hydrochloride as a yellow solid. The
yellow solid was dissolved in ethanol (12 mL) and 2 M NaOH (2.4 mL,
4.8 mmol) was added. The reaction was heated at 60.degree. C. for 1
h. The reaction was cooled to rt and the solvent was removed in
vacuo. The residue was partitioned between dichloromethane (50 mL)
and water (30 mL), and 1 M HCl was added to the mixture until the
pH=7-8. The aqueous layer was extracted with dichloromethane
(2.times.15 mL). The combined organic layers were dried over
MgSO.sub.4, filtered, and concentrated to afford
1-[3-(1-{[tert-butyl(dimethyl)silyl]oxy}cyclohexyl)propyl]-2-(ethoxymethy-
l)-1H-imidazo[4,5-c]quinoline as a brown oil (1.57 g, 96%) that
contained some dichloromethane.
Part H
An aqueous solution of 3 M HCl (3.0 mL) was added to a solution of
1-[3-(1-{[tert-butyl(dimethyl)silyl]oxy}cyclohexyl)propyl]-2-(ethoxymethy-
l)-1H-imidazo[4,5-c]quinoline (prepared as described in part G,
3.16 mmol) in methanol (10 mL). A solid formed and additional
methanol (10 mL) was added. The reaction was stirred at rt for 3 d
and the solvent was removed in vacuo. The residue was dissolved in
dichloromethane (40 mL) and saturated aqueous sodium bicarbonate
(30 mL) was added so that the pH=8. The aqueous layer was extracted
with dichloromethane (20 mL). The combined organic layers were
dried over MgSO.sub.4, filtered, and concentrated to yield
1-{3-[2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]propyl}cyclohexanol
(1.14 g, 98%) as a brown gum.
Part I
To a solution of
1-{3-[2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]propyl}cyclohexanol
(1.10 g, 2.99 mmol) in chloroform (15 mL) at rt was added m-CPBA
(0.96 g, 3.89 mmol) in portions. The reaction was stirred for 1.5
h, then was cooled to 0.degree. C. and concentrated ammonium
hydroxide (5 mL) was added followed by portionwise addition of
p-toluenesulfonyl chloride (0.630 g, 3.29 mmol). The mixture was
stirred at 0.degree. C. for 1 h, then was filtered. The filtrate
was diluted with dichloromethane (30 mL) and saturated aqueous
sodium bicarbonate (30 mL). The layers were separated and the
aqueous layer was extracted with dichloromethane (20 mL). The
organic layers were combined, dried over MgSO.sub.4, filtered, and
concentrated to afford an orange solid, which was purified by HPFC
(silica gel, eluted with 0-35% CMA/chloroform). The appropriate
fractions were concentrated to afford a tan solid that was
crystallized from chloroform/hexanes and dried at 75.degree. C.
under vacuum to afford
1-{3-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]propyl}cycl-
ohexanol as white crystals (600 mg, 53%), mp 175-176.degree. C.
Anal. calcd for C.sub.22H.sub.30N.sub.4O.sub.2: C, 69.08; H, 7.91;
N, 14.65. Found: C, 68.94; H, 8.21; N, 14.53.
Example 13
2-(Ethoxymethyl)-1-({4-[2-(methylsulfonyl)ethoxy]piperidin-4-yl}methyl)-1H-
-imidazo[4,5-c]quinolin-4-amine
##STR00075## Part A
To a solution of tert-butyl
4-{[2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}-4-hydroxypipe-
ridine-1-carboxylate (prepared as described in Part E of Example 4,
1.9 g, 4.3 mmol) in tetrahydrofuran (17 mL) at rt was added solid
NaH (60%, 17 mg, 0.43 mmol). After 10 min, methyl vinyl sulfone
(0.92 g, 8.6 mmol) was added dropwise. After 1 h, the reaction was
quenched with water (50 mL) and extracted with ethyl acetate (50
mL). The organic layer was concentrated under reduced pressure to
afford a yellow oil. Purification by flash chromatography (silica
gel, eluted with 5% methanol/dichloromethane) yielded tert-butyl
4-{[2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}-4-[2-(methyls-
ulfonyl)ethoxy]piperidine-1-carboxylate (0.40 g, 19%).
Part B
To a solution of
4-{[2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}-4-[2-(methyls-
ulfonyl)ethoxy]piperidine-1-carboxylate (0.7 g, 1.28 mmol) in
chloroform (13 mL) at rt was added m-chloroperbenzoic acid (m-CPBA,
0.37 g, 1.28 mmol). After 30 min, the solution was transferred to a
reparatory funnel, diluted with chloroform (50 mL), and washed with
saturated aqueous Na.sub.2CO.sub.3 (50 mL). The organic layer was
washed with saturated aqueous Na.sub.2CO.sub.3 (50 mL) and brine
(50 mL), dried over Na.sub.2SO.sub.4, filtered, and concentrated
under reduced pressure to an orange colored oil. To the oil was
added dichloromethane (6 mL) and concentrated ammonium hydroxide (2
mL). p-Toluenesulfonyl chloride (TsCl, 0.270 g, 1.41 mmol) was
added in portions. After 10 min, the reaction mixture was
partitioned between chloroform (50 mL) and saturated aqueous
Na.sub.2CO.sub.3. The organic layer was washed with brine (50 mL),
dried over Na.sub.2SO.sub.4, filtered, and concentrated under
reduced pressure. The crude product was purified by flash
chromatography (silica gel, eluted with 5%
methanol/dichloromethane) to provide tert-butyl
4-{[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}-4-[2--
(methylsulfonyl)ethoxy]piperidine-1-carboxylate as a white foam
(0.40 g, 56%).
Part C
A solution of HCl in ethanol (4.2 M, 0.8 mL, 3.56 mmol) was added
to a suspension of tert-butyl
4-{[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}-4-[2--
(methylsulfonyl)ethoxy]piperidine-1-carboxylate (0.40 g, 0.71 mmol)
in ethanol (4 mL) at rt. The resulting yellow solution was heated
at reflux for 1.5 h. The reaction was stirred at rt for 16 h, then
was concentrated under reduced pressure. The resulting solid was
dissolved in water (20 mL) and 20% aqueous NaOH was added until the
pH=13. The solution was extracted with dichloromethane (3.times.50
mL). The organic layers were combined, washed with brine (50 mL),
dried over Na.sub.2SO.sub.4, filtered, and concentrated under
reduced pressure to provide a solid that was crystallized from
acetonitrile. The crystals were dried under vacuum at 65.degree. C.
to provide
2-(ethoxymethyl)-1-({4-[2-(methylsulfonyl)ethoxy]piperidin-4-yl}methyl)-1-
H-imidazo[4,5-c]quinolin-4-amine (0.25 g, 76%) as crystalline
plates, mp 212-214.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 8.26 (d, J=8.1 Hz, 1H), 7.61 (d, J=8.1 Hz, 1H), 7.44 (t,
J=8.1 Hz, 1H), 7.26 (t, J=8.1 Hz, 1H), 6.61 (bs, 2H), 4.85 (s, 2H),
4.81 (s, 2H), 3.70 (t, J=5.6 Hz, 2H), 3.55 (q, J=7.5 Hz, 2H), 3.19
(t, J=5.6 Hz, 2H), 2.92 (s, 3H) 2.66-2.58 (m, 4H), 1.84 (bs, 1H),
1.70-1.66 (m, 2H), 1.48-1.38 (m, 2H), 1.16 (t, J=7.5 Hz, 3H); MS
(APCI) m/z 462 (M+H).sup.+; Anal. Cacld for
C.sub.22H.sub.31N.sub.5O.sub.4S: C, 57.25; H, 6.77: N, 15.17.
Found: C, 57.48; H, 7.05; N, 15.57.
Example 14
1-({1-Acetyl-4-[2-(methylsulfonyl)ethoxy]piperidin-4-yl}methyl)-2-(ethoxym-
ethyl)-1H-imidazo[4,5-c]quinolin-4-amine
##STR00076## Part A
To a solution of tert-butyl
4-{[2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}-4-hydroxypipe-
ridine-1-carboxylate (prepared as described in Part E of Example 4,
14.94 g, 33.91 mmol) in ethanol (170 mL) was added a solution of
HCl in ethanol (2.7 M, 31 mL, 84.7 mmol). The solution was heated
at reflux for 1 h, during which time a precipitate formed. The
mixture was allowed to cool to rt and the volatiles were removed
under reduced pressure. To the residue was added water (400 mL)
followed by 50% aqueous NaOH until the pH=10. The solution was
extracted with dichloromethane (3.times.100 mL). The aqueous layer
was treated with 50% aqueous NaOH until the pH=12, then was
extracted with dichloroemethane (2.times.100 mL). The organic
layers were combined, dried over Na.sub.2SO.sub.4, filtered, and
concentrated under reduced pressure. The resulting solid was
triturated with hot ethyl acetate and the remaining solid was
isolated by filtration to afford
4-{[2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}piperidin-4-ol
(7.0 g, 61%) as an off-white powder.
Part B
Acetyl chloride (0.57 mL, 8.1 mmol) was added to a suspension of
4-{[2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}piperidin-4-ol
(2.50 g, 7.34 mmol) and triethylamine (1.50 mL, 11.0 mmol) in
dichloromethane (37 mL) at rt. The resulting solution was stirred
for 1 h. The solution was diluted with dichloromethane (100 mL) and
washed with water (50 mL) and saturated aqueous sodium bicarbonate
(50 mL). The combined aqueous layers were back-extracted with
dichloromethane (50 mL). The combined organic layers were washed
with brine (50 mL), dried over Na.sub.2SO.sub.4, filtered, and
concentrated under reduced pressure to a brown foam. Purification
by flash chromatography (silica gel, eluted with 10%
methanol/dichloromethane) provided
1-acetyl-4-{[2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}piper-
idin-4-ol as a white foam (1.8 g, 64%).
Part C
1-Acetyl-4-{[2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}piper-
idin-4-ol (1.80 g, 4.68 mmol) was converted into
1-({1-acetyl-4-[2-(methylsulfonyl)ethoxy]piperidin-4-yl}methyl)-2-(ethoxy-
methyl)-1H-imidazo[4,5-c]quinoline according to the method
described in Part A of Example 13. Purification by flash
chromatography (silica gel, eluted with 10%
methanol/dichloromethane) yielded
1-({1-acetyl-4-[2-(methylsulfonyl)ethoxy]piperidin-4-yl}methyl)-2-(ethoxy-
methyl)-1H-imidazo[4,5-c]quinoline (0.30 g, 13%) and recovered
starting material,
1-acetyl-4-{[2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]me-
thyl}piperidin-4-ol (1.20 g).
Part D
1-({1-Acetyl-4-[2-(methylsulfonyl)ethoxy]piperidin-4-yl}methyl)-2-(ethoxy-
methyl)-1H-imidazo[4,5-c]quinoline (0.28 g, 0.57 mmol) was
converted into
1-({1-acetyl-4-[2-(methylsulfonyl)ethoxy]piperidin-4-yl}methyl)-2-(ethoxy-
methyl)-1H-imidazo[4,5-c]quinolin-4-amine according to the method
described in Part B of Example 13. Purification by flash
chromatography twice (silica gel, eluted with 10%
methanol/dichloromethane) followed by crystallization from
acetonitrile yielded
1-({1-acetyl-4-[2-(methylsulfonyl)ethoxy]piperidin-4-yl}methyl)-2-(ethoxy-
methyl)-1H-imidazo[4,5-c]quinolin-4-amine (0.10 g, 34%) as
crystalline plates, mp 208-210.degree. C. .sup.1H NMR (300 MHz,
DMSO-d.sub.6) .delta. 8.27 (d, J=8.1 Hz, 1H), 7.61 (d, J=8.1 Hz,
1H), 7.45 (t, J=8.1 Hz, 1H), 7.27 (t, J=8.1 Hz, 1H), 6.62 (bs, 2H),
4.89 (s, 2H), 4.80 (s, 2H), 4.12 (d, J=13.8 Hz, 1H), 3.74 (t, J=5.6
Hz, 2H), 3.55 (q, J=6.8 Hz, 2H), 3.31 (t, J=5.6 Hz, 2H), 3.24-3.16
(m, 2H), 2.97 (s, 3H) 2.72 (t, J=11.8 Hz, 1H), 1.90 (s, 3H),
1.83-1.76 (m, 2H), 1.60-1.44 (m, 2H), 1.14 (t, J=6.8 Hz, 3H); MS
(APCI) m/z 504 (M+H).sup.+; Anal. Cacld for
C.sub.24H.sub.33N.sub.5O.sub.5S: C, 57.24; H, 6.60: N, 13.91.
Found: C, 57.08; H, 6.83; N, 13.90.
Example 15
1-{[4-Amino-2-(ethoxymethyl)-6,7,8,9-tetrahydro-1H-imidazo[4,5-c]quinolin--
1-yl]methyl}cyclopentanol
##STR00077##
A mixture of
1-{[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cyclop-
entanol (prepared as described in Example 3, 0.50 g, 1.47 mmol) and
platinum (IV) oxide (0.25 g) in trifluoroacetic acid (20 mL) was
hydrogenated at 50 psi (3.5.times.10.sup.5 Pa) for 5 d on a Parr
apparatus. The reaction mixture was filtered through CELITE filter
agent and the filtrate was treated with saturated aqueous NaOH
until the pH=14, then was extracted with dichloromethane
(3.times.100 mL). The organic layers were combined, dried over
MgSO.sub.4, filtered, and concentrated to an oil that was purified
by flash chromatography (silica gel, 10% methanol in
dichloromethane). The appropriate fractions were combined and
concentrated to yield a colorless oil. The oil was dissolved in
ethanol and 2.7 M HCl in ethanol (1 mL) was added and the mixture
was concentrated under reduced pressure. The resulting oil was
dissolved in water and Na.sub.2CO.sub.3 was added until the pH=12.
A gummy white solid formed and the mixture was heated at 60.degree.
C. for 20 min until a free flowing precipitate formed. The mixture
was allowed to cool to rt and the precipitate was isolated by
filtration and dried in a vacuum oven at 80.degree. C. to provide
1-{[4-amino-2-(ethoxymethyl)-6,7,8,9-tetrahydro-1H-imidazo[4,5-c]quinolin-
-1-yl]methyl}cyclopentanol as a white solid, mp 171-173.degree. C.
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 5.78 (br s, 2H), 4.77
(br s, 2H), 4.66 (s, 1H), 4.45 (br s, 2H), 3.46 (q, J=7.0 Hz, 2H),
2.95 (m, 2H), 2.66 (m, 2H), 1.82-1.36 (m, 12H), 1.11 (t, J=7.0 Hz,
3H); MS (ESI) m/z 345 (M+H).sup.+; Anal. Calcd for
C.sub.19H.sub.28N.sub.4O.sub.2.0.2H.sub.2O: C, 65.57; H, 8.22; N,
16.10. Found: C, 65.78; H, 8.27; N, 15.70.
Examples 16-53
A mixture (50 mL) of the 1.5 hydrate of the dihydrochloride salt of
4-[(4-amino-2-ethoxymethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]-4-hydro-
xypiperidine (2.26 g, 5 mmol, prepared in a similar manner as
described in Example 5) and anhydrous pyridine was heated until a
solution formed. The solution was allowed to cool and aliquots (1
mL, 0.1 mmol) were transferred to 50 test tubes. Appropriate
amounts of the reagents (1.1 equivalents) listed below were added
to the solutions in the test tubes. The test tubes were shaken
overnight. The solvent was removed from the test tubes by vacuum
centrifugation.
The compounds were purified by preparative high performance liquid
chromatography (prep HPLC) using a Waters Fraction Lynx automated
purification system. The prep HPLC fractions were analyzed using a
Micromass LC/TOF-MS, and the appropriate fractions were centrifuge
evaporated to provide the trifluoroacetate salt of the desired
compound. Column: Zorbax BonusRP, 21.2.times.50 millimeters (mm), 5
micron particle size; non-linear gradient elution from 5-95% B
where A is 0.05% trifluoroacetic acid/water and B is 0.05%
trifluoroacetic acid/acetonitrile; fraction collection by
mass-selective triggering. The table below shows the reagent used
for each example, the structure of the resulting compound, and the
observed accurate mass for the isolated trifluoroacetate salt.
TABLE-US-00001 ##STR00078## Measured Mass Example Reagent R (M + H)
16 Acetyl chloride ##STR00079## 398.2201 17 Methyl chloroformate
##STR00080## 414.2140 18 Cyclopropanecarbonyl chloride ##STR00081##
424.2343 19 Butyryl chloride ##STR00082## 426.2506 20
Cyclobutanecarbonyl chloride ##STR00083## 438.2492 21 Benzoyl
chloride ##STR00084## 460.2353 22 Cyclopentylacetyl chloride
##STR00085## 466.2838 23 3-Cyanobenzoyl chloride ##STR00086##
485.2313 24 3-Methoxybenzoyl chloride ##STR00087## 490.2451 25
3-Chlorobenzoyl chloride ##STR00088## 494.1923 26 Nicotinoyl
chloride hydrochloride ##STR00089## 461.2328 27 trans-2-Phenyl-1-
cyclopropanecarbonyl chloride ##STR00090## 500.2654 28
4-Acetamidobenzoyl chloride ##STR00091## 517.2612 29
Methanesulfonyl chloride ##STR00092## 434.1852 30 Ethanesulfonyl
chloride ##STR00093## 448.2020 31 1-Propanesulfonyl chloride
##STR00094## 462.2150 32 Benzenesulfonyl chloride ##STR00095##
496.2027 33 1-Methylimidazole-4- sulphonyl chloride ##STR00096##
500.2097 34 2-Fluorobenzenesulfonyl chloride ##STR00097## 514.1899
35 3-Fluorobenzenesulfonyl chloride ##STR00098## 514.1904 36
4-Fluorobenzenesulfonyl chloride ##STR00099## 514.1935 37
2-Cyanobenzenesulfonyl chloride ##STR00100## 521.1967 38
3-Cyanobenzenesulfonyl chloride ##STR00101## 521.1950 39
4-Cyanobcnzenesulfonyl chloride ##STR00102## 521.2000 40 Methyl
isocyanate ##STR00103## 413.2282 41 Ethyl isocyanate ##STR00104##
427.2455 42 Isopropyl isocyanate ##STR00105## 441.2593 43 Isopropyl
isothiocycante ##STR00106## 457.2386 44 Phenyl isocyanate
##STR00107## 475.2425 45 Cyclohexyl isocyanate ##STR00108##
481.2922 46 Benzyl isocyanate ##STR00109## 489.2624 47 m-Tolyl
isocyanate ##STR00110## 489.2628 48 3-Methoxyphenyl isocyanate
##STR00111## 505.2539 49 3-Chlorophenyl isocyanate ##STR00112##
509.2057 50 4-Chlorophenyl isocyanate ##STR00113## 509.2052 51
N,N-Dimethylcarbamoyl chloride ##STR00114## 427.2438 52
4-Morpholinylcarbonyl chloride ##STR00115## 469.2555 53 N-Methyl-N-
phenylcarbamoyl chloride ##STR00116## 489.2646
Example 54
N-(1-{[4-Amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cycl-
ohexyl)acetamide
##STR00117## Part A
Sodium cyanide (23.7 g, 482 mmol) was added to a solution of
ammonium hydroxide (28%, 122 mL, 965 mmol) and ammonium chloride
(28.4 mL, 531 mmol) in water (100 mL). Cyclohexanone (50 mL, 482
mmol) was added over 5 min. The reaction was heated at 60.degree.
C. for 6 h, then was allowed to cool to rt and stir overnight. The
mixture was transferred to a separatory funnel and was washed with
dichloromethane (3.times.200 mL). The organic layers were combined,
dried over MgSO.sub.4, filtered, and concentrated under reduced
pressure. Purification by flash chromatography (silica gel, eluted
with 20% hexanes/ethyl acetate) provided
1-aminocyclohexanecarbonitrile as a clear oil (49.5 g, 83%).
Part B
A mixture of 1-aminocyclohexanecarbonitrile (48.5 g, 391 mmol) and
platinum oxide (5.0 g) in 4.2 M HCl in ethanol (200 mL) and 2.7 M
HCl in ethanol (300 mL) was hydrogenated at 50 psi
(3.4.times.10.sup.5 Pa) for 20 h on a Parr apparatus. The reaction
mixture was filtered through CELITE filter agent and the filtrate
was concentrated to yield a clear oil. The oil was triturated with
isopropanol to yield a white solid that was isolated by filtration,
washed with ether, and dried to provide
1-(aminomethyl)cyclohexanamine dihydrochloride (70.0 g, 89%).
Part C
To a 0.degree. C. solution of 4-chloro-3-nitroquinoline (25.0 g,
120 mmol) and triethylamine (84 mL, 599 mmol) in dichloromethane
(500 mL) was added 1-(aminomethyl)cyclohexanamine dihydrochloride
(36.2 g, 180 mmol). The reaction was allowed to warm to rt and
stirred for 20 h. The reaction was transferred to a separatory
funnel and washed with water (200 mL). The water was back-extracted
with dichloromethane (2.times.500 mL). The organic layers were
combined, dried over Na.sub.2SO.sub.4, filtered, and concentrated
under reduced pressure to yield
N-[(1-aminocyclohexyl)methyl]-3-nitroquinolin-4-amine as a yellow
solid (35.5 g, 99%).
Part D
To a 0.degree. C. solution of
N-[(1-aminocyclohexyl)methyl]-3-nitroquinolin-4-amine (38.0 g, 127
mmol) in tetrahydrofuran (250 mL) was added dropwise 2 M aqueous
NaOH (64 mL, 128 mmol). A solution of di-tert-butyl dicarbonate
(27.6 g, 127 mmol) in tetrahydrofuran (150 mL) was added to the
reaction mixture over 60 min. The reaction was allowed to warm to
rt. After 3 d, additional di-tert-butyl dicarbonate (10 g) was
added to the reaction. The solvent was removed under reduced
pressure and the resulting orange oil was dissolved in
dichloromethane (1 L) and washed with water (3.times.500 mL). The
combined aqueous layers were back-extracted with dichloromethane
(500 mL). The organic layers were combined, dried over MgSO.sub.4,
filtered, and concentrated under reduced pressure to yield an
orange oil. Purification by flash chromatography (silica gel,
eluted with 30% ethyl acetate/hexanes) provided tert-butyl
1-{[(3-nitroquinolin-4-yl)amino]methyl}cyclohexylcarbamate as a
yellow solid (29.8 g, 59%).
Part E
A mixture of tert-butyl
1-{[(3-nitroquinolin-4-yl)amino]methyl}cyclohexylcarbamate (29.5 g,
73.7 mmol) and 5% platinum on carbon (0.30 g) in toluene (300 mL)
was hydrogenated at 50 psi (3.5.times.10.sup.5 Pa) for 4 hours (h)
on a Parr apparatus. The reaction mixture was diluted with ethanol
(200 mL) and was filtered through CELITE filter agent. The filtrate
was concentrated to give tert-butyl
1-{[(3-aminoquinolin-4-yl)amino]methyl}cyclohexylcarbamate as a
brown solid (27.3 g, 100%).
Part F
Ethoxyacetyl chloride (9.00 g, 73.4 mmol) was reacted with
tert-butyl
1-{[(3-aminoquinolin-4-yl)amino]methyl}cyclohexylcarbamate (27.2 g,
73.4 mmol) according to the method described in Part E of Example 9
and the resulting product was treated according to the method
described in Part E of Example 9. After the solvent was removed to
yield an oil, the oil was dissolved in ethanol (300 mL) and water
(30 mL). Sodium hydroxide (4.3 g, 108 mmol) was added and the
solution was heated at reflux for 6 h. The volatiles were removed
under reduced pressure and the resulting brown oil was partitioned
between dichloromethane (500 mL) and water. The organic layer was
dried over Na.sub.2SO.sub.4, filtered, and concentrated under
reduced pressure to yield a brown oil. Purification by flash
chromatography (silica gel, 30% ethyl acetate/hexanes) provided
tert-butyl
1-{[2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cyclohexylcarb-
amate as a brown solid (11.9 g, 38%).
Part G
To a solution of tert-butyl
1-{[2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cyclohexylcarb-
amate (24.6 g, 56.1 mmol) in ethanol (100 mL) was added 2.7 M HCl
in ethanol (150 mL). The solution was heated at 65.degree. C. for 4
h, the was allowed to cool to rt overnight. A light brown
precipitate was isolated by filtration and washed with ethanol. The
precipitate was dissolved in water (100 mL) and NaOH was added
until the pH=14. The mixture was extracted with dichloromethane
(3.times.200 mL). The organic layers were combined, dried over
Na.sub.2SO.sub.4, filtered, and concentrated to an oil that was
dissolved in ethanol (100 mL). To the ethanol solution was added
2.7 M HCl in ethanol (18.7 mL). A pale tan solid crashed out of
solution and was isolated by filtration and dried. The solid was
dissolved in water (100 mL) and NaOH was added until the pH=14. The
mixture was extracted with dichloromethane (3.times.200 mL). The
organic layers were combined, dried over Na.sub.2SO.sub.4,
filtered, and concentrated to yield
1-{[2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cyclohexanamin-
e as a light yellow oil (15.1 g, 79%).
Part H
Acetyl chloride (0.036 mL, 0.50 mmol) was added to a 0.degree. C.
solution of
1-{[2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cyclohexanamin-
e (0.17 g, 0.50 mmol) and triethylamine (0.11 mL, 0.75 mmol) in
dichloromethane (5 mL). The solution was stirred at 0 C for 2 h,
then at rt for 1 h. The reaction was repeated on a larger scale
with
1-{[2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cyclohexanamin-
e (2.00 g, 5.91 mmol). The reactions were combined and washed with
water (100 mL). The organic phase was dried over Na.sub.2SO.sub.4,
filtered, and concentrated under reduced pressure to yield a light
yellow oil. Purification by flash chromatography (silica gel, 15%
methanol/ethyl acetate) afforded
N-(1-{[2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cyclohexyl)-
acetamide as a white oil (2.20 g, 90%).
Part I
N-(1-{[2-(Ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cyclohexyl)-
acetamide (2.0 g, 5.26 mmol) was converted to
N-(1-{[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cyc-
lohexyl)acetamide following the method described in part F of
Example 9. The final product was crystallized from ethyl
acetate/hexanes to afford
N-(1-{[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cyc-
lohexyl)acetamide (0.52 g, 25%) as light tan crystals, mp
178-180.degree. C. .sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 8.29
(dd, J=8.3, 1.0 Hz, 1H), 7.80 (dd, J=8.4, 0.9 Hz, 1H), 7.51 (ddd,
J=8.3, 7.0, 1.3 Hz, 1H), 7.32 (ddd, J=8.3, 6.9, 1.4 Hz, 1H), 5.46
(br s, 2H), 5.19 (br s, 1H), 5.07 (br s, 2H), 4.83 (br s, 2H), 3.62
(m, 2H), 2.39 (br s, 2H), 1.94 (s, 3H), 1.65-1.44 (m, 3H),
1.39-0.95 (m, 8H); MS (ESI) m/z 396 (M+H).sup.+; Anal. Calcd for
C.sub.22H.sub.29N.sub.5O.sub.2. 0.25H.sub.2O: C, 66.06; H, 7.43; N,
17.51. Found: C, 65.73; H, 7.61; N, 17.48.
Example 55
N-(1-{[4-Amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cycl-
ohexyl)methanesulfonamide
##STR00118## Part A
Methanesulfonyl chloride (0.75 mL, 9.75 mmol) was added to a
0.degree. C. solution of
1-{[2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cyclohexanamin-
e (2.75 g, 8.13 mmol), 4-dimethylaminopyridine (DMAP, 2.75 g) and
pyridine (11 mL) in dichloromethane (28 mL). The solution was
stirred at 0.degree. C. for 2 h, then at rt for 1 h. The reaction
was washed with water (100 mL). The organic phase was dried over
Na.sub.2SO.sub.4, filtered, and concentrated under reduced pressure
to yield a light yellow oil. Purification by flash chromatography
(silica gel, 20% methanol/ethyl acetate) afforded
N-(1-{[2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cyclohexyl)-
methanesulfonamide as a white solid (2.72 g, 80%).
Part B
N-(1-{[2-(Ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cyclohexyl)-
methanesulfonamide (2.60 g, 6.24 mmol) was converted into
N-(1-{[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cyc-
lohexyl)methanesulfonamide using the method described in Part F of
Example 10. The crude
N-(1-{[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cyc-
lohexyl)methanesulfonamide was purified by flash chromatography
twice (silica gel, eluted with 20% methanol/ethyl acetate for the
first column, and 15% methanol/dichloromethane for the second
column) then crystallized from acetonitrile to afford white
crystals (1.3 g, 48%), mp 186-188.degree. C. .sup.1H NMR (300 MHz,
DMSO-d.sub.6) .delta. 8.39 (m, 1H), 7.61 (dd, J=8.3, 1.4 Hz, 1H),
7.42 (ddd, J=8.3, 7.0, 1.3 Hz, 1H), 7.21 (ddd, J=8.3, 7.1, 1.4 Hz,
1H), 7.03 (br s, 1H), 6.45 (br s, 2H), 5.05 (br s, 2H), 4.84 (br s,
2H), 3.56 (q, J=7.0 Hz, 2H), 3.14 (s, 3H), 2.22-2.07 (m, 2H),
1.64-1.26 (m, 5H), 1.18-1.00 (m, 2H), 1.15 (t, J=7.0 Hz, 3H),
0.90-0.69 (m, 1H); MS (APCI) m/z 432 (M+H).sup.+; Anal. Calcd for
C.sub.21H.sub.29N.sub.5O.sub.3S: C, 58.45; H, 6.77; N, 16.23.
Found: C, 58.34; H, 6.80; N, 16.19.
Example 56
N-(1-{[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cycl-
ohexyl)-N-isopropylurea
##STR00119## Part A
Isopropyl isocyanate (0.15 mL, 1.45 mmol) was added to a solution
of
1-{[2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cyclohexanamin-
e (0.50 g, 1.45 mmol) dichloromethane (5 mL) at rt. After 4 h, the
reaction was set up on a larger scale with
1-{[2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cyclohexanamin-
e (1.50 g, 4.43 mmol). Both reactions were allowed to stir
overnight and additional isopropyl isocyanate (0.5 equivalent) was
added to each reaction. After stirring another day, the reactions
were combined and concentrated under reduced pressure to yield an
oil. The oil was triturated with hexane and
N-(1-{[2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cyclohexyl)-
-N'-isopropylurea was isolated as a white solid (2.23 g, 89%).
Part B
N-(1-{[2-(Ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cyclohexyl)-
-N'-isopropylurea (2.20 g, 5.19 mmol) was converted to
N-(1-{[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cyc-
lohexyl)-N'-isopropylurea following the method described in part F
of Example 9. The crude final product was purified by flash
chromatography (silica gel, eluted with 20% methanol/ethyl acetate)
to provide a tan oil. The oil was triturated with ethyl
acetate/hexanes to provide a white powder that was isolated by
filtration. The white powder was purified by flash chromatography
again (silica gel, 10% methanol/dichloromethane). The resulting oil
was dissolved in ethanol (20 mL) and 1 M HCl in ethanol (1 mL) was
added. After thirty minutes, the volatiles were removed under
reduced pressure and the residue was dissolved in water (100 mL).
Solid Na.sub.2CO.sub.3 was added to the solution until a
precipitate formed. The solid was isolated by filtration, washed
with water, and dried in a vacuum oven at 80.degree. C. to provide
N-(1-{[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cyc-
lohexyl)-N'-isopropylurea as a white solid (0.40 g, 18%), mp
135-160.degree. C. .sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 8.24
(m, 1H), 7.78 (m, 1H), 7.47 (m, 1H), 7.29 (m, 1H), 5.37 (br s, 2H),
5.03 (s, 2H), 4.83 (br s, 2H), 4.24 (br d, J=6.9 Hz, 1H), 4.00 (s,
1H), 3.85-3.74 (m, 1H), 3.64 (q, J=7.0 Hz, 2H), 1.72-0.96 (m, 10H),
1.23 (t, J=7.0 Hz, 3H), 1.14 (d, J=6.6 Hz, 6H); MS (APCI) m/z 439
(M+H).sup.+; Anal. Calcd for C.sub.24H.sub.34N.sub.6O.sub.2.
0.60H.sub.2O: C, 64.15; H, 7.90; N, 18.70. Found: C, 64.05; H,
7.77; N, 18.63.
Example 57
1-[(4-Amino-2-propyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]cycloh-
exanol
##STR00120## Part A
Triethylamine (8.38 mL, 60.1 mmol) was added over 10 min to a
stirred mixture of 4-chloro-3-nitro-1,5-naphthyridine (6.00 g, 28.6
mmol) and 1-aminomethyl-1-cyclohexanol hydrochloride (5.00 g, 30.1
mmol) in dichloromethane (115 mL) at 0.degree. C. The solution was
allowed to warm to rt and more 1-aminomethyl-1-cyclohexanol
hydrochloride (0.2 g) was added. The solution was stirred overnight
and more triethylamine (0.5 mL) was added. After 30 min, the
solution was partitioned between saturated aqueous sodium
bicarbonate (100 mL) and chloroform (200 mL). The aqueous layer was
extracted with chloroform (3.times.200 mL). The combined organic
extracts were washed with saturated aqueous sodium bicarbonate
(2.times.100 mL) and brine (80 mL), dried over MgSO.sub.4,
filtered, concentrated under reduced pressure, and dried under
vacuum to afford
1-{[(3-nitro[1,5]naphthyridin-4-yl)amino]methyl}cyclohexanol as a
yellow solid (8.65 g, 100%).
Part B
A mixture of
1-{[(3-nitro[1,5]naphthyridin-4-yl)amino]methyl}cyclohexanol (4.55
g, 15.1 mmol) and 5% platinum on carbon (0.50 g) in acetonitrile
(100 mL) was hydrogenated at 50 psi (3.5.times.10.sup.5 Pa)
overnight on a Parr apparatus. The reaction mixture was filtered
through CELITE filter agent, which was rinsed with methanol
afterwards. The filtrate was concentrated to give
1-{[(3-amino[1,5]naphthyridin-4-yl)amino]methyl}cyclohexanol. The
1-{[(3-amino[1,5]naphthyridin-4-yl)amino]methyl}cyclohexanol was
concentrated from chloroform several times to remove residual
methanol and was used directly onto the next step.
Part C
A solution of
1-{[(3-amino[1,5]naphthyridin-4-yl)amino]methyl}cyclohexanol
(prepared as described in Part B, 15.1 mmol), trimethyl
orthobutyrate (2.63 mL, 16.6 mmol), and pyridine hydrochloride
(0.650 g, 5.64 mmol) in toluene (100 mL) was heated at reflux
overnight. The solution was allowed to cool to rt, then was
concentrated under reduced pressure. The residue was partitioned
between chloroform (200 mL) and saturated aqueous sodium
bicarbonate (75 mL). The aqueous layer was extracted with
chloroform (2.times.50 mL). The combined organic layers were washed
with brine (50 mL), dried over MgSO.sub.4, filtered, and
concentrated under reduced pressure. The resulting solid was
triturated with ethyl acetate and isolated by filtration. The
filtrate was concentrated and the solid was again triturated with
ethyl acetate; this procedure was repeated two more times. The
white solids were combined and dried under vacuum to yield
1-[(2-propyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]cyclohexanol
(3.40 g, 70% over two steps).
Part D
To a solution of
1-[(2-propyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]cyclohexanol
(1.43 g, 4.41 mmol) in chloroform (20 mL) at rt was added
m-chloroperbenzoic acid (m-CPBA, 70%, 2.17 g, 8.82 mmol). After 1.5
h, the solution was was cooled to 0.degree. C. and concentrated
ammonium hydroxide (5 mL) was added. After 3 min, p-toluenesulfonyl
chloride (TsCl, 0.920 g, 4.85 mmol) was added in portions. After 1
h, the reaction mixture was filtered and the filter cake was washed
with chloroform. The filtrate was washed with saturated aqueous
sodium bicarbonate (50 mL) and dried over Na.sub.2SO.sub.4,
filtered, and concentrated under reduced pressure to yield an
orange foam which was purified twice by HPFC (silica gel, gradient
elution with 0-25% CMA/CHCl.sub.3 where CMA is a solution comprised
of 80% CHCl.sub.3, 18% MeOH, and 2% conc. NH.sub.4OH; followed by
0-30% CMA/CHCl.sub.3). The appropriate fractions were concentrated
and triturated with acetonitrile. The solid was isolated by
filtration and dried at 100.degree. C. under vacuum to yield
1-[(4-amino-2-propyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]cyclo-
hexanol (567 mg, 38%) as a white powder, mp 209.0-211.0.degree. C.
Anal. Calcd for C.sub.19H.sub.25N.sub.5O .0.2H.sub.2O C, 66.35; H,
7.47; N, 20.36; Found: C, 66.62; H, 7.34; N, 20.05.
Example 58
1-{[4-Amino-2-(ethoxymethyl)-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl]methy-
l}cyclohexanol
##STR00121## Part A
Ethoxyacetyl chloride (1.78 g, 14.6 mmol) was added dropwise to a
0.degree. C. solution of
1-{[(3-amino[1,5]naphthyridin-4-yl)amino]methyl}cyclohexanol
(prepared as described in Part B of Example 57, 13.2 mmol) in
dichloromethane (90 mL). After 1.5 h, more ethoxyacetyl chloride
(0.3 mL) was added and stirring was continued for another 30 min.
More ethoxyacetyl chloride (0.4 mL) was added and stirring was
continued overnight. The solvent was removed under reduced pressure
and the residue was dissolved in ethanol (90 mL). Sodium hydroxide
(1.06 g, 26.5 mmol) was added and the reaction was heated at reflux
for about 1 d. The solvent was removed under reduced pressure and
the residue was partitioned between dichloromethane (200 mL) and
water (100 mL). The aqueous phase was extracted with
dichloromethane (2.times.100 mL). The combined organic layers were
washed with brine (50 mL), dried over MgSO.sub.4, filtered, and
concentrated under reduced pressure to yield a brown foam. The foam
was triturated with ethyl acetate and sonicated briefly. A white
solid was isolated by filtration. The filtrate was concentrated and
the trituration process was repeated two more times. The off white
solids were combined and dried to yield
1-{[2-(ethoxymethyl)-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl]methyl}cyclo-
hexanol (3.40 g, 76% over three steps).
Part B
1-{[2-(Ethoxymethyl)-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl]methyl}cyclo-
hexanol (1.50 g, 4.41 mmol) was converted to
1-{[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]-1,5-naphthyridin-1-yl]meth-
yl}cyclohexanol according to the method described in Part D of
Example 57. The final product was purified by HPFC twice (silica
gel, gradient elution with 0-30% CMA/CHCl.sub.3). The appropriate
fractions were concentrated and triturated with acetonitrile. The
solid was isolated by filtration, recrystallized twice from
dichloromethane/hexanes and dried at 100.degree. C. under vacuum to
yield
1-{[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl]meth-
yl}cyclohexanol (350 mg, 22%) as a white powder, mp
171.0-173.0.degree. C. Anal. Calcd for
C.sub.19H.sub.25N.sub.5O.sub.2C, 64.20; H, 7.09; N, 19.70; Found:
C, 63.91; H, 7.40; N, 19.67.
Example 59
1-[(4-Amino-6,7-dimethyl-2-propyl-1H-imidazo[4,5-c]pyridin-1-yl)methyl]cyc-
lohexanol
##STR00122## Part A
A 500 mL round bottom flask was charged with
2,4-dichloro-5,6-dimethyl-3-nitropyridine (6.00 g, 27.1 mmol),
1-aminomethyl-1-cyclohexanol hydrochloride (4.94 g, 29.8 mmol), and
N,N-dimethylformamide (200 mL). The solution was cooled to
0.degree. C. and triethylamine (8.31 mL, 59.6 mmol) was added
dropwise. The solution was heated to 35.degree. C. for 3 d. The
volatiles were removed under reduced pressure and the resulting oil
was partitioned between dichloromethane (300 mL) and water (50 mL).
The organic layer was washed with water (50 mL) and brine (30 mL),
dried over MgSO.sub.4, filtered, concentrated under reduced
pressure, and dried under vacuum to yield
1-{[(2-chloro-5,6-dimethyl-3-nitropyridin-4-yl)amino]methyl}cyclohexanol
that was used without further manipulation in the next step.
Part B
A solution of
1-{[(2-chloro-5,6-dimethyl-3-nitropyridin-4-yl)amino]methyl}cyclohexanol
(prepared as described in Part A, 27.1 mmol), dibenzylamine (15.6
mL, 81.3 mmol), and triethylamine (5.67 mL, 40.7 mmol) in toluene
(100 mL) was heated at reflux for 7 d. The volatiles were removed
under reduced pressure and the residue was partitioned between
chloroform (300 mL) and water (100 mL). The aqueous layer was
extracted with chloroform (2.times.75 mL). The combined organic
layers were washed with brine (50 mL), dried over MgSO.sub.4,
filtered, and concentrated to give a semi-solid. The semi-solid was
triturated with 1:2 ethyl acetate/hexanes and filtered. The
filtrate was concentrated to an orange oil that was purified on a
Biotage (gradient elution, 0-30% ethyl acetate/hexanes) to yield an
oil contained both product and dibenzylamine. The oil was dissolved
in ethyl acetate (100 mL) and 1 M HCl in diethyl ether (50 mL) and
methanol (100 mL) were added. The solution was stirred for 10
minutes and the solvent was removed in vacuo. The residue was
triturated with 1:2 ethyl acetate/hexanes and filtered. The
filtrate was concentrated, and the resulting oil was dissolved in
chloroform (300 mL), washed with saturated aqueous sodium
bicarbonate (50 mL), dried over MgSO.sub.4, filtered, and
concentrated. The material was dissolved in ethyl acetate (400 mL)
and washed with 10% aqueous citric acid (2.times.100 mL), saturated
aqueous sodium bicarbonate (50 mL) and brine (50 mL), dried over
MgSO.sub.4, filtered, and concentrated in vacuo to yield
1-({[2-(dibenzylamino)-5,6-dimethyl-3-nitropyridin-4-yl]amino}methyl)cycl-
ohexanol (10.14 g, 79% yield over two steps).
Part C
A mixture of
1-({[2-(dibenzylamino)-5,6-dimethyl-3-nitropyridin-4-yl]amino}methyl)cycl-
ohexanol (4.00 g, 8.43 mmol) and 5% platinum on carbon (0.40 g) in
ethyl acetate (84 mL) was hydrogenated at 50 psi
(3.4.times.10.sup.5 Pa) for 3 h on a Parr apparatus. The reaction
mixture was filtered through CELITE filter agent, which was rinsed
with ethyl acetate afterwards. The filtrate was concentrated to
give
1-({[3-amino-2-(dibenzylamino)-5,6-dimethylpyridin-4-yl]amino}methyl)cycl-
ohexanol and was used directly in the next step.
Part D
1-({[3-amino-2-(dibenzylamino)-5,6-dimethylpyridin-4-yl]amino}methyl)cycl-
ohexanol (prepared as described in Part C, 8.43 mmol) was converted
to
1-{[4-(dibenzylamino)-6,7-dimethyl-2-propyl-1H-imidazo[4,5-c]pyridin-1-yl-
]methyl}cyclohexanol (4.08 g, 97%) according to the method
described in Part C of Example 57.
Part E
A mixture of
1-{[4-(dibenzylamino)-6,7-dimethyl-2-propyl-1H-imidazo[4,5-c]pyridin-1-yl-
]methyl}cyclohexanol (1.50 g, 3.02 mmol), ammonium formate (2.84 g,
45.0 mmol), and 10% palladium on carbon (1.50 g) in methanol (60
mL) and ethanol (120 mL) was heated at 85.degree. C. for 2 h. More
ammonium formate (1.00 g) was added and heating was continued of 3
h, then the reaction mixture was stirred overnight at rt. The
mixture was filtered through CELITE filter agent and the filtrate
was concentrated in vacuo. The crude product was purified using
HPFC (gradient elution with 10-40% CMA/chloroform). The appropriate
fractions were concentrated and the resulting solid was triturated
with acetonitrile. A solid was isolated by filtration and dried at
100.degree. C. under vacuum to provide
1-[(4-amino-6,7-dimethyl-2-propyl-1H-imidazo[4,5-c]pyridin-1-yl)methyl]cy-
clohexanol as a white powder (0.61 g, 64%), mp 214.0-216.0.degree.
C. Anal. Calcd for C.sub.18H.sub.28N.sub.4O C, 68.32; H, 8.92; N,
17.71; Found: C, 68.06; H, 8.65; N, 17.45
Example 60
4-{[4-Amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}tetra-
hydro-2H-pyran-4-ol
##STR00123## Part A
4-{[2-(2-Methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}tetrahydro-2-
H-pyran-4-ol was prepared according to the general methods of
Example 10 using methoxypropionyl chloride in lieu of ethoxyacetyl
chloride in Part E.
Part B
4-{[2-(2-Methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}tetrahydro-2-
H-pyran-4-ol (2.97 g) was oxidized and then aminated according to
the method of Part I of Example 12 except that the amination was
run at ambient temperature. The crude product was purified by HPFC
eluting with a gradient of 0 to 45% CMA in chloroform to provide a
yellow solid. The solid was triturated with acetonitrile, isolated
by filtration, and dried in a vacuum oven at 85.degree. C. to
provide
4-{[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}tetr-
ahydro-2H-pyran-4-ol as a tan solid, mp 205-206.degree. C. MS (ESI)
m/z 357 (M+H).sup.+; Anal. calcd for
C.sub.19H.sub.24N.sub.4O.sub.3: C, 64.03; H, 6.79; N, 15.72. Found:
C, 63.93; H, 6.79; N, 15.61.
Example 61
4-{[4-Amino-2-(2-hydroxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}tetra-
hydro-2H-pyran-4-ol
##STR00124##
A suspension of
4-{[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}tetr-
ahydro-2H-pyran-4-ol (0.95 g, 2.67 mmol) in dichloromethane (15 mL)
was cooled to 0.degree. C. Boron tribromide (8 mL, 8.00 mmol) was
added and the reaction mixture was allowed to stir overnight while
slowly warming to ambient temperature. The reaction mixture was
concentrated. The residue was taken up in a mixture of methanol (15
mL) and 6M hydrochloric acid (10 mL) and refluxed for 2.5 hours.
The reaction mixture was cooled to ambient temperature and the pH
was adjusted to 8 with 2M sodium hydroxide. The mixture was
extracted with chloroform (12.times.20 mL). The combined extracts
were dried over magnesium sulfate, filtered, and then concentrated
under reduced pressure to provide a yellow solid. This material
purified by HPFC eluting with a gradient of 0 to 45% CMA in
chloroform to provide an off white solid. The solid was triturated
with acetonitrile, isolated by filtration, and dried in a vacuum
oven at 140.degree. C. to provide 0.536 g of
4-{[4-amino-2-(2-hydroxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}tetr-
ahydro-2H-pyran-4-ol as a white solid, mp 237-238.degree. C. MS
(ESI) m/z 343 (M+H).sup.+; Anal. calcd for
C.sub.18H.sub.22N.sub.4O.sub.3: C, 63.14; H, 6.48; N, 16.36. Found:
C, 63.04; H, 6.57; N, 16.19.
Example 62
4-{[4-Amino-2-(hydroxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}tetrah-
ydro-2H-pyran-4-ol
##STR00125## Part A
4-[(2-Chloromethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetrahydro-2H-py-
ran-4-ol was prepared according to the general methods of Example
10 using chloroacetyl chloride in lieu of ethoxyacetyl chloride in
Part E.
Part B
3-Chloroperbenzoic acid (0.46 g) was added to a solution of
4-[(2-chloromethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetrahydro-2H-py-
ran-4-ol (0.44 g) in chloroform (8 mL) and the reaction mixture was
stirred at ambient temperature for 2 hours. The reaction mixture
was diluted with aqueous saturated sodium bicarbonate (30 mL) and
stirred for 20 minutes.
4-[(2-chloromethyl-5-oxy-1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetrahydro-
-2H-pyran-4-ol was isolated by filtration as a white solid.
Part C
Benzenesulfonyl chloride (0.36 mL) was added dropwise to a
suspension of the material from Part B in methanol (8 mL) and
ammonium hydroxide (0.44 mL). The reaction mixture was stirred at
ambient temperature and then filtered to provide
4-[(4-amino-2-chloromethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetrahyd-
ro-2H-pyran-4-ol hydrochloride as a white solid.
Part D
Potassium acetate (0.08 g) was added to a solution of material from
Part C (0.25 g) in N,N-dimethylformamide (4 mL). The reaction
mixture was stirred overnight. Additional potassium acetate (0.08
g) was added and the reaction mixture was stirred overnight. The
solvent was removed under vacuum to provide
4-[(4-amino-2-hydroxymethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetrahy-
dro-2H-pyran-4-ol acetate hydrochloride.
Part E
Potassium carbonate (0.36 g) was added to a solution of the
material from Part D in methanol (8 mL). The reaction mixture was
stirred for 1 hour and then concentrated under reduced pressure.
The residue was diluted with water and then extracted with
chloroform (20.times.10 mL). The combined extracts were dried over
magnesium sulfate, filtered, and then concentrated under reduced
pressure to provide a white solid. The solid was triturated with
acetonitrile, isolated by filtration, and dried in a vacuum oven at
85.degree. C. to provide 71 mg of
4-{[4-amino-2-(hydroxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}tetra-
hydro-2H-pyran-4-ol as a white solid, mp greater than 250.degree.
C. MS (ESI) m/z 329 (M+H).sup.+; Anal. calcd for
C.sub.17H.sub.20N.sub.4O.sub.3: C, 62.18; H, 6.14; N, 17.06. Found:
C, 61.97; H, 6.02; N, 17.00.
Example 63
4-[(4-Amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetrahydro-2H-py-
ran-4-ol
##STR00126## Part A
Trimethylorthovalerate (1.8 mL, 10.4 mmol) and pyridine
hydrochloride (92 mg, 0.8 mmol) were added to a suspension of
4-[(3-aminoquinolin-4-ylamino)methyl]tetrahydropyran-4-ol (8.0
mmol) in toluene (40 mL). The reaction mixture was heated at reflux
for 2.5 hours and then cooled to ambient temperature. A precipitate
was isolated by filtration and dried to provide
4-[(2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetrahydro-2H-pyran-4-o-
l as a white solid, mp 180-181.degree. C. MS (ESI) m/z 340
(M+H).sup.+; Anal. calcd for C.sub.20H.sub.25N.sub.3O.sub.2: C,
70.77; H, 7.42; N, 12.38. Found: C, 70.58; H, 7.53; N, 12.40.
Part B
The material from Part A was oxidized and then aminated according
to the method of Part I of Example 12 except that the amination was
run at ambient temperature. The crude product was triturated with
hot ethanol to provide 0.822 g of
4-[(4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetrahydro-2H-p-
yran-4-ol as a white solid, mp 235-236.degree. C. MS (ESI) m/z 355
(M+H).sup.+; Anal. calcd for C.sub.20H.sub.26N.sub.4O.sub.2: C,
67.77; H, 7.39; N, 15.81. Found: C, 67.57; H, 7.49; N, 15.84.
Example 64
4-[(4-Amino-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetrahydro-2H-p-
yran-4-ol
##STR00127## Part A
Trimethylorthobutyrate (1.9 mL, 12.0 mmol) and pyridine
hydrochloride (58 mg, 0.5 mmol) were added to a suspension of
4-[(3-aminoquinolin-4-ylamino)methyl]tetrahydropyran-4-ol (10.0
mmol) in toluene (50 mL). The reaction mixture was heated at reflux
for 4 hours and then concentrated under reduced pressure. The
residue was triturated with acetonitrile and the filtered to
provide
4-[(2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetrahydro-2H-pyran-4--
ol as a tan solid.
Part B
The material from Part A was oxidized and then aminated according
to the method of Part I of Example 12 except that the amination was
run at ambient temperature. The crude product was triturated with
hot ethanol to provide 0.758 g of
4-[(4-amino-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetrahydro-2H--
pyran-4-ol as a white solid, mp 231-233.degree. C. MS (ESI) m/z 341
(M+H).sup.+; Anal. calcd for C.sub.19H.sub.24N.sub.4O.sub.2: C,
67.04; H, 7.11; N, 16.46. Found: C, 66.85; H, 7.39; N, 16.42.
Example 65
4-[(4-Amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetrahydro-2H-py-
ran-4-ol
##STR00128## Part A
Triethylorthopropionate (2.4 mL, 12.0 mmol) and pyridine
hydrochloride (60 mg, 0.5 mmol) were added to a suspension of
4-[(3-aminoquinolin-4-ylamino)methyl]tetrahydropyran-4-ol (10.0
mmol) in toluene (50 mL). The reaction mixture was heated at reflux
for 2.5 hours and then concentrated under reduced pressure. The
residue was triturated with acetonitrile and the filtered to
provide
4-[(2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetrahydro-2H-pyran-4-o-
l as a tan solid.
Part B
The material from Part A was oxidized and then aminated according
to the method of Part I of Example 12 except that the amination was
run at ambient temperature. The crude product was triturated with
1M sodium hydroxide, isolated by filtration, washed with water, and
dried under vacuum at 85.degree. C. to provide 1.6 g of
4-[(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetrahydro-2H-p-
yran-4-ol as a tan solid, mp greater than 250.degree. C. MS (ESI)
m/z 327 (M+H).sup.+; Anal. calcd for
C.sub.18H.sub.22N.sub.4O.sub.2: C, 66.24; H, 6.79; N, 17.17. Found:
C, 65.99; H, 7.08; N, 17.23.
Example 66
4-[(4-Amino-2-ethoxymethyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]-
tetrahydro-2H-pyran-4-ol
##STR00129## Part A
A solution of 4-chloro-3-nitro[1,5]naphthyridine (16.6 g, 79.0
mmol) in dichloromethane (250 mL) and triethylamine (14.3 mL, 102.7
mmol) was cooled to 4.degree. C. A solution of
4-aminomethyltetrahydropyran-4-ol (11.4 g, 86.9 mmol) in
dichloromethane (70 mL) was added dropwise over a period of 30
minutes. The reaction mixture was allowed to stir at ambient
temperature over the weekend and then it was concentrated under
reduced pressure. The residue was stirred with water (300 mL). The
resulting solid was isolated by filtration, rinsed with water, and
dried in a vacuum oven at 50.degree. C. for 4 hours to provide
22.53 g of
4-[(3-nitro[1,5]naphthyridin-4-ylamino)methyl]tetrahydropyran-4-ol.
Part B
A mixture of
4-[(3-nitro[1,5]naphthyridin-4-ylamino)methyl]tetrahydropyran-4-ol
(12.2 g), 5% platinum on carbon (1.22 g), and ethyl acetate (160
mL) was placed under hydrogen pressure (40 psi, 2.8.times.10.sup.5
Pa) for 3 hours. The reaction mixture was filtered through a layer
of CELITE filter aid and the filter cake was rinsed with 1:1 ethyl
acetate:methanol (150 mL). The filtrate was concentrated under
reduced pressure to provide 12.66 g of
4-[(3-amino[1,5]naphthyridin-4-ylamino)methyl]tetrahydropyran-4-ol
as a thick semi-solid.
Part C
Ethoxyacetyl chloride (1.1 mL, 11.0 mmol) was added dropwise over a
period of 5 minutes to a chilled (0.degree. C.) suspension of
material from Part B (10.0 mmol) in dichloromethane (50 mL). The
reaction mixture was allowed to warm to ambient temperature and
then stirred for two hours. The reaction mixture was concentrated
under reduced pressure to provide
2-ethoxy-N-{4-[(4-hydroxytetrahydropyran-4-ylmethyl)amino][1,5]na-
pthyridin-3-yl}acetamide hydrochloride as an orange solid.
Part D
Triethylamine (4.2 mL, 30.0 mmol) was added to a solution of the
material from Part C in ethanol (40 mL). The reaction mixture was
heated at 60.degree. C. overnight and then concentrated under
reduced pressure. The residue was dissolved in dichloromethane (50
mL) and washed with aqueous saturated sodium bicarbonate (50 mL).
The aqueous layer was back extracted with dichloromethane
(2.times.25 mL). The combined organics were dried over magnesium
sulfate, filtered, and then concentrated under reduced pressure to
provide a dark yellow oil. This material was crystallized from
acetonitrile to provide 2.96 g of an off white solid. A portion
(375 mg) was recrystallized from acetonitrile to provide 281 mg of
4-{[2-(ethoxymethyl)-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl]methyl}te-
trahydro-2H-pyran-4-ol as white needles, mp 168-169.degree. C. MS
(ESI) m/z 343 (M+H).sup.+; Anal. calcd for
C.sub.18H.sub.22N.sub.4O.sub.3: C, 63.14; H, 6.48; N, 16.36. Found:
C, 63.06; H, 6.32; N, 16.28.
Part E
Material from Part D (2.92 g) was oxidized and then aminated
according to the method of Part I of Example 12. The crude product
was purified by HPFC eluting with a gradient of 0 to 30% CMA in
chloroform to provide a tan solid. This material was recrystallized
from methanol to provide 0.404 g of
4-[(4-amino-2-ethoxymethyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)methyl-
]tetrahydro-2H-pyran-4-ol as off-white needles, mp 166-167.degree.
C. MS (ESI) m/z 358 (M+H).sup.+; Anal. calcd for
C.sub.18H.sub.23N.sub.5O.sub.3: C, 60.49; H, 6.49; N, 19.59. Found:
C, 60.43; H, 6.45; N, 19.94.
Example 67
4-[(4-Amino-2-hydroxymethyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)methyl-
]tetrahydro-2H-pyran-4-ol
##STR00130##
Boron tribromide (8.4 mL of 1M in dichloromethane) was added
dropwise over a period of 10 minutes to a chilled (0.degree. C.)
suspension of
4-[(4-amino-2-ethoxymethyl-1H-imidazo[4,5-c]-1,5-naphthyridin-1-yl)methyl-
]tetrahydro-2H-pyran-4-ol (1.00 g, 2.81 mmol) in dichloromethane
(15 mL). The reaction mixture was allowed to slowly warm to ambient
temperature overnight, quenched with methanol (5 mL), and then
concentrated under reduced pressure. The residue was dissolved in
methanol (15 mL) and 6M hydrochloric acid (10 mL). The reaction
mixture was heated at reflux for 6 hours, cooled to ambient
temperature, neutralized with solid sodium bicarbonate and water
(15 mL), and then extracted with chloroform (6.times.15 mL). The
combined organics were dried over magnesium sulfate, filtered, and
then concentrated under reduced pressure to provide 0.72 g of a tan
solid. This material was purified by HPFC eluting with a gradient
of 0 to 50% CMA in chloroform to provide a white solid which was
dried under vacuum at 140.degree. C. for 20 hours to provide 0.39 g
of
4-[(4-amino-2-hydroxymethyl-1H-imidazo[4,5-c]-1,5-naphthyridin-1-yl)methy-
l]tetrahydro-2H-pyran-4-ol as off-white needles, mp greater than
250.degree. C. MS (ESI) m/z 330 (M+H).sup.+; Anal. calcd for
C.sub.16H.sub.19N.sub.5O.sub.3: C, 58.35; H, 5.81; N, 21.26. Found:
C, 58.32; H, 5.81; N, 21.21.
Example 68
4-{[4-Amino-2-(2-hydroxyethyl)-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl]met-
hyl}tetrahydro-2H-pyran-4-ol
##STR00131## Part A
4-{[2-(2-Methoxyethyl)-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl]methyl}tet-
rahydro-2H-pyran-4-ol was prepared according to the method of Parts
A through D of Example 66 using 3-methoxypropionyl chloride in lieu
of ethoxyacetyl chloride in Part C. The product was provided as
white needles, mp 156-157.degree. C. MS (ESI) m/z 343 (M+H).sup.+;
Anal. calcd for C.sub.18H.sub.22N.sub.4O.sub.3: C, 63.14; H, 6.48;
N, 16.36. Found: C, 62.91; H, 6.52; N, 16.53.
Part B
Material from Part A (2.1 g) was oxidized and then aminated
according to the method of Part I of Example 12. The crude product
was purified by HPFC eluting with a gradient of 0 to 50% CMA in
chloroform to provide a pale yellow oil. The oil was triturated
with acetonitrile to provide 0.83 g of
4-{[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c][1,5]naphthyridin-1--
yl]methyl}tetrahydro-2H-pyran-4-ol as a tan solid.
Part C
The ether linkage was cleaved according to the method of Example
67. The crude product was purified by HPFC eluting with a gradient
of 0 to 50% CMA in chloroform to provide a white solid which was
dried under vacuum at 140.degree. C. for 20 hours to provide 0.43 g
of
4-{[4-amino-2-(2-hydroxyethyl)-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl]me-
thyl}tetrahydro-2H-pyran-4-ol as off-white needles, mp
226-227.degree. C. MS (ESI) m/z 344 (M+H).sup.+; Anal. calcd for
C.sub.17H.sub.21N.sub.5O.sub.3: C, 59.46; H, 6.16; N, 20.40. Found:
C, 59.40; H, 6.17; N, 20.35.
Example 69
4-{[4-Amino-2-(3-hydroxypropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl]me-
thyl}tetrahydro-2H-pyran-4-ol
##STR00132## Part A
4-Benzyloxybutyric acid (0.87 mL, 4.93 mmol),
1-hydroxybenzotriazole (0.79 g, 5.83 mmol), and
N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide (1.12 g, 5.83 mmol)
were added to a solution of
4-[(3-amino[1,5]naphthyridin-4-ylamino)methyl]tetrahydropyran-4-ol
(1.23 g, 4.48 mmol) in DMF (20 mL). The reaction mixture was
stirred at ambient temperature for 5.5 hours. An additional 0.5 eq
of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide and
1-hydroxybenzotriazole were added and the reaction mixture was
stirred overnight. An additional 0.3 eq of the acid was added and
the reaction mixture was stirred for an hour. The reaction mixture
was combined with that from another run, diluted with water (100
mL), and extracted with dichloromethane (3.times.50 mL). The
combined organics were washed with brine (75 mL), dried over
magnesium sulfate, and then concentrated under reduced pressure to
provide 8.03 g of a brown oil. This material was purified by HPFC
eluting with a gradient of 0 to 35% CMA in chloroform to provide
2.67 g of
4-benzyloxy-N-4-[(4-hydroxytetrahydropyran-4-ylmethyl)amino][1,-
5]napthyridin-3-yl}butyramide as a yellow oil.
Part B
The material from Part A was combined with a solution of ammonia in
methanol (25 mL of 7M) and placed in a pressure vessel. The vessel
was sealed and then heated at 150.degree. C. for 18 hours. The
reaction mixture was cooled and then concentrated under reduced
pressure. The residue was purified by HPFC eluting with a gradient
of 0 to 40% CMA in chloroform to provide 1.77 g of
4-{[2-(3-benzyloxypropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl]methyl}-
tetrahydro-2H-pyran-4-ol as an off white solid.
Part C
The material from Part B was oxidized and then aminated according
to the method of Part I of Example 12. The crude product was
purified by HPFC eluting with a gradient of 0 to 40% CMA in
chloroform to provide a yellow oil. This material was triturated
with acetonitrile to provide 0.70 g of
4-{[4-amino-2-(3-benzyloxypropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl-
]methyl}tetrahydro-2H-pyran-4-ol as a tan solid.
Part D
Acetyl chloride (0.12 mL, 1.64 mmol) and ethanol (10 mL) were
combined at 0.degree. C. and then stirred at ambient temperature
for 30 minutes. The material from Part C (1.56 mmol) and 10%
palladium on carbon (0.14 g) were added and the mixture was placed
under hydrogen pressure (45 psi, 3.1.times.10.sup.5 Pa) over the
weekend. The reaction mixture was filtered through a layer of
CELITE filter aid and the filter cake was rinsed with methanol (30
mL). The filtrate was concentrated under reduced pressure. The
residue was combined with aqueous saturated sodium bicarbonate (30
mL) and then extracted with chloroform (9.times.15 mL). The
combined organics were dried over magnesium sulfate, filtered, and
then concentrated under reduced pressure to provide a yellow solid.
This material was purified by HPFC eluting with a gradient of 0 to
50% CMA in chloroform to provide 0.36 g of a white solid. This
material was triturated with hot methanol and then dried under
vacuum at 140.degree. C. to provide 140 mg of
4-{[4-amino-2-(3-hydroxypropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl]m-
ethyl}tetrahydro-2H-pyran-4-ol as off-white needles, mp
237-238.degree. C. MS (ESI) m/z 358 (M+H).sup.+; Anal. calcd for
C.sub.18H.sub.23N.sub.5O.sub.3: C, 60.49; H, 6.49; N, 19.59. Found:
C, 60.56; H, 6.48; N, 19.64.
Example 70
4-[(4-Amino-2-propyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]tetrah-
ydro-2H-pyran-4-ol
##STR00133## Part A
Trimethylorthobutyrate (1.9 mL, 12.0 mmol) and pyridine
hydrochloride (23 mg, 0.2 mmol) were added to a suspension of
4-[(3-amino[1,5]naphthyridin-4-ylamino)methyl]tetrahydropyran-4-ol
(10.0 mmol) in toluene (50 mL). The reaction mixture was heated at
reflux overnight and then concentrated under reduced pressure. The
residue was triturated with acetonitrile and the resulting solid
was isolated by filtration to provide 2.26 g of
4-[(2-propyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]tetrahydro-2H-
-pyran-4-ol as a tan solid.
Part B
The material from Part A was oxidized and aminated according to the
method of Part I of Example 12 except that the amination was run at
ambient temperature. The crude product was triturated with
acetonitrile to provide a yellow solid. This material was
recrystallized from hot ethanol to provide pale yellow crystals
which were triturated with hot acetonitrile and then dried under
vacuum at 85.degree. C. to provide 0.546 g of
4-[(4-amino-2-propyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]tetra-
hydro-2H-pyran-4-ol as off-white needles, mp 209-210.degree. C. MS
(ESI) m/z 342 (M+H).sup.+; Anal. calcd for
C.sub.18H.sub.23N.sub.5O.sub.2: C, 63.32; H, 6.79; N, 20.51. Found:
C, 63.44; H, 6.92; N, 20.65.
Example 71
4-[(4-Amino-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]tetrahydro-2H-p-
yran-4-ol
##STR00134## Part A
4-[(1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]tetrahydro-2H-pyran-4--
ol was prepared according to the method of Part A of Example 70
using trimethylorthoformate in lieu of trimethylorthobutyrate.
Part B
The material from Part A was oxidized and aminated according to the
method of Part I of Example 12 except that the amination was run at
5.degree. C. The crude product was purified by HPFC eluting with a
gradient of 0 to 35% CMA in chloroform to provide an off white
solid. This material was triturated with acetonitrile and then
dried in a vacuum oven at 85.degree. C. to provide 0.154 g of
4-[(4-amino-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]tetrahydro-2H--
pyran-4-ol as a beige solid, mp 225-226.degree. C. MS (ESI) m/z 300
(M+H).sup.+; Anal. calcd for C.sub.15H.sub.17N.sub.5O.sub.2: C,
60.19; H, 5.72; N, 23.40. Found: C, 59.97; H, 5.71; N, 23.39.
Example 72
4-[(4-Amino-2-ethyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]tetrahy-
dro-2H-pyran-4-ol
##STR00135## Part A
4-[(2-ethyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]tetrahydro-2H--
pyran-4-ol was prepared according to the method of Part A of
Example 70 using triethylorthopropionate in lieu of
trimethylorthobutyrate.
Part B
The material from Part A was oxidized and aminated according to the
method of Part I of Example 12 except that the amination was run at
5.degree. C. The crude product was triturated sequentially with hot
acetonitrile and hot ethanol and then purified by HPFC eluting with
a gradient of 0 to 30% CMA in chloroform to provide an off white
solid. This material was triturated with acetonitrile and then
dried in a vacuum oven at 85.degree. C. to provide 0.543 g of
4-[(4-amino-2-ethyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]tetrah-
ydro-2H-pyran-4-ol as off-white needles, mp greater than
250.degree. C. MS (ESI) m/z 328 (M+H).sup.+; Anal. calcd for
C.sub.17H.sub.21N.sub.5O.sub.2: C, 62.37; H, 6.47; N, 21.39. Found:
C, 62.38; H, 6.39; N, 21.53.
Example 73
1-[3-(4-Amino-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)propyl]cyclohexanol
##STR00136## Part A
Trimethylorthobutyrate (0.86 mL, 5.41 mmol) and pyridine
hydrochloride (0.03 g, 0.23 mmol) were added to a solution of
N.sup.4-{3-[1-tert-butyldimethylsilanyloxy)cyclohexyl]propyl}quinoline-3,-
4-diamine (4.51 mmol) in toluene (20 mL). The reaction mixture was
refluxed for 2 hours, cooled to ambient temperature, and then
concentrated under reduced pressure. The residue was dissolved in
dichloromethane (100 mL) and washed with aqueous saturated sodium
bicarbonate (50 mL). The aqueous was extracted with dichloromethane
(2.times.20 mL). The combined organics were dried over magnesium
sulfate, filtered, and then concentrated under reduced pressure to
provide 2.23 g of crude
1-{3-[1-tert-butyldimethylsilanyloxy)cyclohexyl]propyl}-2-propyl-
-1H-imidazo[4,5-c]quinoline as an orange goo.
Part B
The tert-butyldimethylsilyl group was removed according to the
method of Part H of Example 12 to provide
1-[3-(2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)propyl]cyclohexanol
as a brown solid.
Part C
The material from Part B was oxidized and then aminated according
to the method of Part I of Example 12. The crude product was
purified by HPFC eluting with a gradient of 0 to 35% CMA in
chloroform to provide a tan solid. This material was recrystallized
3 times from chloroform/hexanes and then dried in a vacuum oven at
75.degree. C. to provide 239 mg of
1-[3-(4-amino-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)propyl]cyclohexanol
as off-white needles, mp 200.5-201.5.degree. C. MS (ESI) m/z 367
(M+H).sup.+; Anal. calcd for C.sub.22H.sub.30N.sub.4O: C, 72.10; H,
8.25; N, 15.29. Found: C, 72.00; H, 8.50; N, 15.42.
Example 74
1-[2-(4-Amino-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)ethyl]cyclohexanol
##STR00137## Part A
N.sup.4-{2-[1-tert-butyldimethylsilanyloxy)cyclohexyl]ethyl}quinoline-3,4-
-diamine was prepared according to the general methods of Parts A
through G of Example 12 except that vinyl magnesium bromide was
used in lieu of allyl magnesium bromide in Part A and the
tert-butyldimethylsilanyl protecting group was installed by
treating a solution of the cyclohexanol in dichloromethane with
tert-butyldimethylsilyl trifluoromethanesulfonate in the presence
of 2,6-lutidine.
Part B
Trimethylorthoacetate (1.1 mL) and pyridine hydrochloride (42 mg,
0.37 mmol) were added to a suspension of
N.sup.4-{2-[1-tert-butyldimethylsilanyloxy)cyclohexyl]ethyl}quinoline-3,4-
-diamine (2.95 g, 7.38 mmol) in toluene (30 mL). The reaction
mixture was refluxed for 2.5 hours, cooled to ambient temperature,
and then concentrated under reduced pressure. The residue was
dissolved in dichloromethane (80 mL) and washed with aqueous
saturated sodium bicarbonate (50 mL). The aqueous was extracted
with dichloromethane (30 mL). The combined organics were dried over
magnesium sulfate, filtered, and then concentrated under reduced
pressure to provide
1-{2-[1-tert-butyldimethylsilanyloxy)cyclohexyl]ethyl}-2-methyl-1H-imidaz-
o[4,5-c]quinoline as a brown solid.
Part C
The tert-butyldimethylsilyl group was removed according to the
method of Part H of Example 12. The crude product was purified by
HPFC eluting with a gradient of 0 to 40% CMA in chloroform to
provide 1.70 g of
1-[2-(2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)ethyl]cyclohexanol as
a tan solid.
Part D
The material from Part C was oxidized and then aminated according
to the method of Part I of Example 12. The crude product was
triturated sequentially with hot methanol and hot ethanol and then
dried in a vacuum oven at 85.degree. C. to provide 0.549 g of
1-[2-(4-amino-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)ethyl]cyclohexanol
as beige needles, mp>252.degree. C. MS (ESI) m/z 325
(M+H).sup.+; Anal. calcd for C.sub.19H.sub.24N.sub.4O .0.02
CHCl.sub.3: C, 69.90; H, 7.41; N, 17.14. Found: C, 69.69; H, 7.41;
N, 16.95.
Example 75
1-[2-(4-Amino-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)ethyl]cyclohexanol
##STR00138##
1-[2-(4-Amino-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)ethyl]cyclohexanol
was prepared according to the method of Parts A through D of
Example 74 using trimethylorthobutyrate in lieu of
trimethylorthoacetate in Part B. The crude product was purified by
HPFC eluting with a gradient of 0 to 40% CMA in chloroform to
provide a tan solid. This material was recrystallized from hot
chloroform and then triturated with hot acetonitrile to provide
0.444 g of pure product as beige needles, mp 181-182.degree. C. MS
(ESI) m/z 353 (M+H).sup.+; Anal. calcd for
C.sub.21H.sub.28N.sub.4O: C, 71.56; H, 8.01; N, 15.90. Found: C,
71.37; H, 8.15; N, 15.82.
Example 76
1-{2-[4-Amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethyl}cycloh-
exanol
##STR00139##
1-{2-[4-Amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]ethyl}cyclo-
hexanol was prepared according to the general methods of Parts G
through I of Example 12 using
N-{2-[1-tert-butyldimethylsilanyloxy)cyclohexyl]ethyl}-3-nitroquinolin-4--
amine in lieu of
N.sup.4-{3-[1-tert-butyldimethylsilanyloxy)cyclohexyl]propyl}-3-nitroquin-
olin-4-amine in Part G. The crude product was purified by HPFC
eluting with a gradient of 0 to 25% CMA in chloroform to provide a
tan solid. This material was recrystallized from hot chloroform to
provide 0.346 g of pure product as off-white needles, mp
205-206.degree. C. MS (ESI) m/z 369 (M+H).sup.+; Anal. calcd for
C.sub.21H.sub.28N.sub.4O.sub.2: C, 68.45; H, 7.66; N, 15.20. Found:
C, 68.38; H, 7.74; N, 15.13.
Example 77
N-({4-Amino-1-[(1-hydroxycyclohexyl)methyl]-1H-imidazo[4,5-c]quinolin-2-yl-
}methyl)cyclopropanecarboxamide
##STR00140## Part A
Potassium phthalimide (2.59 g, 14.0 mmol) was added to a solution
of
1-[(4-amino-2-chloromethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclohex-
anol (13.3 mmol) in DMF (50 mL). The reaction mixture was stirred
at ambient temperature overnight. Additional potassium phthalimide
(1.0 g) was added. The reaction mixture was stirred for 5 hours and
then concentrated under reduced pressure. The residue was
triturated with methanol to provide 6.91 g of crude
2-({4-amino-1-[(1-hydroxycyclohexyl)methyl]-1H-imidazo[4,5-c]quinolin-2-y-
l}methyl)isoindole-1,3-dione as a white solid.
Part B
Hydrazine (2.1 mL, 66.5 mmol) was added to a suspension of the
material from Part A in ethanol (50 mL). The reaction mixture was
stirred at ambient temperature for 24 hours and then concentrated
under reduced pressure. The residue was sonicated with 1M
hydrochloric acid (50 mL) and then filtered. The filtrate was
adjusted to pH 8 with solid sodium bicarbonate. The resulting
precipitate was isolated by filtration and dried in a vacuum oven
at 50.degree. C. to provide 2.99 g of
1-[(4-amino-2-aminomethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclohexa-
nol as a white powder.
Part C
Triethylamine (0.28 mL, 2.01 mmol) was added to a suspension of
material from Part B (0.503 g, 1.55 mmol) in dichloromethane (12
mL). The mixture was cooled to 0.degree. C. and cyclopropylcarbonyl
chloride (0.15 mL, 1.62 mmol) was added. The reaction mixture was
stirred overnight at ambient temperature and then diluted with
dichloromethane (50 mL) and aqueous saturated sodium bicarbonate
(40 mL). The layers were separated and the aqueous layer was
extracted with dichloromethane (2.times.20 mL). The combined
organics were dried over magnesium sulfate, filtered, and then
concentrated under reduced pressure to provide 0.70 g of a white
solid. This material was purified by HPFC eluting with a gradient
of 0 to 45% CMA in chloroform to provide 0.56 g of a white powder.
This material was triturated with hot acetonitrile, isolated by
filtration, and dried under high vacuum at 100.degree. C. to
provide 0.440 g of
N-({4-amino-1-[(1-hydroxycyclohexyl)methyl]-1H-imidazo[4,5-c]quinolin-2-y-
l}methyl)cyclopropanecarboxamide as white needles, mp is greater
than 250.degree. C. MS (ESI) m/z 394 (M+H).sup.+; Anal. calcd for
C.sub.22H.sub.27N.sub.5O.sub.2: C, 67.15; H, 6.92; N, 17.80. Found:
C, 66.93; H, 7.07; N, 17.92.
Example 78
1-[(4-Amino-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclohexanol
##STR00141## Part A
A mixture of 1-[(3-nitroquinolin-4-ylamino)methyl]cyclohexanol
(10.0 g, 33.2 mmol), 5% platinum on carbon (1.0 g), and ethyl
acetate (140 mL) was placed under hydrogen pressure (40 psi,
2.8.times.10.sup.5 Pa) for 2.5 hours. The reaction mixture was
filtered through a layer of CELITE filter aid and the filter cake
was rinsed with ethyl acetate (100 mL). The filtrate was
concentrated under reduced pressure to provide
1-[(3-aminoquinolin-4-ylamino)methyl]cyclohexanol as an orange
gooey solid.
Part B
Trimethylorthoacetate (1.7 mL, 13.2 mmol) was added to a suspension
of material from Part A (11.0 mmol) in toluene (45 mL). The
reaction mixture was heated at reflux for 6 hours, allowed to cool
to ambient temperature, and then concentrated under reduced
pressure. The residue was triturated with acetonitrile to provide
2.61 g of
1-[(2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclohexanol as
a tan solid.
Part C
The material from Part B was oxidized and then animated using the
method of Part I of Example 12 except that the amination was run at
ambient temperature. The crude product was triturated sequentially
with 2M sodium hydroxide and hot ethanol to provide 1.00 g of
1-[(4-amino-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclohexanol
as beige needles, mp is greater than 250.degree. C. MS (ESI) m/z
311 (M+H).sup.+; Anal. calcd for C.sub.18H.sub.22N.sub.4O: C,
69.65; H, 7.14; N, 18.05. Found: C, 69.64; H, 7.40; N, 18.35.
Example 79
1-[(4-Amino-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclohexanol
##STR00142##
1-[(4-Amino-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclohexanol was
prepared according to the general methods of Example 78 except that
trimethylorthoformate was used in lieu of trimethylorthoacetate in
Part B. The crude product was triturated sequentially with 1M
sodium hydroxide and hot ethanol and then further purified by HPFC
eluting with a gradient of 0 to 50% CMA in chloroform to provide an
off-white solid. This material was triturated with boiling methanol
and then dried in a vacuum oven at 130.degree. C. to provide
product as off-white needles, mp greater than 250.degree. C. MS
(ESI) m/z 297 (M+H).sup.+; Anal. calcd for
C.sub.17H.sub.20N.sub.4O: C, 68.90; H, 6.80; N, 18.90. Found: C,
68.57; H, 6.62; N, 18.75.
Example 80
1-{[4-Amino-2-(hydroxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cycloh-
exanol
##STR00143## Part A
Ethyl chloroacetimidate hydrochloride (1.90 g, 12.0 mmol) was added
to a solution of 1-[(3-aminoquinolin-4-ylamino)methyl]cyclohexanol
(10.0 mmol) in 1,2-dichloroethane (70 mL) and the reaction mixture
was heated at 65.degree. C. for 8 hours. Additional imidate (1.2
eq) was added and the reaction mixture was heated at 65.degree. C.
overnight. Additional imidate (2 eq) was added in portions over a
period of 6 hours. The reaction mixture was cooled to ambient
temperature. A solid was isolated by filtration and rinsed with
dichloromethane. The solid was stirred with water for 30 minutes,
isolated by filtration, and then dried to provide 2.77 g of
1-(2-chloromethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cycloh-
exanol.
Part B
A portion (2.34 g, 7.09 mmol) of the material from Part A was
oxidized and then animated using the method of Part I of Example 12
except that the amination was run at ambient temperature. The crude
product was triturated with acetonitrile to provide 0.57 g of
1-{[4-amino-2-(chloromethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cycloh-
exanol as a tan solid.
Part C
Potassium acetate (0.28 g, 2.89 mmol) was added to a solution of
1-{[4-amino-2-(chloromethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cycloh-
exanol (0.83 g, 2.41 mmol) in DMF (10 mL). The reaction mixture was
stirred at ambient temperature overnight and then concentrated
under reduced pressure to provide crude
[4-amino-1-(1-hydroxycyclohexylmethyl)-1H-imidazo[4,5-c]quinolin-2-yl]met-
hyl acetate.
Part D
Potassium carbonate (0.67 g, 4.82 mmol) was added to a solution of
the material from Part C in methanol (10 mL). The reaction mixture
was stirred at ambient temperature for 1 hour and then concentrated
under reduced pressure. The residue was triturated sequentially
with water and hot acetonitrile and then dried in a vacuum oven at
85.degree. C. to provide 0.458 g of
1-{[4-amino-2-(hydroxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cyclo-
hexanol as tan needles, mp 244-248.degree. C. MS (ESI) m/z 327
(M+H).sup.+; Anal. calcd for C.sub.18H.sub.22N.sub.4O.sub.2: C,
66.24; H, 6.79; N, 17.17. Found: C, 66.23; H, 6.57; N, 17.04.
Example 81
4-[2-(4-Amino-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)ethyl]tetrahydro-2H--
pyran-4-ol
##STR00144## Part A
N-{2-[4-tert-butyldimethylsilanyloxy)tetrahydropyran-4-yl]ethyl}-3-nitroq-
uinolin-4-amine was prepared according to the general method of
Part A of Example 74 except that tetrahydropyran-4-one was used in
lieu of cyclohexanone.
Part B
Acetic acid (27 mL) and water (9 mL) were added to a solution of
N-{2-[4-tert-butyldimethylsilanyloxy)tetrahydropyran-4-yl]ethyl}-3-nitroq-
uinolin-4-amine in tetrahydrofuran (THF, 9 mL). The reaction
mixture was heated at 50.degree. C. for 2 hours. Analysis indicated
that the protecting group was still in place. 6M hydrochloric acid
(5 mL) was added, the reaction mixture was heated at 50.degree. C.
for 48 hours, and then concentrated under reduced pressure. The
residue was slurried with aqueous saturated sodium bicarbonate (50
mL) and the pH was adjusted to 8 with solid sodium bicarbonate. A
solid was isolated by filtration and then triturated with
dichloromethane to provide 3.43 g of
4-[2-(3-nitroquinolin-4-ylamino)ethyl]tetrahydropyran-4-ol as a
yellow solid.
Part C
A mixture of the material from Part B (3.43 g, 10.8 mmol), 5%
platinum on carbon (0.34 g), and ethyl acetate (50 mL) was placed
under hydrogen pressure (40 psi, 2.8.times.10.sup.5 Pa) for 3
hours. The reaction mixture was filtered through a layer of CELITE
filter aid and the filter cake was rinsed with ethyl acetate (100
mL). The filtrate was concentrated under reduced pressure to
provide 2.92 g of
4-[2-(3-aminoquinolin-4-ylamino)ethyl]tetrahydropyran-4-ol as a
yellow solid.
Part D
Trimethylorthobutyrate (0.93 mL, 5.88 mmol) and pyridine
hydrochloride (27 mg, 0.23 mmol) were added to a suspension of a
portion (1.30 g, 4.52 mmol) of the material from Part C in toluene
(20 mL). The reaction mixture was heated at reflux for 3 hours,
allowed to cool to ambient temperature, and then concentrated under
reduced pressure. The residue was dissolved in dichloromethane (20
mL), decolorized with charcoal, and then concentrated under reduced
pressure to provide a yellow solid. This material was
recrystallized from acetonitrile to provide 0.491 g of
4-[2-(2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)ethyl]tetrahydro-2H-pyran-4-
-ol as white needles, mp 186-188.degree. C. MS (ESI) m/z 340
(M+H).sup.+; Anal. calcd for C.sub.20H.sub.25N.sub.3O.sub.2: C,
70.77; H, 7.42; N, 12.38. Found: C, 70.63; H, 7.31; N, 12.43.
Part E
The material from Part D was oxidized and then animated using the
method of Part I of Example 12. The crude product was triturated
with 2M sodium hydroxide. The resulting solid was recrystallized
from chloroform/hexanes and dried under vacuum at 85.degree. C. to
provide 0.322 g of
4-[2-(4-amino-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)ethyl]tetrahydro-2H-
-pyran-4-ol as beige needles, mp 181-183.degree. C. MS (ESI) m/z
355 (M+H).sup.+; Anal. calcd for C.sub.20H.sub.26N.sub.4O.sub.2: C,
67.77; H, 7.39; N, 15.81. Found: C, 67.62; H, 7.59; N, 15.84.
Example 82
4-[2-(4-Amino-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)ethyl]tetrahydro-2H--
pyran-4-ol
##STR00145## Part A
4-[2-(2-Methyl-1H-imidazo[4,5-c]quinolin-1-yl)ethyl]tetrahydro-2H-pyran-4-
-ol was prepared according to the methods of Parts A through D of
Example 81 except that trimethylorthoacetate was used in lieu of
trimethylorthobutyrate in Part D. The crude product was triturated
with acetonitrile to provide 0.69 g of product as a grey solid.
Part B
The material from Part A was oxidized and then animated using the
method of Part I of Example 12. The crude product was triturated
with 2M sodium hydroxide. The resulting solid was recrystallized
from chloroform/hexanes and dried under vacuum at 120.degree. C. to
provide 0.363 g of
4-[2-(4-amino-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)ethyl]tetrahydro-2H-
-pyran-4-ol as beige needles, mp greater than 253.degree. C. MS
(ESI) m/z 327 (M+H).sup.+; Anal. calcd for
C.sub.18H.sub.22N.sub.4O.sub.2: C, 66.24; H, 6.79; N, 17.17. Found:
C, 65.98; H, 6.80; N, 16.97.
Example 83
4-[2-(4-Amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)ethyl]tetrahydro-2H-p-
yran-4-ol
##STR00146## Part A
4-[2-(2-Ethyl-1H-imidazo[4,5-c]quinolin-1-yl)ethyl]tetrahydro-2H-pyran-4--
ol was prepared according to the methods of Parts A through D of
Example 81 except that triethylorthopropionate was used in lieu of
trimethylorthobutyrate in Part D. The crude product was triturated
with acetonitrile to provide 0.78 g of product as a grey solid.
Part B
The material from Part A was oxidized and then animated using the
method of Part I of Example 12. The crude product was triturated
with 2M sodium hydroxide. The resulting solid was recrystallized
from chloroform/hexanes and dried under vacuum at 120.degree. C. to
provide 0.405 g of
4-[2-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)ethyl]tetrahydro-2H--
pyran-4-ol as yellow needles, mp 243-244.degree. C. MS (ESI) m/z
341 (M+H).sup.+; Anal. calcd for C.sub.19H.sub.24N.sub.4O.sub.2: C,
67.04; H, 7.11; N, 16.46. Found: C, 66.81; H, 7.28; N, 16.29.
Example 84
1-[2-(4-Amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)ethyl]cyclopropanol
##STR00147## Part A
Sodium carbonate (21.1 g, 199 mmol) was added to a suspension of
.beta.-alanine ethyl ester hydrochloride (10.2 g, 66.4 mmol) and
benzyl bromide (16.2 mL, 136 mmol) in acetonitrile (265 mL). The
reaction mixture was stirred at ambient temperature overnight and
then filtered through a layer of CELITE filter aid. The filter cake
was rinsed with acetonitrile (100 mL). The filtrate was
concentrated under reduced pressure to provide 20.28 g of ethyl
3-dibenzylaminopropionate as a pale yellow oil.
Part B
Titanium(IV) isopropoxide (3.9 mL, 13.28 mmol) was added to a
solution of the material from Part A in diethyl ether. The mixture
was cooled to 4.degree. C. and ethylmagnesium bromide (63 mL of
3.16 M in diethyl ether) was added dropwise over a period of 90
minutes while maintaining the temperature at 1.5-4.degree. C. The
reaction mixture was stirred at ambient temperature overnight.
Hydrochloric acid (75 mL of 3 M) was added and the reaction mixture
was stirred at ambient temperature for 2 hours. The reaction
mixture was made basic with solid sodium bicarbonate and diluted
with water (200 mL). The layers were separated. The aqueous layer
was extracted with diethyl ether (4.times.100 mL). The combined
organics were dried over magnesium sulfate, filtered, and then
concentrated under reduced pressure to provide a yellow oil. This
material was purified by HPFC eluting with a gradient of 0 to 40%
ethyl acetate in hexanes to provide 6.73 g of
1-[2-(dibenzylamino)ethyl]cyclopropanol as a pale yellow oil.
Part C
Ammonium formate (6.03 g, 95.7 mmol) and 10% palladium on carbon
(1.10 g) were added to a solution of the material from Part B in
methanol (95 mL). The reaction mixture was stirred at 65.degree. C.
for 2 hours and then filtered through a layer of CELITE filter aid.
The filter cake was rinsed with methanol (70 mL). The filtrate was
concentrated under reduced pressure to provide 2.78 g of crude
1-(2-aminoethyl)cyclopropanol.
Part D
The material from Part C was dissolved in a mixture of
dichloromethane (65 mL) and triethylamine (6.0 mL, 43.4 mmol). The
solution was cooled to 0.degree. C. and then
4-chloro-3-nitroquinoline (4.53 g, 21.7 mmol) was added in portions
over a period of 5 minutes. The reaction mixture was stirred over
the weekend while slowly warming to ambient temperature. The
reaction mixture was diluted with dichloromethane (20 mL) and
aqueous saturated sodium bicarbonate (40 mL). The layers were
separated and the aqueous layer was extracted with dichloromethane
(2.times.15 mL). The combined organics were dried over magnesium
sulfate, filtered, and then concentrated under reduced pressure.
The residue was triturated with acetonitrile to provide 3.16 g of
1-[2-(3-nitroquinolin-4-ylamino)ethyl]cyclopropanol as a yellow
solid.
Part E
A mixture of the material from Part D, 5% platinum on carbon (0.32
g), and ethyl acetate (50 mL) was placed under hydrogen pressure
(40 psi, 2.8.times.10.sup.5 Pa) for 3 hours. The reaction mixture
was filtered through a layer of CELITE filter aid and the filter
cake was rinsed with ethyl acetate (75 mL). The filtrate was
concentrated under reduced pressure to provide crude
1-[2-(3-aminoquinolin-4-ylamino)ethyl]cyclopropanol.
Part F
Triethylorthopropionate (1.2 mL, 5.78 mmol) and pyridine
hydrochloride (45 mg, 0.39 mmol) were added to a suspension of the
material from Part E in toluene (16 mL). The reaction mixture was
heated at reflux for 2.5 hours, allowed to cool to ambient
temperature, and the precipitate was isolated by filtration to
provide 0.68 g of
1-[2-(2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)ethyl]cyclopropanol as
a white solid.
Part G
The material from Part F was oxidized and then aminated according
to the general method of Part I of Example 12. The crude product
was triturated with 2M sodium hydroxide, recrystallized from
chloroform/methanol 99/1 and hexanes, and then dried in a vacuum
oven at 85.degree. C. to provide 300 mg of
1-[2-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)ethyl]cycl-
opropanol as white needles, mp 199-200.degree. C. MS (ESI) m/z 297
(M+H).sup.+; Anal. calcd for C.sub.17H.sub.20N.sub.4O: C, 68.90; H,
6.80; N, 18.90. Found: C, 68.72; H, 7.04; N, 18.83.
Example 85
1-[2-(4-Amino-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)ethyl]cyclopropanol
##STR00148##
1-[2-(4-Amino-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)ethyl]cyclopropanol
was prepared and purified according to the methods of Parts A
through G of Example 84 using trimethylorthoacetate in lieu of
triethylorthopropionate in Part F. The product was provided as
white needles, mp decomposed at 203.degree. C. MS (ESI) m/z 283
(M+H).sup.+; Anal. calcd for C.sub.16H.sub.18N.sub.4O: C, 68.06; H,
6.43; N, 19.84. Found: C, 67.86; H, 6.33; N, 19.87.
Example 86
1-[2-(4-Amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl)ethyl]cyclop-
ropanol
##STR00149## Part A
Ethoxyacetyl chloride (0.43 mL) was added to a cooled (0.degree.
C.) solution of 1-[2-(3-aminoquinolin-4-ylamino)ethyl]cyclopropanol
(3.85 mmol) in dichloromethane (16 mL). The reaction mixture was
stirred at 0-5.degree. C. for 60 minutes and then concentrated
under reduced pressure to provide crude
2-ethoxy-N-{4-[2-(1-hydroxycyclopropyl)ethylamino]quinolin-3-yl}acetamide
hydrochloride.
Part B
Triethylamine (1.6 mL) was added to a solution of the material from
Part A in ethanol (16 mL). The reaction mixture was stirred at
ambient temperature overnight and then at 60.degree. C. for 2
hours. The reaction mixture was concentrated under reduced pressure
and the residue was partitioned between dichloromethane (50 mL) and
aqueous saturated sodium bicarbonate (40 mL). The aqueous layer was
separated and extracted with dichloromethane (2.times.20 mL). The
combined organics were dried over magnesium sulfate, filtered, and
then concentrated under reduced pressure to provide a green solid.
This material was triturated with acetonitrile to provide 0.77 g of
1-[2-(2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl)ethyl]cyclopropanol
as a white solid.
Part C
The material from Part F was oxidized and then aminated according
to the general method of Part I of Example 12. The crude product
was triturated with 2M sodium hydroxide, recrystallized from
chloroform/methanol 99/1 and hexanes, and then dried in a vacuum
oven at 85.degree. C. to provide 0.333 g of
1-[2-(4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl)ethyl]cyclo-
propanol as white needles, mp 210-211.degree. C. MS (ESI) m/z 327
(M+H).sup.+; Anal. calcd for C.sub.18H.sub.22N.sub.4O.sub.2: C,
66.24; H, 6.79; N, 17.17. Found: C, 65.98; H, 6.82; N, 17.08.
Example 87
1-[3-(4-Amino-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)propyl]cyclopropanol
##STR00150##
1-[3-(4-amino-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)propyl]cyclopropano-
l was prepared according to the general methods of Parts A through
G of Example 84 except that ethyl 4-aminobutyrate hydrochloride was
used in lieu of .beta.-alanine ethyl ester hydrochloride in Part A
and trimethylorthoacetate was used in lieu of
triethylorthopropionate in Part F. The crude product was triturated
with 2M sodium hydroxide and the resulting tan solid was purified
by HPFC eluting with a gradient of 0 to 60% CMA in chloroform to
provide 0.57 g of an off white solid. This material was triturated
with hot acetonitrile and then dried in a vacuum oven at 85.degree.
C. to provide 0.34 g of product as off-white needles, mp
210-212.degree. C. MS (ESI) m/z 297 (M+H).sup.+; Anal. calcd for
C.sub.17H.sub.20N.sub.4O: C, 68.90; H, 6.80; N, 18.90. Found: C,
68.69; H, 7.06; N, 19.07.
Example 88
1-[(4-Amino-2-ethyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]cyclopr-
opanol
##STR00151## Part A
Ethyl bromoacetate (19.52 mL, 176 mol) was added in a single
portion to a chilled (0.degree. C.) solution of dibenzylamine
(33.84 mL, 176 mmol) and triethylamine (27 mL, 193.6 mmol) in THF.
The reaction mixture was stirred overnight at ambient temperature.
Additional triethylamine (30 mL) and THF (100 mL) were added and
the reaction mixture was heated at 50.degree. C. for 1.5 hours.
Additional ethyl bromoacetate (13 mL) was added and the reaction
mixture was heated for 1 hour and then stirred at ambient
temperature overnight. About half of the THF was removed under
reduced pressure. The mixture was diluted with water (300 mL) and
then extracted with ethyl acetate (2.times.400 mL). The combined
extracts were washed sequentially with water and with brine, dried
over sodium sulfate, filtered, and then concentrated under reduced
pressure. The residue was purified by flash chromatography (700 g
of silica gel, eluting with 20% ethyl acetate in hexanes) to
provide 37.12 g of ethyl dibenzylaminoacetate as a colorless
oil.
Part B
1-[(4-Amino-2-ethyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]cyclop-
ropanol was prepared according to the general methods of Parts B
through G of Example 84 using ethyl dibenzylaminoacetate in lieu of
ethyl 3-dibenzylaminopropionate in Part B and
4-chloro-3-nitronaphthyridine in lieu of 4-chloro-3-nitroquinoline
in Part D. The crude product was triturated with acetonitrile to
provide a tan solid. This material was purified by HPFC eluting
with a gradient of 0-35% CMA in chloroform to provide an off white
solid. This material was triturated with hot acetonitrile and then
dried in a vacuum oven at 85.degree. C. to provide 0.515 g of
product as an off-white solid, mp 210-212.degree. C. MS (APCI) m/z
284 (M+H).sup.+; Anal. calcd for C.sub.15H.sub.17N.sub.5O: C,
63.59; H, 6.05; N, 24.72. Found: C, 63.27; H, 5.99; N, 25.06.
Example 89
1-{[4-Amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cyclopr-
opanol
##STR00152## Part A
1-[(3-Aminoquinolin-4-ylamino)methyl]cyclopropanol was prepared
according to the methods of Parts B through E of Example 84 using
ethyl dibenzylaminoacetate in lieu of ethyl
3-dibenzylaminopropionate in Part B.
Part B
1-{[4-Amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cyclop-
ropanol was prepared according to the methods of Parts A through C
of Example 86 using
1-[(3-aminoquinolin-4-ylamino)methyl]cyclopropanol in lieu of
1-[2-(3-aminoquinolin-4-ylamino)ethyl]cyclopropanol in Part A. The
crude was purified by HPFC eluting with a gradient of 0-50% CMA in
chloroform to provide a tan solid. This material was recrystallized
from chloroform and hexanes and dried in a vacuum oven at
85.degree. C. to provide product as tan crystals, mp
185-186.degree. C. MS (ESI) m/z 313 (M+H).sup.+; Anal. calcd for
C.sub.17H.sub.20N.sub.4O.sub.2: C, 65.37; H, 6.45; N, 17.94. Found:
C, 65.14; H, 6.43; N, 17.92.
Example 90
1-[(4-Amino-2-propyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]cyclop-
ropanol
##STR00153##
1-[(4-Amino-2-propyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]cyclo-
propanol was prepared according to the general methods of Parts D
through G of Example 84 using 1-(aminomethyl)cyclopropanol in lieu
of 1-(2-aminoethyl)cyclopropanol in Part D,
4-chloro-3-nitronaphthyridine in lieu of 4-chloro-3-nitroquinoline
in Part D, and trimethyl orthobutyrate in lieu of triethyl
orthopropionate in Part F. The crude product was triturated with
hot acetonitrile to provide a tan solid. Which was recrystallized
from chloroform and hexanes and dried at 140.degree. C. under
vacuum to provide product as an off-white solid, mp 199-200.degree.
C. MS (ESI) m/z 298 (M+H).sup.+; Anal. calcd for
C.sub.16H.sub.19N.sub.5O: C, 64.63; H, 6.44; N, 23.55. Found: C,
64.32; H, 6.62; N, 23.67.
Example 91
1-[(4-Amino-2-(ethoxymethyl)-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)methy-
l]cyclopropanol
##STR00154##
1-[(4-Amino-2-(ethoxymethyl)-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)meth-
yl]cyclopropanol was prepared according to the general methods of
Example 89 using 4-chloro-3-nitronaphthyridine in lieu of
4-chloro-3-nitroquinoline in Part A. The crude product was purified
by HPFC eluting with a gradient of 0-35% CMA in chloroform followed
by recrystallization from hot acetonitrile to provide product as an
off-white solid, mp 178-179.degree. C. MS (APCI) m/z 314
(M+H).sup.+; Anal. calcd for C.sub.16H.sub.19N.sub.5O.sub.2: C,
61.33; H, 6.11; N, 22.35. Found: C, 60.99; H, 6.09; N, 22.52.
Example 92
N-(1-{[4-Amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cycl-
opropyl)methanesulfonamide
##STR00155## Part A
Ethyl cyanoacetate (15 mL, 141 mmol) was added to a mixture of
potassium carbonate (48.7 g, 353 mmol) and acetone (200 mL).
1,2-Dibromoethane (13.4 mL, 155 mmol) was added dropwise over a
period of 8 minutes. The reaction mixture was refluxed overnight.
More 1,2-dibromoethane (1.8 mL) was added and the reaction mixture
was refluxed for 4 hours. The reaction mixture was filtered through
a layer of CELITE filter aid. The filter cake was rinsed with
acetone (200 mL). The filtrate was concentrated under reduced
pressure to provide ethyl 1-cyanocyclopropionate as a pale orange
oil.
Part B
Concentrated hydrochloric acid (25 mL) and platinum oxide (0.98 g)
were added to a solution of the material from Part A in ethanol
(225 mL). The mixture was placed under hydrogen pressure (40 psi,
2.8.times.10.sup.5 Pa) on a Parr apparatus for 20 hours. The
reaction mixture was filtered through a layer of CELITE filter aid.
The filter cake was rinsed with methanol (200 mL). The filtrate was
concentrated under reduced pressure. The residue was reconcentrated
under reduced pressure three times from methanol and twice from
toluene to provide 31.7 g of ethyl 1-aminomethylcyclopropionate
hydrochloride.
Part C
Triethylamine (41 mL, 294 mmol) was added to a suspension of
4-chloro-3-nitroquinoline (24.5 g, 118 mmol) in dichloromethane
(250 mL). The mixture was cooled to 5.degree. C. A solution of the
material from Part B in dichloromethane (200 mL) was added over a
period of 15 minutes. The reaction mixture was stirred at 5.degree.
C. for 1 hour and then at ambient temperature overnight. The
reaction mixture was washed with aqueous saturated sodium
bicarbonate (250 mL). The aqueous layer was back extracted with
dichloromethane (2.times.50 mL). The combined organics were dried
over magnesium sulfate, filtered, and then concentrated under
reduced pressure to provide an orange oil. This material was
recrystallized from acetonitrile to provide 21.47 g of ethyl
1-[(3-nitroquinolin-4-ylamino)methyl]cyclopropionate as a bright
yellow solid.
Part D
A mixture of material from Part C (8.0 g, 25.4 mmol), 5% platinum
on carbon (0.80 g), and ethyl acetate (100 mL) was placed under
hydrogen pressure (30 psi, 2.1.times.10.sup.5 Pa) on a Parr
apparatus for 3 hours. The reaction mixture was filtered through a
layer of CELITE filter aid. The filter cake was rinsed with ethyl
acetate (50 mL). The filtrate was concentrated under reduced
pressure to provide ethyl
1-[(3-aminoquinolin-4-ylamino)methyl]cyclopropionate as a yellow
solid.
Part E
Ethoxyacetyl chloride (2.9 mL, 28 mmol) was added dropwise over a
period of 5 minutes to a chilled (0.degree. C.) solution of the
material from Part D in dichloromethane (100 mL). The reaction
mixture was allowed to slowly warm to ambient temperature overnight
and then concentrated under reduced pressure to provide crude ethyl
1-{[3-(2-ethoxyacetylamino)quinolin-4-ylamino]methyl}cyclopropionate
hydrochloride.
Part F
Triethylamine (10.6 mL, 76.2 mmol) was added to a solution of the
material from Part E in ethanol (100 mL). The reaction mixture was
heated at 60.degree. C. overnight and then concentrated under
reduced pressure. The residue was dissolved in dichloromethane (100
mL) and washed with aqueous saturated sodium bicarbonate (75 mL).
The aqueous layer was back extracted with dichloromethane
(2.times.35 mL). The combined organics were dried over magnesium
sulfate, filtered, and then concentrated under reduced pressure to
provide 9.5 g of ethyl
1-[(2-ethoxymethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclopropionate
as a brown semisolid.
Part G
Sodium hydroxide (8.5 mL of 6 M) was added to a solution of the
material from Part F in ethanol (80 mL). The reaction mixture was
stirred at ambient temperature for 3 hours and then concentrated
under reduced pressure. The residue was slurried with water (60
mL). The pH of the mixture was adjusted to 12 and then it was
extracted with diethyl ether (3.times.20 mL). The pH of the aqueous
was adjusted to 4 and a precipitate formed. The precipitate was
isolated by filtration to provide 4.36 g of
1-[(2-ethoxymethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclop-
ropropanecarboxylic acid.
Part H
Triethylamine (3.9 mL, 27.7 mol) and diphenylphosphoryl azide (2.2
mL, 10.1 mmol) were added to a chilled (0.degree. C.) suspension of
material from Part G (3.00 g, 9.2 mmol) in toluene (45 mL). The
reaction mixture was stirred at 0.degree. C. for 2 hours, warmed to
ambient temperature, and then stirred for an additional 4 hours.
Tert-butanol was added and the reaction mixture was refluxed
overnight. The reaction mixture was diluted with dichloromethane
(50 mL) and aqueous saturated sodium bicarbonate (75 mL). The
aqueous was back extracted with dichloromethane (2.times.30 mL).
The combined organics were dried over magnesium sulfate, filtered,
and then concentrated under reduced pressure to provide 3.41 g of
tert-butyl
{1-[(2-ethoxymethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclopropyl}car-
bamate as an off white foam.
Part I
Hydrochloric acid (2 mL of 6M) was added to a solution of material
from Part H (0.49 g, 1.24 mmol) in ethanol (4 mL). The reaction
mixture was heated at 50.degree. C. for 4 hours, cooled to ambient
temperature, and then concentrated under reduced pressure. The
residue was concentrated under reduced pressure from methanol 3
times. The resulting solid was triturated with acetonitrile to
provide 0.43 g of
1-[(2-ethoxymethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclopropylamine
hydrochloride.
Part J
Methanesulfonyl chloride (0.12 mL, 1.6 mmol) was added dropwise to
a chilled (0.degree. C. solution of the material from Part I in
dichloromethane (8 mL) and triethylamine (0.52 mL, 3.7 mmol). The
reaction mixture was allowed to stir at 0-5.degree. C. for 2.5
hours. The reaction mixture was diluted with dichloromethane (25
mL) and aqueous saturated sodium bicarbonate (25 mL). The aqueous
was back extracted with dichloromethane (2.times.10 mL). The
combined organics were dried over magnesium sulfate, filtered, and
then concentrated under reduced pressure to provide 0.48 g of
N-(1-{[2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cyclopropyl-
)methanesulfonamide as a white solid.
Part K
The material from Part J was oxidized and then aminated according
to the methods of Part I of Example 12. The crude product was
purified by HPFC eluting with a gradient of 0-35% CMA in chloroform
to provide a yellow gooey solid. This material was combined with 2M
hydrochloric acid and stirred for 1 hour. The mixture was made
basic (pH 8) with solid sodium bicarbonate. The resulting solid was
isolated by filtration, washed with water, and then dried in a
vacuum oven at 85.degree. C. to provide 201 mg of
N-(1-{[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}-
cyclopropyl)methanesulfonamide as white needles, mp dehydrates at
98 C, no discernible melting point .degree. C. MS (ESI) m/z 390
(M+H).sup.+; Anal. calcd for
C.sub.18H.sub.23N.sub.5O.sub.3S*1.8H.sub.2O: C, 51.24; H, 6.35; N,
16.60. Found: C, 51.19; H, 6.36; N, 16.38.
Example 93
1-[(4-Amino-2-ethoxymethyl-6,7-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl)meth-
yl]cyclohexanol
##STR00156## Part A
1-[(3-Amino-2-dibenzylamino-5,6-dimethylpyridin-4-ylamino)methyl]cyclohex-
anol (0.94 g, 2.1 mmol, prepared as described in Parts A through C
of Example 59 was reacted with ethoxyacetyl chloride (0.31 g, 2.52
mmol) according to the general method of Part A of Example 58. The
resulting amide was cyclized according to the general method of
Part A of Example 58 to provide 0.67 g of
1-[(4-dibenzylamino-2-ethoxymethyl-6,7-dimethyl-1H-imidazo[4,5-c]pyridin--
1-yl)methyl]cyclohexanol as a white solid.
Part B
The benzyl groups were removed from the material from Part A using
the general method of Part E of Example 59. The crude product was
recrystallized from acetonitrile to provide 321 mg of
1-[(4-amino-2-ethoxymethyl-6,7-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl)met-
hyl]cyclohexanol as white needles, mp 194.0-195.0.degree. C. Anal.
Calcd for C.sub.18H.sub.28N.sub.4O.sub.2C, 65.03; H, 8.49; N,
16.85; Found: C, 64.92; H, 8.42; N, 17.11.
Example 94
2-Ethoxymethyl-1-(1-methoxycyclohexyl)-6,7-dimethyl-1H-imidazo[4,5-c]pyrid-
in-4-amine
##STR00157## Part A
Under a nitrogen atmosphere iodomethane (0.58 mL, 9.3 mmol) and
1-[(4-dibenzylamino-2-ethoxymethyl-6,7-dimethyl-1H-imidazo[4,5-c]pyridin--
1-yl)methyl]cyclohexanol (1.59 g, 3.10 mmol) were added to a
mixture of potassium hydride (0.87 g of 30 wt %, 6.5 mmol) and
tetrahydrofuran (31 mL). The reaction mixture was stirred at
ambient temperature for 1 hour and then quenched with methanol.
Water and a few drops of acetic acid were added until the reaction
mixture was slightly acidic. The volume of the reaction mixture was
reduced under vacuum and then it was diluted with water (20 mL) and
hexanes (20 mL). A solid was isolated by filtration, rinsed with
water and hexanes, and then dried in a vacuum oven at 70.degree. C.
to provide 1.50 g of
dibenzyl[2-ethoxymethyl-1-(1-methoxycyclohexyl)-6,7-dimethyl-1H-imidazo[4-
,5-c]pyridin-4-yl]amine.
Part B
The benzyl groups were removed from the material from Part A using
the general method of Part E of Example 59. The crude product was
recrystallized from acetonitrile. The resulting solid was dissolved
in dichloromethane (150 mL), washed with saturated aqueous sodium
bicarbonate (50 mL) and brine (30 mL), dried over sodium sulfate,
filtered, and concentrated under reduced pressure. The residue was
recrystallized from acetonitrile to provide
2-ethoxymethyl-1-(1-methoxycyclohexyl)-6,7-dimethyl-1H-imidazo[4,5-c]pyri-
din-4-amine as white needles, mp 172.0-173.0.degree. C. Anal. Calcd
for C.sub.19H.sub.30N.sub.4O.sub.2C, 65.87; H, 8.73; N, 16.17;
Found: C, 65.64; H, 8.93; N, 16.32.
Example 95
1-(1-Methoxycyclohexyl)-6,7-dimethyl-2-propyl-1H-imidazo[4,5-c]]pyridin-4--
amine
##STR00158##
1-(1-Methoxycyclohexyl)-6,7-dimethyl-2-propyl-1H-imidazo[4,5-c]pyridin-4--
amine was prepared according to the general methods of Example 94
using
1-[(4-dibenzylamino-6,7-dimethyl-2-propyl-1H-imidazo[4,5-]pyridin-1-yl)me-
thyl]cyclohexanol (Example 59, Parts A through D) in lieu of
1-[(4-dibenzylamino-2-ethoxymethyl-6,7-dimethyl-1H-imidazo[4,5-c]pyridin--
1-yl)methyl]cyclohexanol in Part A. The crude product was
recrystallized from acetonitrile to provide pure product as white
needles, mp 192.0-193.0.degree. C. Anal. Calcd for
C.sub.19H.sub.30N.sub.4OC, 69.06; H, 9.15; N, 16.95; Found: C,
68.79; H, 9.27; N, 16.88.
Example 96
2-Ethoxymethyl-1-(1-methoxycyclohexyl)-1H-imidazo[4,5-c][1,5]naphthyridin--
4-amine
##STR00159## Part A
1-[(2-Ethoxymethyl-1H-imidazo[4,5-c][1,5]napthyridin-1-yl)methyl]cyclohex-
anol (1.87 g, 5.49 mmol, Example 58 Part A) was treated with
iodomethane according to the general method of Part A of Example 94
to provide 1.75 g of
2-ethoxymethyl-1-(1-methoxycyclohexyl)-1H-imidazo[4,5-c][1,5]naphthyri-
dine.
Part B
The material from Part A was oxidized and then aminated according
to the general method of Part D of Example 57. The crude product
was purified twice by HPFC eluting the first time with a gradient
of 0-35% CMA in chloroform and the second time with a gradient of
0-30% CMA in chloroform and then recrystallized from acetonitrile
to provide 304 mg of
2-ethoxymethyl-1-(1-methoxycyclohexyl)-1H-imidazo[4,5-c][1,5]naphthyridin-
-4-amine as an off-white powder, mp 160.0-161.0.degree. C. Anal.
Calcd for C.sub.20H.sub.27N.sub.5O.sub.2C, 65.02; H, 7.37; N,
18.96; Found: C, 65.03; H, 7.43; N, 18.94.
Example 97
1-(1-Methoxycyclohexyl)-2-propyl-1H-imidazo[4,5-c][1,5]naphthyridin-4-amin-
e
##STR00160##
1-(1-Methoxycyclohexyl)-2-propyl-1H-imidazo[4,5-c][1,5]naphthyridin-4-ami-
ne was prepared according to the general methods of Example 96
using
1-[(2-propyl-1H-imidazo[4,5-c][1,5]napthyridin-1-yl)methyl]cyclohexanol
in lieu of
1-[(2-ethoxymethyl-1H-imidazo[4,5-c][1,5]napthyridin-1-yl)methyl]cyclohex-
anol. The crude product was purified twice by HPFC eluting with a
gradient of 0-30% CMA in chloroform and then triturated twice with
acetonitrile to provide pure product as an off-white powder, mp
187.0-188.0.degree. C. Anal. Calcd for C.sub.20H.sub.27N.sub.5OC,
67.96; H, 7.70; N, 19.81; Found: C, 67.63; H, 7.84; N, 19.96.
Example 98
1-[(4-Amino-2-propyl-1H-imidazo[4,5-c][1,5]napthyridin-1-yl)methyl]cyclope-
ntanol
##STR00161##
1-[(4-Amino-2-propyl-1H-imidazo[4,5-c][1,5]napthyridin-1-yl)methyl]cyclop-
entanol was prepared according to the general methods of Example 57
Parts A through D using 1-(aminomethyl)cyclopentanol in lieu of
1-(aminomethyl)cyclohexanol in Part A. The crude product was
purified by HPFC eluting with a gradient of 0-30% CMA in chloroform
and then triturated sequentially with acetonitrile and ethyl
acetate to provide pure product as a white powder, mp
184.0-186.0.degree. C. Anal. Calcd for C.sub.18H.sub.23N.sub.5O C,
66.44; H, 7.12; N, 21.52; Found: C, 66.18; H, 7.31; N, 21.45.
Example 99
1-[(4-Amino-2-propyl-6,7,8,9-tetrahydro-1H-imidazo[4,5-c][1,5]napthyridin--
1-yl)methyl]cyclopentanol
##STR00162##
A mixture of
1-[(4-amino-2-propyl-1H-imidazo[4,5-c][1,5]napthyridin-1-yl)methyl]cyclop-
entanol (511 mg), platinum oxide (511 mg), and trifluoroacetic acid
was placed under hydrogen pressure (50 psi, 3.4.times.10.sup.5 Pa)
overnight on a Parr apparatus. The mixture was filtered through a
layer of CELITE filter aid and the filter cake was rinsed with
methanol. The filtrate was concentrated under reduced pressure. The
residue was combined with concentrated hydrochloric acid (2 mL) and
stirred at ambient temperature for 2 hours. The mixture was diluted
with water (10 mL) and then cooled to 0.degree. C. The pH was
adjusted to 12 with 6N sodium hydroxide and then the mixture was
extracted with dichloromethane (3.times.50 mL). The combined
organics were washed with brine (20 mL), dried over sodium sulfate,
filtered, and then concentrated under reduced pressure. The residue
was triturated with acetonitrile, purified by HPFC eluting with a
gradient of 0-35% CMA in chloroform, and then triturated with
acetonitrile to provide 167 mg of
1-[(4-amino-2-propyl-6,7,8,9-tetrahydro-1H-imidazo[4,5-c][1,5]napthyridin-
-1-yl)methyl]cyclopentanol as a white powder, mp
207.0-208.0.degree. C. Anal. Calcd for C.sub.18H.sub.27N.sub.5O
.0.25H.sub.2OC, 64.74; H, 8.30; N, 20.97; Found: C, 64.71; H, 8.29;
N, 20.98.
Example 100
1-[(4-Amino-2-ethoxymethyl-1H-imidazo[4,5-c][1,5]napthyridin-1-yl)methyl]c-
yclopentanol
##STR00163##
1-[(4-Amino-2-ethoxymethyl-1H-imidazo[4,5-c][1,5]napthyridin-1-yl)methyl]-
cyclopentanol was prepared according to the general methods of
Example 58 using 1-(aminomethyl)cyclopentanol in lieu of
1-(aminomethyl)cyclohexanol. The crude product was purified by HPFC
eluting with a gradient of 0-30% CMA in chloroform, triturated with
acetonitrile, and then recrystallized from ethyl acetate/hexanes to
provide pure product as an off-white powder, mp 165.0-166.0.degree.
C. Anal. Calcd for C.sub.18H.sub.23N.sub.5O.sub.2C, 63.32; H, 6.79;
N, 20.51, Found: C, 63.07; H, 7.01; N, 20.35.
Example 101
1-[(4-Amino-2-ethoxymethyl-6,7,8,9-tetrahydro-1H-imidazo[4,5-c][1,5]napthy-
ridin-1-yl)methyl]cyclopentanol
##STR00164##
1-[(4-Amino-2-ethoxymethyl-1H-imidazo[4,5-c][1,5]napthyridin-1-yl)methyl]-
cyclopentanol (503 mg) was reduced according to the method of
Example 100. The crude product was triturated twice with
acetonitrile to provide 329 mg of pure product as a white powder,
mp 207.0-208.0.degree. C. Anal. Calcd for
C.sub.18H.sub.27N.sub.5O.sub.2C, 62.59; H, 7.88; N, 20.27; Found:
C, 62.36; H, 7.82; N, 20.42.
Example 102
1-[(4-Amino-2-propyl-1H-imidazo[4,5-c][1,5]napthyridin-1-yl)methyl]cyclobu-
tanol
##STR00165##
1-[(4-Amino-2-propyl-1H-imidazo[4,5-c][1,5]napthyridin-1-yl)methyl]cyclob-
utanol was prepared according to the general methods of Example 57
Parts A through D using 1-(aminomethyl)cyclobutanol in lieu of
1-(aminomethyl)cyclohexanol in Part A. The crude product was
triturated sequentially with acetonitrile and ethyl acetate and
then recrystallized from chloroform/hexanes to provide pure product
as a white powder, mp 226.0-227.0.degree. C. Anal. Calcd for
C.sub.17H.sub.21N.sub.5O .0.1H.sub.2O C, 65.20; H, 6.82; N, 22.36;
Found: C, 64.95; H, 6.94; N, 22.40.
Example 103
1-[(4-Amino-2-ethoxymethyl-1H-imidazo[4,5-c][1,5]napthyridin-1-yl)methyl]c-
yclobutanol
##STR00166##
1-[(4-Amino-2-ethoxymethyl-1H-imidazo[4,5-c][1,5]napthyridin-1-yl)methyl]-
cyclobutanol was prepared according to the general methods of
Example 58 using 1-(aminomethyl)cyclobutanol in lieu of
1-(aminomethyl)cyclohexanol. The crude product was triturated
sequentially with acetonitrile and ethyl acetate, recrystallized
twice from chloroform/hexanes, purified by HPFC eluting with a
gradient of 0-25% CMA in chloroform, and then triturated with
acetonitrile to provide pure product as a white powder, mp
162.0-163.0.degree. C. Anal. Calcd for
C.sub.17H.sub.21N.sub.5O.sub.2.0.2H.sub.2OC, 61.69; H, 6.52; N,
21.16; Found: C, 61.51; H, 6.47; N, 21.13.
Example 104
1-[(4-Amino-2-hydroxymethyl-1H-imidazo[4,5-c][1,5]napthyridin-1-yl)methyl]-
cyclobutanol
##STR00167##
Under a nitrogen atmosphere boron tribromide (6.15 mL of 1M in
dichloromethane) was added dropwise over a period of 10 minutes to
a chilled (0.degree. C.) solution of
1-[(4-amino-2-ethoxymethyl-1H-imidazo[4,5-c][1,5]napthyridin-1-yl)methyl]-
cyclobutanol (0.67 g, 2.0 mmol) in dichloromethane (20 mL). The
reaction mixture was allowed to warm to ambient temperature and was
stirred overnight. The reaction mixture was cooled to 0.degree. C.
and then more boron tribromide (1.0 mL) was added. The reaction
mixture was stirred at ambient temperature for 4 hours. Methanol
(10 mL) and hydrochloric acid (10 mL of 6N) were added and the
reaction mixture was heated at reflux for 1 hour. The reaction
mixture was allowed to cool to ambient temperature and was then
made basic with 6N sodium hydroxide. A portion of the solvent was
removed under vacuum, water (10 mL) was added, and the mixture was
sonicated. A solid was isolated by filtration and rinsed with
water. The aqueous filtrate was extracted with chloroform
(3.times.80 mL). The combined organics were washed with brine (20
mL), dried over sodium sulfate, filtered, and then concentrated
under reduced pressure. The residue was combined with the isolated
solid and then purified by HPFC eluting with a gradient of 0-30%
CMA in chloroform, triturated with acetonitrile, and dried. The
resulting material was suspended in water (70 mL) and heated to
90.degree. C. Concentrated hydrochloric acid (about 0.8 mL) was
added until a solution was obtained. The hot solution was made
basic with solid sodium bicarbonate and then allowed to cool. A
precipitate was isolated by filtration, washed well with water, and
then dried to provide
1-[(4-amino-2-hydroxymethyl-1H-imidazo[4,5-c][1,5]napthyridin-1-yl)methyl-
]cyclobutanol as a white powder, mp 244.0-246.0.degree. C. Anal.
Calcd for C.sub.15H.sub.17N.sub.5O.sub.2C, 60.19; H, 5.72; N,
23.40; Found: C, 59.97; H, 5.81; N, 23.31.
Example 105
1-[(4-Amino-2-propyl-6,7-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl)methyl]cyc-
lobutanol
##STR00168##
1-[(4-Amino-2-propyl-6,7-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl)methyl]cy-
clobutanol was prepared according to the general methods of Example
59 using 1-(aminomethyl)cyclobutanol in lieu of
1-(aminomethyl)cyclohexanol in Part A. The crude product was
triturated with acetonitrile, purified by HPFC eluting with a
gradient of 0-50% CMA in chloroform, triturated with 1N sodium
hydroxide, washed with water, dried, triturated with hot ethyl
acetate, and then dried to provide pure product as a white powder,
mp 180.0-181.0.degree. C. Anal. Calcd for C.sub.16H.sub.24N.sub.4O
C, 66.64; H, 8.39; N, 19.43; Found: C, 66.49; H, 8.74; N,
19.60.
Example 106
1-[(4-Amino-2,6,7-trimethyl-1H-imidazo[4,5-c]pyridin-1-yl)methyl]cyclobuta-
nol
##STR00169##
1-[(4-amino-2,6,7-trimethyl-1H-imidazo[4,5-c]pyridin-1-yl)methyl]cyclobut-
anol was prepared according to the general methods of Example 59
using 1-(aminomethyl)cyclobutanol in lieu of
1-(aminomethyl)cyclohexanol in Part A and trimethylorthoacetate in
lieu of trimethylorthobutyrate in Part D. The crude product was
purified by HPFC eluting with a gradient of 0-50% CMA in
chloroform, triturated with 1N sodium hydroxide, and then it was
suspended in water (70 mL). Concentrated hydrochloric acid (1.0 mL)
was added and the mixture was heated to 90.degree. C. The hot
solution was made basic with solid sodium bicarbonate and then
allowed to cool. A precipitate was isolated by filtration, washed
well with water, and then dried to provide pure product as a white
powder, mp>250.0.degree. C. Anal. Calcd for
C.sub.14H.sub.20N.sub.4O C, 64.59; H, 7.74; N, 21.52; Found: C,
64.57; H, 7.81; N, 21.61.
Example 107
1-[(4-Amino-2-ethoxymethyl-6,7-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl)meth-
yl]cyclobutanol
##STR00170##
1-[(4-Amino-2-ethoxymethyl-6,7-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl)met-
hyl]cyclobutanol was prepared according to the general methods of
Example 93 using
1-[(3-amino-2-dibenzylamino-5,6-dimethylpyridin-4-ylamino)methyl-
]cyclobutanol in lieu of
1-[(3-amino-2-dibenzylamino-5,6-dimethylpyridin-4-ylamino)methyl]cyclohex-
anol in Part A. The crude product was purified by HPFC eluting with
a gradient of 0-50% CMA in chloroform and then suspended in water
(70 mL). Concentrated hydrochloric acid (2 mL) was added and the
mixture was heated to 90.degree. C. The hot solution was made basic
(pH 8) with solid sodium bicarbonate. Sodium hydroxide (1N) was
added until the solution became cloudy. The solution was allowed to
cool to ambient temperature. A precipitate was isolated by
filtration, washed well with water, and then dried to provide pure
product as a white powder, mp 190.0-191.0.degree. C. Anal. Calcd
for C.sub.16H.sub.24N.sub.4O.sub.2C, 63.13; H, 7.95; N, 18.41;
Found: C, 63.01; H, 8.04; N, 18.48.
Example 108
1-[(4-Amino-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclobutanol
##STR00171##
1-[(4-Amino-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclobutanol
was prepared according to the general methods of Example 57 using
4-chloro-3-nitroquinoline in lieu of 4-chloro-3-nitronaphthyridine
and 1-(aminomethyl)cyclobutanol in lieu of
1-(aminomethyl)cyclohexanol in Part A and trimethylorthoacetate in
lieu of trimethylorthobutyrate in Part C. The crude product was
triturated sequentially with ethyl acetate, hot chloroform, and
acetonitrile, purified by HPFC eluting with a gradient of 0-40% CMA
in chloroform, and then suspended in water (100 mL). Concentrated
hydrochloric acid (2 mL) was added and the mixture was heated to
90.degree. C. The hot solution was made basic (pH 10) with solid
sodium bicarbonate. The solution was allowed to cool to ambient
temperature. A precipitate was isolated by filtration, washed well
with water, and then dried to provide pure product as a white
powder, mp>250.0.degree. C. Anal. Calcd for
C.sub.16H.sub.18N.sub.4O C, 68.06; H, 6.43; N, 19.84; Found: C,
67.99; H, 6.54; N, 19.81.
Example 109
1-[(4-Amino-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclobutanol
##STR00172## Part A
1-[(4-Chloro-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclobutanol
was prepared according to the general methods of Example 57 using
2,4-dichloro-3-nitroquinoline in lieu of
4-chloro-3-nitronaphthyridine and 1-(aminomethyl)cyclobutanol in
lieu of 1-(aminomethyl)cyclohexanol in Part A.
Part B
1-[(4-Chloro-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclobutanol
(1.56 g) was combined with a solution of ammonia in methanol (23
mL). The mixture was heated at 150.degree. C. in a pressure vessel
for 2 days. A portion of the solvent was removed under vacuum and
then the mixture was diluted with additional methanol. A solid was
isolated by filtration, washed with methanol, triturated with
acetonitrile, and then dried. The material was suspended in water
(70 mL). Concentrated hydrochloric acid (1.4 mL) was added and the
mixture was heated at 90.degree. C. for 30 minutes. The hot
solution was neutralized with solid sodium bicarbonate. The
solution was allowed to cool to ambient temperature. A precipitate
was isolated by filtration, washed well with water, and then dried
to provide
1-[(4-amino-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclob-
utanol as a white powder, mp 228.0-229.0.degree. C. Anal. Calcd for
C.sub.18H.sub.22N.sub.4O C, 69.65; H, 7.14; N, 18.05; Found: C,
69.36; H, 7.24; N, 18.03.
Example 110
1-[(4-Amino-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclobutanol
##STR00173##
1-[(4-Amino-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclobutanol was
prepared according to the general methods of Example 109 using
trimethylorthoformate in lieu of trimethylorthobutyrate. The crude
product was triturated with refluxing 1:1 ethyl
acetate:acetonitrile, purified by HPFC eluting with a gradient of
0-45% CMA in chloroform, triturated with 1:1 water:acetonitrile,
and then suspended in water (80 mL). Concentrated hydrochloric acid
(1.5 mL) was added and the mixture was heated at 90.degree. C. for
10 minutes. The hot solution was made basic (pH 9) with solid
sodium bicarbonate. The solution was allowed to cool to ambient
temperature. A precipitate was isolated by filtration, washed well
with water, and then dried. This material was triturated with
sodium hydroxide (15 mL of 1N), isolated by filtration, washed well
with water, and then dried to provide pure product as a white
powder, mp>250.0.degree. C. Anal. Calcd for
C.sub.15H.sub.16N.sub.4O C, 67.15; H, 6.01; N, 20.88; Found: C,
67.06; H, 6.01; N, 21.09.
Example 111
1-[(4-Amino-2-hydroxymethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclobut-
anol
##STR00174## Part A
1-[(4-Amino-2-chloromethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclobut-
anol was prepared according to the general methods of Example 103
except that chloroacetyl chloride was used in lieu of ethoxyacetyl
chloride and triethylamine was used in lieu of sodium
hydroxide.
Part B
1-[(4-Amino-2-chloromethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclobut-
anol was converted to
1-[(4-amino-2-hydroxymethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclobu-
tanol according to the general methods of Parts D and E of Example
62. The crude product was triturated with 1:1 ethyl
acetate:methanol, dried, and then suspended in water (90 mL).
Concentrated hydrochloric acid (1.5 mL) was added and the mixture
was heated at 90.degree. C. for 3 minutes. The mixture was allowed
to cool to ambient temperature and was then made basic with solid
sodium bicarbonate. A solid was isolated by filtration, rinsed well
with water, dried, and then purified by HPFC eluting with a
gradient of 0-60% CMA in chloroform. The resulting solid was
triturated with acetonitrile, dried, and then suspended in water
(80 mL). Concentrated hydrochloric acid (1.5 mL) was added and the
mixture was heated at 90.degree. C. for 10 minutes. The hot
solution was made basic (pH 9) with solid sodium bicarbonate. The
solution was allowed to cool to ambient temperature. A precipitate
was isolated by filtration, washed well with water, and then dried
to provide pure product as a white powder, mp>250.0.degree. C.
Anal. Calcd for C.sub.16H.sub.18N.sub.4O.sub.2C, 64.41; H, 6.08; N,
18.78; Found: C, 64.30; H, 6.10; N, 18.54.
Example 112
1-[(4-Amino-2,6,7-trimethyl-1H-imidazo[4,5-c]pyridin-1-yl)methyl]tetrahydr-
o-2H-pyran-4-ol
##STR00175## Part A
Under a nitrogen atmosphere
2,4-dichloro-5,6-dimethyl-3-nitropyridine (25 g, 113 mmol) was
added to a solution of 4-(aminomethyl)tetrahydro-2H-pyran-4-ol (17
g, 130 mmol) in DMF (375 mL). Triethylamine (18 mL, 130 mmol) was
added slowly and the reaction mixture was stirred at ambient
temperature over the weekend. The reaction mixture was concentrated
under reduced pressure and the residue was partitioned between
ethyl acetate (700 mL) and saturated aqueous sodium bicarbonate
(100 mL). The organic layer was washed with water (3.times.100 mL)
and brine (50 mL), dried over magnesium sulfate, filtered, and then
concentrated under reduced pressure to provide an orange solid.
This material was triturated with ethyl acetate to provide 6.38 g
of
4-{[(2-chloro-5,6-dimethyl-3-nitropyridin-4-yl)amino]methyl}tetrahydro-2H-
-pyran-4-ol as a yellow solid. An additional 4.36 g of product was
recovered from the mother liquor.
Part B
4-{[(2-Chloro-5,6-dimethyl-3-nitropyridin-4-yl)amino]methyl}tetrahydro-2H-
-pyran-4-ol (8.74 g, 27.7 mmol), 10% platinum on carbon (874 mg),
and ethyl acetate (185 mL) were combined and placed under hydrogen
pressure (50 psi, 3.4.times.10.sup.5 Pa) on a Parr apparatus for 4
hours. The reaction mixture was filtered through a layer of CELITE
filter aid and the filter cake was washed with 1:1 ethyl
acetate:methanol. The filtrate was concentrated under reduced
pressure to provide crude
4-{[(3-amino-2-chloro-5,6-dimethylpyridin-4-yl)amino]methyl}tetrahydro-2H-
-pyran-4-ol.
Part C
Under a nitrogen atmosphere a mixture of the material from Part B,
trimethylorthoacetate (1.94 mL, 15.2 mmol), pyridine hydrochloride
(240 mg), and toluene was heated at reflux overnight. The reaction
mixture was allowed to cool to ambient temperature. A precipitate
was isolated by filtration to provide 2.35 g of
1-[(4-chloro-2,6,7-trimethyl-1H-imidazo[4,5-c]pyridin-1-yl)methyl]tetrahy-
dro-2H-pyran-4-ol as a white solid. An additional 1.15 g was
isolated from the mother liquor. A portion was recrystallized from
ethyl acetate hexanes to provide pure product as a white powder, mp
217.0-218.0.degree. C. Anal. Calcd for
C.sub.15H.sub.20ClN.sub.3O.sub.2C, 58.16; H, 6.51; N, 13.56; Cl,
11.44; Found: C, 58.14; H, 6.37; N, 13.31; Cl, 11.30.
Part D
1-[(4-Chloro-2,6,7-trimethyl-1H-imidazo[4,5-c]pyridin-1-yl)methyl]tetrahy-
dro-2H-pyran-4-ol (1.00 g, 3.23 mmol), benzylamine (3.53 mL, 32.3
mmol), pyridine hydrochloride (2.52 g, 16.2 mmol) and
2,2,2-trifluoroethanol (10 mL) were combined in a process vial and
heated in a microwave at 160.degree. for 2.5 hours. The reaction
mixture was concentrated under reduced pressure. The residue was
dissolved in chloroform (200 mL), washed with saturated aqueous
sodium bicarbonate (3.times.50 mL) and brine (30 mL), dried over
magnesium sulfate, filtered, and then concentrated under reduced
pressure to provide a yellow solid. This material was triturated
with acetonitrile to provide 1.14 g of
1-{[4-(benzylamino)-2,6,7-trimethyl-1H-imidazo[4,5-c]pyridin-1-yl]methyl}-
tetrahydro-2H-pyran-4-ol as a white solid.
Part E
The benzyl group was removed from the material from Part D
according to the general method of Part E of Example 59. The crude
product was triturated with acetonitrile and dried to provide a
white solid. This material was dissolved in chloroform (200 mL),
washed with saturated aqueous sodium bicarbonate (2.times.40 mL)
and brine (30 mL), dried over sodium sulfate, filtered, and then
concentrated under reduced pressure. The residue was triturated
with acetonitrile and dried to provide
1-[(4-amino-2,6,7-trimethyl-1H-imidazo[4,5-c]pyridin-1-yl)methyl]tetrahyd-
ro-2H-pyran-4-ol as a white powder, mp>250.0.degree. C. Anal.
Calcd for C.sub.15H.sub.22N.sub.4O.sub.2C, 62.05; H, 7.64; N,
19.30; Found: C, 61.89; H, 7.77; N, 19.34.
Example 113
1-[(2,6,7-Trimethyl-1H-imidazo[4,5-c]pyridin-1-yl)methyl]tetrahydro-2H-pyr-
an-4-ol
##STR00176##
A mixture of
1-[(4-chloro-2,6,7-trimethyl-1H-imidazo[4,5-c]pyridin-1-yl)methyl]tetrahy-
dro-2H-pyran-4-ol (1.0 g), 10% palladium on carbon (200 mg), and
ethanol (16 mL) were combined and placed under hydrogen pressure
(50 psi, 3.4.times.10.sup.5 Pa) on a Parr apparatus for 6 days. The
reaction mixture was filtered through a layer of CELITE filter aid
and the filter cake was washed with methanol. The filtrate was
concentrated under reduced pressure. The residue was triturated
with acetonitrile to provide a solid. This material was dissolved
in dichloromethane (100 mL) and washed with sodium hydroxide (1N,
2.times.30 mL) and brine, dried over sodium sulfate, filtered, and
then concentrated under reduced pressure. The residue was
triturated with acetonitrile to provide
1-[(2,6,7-trimethyl-1H-imidazo[4,5-c]pyridin-1-yl)methyl]tetrahydro-2H-py-
ran-4-ol as a white powder, mp 246.0-248.0.degree. C. Anal. Calcd
for C.sub.15H.sub.21N.sub.3O.sub.2C, 65.43; H, 7.69; N, 15.26;
Found: C, 65.53; H, 7.79; N, 15.42.
Example 114
1-[(4-Amino-2-ethoxymethyl-6,7-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl)meth-
yl]tetrahydro-2H-pyran-4-ol
##STR00177## Part A
Under a nitrogen atmosphere ethoxyacetyl chloride (2.26 g, 16.6
mmol) was added dropwise to a chilled (0.degree. C.) suspension of
4-{[(3-amino-2-chloro-5,6-dimethylpyridin-4-yl)amino]methyl}tetrahydro-2H-
-pyran-4-ol (3.96 g) in dichloromethane (140 mL). The reaction
mixture was stirred at ambient temperature overnight. The reaction
mixture was cooled to 0.degree. C., more ethoxyacetyl chloride (0.3
mL) was added, and the reaction mixture was stirred at ambient
temperature for an additional 4 hours. The reaction mixture was
concentrated under reduced pressure to provide crude
N-(2-chloro-4-{[(4-hydroxytetrahydro-2H-pyran-4-yl)methyl]amino}-5,6-dime-
thylpyridin-3-yl)-2-ethoxyacetamide.
Part B
Sodium hydroxide (1.11 g, 27.7 mmol) was added to a suspension of
the material from Part A in ethanol (138 mL). The reaction mixture
was heated at reflux for 1.5 hours and then concentrated under
reduced pressure. The residue was dissolved in dichloromethane (400
mL), washed with water (2.times.80 mL) and brine (40 mL), dried
over magnesium sulfate, filtered, and then concentrated under
reduced pressure to provide 4.46 g of a yellow solid. This material
was triturated with ethyl acetate and then recrystallized from
ethyl acetate/hexanes to provide
1-[(4-chloro-2-ethoxymethyl-6,7-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl)me-
thyl]tetrahydro-2H-pyran-4-ol as a white powder, mp
151.0-152.0.degree. C. Anal. Calcd for
C.sub.17H.sub.24ClN.sub.3O.sub.3C, 57.70; H, 6.84; N, 11.88; Cl,
10.02; Found: C, 57.57; H, 6.87; N, 11.68; Cl, 10.00.
Part C
1-[(4-Chloro-2-ethoxymethyl-6,7-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl)me-
thyl]tetrahydro-2H-pyran-4-ol (1.4 g) was converted to
1-[(4-amino-2-ethoxymethyl-6,7-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl)met-
hyl]tetrahydro-2H-pyran-4-ol according to the general methods of
Parts D and E of Example 112. The crude product was dissolved in
chloroform (200 mL) and methanol (10 mL), washed with saturated
aqueous sodium bicarbonate (2.times.40 mL) and brine (30 mL), dried
over sodium sulfate, filtered, and then concentrated under reduced
pressure. The residue was triturated with acetonitrile and dried to
provide pure product as a white powder, mp 197.0-198.0.degree. C.
Anal. Calcd for C.sub.17H.sub.26N.sub.4O.sub.3C, 61.06; H, 7.84; N,
16.75; Found: C, 60.91; H, 8.18; N, 16.87.
Example 115
1-[(2-Ethoxymethyl-6,7-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl)methyl]tetra-
hydro-2H-pyran-4-ol
##STR00178##
A mixture of
1-[(4-chloro-2-ethoxymethyl-6,7-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl)me-
thyl]tetrahydro-2H-pyran-4-ol (1.0 g), 10% palladium on carbon (200
mg), and ethanol (16 mL) were combined and placed under hydrogen
pressure (50 psi, 3.4.times.10.sup.5 Pa) on a Parr apparatus for 1
week. The reaction mixture was filtered through a layer of CELITE
filter aid and the filter cake was washed with methanol. The
filtrate was concentrated under reduced pressure. The residue was
dissolved in dichloromethane (150 mL) and washed with sodium
hydroxide (1N, 2.times.20 mL) and brine (20 mL), dried over sodium
sulfate, filtered, and then concentrated under reduced pressure.
The residue was triturated with acetonitrile and then
recrystallized from acetonitrile to provide
1-[(2-ethoxymethyl-6,7-dimethyl-1H-imidazo[4,5-c]pyridin-1-yl)methyl]tetr-
ahydro-2H-pyran-4-ol as a white powder, mp 144.0-145.0.degree. C.
Anal. Calcd for C.sub.17H.sub.25N.sub.3O.sub.3C, 63.93; H, 7.89; N,
13.16; Found: C, 63.68; H, 7.89; N, 13.04.
Example 116
4-[(4-Amino-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetrahydro-2H-t-
hiopyran-4-ol
##STR00179## Part A
Under a nitrogen atmosphere sodium methoxide (1.03 mL of 25 wt % in
methanol, 4.51 mmol) was added dropwise to a solution of
tetrahydro-4H-thiopyran-4-one (10.48 g, 90.20 mol) and nitromethane
(7.33 mL, 135.3 mmol) in ethanol (6 mL). The reaction mixture was
stirred at ambient temperature for 5 days and then concentrated
under reduced pressure. The residue was partitioned between
chloroform (400 mL) and water (60 mL). The aqueous was extracted
with chloroform (5.times.100 mL). The combined organics were dried
over magnesium sulfate, filtered, and then concentrated under
reduced pressure. The residue was purified by HPFC eluting with a
gradient of 3-35% ethyl acetate in hexanes to provide 10.23 g of
4-(nitromethyl)tetrahydro-2H-thiopyran-4-ol.
Part B
The material from Part B, 20% palladium hydroxide on carbon (2.0
g), and ethanol (165 mL) were combined and placed under hydrogen
pressure (50 psi, 3.4.times.10.sup.5 Pa) on a Parr apparatus for 1
week. The reaction mixture was filtered through a layer of CELITE
filter aid and the filter cake was washed with methanol. The
filtrate was concentrated under reduced pressure. The residue was
dried under high vacuum to provide 8.54 g of
4-(aminomethyl)tetrahydro-2H-thiopyran-4-ol as a white
semi-solid.
Part C
Under a nitrogen atmosphere triethylamine (3.91 mL, 28.0 mmol) was
added to a chilled (0.degree. C.) solution of
2,4-dichloro-3-nitroquinoline (7.22 g, 26.7 mmol) in
dichloromethane (100 mL). A solution of
4-(aminomethyl)tetrahydro-2H-thiopyran-4-ol (4.12 g, 28.0 mmol) in
dichloromethane (30 mL) was added dropwise. The reaction mixture
was stirred at ambient temperature overnight and then concentrated
under reduced pressure. The orange residue was combined with
saturated aqueous sodium bicarbonate (50 mL) and ethyl acetate (40
mL), sonicated for 10 minutes, and then filtered. The isolated
solid was washed extensively with water and then dried to provide
5.63 g of
4-{[(2-chloro-3-nitroquinolin-4-yl)amino]methyl}tetrahydro-2H-thiopyran-4-
-ol as a yellow solid.
Part D
A portion (1.00 g) of the material from Part C, 5% platinum on
carbon (200 mg g) and ethyl acetate (28 mL) were combined and
placed under hydrogen pressure (50 psi, 3.4.times.10.sup.5 Pa) on a
Parr apparatus overnight. The reaction mixture was filtered through
a layer of CELITE filter aid and the filter cake was washed with
methanol. The filtrate was concentrated under reduced pressure to
provide
4-{[(3-amino-2-chloroquinolin-4-yl)amino]methyl}tetrahydro-2H-thiopyran-4-
-ol as an off-white solid.
Part E
Under a nitrogen atmosphere butyryl chloride (322 .mu.L, 3.11 mmol)
was added dropwise was added to a suspension of
4-{[(3-amino-2-chloroquinolin-4-yl)amino]methyl}tetrahydro-2H-thiopyran-4-
-ol (0.92 g, 2.83 mmol) in dichloromethane (28 mL). After 2 hours
triethylamine (0.79 mL, 5.66 mol) was added and the reaction
mixture was stirred for 2 hours. More butyryl chloride (0.2 mL) and
triethylamine (0.30 mL) were added. The reaction mixture was
stirred for an additional hour and then diluted with saturated
aqueous sodium bicarbonate (50 mL) and extracted with
dichloromethane (3.times.60 mL). The combined organics were washed
with saturated aqueous sodium bicarbonate (40 mL) and brine (30
mL), dried over sodium sulfate, filtered, and then concentrated
under reduced pressure to provide
N-(2-chloro-4-{[(4-hydroxytetrahydro-2Hthiopyran-4-yl)methyl]amino}quinol-
in-3-yl)butanamide as an off-white solid.
Part F
The material from Part E was combined with a solution of ammonia in
methanol (17 mL of 7N) in a pressure vessel. The vessel was sealed
and heated at 150.degree. C. for 24 hours. A solid was isolated by
filtration and rinsed with methanol to provide 0.60 g of yellow
needles. This material was combined with acetonitrile and
sonicated. A white solid was isolated by filtration, rinsed with
acetonitrile, and dried under high vacuum at 120.degree. C. to
provide 538 mg of
4-[(4-amino-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetrahydro-2H--
thiopyran-4-ol as a white powder, mp 243.0-244.0.degree. C. Anal.
Calcd for C.sub.19H.sub.24N.sub.4OS C, 64.02; H, 6.79; N, 15.72;
Found: C, 64.20; H, 6.99; N, 15.52.
Example 117
4-[(4-Amino-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetrahydro-2H-t-
hiopyran-4-ol 1,1-dioxide
##STR00180##
Under a nitrogen atmosphere 3-chloroperbenzoic acid (1.20 g of 70%,
4.89 mmol) was added to a cooled (0.degree. C.) solution of
4-[(4-amino-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetrahydro-2H--
thiopyran-4-ol (0.79 g, 2.22 mmol) in chloroform (22 mL) and
methanol (22 mL). The reaction mixture was warmed to ambient
temperature. The reaction mixture was treated with additional
3-chloroperbenzoic acid (0.8 g total) and stirred until analysis by
LC-MS (liquid chromatography-mass spectroscopy) indicated that the
reaction was complete. The reaction mixture was diluted with
saturated aqueous sodium carbonate (50 mL) and then extracted with
chloroform (4.times.50 mL). The combined organics were washed with
brine (20 mL), dried over sodium sulfate, filtered, and then
concentrated under reduced pressure to provide 1.1 g of a brown
solid. This material was purified by HPFC eluting with a gradient
of 0-30% CMA in chloroform to give 0.43 g of a solid. This material
was triturated with acetonitrile and dried under high vacuum at
130.degree. C. to provide 266 mg of
4-[(4-amino-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetrahydro-2H--
thiopyran-4-ol 1,1-dioxide as a tan powder, mp>250.0.degree. C.
Anal. Calcd for C.sub.19H.sub.24N.sub.4O.sub.3S C, 58.74; H, 6.23;
N, 14.42; Found: C, 58.71; H, 6.14; N, 14.42.
Example 118
4-[(4-Amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetrahydro-2H-th-
iopyran-4-ol
##STR00181##
4-[(4-Amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetrahydro-2H-t-
hiopyran-4-ol was prepared according to the general methods of
Example 116 using propionyl chloride in lieu of butyryl chloride in
Part E. The crude product was recrystallized from
methanol/chloroform, isolated by filtration, rinsed with chloroform
and methanol, and then dried under high vacuum at 130.degree. C. to
provide pure product as a white powder, mp>250.0.degree. C.
Anal. Calcd for C.sub.18H.sub.22N.sub.4OS .0.2H.sub.2O C, 62.47; H,
6.52; N, 16.19; Found: C, 62.47; H, 6.37; N, 16.09.
Example 119
4-[(4-Amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetrahydro-2H-th-
iopyran-4-ol 1,1 dioxide
##STR00182##
4-[(4-Amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetrahydro-2H-t-
hiopyran-4-ol (900 mg) was oxidized according to the method of
Example 117. The crude product (1.1 g of a brown solid) was
triturated with acetonitrile, and then purified by HPFC eluting
with a gradient of 0-40% CMA in chloroform to provide 1.1 g of a
brown solid. This material was triturated with acetonitrile and
dried under high vacuum at 120.degree. C. to provide 330 mg of
4-[(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetrahydro-2H-t-
hiopyran-4-ol 1,1 dioxide as a white powder, mp>250.0.degree. C.
Anal. Calcd for C.sub.18H.sub.22N.sub.4O.sub.3S C, 57.74; H, 5.92;
N, 14.96; Found: C, 57.51; H, 5.97; N, 15.13.
Example 120
tert-Butyl
4-[(4-amino-2-ethyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)met-
hyl]-4-hydroxypiperidine-1-carboxylate
##STR00183## Part A
Under a nitrogen atmosphere a solution of tert-butyl
4-(aminomethyl)-4-hydroxypiperidine-1-carboxylate (38.9 g, 169
mmol, prepared according to Parts A and B of Example 4) in
dichloromethane (420 mL) was cooled to 0.degree. C. Triethylamine
(23.6 mL, 169 mmol) was added followed by the portionwise addition
of 4-chloro-3-nitronaphthyridine (30.8 g, 147 mmol). The reaction
mixture was stirred at ambient temperature overnight and then
diluted with saturated aqueous sodium bicarbonate (200 mL). The
layers were separated and the aqueous was extracted with
dichloromethane (3.times.100 mL). The combined organics were
concentrated under reduced pressure to provide a dark yellow solid.
This material was triturated with saturated aqueous sodium
bicarbonate, isolated by filtration, rinsed well with water, and
then dried in a vacuum oven at 70.degree. C. overnight to provide
58.85 g of tert-butyl
4-hydroxy-4-{[(3-nitro[1,5]naphthyridin-4-yl)amino]methyl}piperidine-1-ca-
rboxylate as a yellow solid.
Part B
The material from Part A, 5% platinum on carbon (5.89 g), and ethyl
acetate (500 mL) were combined and placed under hydrogen pressure
(30 psi, 2.1.times.10.sup.5 Pa) on a Parr apparatus for 2.5 hours.
The reaction mixture was filtered through a layer of CELITE filter
aid and the filter cake was washed with ethyl acetate. The filtrate
was concentrated under reduced pressure to provide tert-butyl
4-hydroxy-4-{[(3-amino[1,5]naphthyridin-4-yl)amino]methyl}piperidine-1-ca-
rboxylate.
Part C
Under a nitrogen atmosphere a portion (27.24 g, 72.9 mmol) of the
material from Part B was combined with toluene (300 mL),
triethylorthopropionate (16.1 mL, 80.2 mmol), and pyridine
hydrochloride (1.3 g, 10.9 mmol). The reaction mixture was stirred
at reflux for 3 hours, allowed to cool to ambient temperature, and
then concentrated under reduced pressure. The residue was dried
under high vacuum, dissolved in chloroform (500 mL), washed with
saturated aqueous sodium bicarbonate (2.times.80 mL) and brine (40
mL), dried over magnesium sulfate, filtered, and then concentrated
under reduced pressure to provide 34 g of a yellow solid. This
material was triturated with ethyl acetate/hexanes, isolated by
filtration, rinsed with hexanes, and then dried to provide
tert-butyl
4-[(2-ethyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]-4-hydroxypipe-
ridine-1-carboxylate. A portion (2 g) of this material was
recrystallized from ethyl acetate/hexanes, isolated by filtration,
rinsed with hexanes, and then dried under vacuum at 120.degree. C.
to provide 1.1 g of pure product as a white powder, mp
155.0-156.0.degree. C. Anal. Calcd for
C.sub.22H.sub.29N.sub.5O.sub.3C, 64.21; H, 7.10; N, 17.02; Found:
C, 63.99; H, 6.88; N, 16.90.
Part D
Under a nitrogen atmosphere, 3-chloroperoxybenzoic acid (13.8 g of
70%, 56.0 mmol) was added to a solution of tert-butyl
4-[(2-ethyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]-4-hydroxypipe-
ridine-1-carboxylate (16.5 g, 40.0 mmol) in chloroform (160 mL).
After 1.5 hours the reaction mixture was concentrated under reduced
pressure to provide a yellow foam. Under a nitrogen atmosphere this
material was dissolved in methanol (160 mL) and then cooled to
0.degree. C. Ammonium hydroxide (13.3 mL, 200 mmol) was slowly
added followed by the dropwise addition of benzenesulfonyl chloride
(10.7 mL, 84.0 mmol). The reaction mixture was stirred at 0.degree.
C. for 1.5 hours and then concentrated under reduced pressure. The
residue was partitioned between chloroform (400 mL) and saturated
aqueous sodium bicarbonate (50 mL). The organic was washed with
saturated aqueous sodium bicarbonate (50 mL) and brine (30 mL),
dried over magnesium sulfate, filtered, and then concentrated under
reduced pressure. The residue was triturated with ethyl acetate to
provide a yellow solid. This material was triturated with saturated
aqueous sodium carbonate to provide 7.2 g of a yellow solid. A
portion (1.2 g) of this material was triturated twice with
acetonitrile, isolated by filtration, and dried under vacuum at
120.degree. C. to provide 736 mg of tert-butyl
4-[(4-amino-2-ethyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]-4-hyd-
roxypiperidine-1-carboxylate as a white powder, mp
233.0-235.0.degree. C. Anal. Calcd for
C.sub.22H.sub.30N.sub.6O.sub.3C, 61.95; H, 7.09; N, 19.70; Found:
C, 61.78; H, 7.15; N, 19.51.
Example 121
4-[(4-Amino-2-ethyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]piperid-
in-4-ol
##STR00184## Part A
Under a nitrogen atmosphere a mixture of tert-butyl
4-[(4-amino-2-ethyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]-4-hyd-
roxypiperidine-1-carboxylate (6.00 g), aqueous hydrochloric acid
(14 mL of 6M), and ethanol (56 mL) was heated at 50.degree. C.
overnight. The reaction mixture was concentrated under reduced
pressure. The residue was concentrated from methanol 3 times,
triturated with acetonitrile, isolated by filtration, washed with
acetonitrile, and then dried under high vacuum to provide 5.55 g of
4-[(4-amino-2-ethyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]piperi-
din-4-ol dihydrochloride as a tan powder.
Part B
A mixture of
4-[(4-amino-2-ethyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]piperi-
din-4-ol dihydrochloride (0.80 g) and 1N sodium hydroxide (8 mL)
was sonicated for 2 minutes. A solid was isolated by filtration,
washed with water, and dried. This procedure was repeated and the
material was dried under high vacuum at 120.degree. C. to provide
0.61 g of
4-[(4-amino-2-ethyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]piperi-
din-4-ol as a tan powder, mp 232.0-233.0.degree. C. Anal. Calcd for
C.sub.17H.sub.22N.sub.6O C, 62.56; H, 6.79; N, 25.75; Found: C,
62.43; H, 7.04; N, 25.78.
Example 122
4-[(4-Amino-2-ethyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]-1-(mor-
pholin-4-ylcarbonyl)piperidin-4-ol
##STR00185##
Under a nitrogen atmosphere triethylamine (1.39 mL, 10.0 mmol) was
added to a suspension of
4-[(4-amino-2-ethyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]piperi-
din-4-ol dihydrochloride (1.00 g, 2.50 mmol) in dichloromethane (25
mL). The mixture was cooled to -5.degree. C. 4-Morpholinecarbonyl
chloride (292 .mu.L, 2.50 mmol) was added and the reaction mixture
was allowed to slowly warm to ambient temperature. The reaction
mixture was stirred at ambient temperature for 2 days and then at
30.degree. C. for 2 days. More 4-morpholinecarbonyl chloride (30
.mu.L) was added and the reaction mixture was stirred at 30.degree.
C. for 5 days. The reaction mixture was concentrated under reduced
pressure. The residue was partitioned between chloroform (150 mL)
and saturated aqueous sodium carbonate (30 mL). The organic was
washed with saturated aqueous sodium carbonate (20 mL) and brine
(20 mL), dried over sodium sulfate, filtered, and then concentrated
under reduced pressure to provide an off white solid. This material
was triturated with acetonitrile, recrystallized from
chloroform/hexanes, isolated by filtration, washed with hexanes,
and dried under high vacuum at 130.degree. C. to provide 0.97 g of
4-[(4-amino-2-ethyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]-1-(mo-
rpholin-4-ylcarbonyl)piperidin-4-ol as a white powder,
mp>255.0.degree. C. Anal. Calcd for
C.sub.22H.sub.29N.sub.7O.sub.3.0.25H.sub.2OC, 59.51; H, 6.70; N,
22.08. Found: C, 59.32; H, 6.36; N, 22.00.
Example 123
4-[(4-Amino-2-ethyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]-1-(met-
hylsulfonyl)piperidin-4-ol
##STR00186##
Under a nitrogen atmosphere triethylamine (1.12 mL, 8.06 mmol) was
added to a suspension of
4-[(4-amino-2-ethyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]piperi-
din-4-ol dihydrochloride (1.04 g, 2.60 mmol) in chloroform (26 mL).
Methanesulfonic anhydride (0.50 g, 2.86 mmol) was added and the
reaction mixture was stirred at ambient temperature. After 1.5
hours more methanesulfonic anhydride (0.25 g) was added and a
solution was obtained. On two successive days more methanesulfonic
anhydride (0.50 g) and triethylamine (360 .mu.L) were added. The
reaction mixture was stirred for 2 hours after the second addition
and then concentrated under reduced pressure. The residue was
triturated with saturated aqueous sodium bicarbonate, isolated by
filtration, washed with water, triturated with hot chloroform,
isolated by filtration, washed with chloroform and hexanes, dried,
triturated with acetonitrile, sonicated, isolated by filtration,
and then dried under high vacuum at 130.degree. C. to provide
4-[(4-amino-2-ethyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]-1-(me-
thylsulfonyl)piperidin-4-ol as a white powder, mp>255.0.degree.
C. Anal. Calcd for C.sub.18H.sub.24N.sub.6O.sub.3S C, 53.45; H,
5.98; N, 20.78; Found: C, 53.55; H, 5.71; N, 20.75.
Example 124
tert-butyl
4-[(4-Amino-2-methyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)me-
thyl]-4-hydroxypiperidine-1-carboxylate
##STR00187## Part A
tert-Butyl
4-[(2-methyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]-4-hydroxypip-
eridine-1-carboxylate was prepared according to the methods of
Parts A through C of Example 120 using trimethylorthoacetate in
lieu of triethylorthopropionate in Part C. The product was provided
as a white powder, mp 175.0-176.0.degree. C. Anal. Calcd for
C.sub.21H.sub.27N.sub.5O.sub.3C, 63.46; H, 6.85; N, 17.62; Found:
C, 63.30; H, 6.77; N, 17.53.
Part B
tert-Butyl
4-[(2-methyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]-4-hydroxypip-
eridine-1-carboxylate (15.9 g) was oxidized and then aminated
according to the methods of Part D of Example 120. The crude
product was triturated with ethyl acetate to provide 5.8 g of a
yellow solid. A portion (0.8 g) of this material was twice
triturated with acetonitrile, isolated by filtration, and dried
under high vacuum at 120.degree. C. to provide tert-butyl
4-[(4-amino-2-methyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]-4-hy-
droxypiperidine-1-carboxylate as a white powder, mp
233.0-235.0.degree. C. Anal. Calcd for
C.sub.21H.sub.28N.sub.6O.sub.3.0.5H.sub.2OC, 59.84; H, 6.93; N,
19.94; Found: C, 59.96; H, 6.78; N, 19.59.
Example 125
4-[(4-Amino-2-methyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]piperi-
din-4-ol
##STR00188## Part A
Under a nitrogen atmosphere a mixture of tert-butyl
4-[(4-amino-m2-ethyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]-4-hy-
droxypiperidine-1-carboxylate (5.00 g), aqueous hydrochloric acid
(12 mL of 6M), and ethanol (48 mL) was heated at 50.degree. C.
overnight. The reaction mixture was concentrated under reduced
pressure. The residue was concentrated from methanol 3 times,
triturated with acetonitrile, isolated by filtration, washed with
acetonitrile, and then dried under high vacuum to provide 4.67 g of
4-[(4-amino-2-methyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]piper-
idin-4-ol dihydrochloride as a pale yellow solid.
Part B
A mixture of
4-[(4-amino-2-methyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]piper-
idin-4-ol dihydrochloride (0.80 g) and 1N sodium hydroxide (8 mL)
was sonicated for 2 minutes. A solid was isolated by filtration,
washed with water, and dried under high vacuum at 100.degree. C. to
provide 0.50 g of
4-[(4-amino-2-methyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]piper-
idin-4-ol as a yellow powder, mp>260.0.degree. C. Anal. Calcd
for C.sub.16H.sub.20N.sub.6O C, 61.52; H, 6.45; N, 26.90; Found: C,
61.23; H, 6.39; N, 26.92.
Example 126
4-[(4-Amino-2-methyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]-1-(mo-
rpholin-4-ylcarbonyl)piperidin-4-ol
##STR00189##
4-[(4-Amino-2-methyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]-1-(m-
orpholin-4-ylcarbonyl)piperidin-4-ol was prepared and purified
according to the general method of Example 122 using
4-[(4-amino-2-methyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]piper-
idin-4-ol dihydrochloride in lieu of
4-[(4-amino-2-ethyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]piperi-
din-4-ol dihydrochloride. The product was provided as a white
powder, mp 245.0-248.0.degree. C. Anal. Calcd for
C.sub.21H.sub.27N.sub.7O.sub.3C, 59.28; H, 6.40; N, 23.04; Found:
C, 58.98; H, 6.67; N, 22.91.
Example 127
4-[(4-Amino-2-methyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]-1-(me-
thylsulfonyl)piperidin-4-ol
##STR00190##
4-[(4-Amino-2-methyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]-1-(m-
ethylsulfonyl)piperidin-4-ol was prepared and purified according to
the general method of Example 123 using
4-[(4-amino-2-methyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]piper-
idin-4-ol dihydrochloride in lieu of
4-[(4-amino-2-ethyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]piperi-
din-4-ol dihydrochloride. The product was provided as a white
powder, mp>255.0.degree. C. Anal. Calcd for
C.sub.17H.sub.22N.sub.6O.sub.3S C, 52.29; H, 5.68; N, 21.52; Found:
C, 52.14; H, 5.39; N, 21.38.
Example 128
1-[(1-Aminocyclohexyl)methyl]-2-ethoxymethyl-1H-imidazo[4,5-c]quinolin-4-a-
mine
##STR00191## Part A
Tert-butyl
1-[(2-ethoxymethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclohexylcarbam-
ate (3.80 g, Example 54 Parts A through F) was oxidized and
aminated according to the general methods of Part F of Example 10
to provide 2.46 g of tert-butyl
1-[(4-amino-2-ethoxymethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclohex-
ylcarbamate as a light tan frothy solid, mp 82.0-92.0.degree.
C.
Part B
Under a nitrogen atmosphere a mixture of the material from Part A,
hydrochloric acid (25 mL of 2.7M in ethanol), and ethanol (50 mL)
was heated at reflux for 2 hours. The reaction mixture was diluted
with isopropanol. A solid was isolated by filtration and then
partitioned between dichloromethane (100 mL) and 5% sodium
carbonate (100 mL). The aqueous layer was extracted with
dichloromethane (2.times.100 mL). The organics were combined, dried
over magnesium sulfate, filtered, and then concentrated under
reduced pressure to provide a light yellow oil. This material was
purified by column chromatography (silica gel eluting with 90/10
dichloromethane/methanol) to provide a clear oil. The oil was
dissolved in methanol and then concentrated under reduced pressure
to provide 1.10 g of
1-[(1-aminocyclohexyl)methyl]-2-ethoxymethyl-1H-imidazo[4,5-c]quinolin-4--
amine as a white frothy solid, mp 166-168.degree. C. .sup.1H NMR
(300 MHz, CDCl.sub.3) .delta. 8.26 (m, 1H), 7.80 (m, 1H), 7.49
(ddd, J=8.3, 6.9, 1.4 Hz, 1H), 7.30 (ddd, J=8.3, 6.9, 1.4 Hz, 1H),
5.45 (br s, 2H), 5.02 (br s, 2H), 4.66 (br s, 2H), 3.57 (q, J=7.0
Hz, 2H), 1.70-1.37 (m, 10H), 1.29-0.94 (m, 2H), 1.23 (t, J=7.0 Hz,
3H); MS (APCI) m/z 354 (M+H).sup.+; Anal. Calcd for
C.sub.20H.sub.27N.sub.5O .0.25H.sub.2O: C, 67.11; H, 7.74; N,
19.56. Found: C, 67.06; H, 7.74; N, 19.36.
Example 129
Ethyl
1-[(4-amino-2-ethoxymethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyc-
lohexylcarbamate
##STR00192## Part A
Under a nitrogen atmosphere a mixture of
1-[(2-ethoxymethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclohexylamine
(2.00 g, 5.91 mmol, Example 54 Parts A through G) and THF (40 mL)
was cooled in an ice bath. Sodium hydroxide (0.24 g, 5.97 mmol, in
3 mL of water) was added dropwise followed by diethylpyrocarbonate
(0.87 mL, 5.91 mmol). After two days an additional 0.5 eq of both
sodium hydroxide and diethylpyrocarbonate were added. After 5 days
the reaction mixture was concentrated under reduced pressure. The
residue was partitioned between water (100 mL) and dichloromethane
(100 mL). The organic was dried over magnesium sulfate, filtered,
and then concentrated under reduced pressure to provide an oil.
This material was purified by column chromatography (silica gel
eluting with 95/5 ethyl acetate/methanol) to provide 1.89 g of
ethyl
1-[(2-ethoxymethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclohe-
xylcarbamate as a clear oil.
Part B
The material from Part A was oxidized and then aminated according
to the general methods of Part F of Example 9. Crude product (0.25
g of an amber oil) was dissolved in hot ethyl acetate/hexanes and
the solution was cooled to provide a solid. This material was
dissolved in methanol and then concentrated under reduced pressure
to provide 67 mg of ethyl
1-[(4-amino-2-ethoxymethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclohex-
ylcarbamate as a white frothy solid, mp 95-100.degree. C. .sup.1H
NMR (300 MHz, CDCl.sub.3) .delta. 8.24 (m, 1H), 7.80 (dd, J=8.3,
1.0 Hz, 1H), 7.50 (ddd, J=8.3, 7.0, 1.3 Hz, 1H), 7.31 (ddd, J=8.3,
7.0, 1.3 Hz, 1H), 5.45 (br s, 2H), 5.00 (s, 2H), 4.83 (br s, 2H),
4.54 (br s, 1H), 4.07 (q, J=7.1 Hz, 2H), 3.59 (q, J=7.0 Hz, 2H),
1.79-0.96 (m, 10H), 1.24 (t, J=7.0 Hz, 3H), 1.21 (t, J=7.2 Hz, 3H);
MS (APCI) m/z 426 (M+H).sup.+; Anal. Calcd for
C.sub.23H.sub.31N.sub.5O.sub.3. 0.25H.sub.2O: C, 64.24; H, 7.38; N,
16.29. Found: C, 63.99; H, 7.41; N, 16.31.
Example 130
1-{[4-Amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cyclo-
butanol
##STR00193## Part A
Under a nitrogen atmosphere a mixture of
1-[(3-aminoquinolin-4-ylamino)methyl]cyclobutanol (6.65 g, 27.3
mmol, Example 8 Parts A through D), triethylamine (3.81 mL, 27.3
mmol), and dichloromethane (200 mL) was cooled in an ice bath.
3-Methoxypropionyl chloride (3.35 g, 27.3 mmol) was added dropwise.
The reaction mixture was kept cool for 2 hours and then allowed to
warm to ambient temperature overnight. More acid chloride (0.25 eq)
was added and the reaction mixture was stirred for 4 hours. The
reaction mixture was washed with water. The organic layer was
concentrated under reduced pressure to provide crude amide
intermediate as an orange foamy solid. This material was purified
by column chromatography (silica gel eluting with 80/20
dichloromethane/methanol) to provide 5.2 g of a white foamy solid.
This material was dissolved in ethanol (100 mL) and triethylamine
(10 mL). The solution was refluxed for 4 days and then concentrated
under reduced pressure. The residue was purified by column
chromatography (silica gel eluting with 85/15 ethyl
acetate/methanol) to provide 3.51 g of
1-{[2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cyclobutanol
as a white foamy solid.
Part B
The material from Part A was oxidized and then aminated according
to the general methods of Part F of Example 9. The crude product
was purified by column chromatography (silica gel eluting with a
gradient of 10-20% methanol in dichloromethane) to provide a light
tan oil. This material was triturated with acetonitrile. The
resulting solid was isolated by filtration and dried in a vacuum
oven at 80.degree. C. to provide 1.85 g of
1-{[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}c-
yclobutanol as light tan crystals, mp 169-171.degree. C. .sup.1H
NMR (300 MHz, DMSO-d.sub.6) .delta. 8.31 (m, 1H), 7.60 (dd, J=8.3,
1.3 Hz, 1H), 7.38 (ddd, J=8.2, 7.1, 1.2 Hz, 1H), 7.21 (ddd, J=8.3,
6.9, 1.3 Hz, 1H), 6.44 (br s, 2H), 5.53 (s, 1H), 4.70 (br s, 2H),
3.81 (t, J=6.9 Hz, 2H), 3.29 (t, J=6.9 Hz, 2H), 3.28 (s, 3H), 2.08
(m, 2H), 1.90 (m, 2H), 1.73 (m, 2H); MS (APCI) m/z 327 (M+H).sup.+;
Anal. Calcd for C.sub.18H.sub.22N.sub.4O.sub.2: C, 66.24; H, 6.79;
N, 17.16. Found: C, 66.05; H, 6.64; N, 17.28.
Example 131
1-{[4-Amino-2-(2-hydroxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cyclo-
butanol
##STR00194##
Under a nitrogen atmosphere a mixture of
1-{[4-amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cycl-
obutanol (1.43 g, 4.38 mmol) and dichloromethane (30 mL) was cooled
in an ice bath. Boron tribromide (11.0 mL of 1M in dichloromethane)
was added dropwise. The reaction mixture was allowed to warm to
ambient temperature after 1 hour and then stirred for 6 hours. The
reaction mixture was combined with a smaller scale run. Methanol
(20 mL) was added and the reaction mixture was stirred for 20
minutes. Hydrochloric acid (20 mL of 6N) was added. The reaction
mixture was heated at 40.degree. C. for 2 hours and then allowed to
stir at ambient temperature overnight. The reaction mixture was
made basic (pH 13) with 50% sodium hydroxide and then extracted
with dichloromethane (5.times.100 mL). The combined organics were
concentrated under reduced pressure. The residue was purified by
column chromatography (silica gel eluting with a gradient of 10-30%
methanol in dichloromethane) to provide 1.2 g of a white frothy
solid. This material was triturated with ethyl acetate to provide a
white solid which was recrystallized from water (100 mL) to provide
0.83 g of
1-{[4-amino-2-(2-hydroxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cycl-
obutanol as white needles, mp 132-137.degree. C. .sup.1H NMR (300
MHz, DMSO-d.sub.6) .delta. 8.31 (m, 1H), 7.59 (dd, J=8.3, 1.2 Hz,
1H), 7.38 (ddd, J=8.2, 7.1, 1.1 Hz, 1H), 7.20 (ddd, J=8.3, 6.9, 1.2
Hz, 1H), 6.47 (br s, 2H), 5.52 (s, 1H), 4.85 (t, J=5.6 Hz, 1H),
4.71 (br s, 2H), 3.86 (m, 2H), 3.19 (t, J=6.6 Hz, 2H), 2.09 (m,
2H), 1.90 (m, 2H), 1.72 (m, 2H); MS (APCI) m/z 313 (M+H).sup.+;
Anal. Calcd for C.sub.17H.sub.20N.sub.4O.sub.2.0.50H.sub.2O: C,
63.53; H, 6.59; N, 17.43. Found: C, 63.76; H, 6.19; N, 17.52.
Example 132
1-[4-Amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclobutanol
##STR00195##
1-[4-Chloro-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclobutanol
(2.95 g, 9.34 mmol, prepared according to the general methods of
Example 8 using 2,4-dichloro-3-nitroquinoline in lieu of
4-chloro-3-nitroquinoline in Part C and propionyl chloride in lieu
of ethoxyacetyl chloride in Part E), ammonium chloride (0.50 g,
9.34 mmol), and ammonia in methanol (90 mL of 7.0 N) were combined
in a bomb reactor. The reactor was sealed and heated at 150.degree.
for 48 hours. The reaction mixture was filtered and concentrated
under reduced pressure to provide a tan solid. This material was
recrystallized from acetonitrile/ethanol and dried under vacuum at
80.degree. C. to provide 1.14 g of
1-[4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclob-
utanol as light tan crystals, mp 226-228.degree. C. .sup.1H NMR
(300 MHz, DMSO-d.sub.6) .delta. 8.30 (m, 1H), 7.59 (dd, J=8.3, 1.2
Hz, 1H), 7.37 (ddd, J=8.3, 7.0, 1.2 Hz, 1H), 7.20 (ddd, J=8.3, 6.9,
1.2 Hz, 1H), 6.40 (br s, 2H), 5.51 (s, 1H), 4.65 (br s, 2H), 3.03
(q, J=7.4 Hz, 2H), 2.08 (m, 2H), 1.90 (m, 2H), 1.71 (m, 2H), 1.35
(t, J=7.4 Hz, 3H); MS (APCI) m/z 297 (M+H).sup.+; Anal. Calcd for
C.sub.17H.sub.20N.sub.4O: C, 68.90; H, 6.80; N, 18.90. Found: C,
68.71; H, 7.16; N, 18.94.
Example 133
1-[4-Amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclobutanol
##STR00196##
1-[4-Amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclobutanol
was prepared according to the method of Example 132 using valeryl
chloride in lieu of propionyl chloride. The crude product was
partitioned between 5% sodium carbonate (100 mL) and
dichloromethane (200 mL). The organic was concentrated under
reduced pressure to provide a tan solid, which was purified by
column chromatography (silica gel eluting with 85/15
dichloromethane/methanol) to provide a white solid. This solid was
recrystallized from isopropanol then dissolved in methanol. The
solution was concentrated under reduced pressure to provide a white
solid, which was dried under vacuum at 80.degree. C. to provide
pure product as a white solid, mp 186-188.degree. C. .sup.1H NMR
(300 MHz, DMSO-d.sub.6) .delta. 8.30 (m, 1H), 7.59 (dd, J=8.4, 1.2
Hz, 1H), 7.37 (ddd, J=8.3, 7.0, 1.2 Hz, 1H), 7.20 (ddd, J=8.3, 6.9,
1.2 Hz, 1H), 6.40 (br s, 2H), 5.50 (s, 1H), 4.65 (br s, 2H), 3.00
(m, 2H), 2.08 (m, 2H), 1.98-1.58 (m, 6H), 1.43 (sextet, J=7.4 Hz,
2H), 0.94 (t, J=7.3 Hz, 3H); MS (APCI) m/z 325 (M+H).sup.+; Anal.
Calcd for C.sub.19H.sub.24N.sub.4O: C, 70.34; H, 7.46; N, 17.27.
Found: C, 70.26; H, 7.62; N, 17.27.
Example 134
4-[(4-Amino-2-ethoxymethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]-4-hydrox-
y-N-phenylpiperidine-1-carboxamide
##STR00197## Part A
Under a nitrogen atmosphere a mixture of trifluoroacetic acid (40
mL) and dichloromethane (200 mL) was chilled in an ice bath. A
solution of tert-butyl
4-[(2-ethoxymethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]-4-hydroxypiperi-
dine-1-carboxylate (20 g, Example 4 Parts A through E) in
dichloromethane (200 mL) was slowly added. The reaction mixture was
allowed to warm to ambient temperature, stirred for 6 hours, and
then concentrated under reduced pressure to provide a dark amber
oil. The oil was dissolved in water (200 mL), the pH was adjusted
to 13 with 50% sodium hydroxide, and the mixture was extracted with
dichloromethane. The combined extracts were dried over magnesium
sulfate, filtered, and concentrated under reduced pressure to
provide 15.2 g of
4-[(2-ethoxymethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]piperidin-4-ol
as a tan frothy solid.
Part B
Under a nitrogen atmosphere phenyl isocyanate (1.00 mL, 9.25 mmol)
was added dropwise to a chilled mixture of
4-[(2-ethoxymethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]piperidin-4-ol
(3.00 g, 8.81 mmol) and dichloromethane (90 mL). The reaction
mixture was allowed to warm to ambient temperature. After 2 hours
the reaction mixture was concentrated under reduced pressure to
provide an orange oil. This material was triturated with diethyl
ether to provide 4.1 g of
4-[(2-ethoxymethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]-4-hydroxy-N-phe-
nylpiperidine-1-carboxamide as a light orange solid.
Part C
The material from Part B was oxidized and aminated according to the
general methods of Part F of Example 10. The crude product was
purified by column chromatography (eluting with a gradient of
10-30% methanol in dichloromethane) to provide 1.5 g of a white
frothy solid. This material was recrystallized from acetonitrile
(12 mL) and dried under vacuum at 80.degree. C. to provide
4-[(4-amino-2-ethoxymethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]-4-hydro-
xy-N-phenylpiperidine-1-carboxamide as white crystals, mp
184-186.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 8.40
(s, 1H), 8.34 (m, 1H), 7.59 (dd, J=8.4, 1.2 Hz, 1H), 7.45-7.36 (m,
3H), 7.24-7.16 (m, 3H), 6.90 (ddd, J=8.4, 7.2, 1.1 Hz, 1H), 6.56
(br s, 2H), 5.29-4.34 (m, 4H), 5.02 (s, 1H), 3.90 (m, 2H), 3.53 (q,
J=7.0 Hz, 2H), 2.95 (m, 2H), 1.75 (m, 2H), 1.39 (br s, 2H), 1.14
(t, J=7.0 Hz, 3H); MS (APCI) m/z 475 (M+H).sup.+; Anal. Calcd for
C.sub.26H.sub.30N.sub.6O.sub.3.0.25H.sub.2O: C, 65.19; H, 6.42; N,
17.54. Found: C, 64.80; H, 6.38; N, 17.45.
Example 135
4-[4-Amino-2-ethoxymethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]-1-(cyclop-
ropylcarbonyl)piperidin-4-ol
##STR00198## Part A
Under a nitrogen atmosphere cyclopropanecarbonyl chloride (0.84 mL,
9.25 mmol) was added dropwise to a chilled mixture of
4-[(2-ethoxymethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]piperidin-4-ol
(3.00 g, 8.81 mmol), triethylamine (1.47 mL, 10.6 mmol) and
dichloromethane (90 mL). The reaction mixture was allowed to warm
to ambient temperature. After 2 hours the reaction mixture was
washed with water. The organic layer was concentrated under reduced
pressure. The residue was purified by column chromatography (silica
gel eluting with 90/10 dichloromethane/methanol) to provide 3.16 g
of
4-[2-ethoxymethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]-1-(cyclopropylca-
rbonyl)piperidin-4-ol as a light orange frothy solid.
Part B
The material from Part A was oxidized and aminated according to the
general methods of Part F of Example 10. The crude product was
purified by column chromatography (silica gel eluting with a
gradient of 15-20% methanol in dichloromethane) to provide 1.9 g of
a white frothy solid. This material product was purified by column
chromatography (silica gel eluting with 80/20 ethyl
acetate/methanol) to provide a clear oil. This material was
dissolved in hot water (100 mL) and the solution was allowed to
cool to ambient temperature. A precipitate was isolated by
filtration and dried under vacuum at 60.degree. C. to provide 1.39
g of
4-[4-amino-2-ethoxymethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]-1-(cyclo-
propylcarbonyl)piperidin-4-ol as white crystals, mp 128-131.degree.
C. .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 8.33 (m, 1H), 7.59
(dd, J=8.3, 1.2 Hz, 1H), 7.40 (m, 1H), 7.21 (ddd, J=8.3, 6.9, 1.3
Hz, 1H), 6.56 (br s, 2H), 5.40-4.40 (m, 4H), 5.07 (s, 1H), 4.10 (m,
2H), 3.53 (q, J=7.0 Hz, 2H), 2.97 (m, 2H), 2.00-1.20 (m, 5H), 1.13
(t, J=7.0 Hz, 3H), 0.79-0.56 (m, 4H); MS (APCI) m/z 424
(M+H).sup.+; Anal. Calcd for
C.sub.23H.sub.29N.sub.5O.sub.3.1.00H.sub.2O: C, 62.57; H, 7.08; N,
15.86. Found: C, 62.78; H, 7.04; N, 15.92.
Example 136
4-[4-Amino-2-ethoxymethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]-4-hydroxy-
-N,N-dimethylpiperidine-1-carboxamide
##STR00199##
4-[4-Amino-2-ethoxymethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]-4-hydrox-
y-N,N-dimethylpiperidine-1-carboxamide was prepared according to
the general methods of Example 135 using dimethylcarbamoyl chloride
in lieu of cyclopropanecarbonyl chloride in Part A. The crude
product was purified by column chromatography (eluting with a
gradient of 15-20% methanol in dichloromethane) to provide a white
solid. This material was recrystallized from acetonitrile to
provide 1.3 g of a tan solid. The solid was dissolved in methanol
and concentrated hydrochloric acid was added. The mixture was
stirred for 30 minutes and then concentrated under reduced pressure
to provide the hydrochloride salt as an oil. The oil was dissolved
in water (100 mL) and then sodium carbonate (5 g) was added. A
precipitate was isolated by filtration and dried in a vacuum oven
at 50.degree. C. to provide 0.92 g of pure product as a white
powder, mp 115-125.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6)
.delta. 8.32 (m, 1H), 7.59 (dd, J=8.3, 1.2 Hz, 1H), 7.40 (m, 1H),
7.20 (ddd, J=8.2, 6.9, 1.2 Hz, 1H), 6.57 (br s, 2H), 5.50-4.20 (m,
4H), 4.95 (s, 1H), 3.52 (q, J=7.0 Hz, 2H), 3.28 (m, 2H), 2.89 (m,
2H), 2.68 (s, 6H), 1.75 (m, 2H), 1.34 (m, 2H), 1.13 (t, J=6.9 Hz,
3H); MS (APCI) m/z 427 (M+H).sup.+; Anal. Calcd for
C.sub.22H.sub.30N.sub.6O.sub.3: C, 61.95; H, 7.09; N, 19.70. Found:
C, 61.71; H, 7.18; N, 19.50.
Example 137
4-[4-Amino-2-ethoxymethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]-1-(propyl-
sulfonyl)piperidin-4-ol
##STR00200## Part A
Under a nitrogen atmosphere, 1-propanesulfonyl chloride (1.04 mL,
9.25 mmol) was added dropwise to a chilled mixture of
4-[(2-ethoxymethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]piperidin-4-ol
(3.00 g, 8.81 mmol), dimethylaminopyridine (3.00 g), pyridine (10
mL), and dichloromethane (60 mL). The reaction mixture was allowed
to warm to ambient temperature. After 2 hours the reaction mixture
was concentrated under reduced pressure. The residue was
partitioned between water (100 mL) and dichloromethane (100 mL).
The aqueous layer was extracted with dichloromethane (2.times.100
mL). The combined organics were concentrated under reduced pressure
to provide an orange oil. The oil was purified by column
chromatography (silica gel eluting with 95/5
dichloromethane/methanol) to provide 3.68 g of
4-[(2-ethoxymethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]-1-(propylsulfon-
yl)piperidin-4-o as a light orange frothy solid.
Part B
The material from Part A was oxidized and aminated according to the
general methods of Part F of Example 10. The crude product was
purified by column chromatography (silica gel eluting with 90/10
dichloromethane/methanol) to provide a white solid. This material
was recrystallized for ethyl acetate to provide 1.8 g of a white
crystalline solid. This solid was purified by column chromatography
(silica gel eluting with 80/20 ethyl acetate/methanol) to provide a
clear oil. The oil was triturated with hot water. The resulting
solid was isolated by filtration and dried in a vacuum oven at
80.degree. C. to provide
4-[4-amino-2-ethoxymethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]-1-(propy-
lsulfonyl)piperidin-4-ol as white crystals, mp 211-213.degree. C.
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 8.34 (m, 1H), 7.60 (dd,
J=8.3, 1.1 Hz, 1H), 7.41 (m, 1H), 7.23 (m, 1H), 6.57 (br s, 2H),
5.50-4.20 (m, 4H), 5.05 (s, 1H), 3.53 (q, J=6.9 Hz, 2H), 3.35 (m,
2H), 3.05-2.80 (m, 4H), 1.95-1.20 (m, 6H), 1.14 (t, J=7.0 Hz, 3H),
0.96 (t, J=7.3 Hz, 3H); MS (APCI) m/z 462 (M+H).sup.+; Anal. Calcd
for C.sub.22H.sub.31N.sub.5O.sub.4S: C, 57.25; H, 6.77; N, 15.17.
Found: C, 57.10; H, 6.97; N, 15.24.
Example 138
4-[4-Amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]-1-(methylsulfony-
l)piperidin-4-ol
##STR00201## Part A
The BOC protecting group was removed from tert-butyl
4-[(4-chloro-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]-4-hydroxypipe-
ridine-1-carboxylate (3.55 g, prepared according to the general
methods of Example 4 using 2,4-dichloro-3-nitroquinoline in lieu of
4-chloro-3-nitroquinoline in Part C and valeryl chloride in lieu of
ethoxyacetyl chloride in Part E) using the method of Part A of
Example 134 to provide 2.60 g of
4-[4-chloro-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]piperidin-4-ol
as a tan solid.
Part B
Under a nitrogen atmosphere, methanesulfonyl chloride (0.53 mL,
7.18 mmol) was added dropwise to a chilled mixture of the material
from Part A (2.55 g, 6.84 mmol), dimethylaminopyridine (1.27 g),
pyridine (10 mL), and dichloromethane (75 mL). The reaction was
maintained at 0.degree. C. for 2 hours and then allowed to warm to
ambient temperature. After 16 hours the reaction mixture was washed
with water (100 mL). The aqueous layer was extracted with
dichloromethane (2.times.100 mL). The combined organics were
concentrated under reduced pressure. The residue was purified by
column chromatography (silica gel eluting with 95/5
dichloromethane/methanol) to provide 2.60 g of
4-[4-chloro-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]-1-(methylsulfo-
nyl)piperidin-4-ol as a white foamy solid.
Part C
A portion (2.35 g, 5.21 mmol) of the material from Part B, ammonium
chloride (0.28 g, 5.21 mmol), and ammonia in methanol (50 mL of 7.0
N) were combined in a bomb reactor. The reactor was sealed and
heated at 150.degree. for 48 hours. The reaction mixture was
filtered and then concentrated under reduced pressure. The residue
was partitioned between 5% sodium carbonate and dichloromethane.
The aqueous layer was extracted with dichloromethane (.times.2).
The combined organics were concentrated under reduced pressure to
provide an amber oil. The oil was purified by column chromatography
(silica gel eluting with 90/10 dichloromethane/methanol) to provide
a clear oil. This material was triturated with acetonitrile to
provide a solid. The solid was suspended in water (100 mL),
concentrated hydrochloric acid (5 mL) was added, and the mixture
was stirred for 2 hours. Sodium carbonate (10 g) was added and the
mixture was heated at 45.degree. C. for 1 hour. The mixture was
allowed to cool to ambient temperature. A solid was isolated by
filtration and dried in a vacuum oven at 80.degree. C. to provide
1.43 g of
4-[4-amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]-1-(methylsul-
fonyl)piperidin-4-ol as a white solid, mp 240-242.degree. C.
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 8.32 (m, 1H), 7.58 (dd,
J=8.3, 1.2 Hz, 1H), 7.37 (m, 1H), 7.21 (ddd, J=8.3, 6.9, 1.3 Hz,
1H), 6.40 (br s, 2H), 5.00-4.20 (m, 2H), 4.94 (s, 1H), 3.34 (m,
2H), 3.32 (br t, J=7.7 Hz, 2H), 2.85 (m, 2H), 2.81 (s, 3H),
2.00-1.10 (m, 6H), 1.43 (sextet, J=7.4 Hz, 2H), 0.95 (t, J=7.3 Hz,
3H); MS (APCI) m/z 432 (M+H).sup.+; Anal. Calcd for
C.sub.21H.sub.29N.sub.5O.sub.3S.0.25H.sub.2O: C, 57.84; H, 6.82; N,
16.06. Found: C, 57.71; H, 7.00; N, 16.00.
Example 139
4-[4-Amino-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]-1-(methylsulfon-
yl)piperidin-4-ol
##STR00202##
4-[4-Amino-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]-1-(methylsulfo-
nyl)piperidin-4-ol was prepared according to the general methods of
Example 138 using butyry chloride in lieu of valeryl chloride. The
crude product was purified by column chromatography (silica gel
eluting with a gradient of 10-20% methanol in dichloromethane) to
provide a white solid. This material was recrystallized from
acetonitrile and then from methanol. The resulting solid was
dissolved in water (100 mL), concentrated hydrochloric acid (10 mL)
was added, and the mixture was stirred for 1 hour. Sodium carbonate
(10 g) was added and the mixture was heated at 40.degree. C. for 1
hour. A solid was isolated by filtration and dried in a vacuum oven
at 80.degree. C. to provide pure product as a white solid,
mp>250.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6, 354 K)
.delta. 8.29 (m, 1H), 7.60 (dd, J=8.3, 1.2 Hz, 1H), 7.36 (ddd,
J=8.2, 7.0, 1.2 Hz, 1H), 7.20 (ddd, J=8.2, 7.0, 1.2 Hz, 1H), 6.06
(br s, 2H), 4.72 (br s, 1H), 4.60 (br s, 2H), 3.36 (m, 2H),
3.06-2.84 (m, 4H), 2.78 (s, 3H), 1.94-1.72 (m, 4H), 1.53 (m, 2H),
1.02 (t, J=7.3 Hz, 3H); MS (APCI) m/z 418 (M+H).sup.+; Anal. Calcd
for C.sub.20H.sub.27N.sub.5O.sub.3S.0.50H.sub.2O: C, 56.32; H,
6.62; N, 16.42. Found: C, 56.41; H, 6.39; N, 16.49.
Example 140
4-[4-Amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]-1-(methylsulfony-
l)piperidin-4-ol
##STR00203##
4-[4-Amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]-1-(methylsulfon-
yl)piperidin-4-ol was prepared according to the general methods of
Example 138 using propionyl chloride in lieu of valeryl chloride.
The crude product was suspended in water, isolated by filtration,
and then dried to provide a white solid. This material was
recrystallized twice from acetonitrile to provide 0.95 g of pure
product as white needles, mp 260-262.degree. C. .sup.1H NMR (300
MHz, DMSO-d.sub.6, 354 K) .delta. 8.29 (dd, J=8.3, 1.0 Hz, 1H),
7.60 (dd, J=8.3, 1.1 Hz, 1H), 7.36 (ddd, J=8.3, 7.0, 1.3 Hz, 1H),
7.20 (ddd, J=8.3, 6.9, 1.4 Hz, 1H), 6.04 (br s, 2H), 4.73 (br s,
1H), 4.60 (s, 2H), 3.37 (m, 2H), 3.03 (q, J=7.5 Hz, 2H), 2.92 (m,
2H), 2.78 (s, 3H), 1.80 (app. td, J=12.8, 4.7 Hz, 2H), 1.53 (m,
2H), 1.37 (t, J=7.5 Hz, 3H); MS (APCI) m/z 404 (M+H).sup.+; Anal.
Calcd for C.sub.19H.sub.25N.sub.5O.sub.3S: C, 56.56; H, 6.25; N,
17.36. Found: C, 56.38; H, 6.45; N, 17.53.
Example 141
4-[4-Amino-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]-1-(methylsulfon-
yl)piperidin-4-ol
##STR00204##
4-[4-Amino-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]-1-(methylsulfo-
nyl)piperidin-4-ol was prepared according to the general methods of
Example 138 using acetyl chloride in lieu of valeryl chloride. The
crude product was isolated by filtration, washed with methanol, and
then dissolved in hot DMF. The solution was allowed to cool to
ambient temperature. A solid was isolated by filtration, washed
with DMF, and then dissolved in hot water. A precipitate was
isolated by filtration and dried under vacuum at 80.degree. C. to
provide pure product as a white solid, mp 294-296.degree. C.
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 8.33 (m, 1H), 7.58 (dd,
J=8.3, 1.2 Hz, 1H), 7.37 (m, 1H), 7.20 (m, 1H), 6.44 (br s, 2H),
4.97 (s, 1H), 4.60 (br s, 2H), 3.34 (m, 2H), 2.87 (m, 2H), 2.82 (s,
3H), 2.66 (s, 3H), 1.85 (m, 2H), 1.54 (m, 2H); MS (APCI) m/z 390
(M+H).sup.+; Anal. Calcd for C.sub.18H.sub.23N.sub.5O.sub.3S: C,
55.51; H, 5.95; N, 17.98. Found: C, 55.29; H, 6.18; N, 17.95.
Example 142
4-[4-Amino-1H-imidazo[4,5-c]quinolin-1-yl)methyl]-1-(methylsulfonyl)piperi-
din-4-ol
##STR00205## Part A
Under a nitrogen atmosphere, tert-butyl 4
{[(3-amino-2-chloroquinolin-4-yl)amino]methyl}-4-hydroxypiperidine-1-carb-
oxylate (0.25 g, 0.61 mmol, prepared according to the general
methods of Example 4 Parts A through D using
2,4-dichloro-3-nitroquinoline in lieu of 4-chloro-3-nitroquinoline
in Part C), toluene (5 mL), pyridine hydrochloride (0.02 g), and
triethylorthoformate (0.11 mL, 0.65 mmol) was heated at reflux for
2 hours. More triethylorthoformate (0.5 eq) was added and the
reaction mixture was heated for an additional hour. The reaction
was rerun in the same manner using 5.25 g of tert-butyl 4
{[(3-amino-2-chloroquinolin-4-yl)amino]methyl}-4-hydroxypiperidine-1-carb-
oxylate. The small and larger scale reaction mixtures were combined
and washed with water (50 mL). The aqueous layer was extracted with
dichloromethane (2.times.100 mL). The organic layers were combined
and concentrated under reduced pressure. The residue was purified
by column chromatography (silica gel eluting with a gradient of
0-10% methanol in ethyl acetate) to provide 4.08 g of tert-butyl
4-[(4-chloro-1H-imidazo[4,5-c]quinolin-1-yl)methyl]-4-hydroxypiperidine-1-
-carboxylate as a tan frothy solid.
Part B
The material from part A was converted to
4-[4-amino-1H-imidazo[4,5-c]quinolin-1-yl)methyl]-1-(methylsulfonyl)piper-
idin-4-ol according to the general methods of Example 138. The
crude product was isolated by filtration, washed with methanol,
recrystallized from methanol/water, and then dried in a vacuum oven
at 80.degree. C. to provide 0.84 g of pure product as white
needles, mp>250.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6,
354 K) .delta. 8.33 (m, 1H), 8.04 (s, 1H), 7.61 (m, 1H), 7.40 (ddd,
J=8.3, 7.0, 1.3 Hz, 1H), 7.22 (ddd, J=8.3, 6.9, 1.3 Hz, 1H), 6.18
(br s, 2H), 4.81 (br s, 1H), 4.61 (s, 2H), 3.40 (m, 2H), 2.99 (m,
2H), 2.80 (s, 3H), 1.78 (m, 2H), 1.53 (m, 2H); MS (APCI) m/z 376
(M+H).sup.+; Anal. Calcd for C.sub.17H.sub.21N.sub.5O.sub.3S: C,
54.38; H, 5.64; N, 18.65. Found: C, 54.18; H, 5.68; N, 18.64.
Example 143
1-[(4-Aminotetrahydro-2H-pyran-4-yl)methyl]-2-ethoxymethyl-1H-imidazo[4,5--
c]quinolin-4-amine
##STR00206## Part A
Tert-Butyl
{4-[(2-ethoxymethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetrahydropyran-
-4-yl}-carbamate (1.70 g, prepared according to the general methods
of Parts A through F of Example 54 using tetrahydro-4H-pyran-4-one
in lieu of cyclohexanone in Part A) was oxidized and aminated
according to the general method of Part F of Example 10 to provide
1.13 g of tent-Butyl
{4-[(4-amino-2-ethoxymethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetrahy-
dropyran-4-yl}-carbamate as a light brown solid.
Part B
The material from Part A was combined with hydrochloric acid (20 mL
of 2.8 M in ethanol) and heated at reflux for six hours. The
reaction mixture was concentrated under reduced pressure and the
residue was partitioned between 10% sodium hydroxide (100 mL) and
dichloromethane (100 mL). The aqueous layer was extracted with
dichloromethane (2.times.100 mL). The pH of the aqueous was
adjusted to pH 11 with hydrochloric acid and sodium carbonate and
then extracted with dichloromethane (3.times.100 mL). The combined
organics were dried over sodium sulfate, filtered, and then
concentrated under reduced pressure to provide 0.95 g of an amber
oil. This material was purified by column chromatography (silica
gel eluting with 90/10 dichloromethane/methanol) to provide 0.45 g
of a white solid. This material was dissolved in methanol and then
dried in a vacuum oven at 40.degree. C. to provide
1-[(4-aminotetrahydro-2H-pyran-4-yl)methyl]-2-ethoxymethyl-1H-imidazo[4,5-
-c]quinolin-4-amine as a white frothy solid, mp 53-63.degree. C.
.sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 8.19 (dd, J=8.3, 1.0 Hz,
1H), 7.81 (dd, J=8.4, 0.9 Hz, 1H), 7.51 (ddd, J=8.4, 7.0, 1.4 Hz,
1H), 7.30 (ddd, J=8.3, 7.0, 1.3 Hz, 1H), 5.50 (br s, 2H), 4.97 (br
s, 2H), 4.69 (br s, 2H), 3.82-3.63 (m, 4H), 3.59 (q, J=7.0 Hz, 2H),
2.10-1.27 (m, 6H), 1.24 (t, J=7.0 Hz, 3H); MS (ESI) m/z 356
(M+H).sup.+; Anal. Calcd for
C.sub.19H.sub.25N.sub.5O.sub.2.0.50H.sub.2O: C, 62.62; H, 7.19; N,
19.22. Found: C, 62.61; H, 7.20; N, 19.20.
Example 144
N-{[4-(4-Amino-2-ethoxymethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetrah-
ydropyran-4-yl}methanesulfonamide
##STR00207## Part A
Under a nitrogen atmosphere, a mixture of tent-Butyl
{4-[(2-ethoxymethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetrahydropyran-
-4-yl}carbamate (3.0 g, prepared according to the general methods
of Parts A through F of Example 54 using tetrahydro-4H-pyran-4-one
in lieu of cyclohexanone in Part A), hydrochloric acid (12.2 mL of
2.8 M in ethanol), and ethanol (18 mL) was heated at reflux for 4
hours. The reaction mixture was allowed to cool to ambient
temperature and was then concentrated under reduced pressure. The
residue was combined with isopropanol (100 mL). A solid was
isolated by filtration to provide 2.56 g of
4-[(2-ethoxymethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetrahydrop-
yran-4-amine as a tan solid.
Part B
Under a nitrogen atmosphere, methanesulfonyl chloride (0.068 mL,
0.88 mmol) was added dropwise to a chilled mixture of the material
from Part A (0.25 g, 0.73 mmol), dimethylaminopyridine (0.25 g),
pyridine (2 mL), and dichloromethane (2.5 mL). The reaction was
maintained at 0.degree. C. for 1 hour, allowed to warm to ambient
temperature, and then stirred for 16 hours. The reaction was
repeated on a larger scale using the remainder of the material from
Part A. The reaction mixtures were combined and concentrated under
reduced pressure. The residue was partitioned between water (100
mL) and dichloromethane (100 mL). The aqueous layer was extracted
with dichloromethane (100 mL). The combined organics were dried
over magnesium sulfate, filtered, and then concentrated under
reduced pressure. The residue was purified by column chromatography
(silica gel eluting with 80/20 ethyl acetate/methanol) to provide
1.64 g of
N-{[4-(2-ethoxymethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetrahydropyr-
an-4-yl}methanesulfonamide as a light yellow solid.
Part C
The material from Part B was oxidized and aminated according to the
general method of Part F of Example 10. The crude product was
partitioned between water (100 mL) and dichloromethane (100 mL).
The aqueous layer was extracted with dichloromethane (2.times.100
mL). The pH of the aqueous was adjusted to pH 11 with hydrochloric
acid and sodium carbonate and then extracted with dichloromethane
(2.times.100 mL). The combined organics were dried over magnesium
sulfate, filtered, and then concentrated under reduced pressure to
provide a clear oil. The oil was purified by column chromatography
(silica gel eluting with 90/10 dichloromethane/methanol) to provide
0.90 g of a clear oil. This material was dissolved in methanol and
then dried in a vacuum oven at 50.degree. C. to provide 0.86 g of
N-{[4-(4-amino-2-ethoxymethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetra-
hydropyran-4-yl}methanesulfonamide as a white frothy solid, mp
97-110.degree. C. .sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 8.20
(dd, J=8.3, 0.9 Hz, 1H), 7.80 (dd, J=8.4, 1.1 Hz, 1H), 7.51 (ddd,
J=8.3, 7.0, 1.3 Hz, 1H), 7.29 (ddd, J=8.3, 6.9, 1.3 Hz, 1H), 6.02
(br s, 1H), 5.66 (br s, 2H), 5.25 (br s, 2H), 4.90 (br s, 2H),
3.78-3.58 (m, 4H), 3.68 (q, J=7.0 Hz, 2H), 3.20 (s, 3H), 2.70-1.30
(m, 4H), 1.23 (t, J=7.0 Hz, 3H); MS (APCI) m/z 434 (M+H).sup.+;
Anal. Calcd for C.sub.20H.sub.27N.sub.5O.sub.4S.0.75H.sub.2O: C,
53.74; H, 6.43; N, 15.67. Found: C, 53.87; H, 6.34; N, 15.70.
Example 145
1-[(4-Amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclohexanol
##STR00208##
1-[(4-Amino-2-butyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclohexanol
was prepared according to the general methods of Example 1 using
valeryl chloride in lieu of ethoxyacetyl chloride in Part B. The
crude product was recrystallized from acetonitrile to provide pure
product as a brown solid, mp 218-220.degree. C. .sup.1H NMR (300
MHz, DMSO-d.sub.6) .delta. 8.30 (d, J=8.1 Hz, 1H), 7.57 (d, J=6.9
Hz, 1H), 7.36 (t, J=6.9 Hz, 1H), 7.19 (t, J=8.1 Hz, 1H), 6.37, (br
s, 2H), 4.53 (s, 1H), 4.51 (br s, 1H), 3.01 (t, J=8.1 Hz, 2H), 1.79
(pent, J=7.5 Hz, 2H), 1.46 (hex, J=7.5 Hz, 2H), 1.43 (m, 10H), 1.10
(br s, 1H), 0.94 (t, J=6.9 Hz, 3H); MS (APCI) m/z 353 (M+H).sup.+;
Anal. calcd for C.sub.21H.sub.28N.sub.4O: C, 71.56; H, 8.01; N,
15.89. Found: C, 71.29; H, 8.01; N, 16.02.
Example 146
1-{[4-Amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cyclo-
hexanol
##STR00209##
1-{[4-Amino-2-(2-methoxyethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cycl-
ohexanol was prepared according to the general methods of Example 1
using 3-methoxypropionyl chloride in lieu of ethoxyacetyl chloride
in Part B. The crude product was purified by column chromatography
(silica gel eluting with 5% methanol in chloroform), recrystallized
from acetonitrile/water, and then dried in a vacuum oven at
105.degree. C. to provide hydrated product as a light brown solid,
mp 189-191.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta.
8.30 (d, J=8.1 Hz, 1H), 7.57 (d, J=8.1 Hz, 1H), 7.37 (t, J=8.1 Hz,
1H), 7.19 (t, J=8.1 Hz, 1H), 6.39, (br s, 2H), 4.56 (s, 1H), 4.54
(br s, 1H), 3.81 (t, J=6.9 Hz, 2H), 3.30 (m, 2H), 3.28 (s, 3H),
1.47 (m, 10H), 1.10 (br s, 1H); MS (APCI) m/z 355 (M+H).sup.+;
Anal. calcd for C.sub.20H.sub.26N.sub.4O.sub.2.0.29H.sub.2O: C,
66.79; H, 7.45; N, 15.58. Found: C, 66.74; H, 7.54; N, 15.81.
Example 147
1-[(4-Amino-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclohexanol
##STR00210##
1-[(4-Amino-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclohexanol
was prepared according to the general methods of Example 1 using
butyryl chloride in lieu of ethoxyacetyl chloride in Part B. The
crude product was purified twice by HPFC eluting the first time
with a gradient of 2-40% CMA in chloroform and the second time with
a gradient of 8-25% CMA in chloroform to provide pure product as an
off-white solid, mp 250-252.degree. C. .sup.1H NMR (300 MHz,
DMSO-d.sub.6) .delta. 8.30 (d, J=7.5 Hz, 1H), 7.57 (d, J=7.5 Hz,
1H), 7.36 (t, J=7.5 Hz, 1H), 7.19 (t, J=7.5 Hz, 1H), 6.36, (br s,
2H), 4.52 (s, 1H), 4.49 (br s, 1H), 2.99 (t, J=7.5 Hz, 2H), 1.83
(hex, J=7.5 Hz, 2H), 1.46 (m, 10H), 1.10 (br s, 1H), 1.00 (t, J=7.5
Hz, 3H); MS (APCI) m/z 339 (M+H).sup.+; Anal. calcd for
C.sub.20H.sub.26N.sub.4O: C, 70.98; H, 7.74; N, 16.55. Found: C,
70.73; H, 7.73; N, 16.44.
Example 148
1-[(4-Amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclohexanol
##STR00211##
1-[(4-Amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclohexanol
was prepared according to the general methods of Example 1 using
propionyl chloride in lieu of ethoxyacetyl chloride in Part B. The
crude product was recrystallized from acetonitrile/water to provide
pure product as a brown solid, mp 217-218.degree. C. .sup.1H NMR
(300 MHz, DMSO-d.sub.6) .delta. 8.31 (d, J=7.5 Hz, 1H), 7.57 (d,
J=7.5 Hz, 1H), 7.36 (t, J=7.5 Hz, 1H), 7.19 (t, J=7.5 Hz, 1H),
6.36, (br s, 2H), 4.53 (s, 1H), 4.49 (br s, 1H), 3.04 (q, J=7.5 Hz,
2H), 1.46 (m, 10H), 1.35 (t, J=7.5 Hz, 3H), 1.10 (br s, 1H); MS
(APCI) m/z 325 (M+H).sup.+; Anal. calcd for
C.sub.19H.sub.24N.sub.4O: C, 70.34; H, 7.46; N, 17.27. Found: C,
70.06; H, 7.34; N, 17.21.
Example 149
4-[(4-Amino-1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetrahydro-2H-pyran-4-ol
##STR00212## Part A
4-[(1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetrahydro-2H-pyran-4-ol
was prepared according to the general methods of Example 11 using
triethyl orthoformate in lieu of triethyl orthoacetate in Part
A.
Part B
4-[(1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetrahydro-2H-pyran-4-ol
was oxidized and then aminated according to the general methods of
Part E of Example 2. The crude product was purified by column
chromatography (silica gel eluting with 9% methanol in chloroform)
and then by HPFC eluting with a gradient of 8-35% CMA in
chloroform. The resulting material was triturated with methanol and
then dried in a vacuum oven at 105.degree. C. to provide
4-[(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetrahydro-2H-pyran-4-o-
l as a brown solid, mp 260-262.degree. C. .sup.1H NMR (300 MHz,
DMSO-d.sub.6) .delta. 8.37 (d, J=8.1 Hz, 1H), 8.08 (s, 1H), 7.59
(d, J=8.1 Hz, 1H), 7.41 (t, J=8.1 Hz, 1H), 7.21 (t, J=8.1 Hz, 1H),
6.51, (br s, 2H), 4.91 (s, 1H), 4.57 (br s, 2H), 3.58 (m, 4H), 1.76
(dt, J=6.9 Hz, 2H), 1.31 (d, J=6.9 Hz, 2H); MS (APCI) m/z 299
(M+H).sup.+; Anal. calcd for C.sub.16H.sub.18N.sub.4O.sub.2: C,
64.41; H, 6.08; N, 18.78. Found: C, 64.04; H, 5.87; N, 18.83.
Example 150
1-[(4-Amino-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclopentanol
##STR00213##
1-[(4-Amino-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclopentanol
was prepared according to the general methods of Example 3 using
acetyl chloride in lieu of ethoxyacetyl chloride in Part E. The
crude product was isolated by filtration, rinsed with methanol, and
then dried. This material was triturated with hot
acetonitrile/water, isolated by filtration without cooling, rinsed
with water, and then dried. The resulting material was triturated
with 1N aqueous hydrochloric acid (20 mL/g) for 2 hours. A solid
was isolated by filtration. This solid was triturated with a
minimum amount of water and then the pH was adjusted to pH 14 using
50% aqueous sodium hydroxide. A solid was isolated by filtration,
rinsed with water, and then dried in a vacuum oven at 108.degree.
C. to provide pure product as an off-white solid, mp
306.5-307.5.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta.
8.26 (d, J=8.1 Hz, 1H), 7.57 (d, J=8.1 Hz, 1H), 7.37 (d, J=7.5 Hz,
1H), 7.19 (t, J=7.5 Hz, 1H), 6.42 (br s, 2H), 4.73 (s, 1H), 4.67
(s, 2H), 2.65 (s, 3H), 1.66 (m, 4H), 1.55 (m, 4H); MS (APCI) m/z
297 (M+H).sup.+; Anal. calcd for C.sub.17H.sub.20N.sub.4O: C,
68.89; H, 6.80; N, 18.90. Found: C, 68.62; H, 6.60; N, 18.76.
Example 151
1-[(4-Amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclopentanol
##STR00214##
1-[(4-Amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclopentanol
was prepared according to the general methods of Example 3 using
propionyl chloride in lieu of ethoxyacetyl chloride in Part E. The
crude product was recrystallized from acetonitrile/water then
triturated with 1N aqueous sodium hydroxide, isolated by
filtration, rinsed with water, and dried under vacuum at
100.degree. C. to provide pure product as an off-white solid, mp
251.0-252.5.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta.
8.26 (d, J=7.5 Hz, 1H), 7.58 (d, J=8.1 Hz, 1H), 7.37 (d, J=8.1 Hz,
1H), 7.19 (t, J=8.1 Hz, 1H), 6.38 (br s, 2H), 4.71 (s, 1H), 4.68
(s, 2H), 3.03 (q, J=7.5 Hz, 2H), 1.64 (m, 4H), 1.53 (m, 4H), 1.35
(t, J=7.5 Hz, 3H); MS (APCI) m/z 311 (M+H).sup.+; Anal. calcd for
C.sub.18H.sub.22N.sub.4O: C, 69.65; H, 7.14; N, 18.05. Found: C,
69.45; H, 6.88; N, 17.94.
Example 152
1-[(4-Amino-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclopentanol
##STR00215##
1-[(4-Amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclopentanol
was prepared according to the general methods of Example 3 using
butyryl chloride in lieu of ethoxyacetyl chloride in Part E. The
crude product was isolated by filtration, triturated with a minimum
amount of chloroform, isolated by filtration, and dried. The
resulting material was triturated with 1N aqueous sodium hydroxide,
isolated by filtration, and dried under vacuum at 100.degree. C. to
provide pure product as an off-white solid, mp 209.5-210.5.degree.
C. .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 8.26 (d, J=8.1 Hz,
1H), 7.58 (d, J=7.5 Hz, 1H), 7.37 (d, J=8.1 Hz, 1H), 7.19 (t, J=8.1
Hz, 1H), 6.38 (br s, 2H), 4.71 (s, 1H), 4.69 (s, 2H), 2.98 (t,
J=7.5 Hz, 2H), 1.84 (hex, J=7.5 Hz, 2H), 1.63 (m, 4H), 1.53 (m,
4H), 1.00 (t, J=7.5 Hz, 3H); MS (APCI) m/z 325 (M+H).sup.+; Anal.
calcd for C.sub.19H.sub.24N.sub.4O: C, 70.34; H, 7.46; N, 17.27.
Found: C, 70.27; H, 7.43; N, 17.30.
Example 153
1-[(4-Amino-7-bromo-2-ethoxymethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]c-
yclopentanol
##STR00216##
1-[(4-Amino-7-bromo-2-ethoxymethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]-
cyclopentanol was prepared according to the general methods of
Example 3 using 7-bromo-4-chloro-3-nitroquinoline in lieu of
4-chloro-3-nitroquinoline in Part C. The crude product was
recrystallized from acetonitrile and then from toluene to provide
pure product as a brown solid, mp 128-130.degree. C. .sup.1H NMR
(300 MHz, DMSO-d.sub.6) .delta. 8.24 (d, J=9.4 Hz, 1H), 7.71 (s,
1H), 7.31 (d, J=8.7 Hz, 1H), 6.81 (br s, 2H), 4.87 (br s, 2H), 4.78
(s, 2H), 4.76 (s, 1H), 3.52 (q, J=6.9 Hz, 2H), 1.66 (m, 4H), 1.51
(m, 4H), 1.13 (t, J=6.9 Hz, 3H); MS (APCI) m/z 420 (M+H).sup.+;
Anal. calcd for C.sub.19H.sub.23BrN.sub.4O.sub.2: C, 54.42; H,
5.53; N, 13.36. Found: C, 54.18; H, 5.29; N, 13.10.
Example 154
1-[(4-Amino-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclopentanol
##STR00217## Part A
A mixture of 1-{{(3-aminoquinolin-1-yl)amino]methyl}cyclopentanol
(2.00 g, 7.8 mmol, Example 3 Parts A through D), triethyl
orthoformate (1.36 mL, 8.2 mmol), pyridine hydrochloride (0.2 g),
and toluene (20 mL) was heated at reflux for 3.5 hours. The
reaction mixture was allowed to cool to ambient temperature. A
solid was isolated by filtration and dried. The solid was
triturated with a minimum amount of saturated aqueous sodium
bicarbonate for 1 hour. The solid was filtered and then dried to
provide 1.85 g of
1-[(1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclopentanol as a white
solid.
Part B
The material from Part A was oxidized and then aminated according
to the general methods of Parts B and C of Example 62. The crude
product was isolated by filtration, rinsed with methanol,
triturated with 1N aqueous sodium hydroxide, isolated by
filtration, and then dried in a vacuum oven at 100.degree. C. to
provide
1-[(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclopentanol as
a white solid, mp 253.5-255.0.degree. C. .sup.1H NMR (300 MHz,
DMSO-d.sub.6) .delta. 8.31 (d, J=8.1 Hz, 1H), 8.14 (s, 1H), 7.59
(d, J=7.5 Hz, 1H), 7.40 (t, J=7.5 Hz, 1H), 7.21 (t, J=7.5 Hz, 1H),
6.50, (br s, 2H), 4.79 (s, 1H), 4.67 (s, 2H), 4.69 (m, 4H), 4.55
(m, 4H); MS (APCI) m/z 283 (M+H).sup.+; Anal. calcd for
C.sub.16H.sub.18N.sub.4O: C, 68.06; H, 6.43; N, 19.84. Found: C,
67.89; H, 6.29; N, 20.07.
Example 155
1-[(4-Amino-7-bromo-2-ethoxymethyl-1H-imidazo[4,5-c][1,5]napthyridin-1-yl)-
methyl]cyclopentanol
##STR00218## Part A
A mixture of triethyl orthoformate (10 mL, 60.1 mmol) and
2,2-dimethyl-[1,3]-dioxane-4,6-dione (40.9 g, 0.23 mol) (Meldrum's
acid) was heated at 92.degree. C. for 90 minutes and then cooled to
70.degree. C. over one hour. 3-Amino-5-bromopyridine (40.9 g, 0.20
mol) was slowly added over 10 minutes with an ethanol rinse while
maintaining the reaction temperature between 60 and 70.degree. C.
The reaction was then heated for an additional 20 minutes and
allowed to cool to room temperature. The reaction mixture was
filtered and washed with ethanol (150 mL) yielding a tan solid. The
solid was dried under vacuum for 2 hours to yield 59.14 g of
5-{[(5-bromopyridin-3-yl)imino]methyl}-2,2-dimethyl-1,3-dioxane-4,6-dione
as a light yellow crystalline solid, mp 200-202.degree. C.
.sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 11.26 (d, J=14.3 Hz, 1H),
8.80 (d, J=2.3 Hz, 1H), 8.62 (d, J=14.3 Hz, 1H), 8.56 (d, J=1.9 Hz,
1H), 8.44-8.40 (m, 1H), 1.68 (s, 6H).
Part B
5-{[(5-Bromopyridin-3-yl)imino]methyl}-2,2-dimethyl-1,3-dioxane-4,6-dione
(59 g, 0.18 mol) was slowly added to DOWTHERM A heat transfer fluid
(2000 mL) over a period of 5 minutes at 235-238.degree. C.
Following addition, the reaction was maintained for an additional 5
minutes and then allowed to cool to 40.degree. C. A brown
precipitate formed, which was filtered and washed with hexanes (150
mL). The brown solid was suspended in an ethanol/water mixture
(90:10, 1500 mL), heated to a boil for 30 minutes, isolated by
filtration, and washed with ethanol (200 mL) to yield 30.8 g of
7-bromo[1,5]naphthyridin-4-ol as a dark brown powder.
.sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 11.81 (br s, 1H), 8.69
(d, J=1.9 Hz, 1H), 8.21 (d, J=1.9 Hz, 1H), 7.95 (d, J=7.7 Hz, 1H),
6.22 (d, J=7.5 Hz, 1H).
Part C
A mixture of 7-bromo[1,5]naphthyridin-4-ol (33 g, 0.147 mol) and
fuming nitric acid (350 mL) was heated at reflux (90.degree. C.
internal reaction vessel temperature) for 3 hours. The reaction
mixture was cooled to 50.degree. C., poured over 1 L of ice and
neutralized to pH 2-3 with a solution of 50% aqueous NaOH. The
resulting precipitate was filtered, washed with water, and dried
over vacuum for 3 days to yield 25.1 g of
7-bromo-3-nitro[1,5]naphthyridin-4-ol as a yellow crystalline
solid.
.sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 13.06(br s, 1H), 9.26(s,
1H), 8.88 (d, J=2.0 Hz, 1H), 8.37(d, J=2.0 Hz, 1H).
Part D
Phosphorous oxychloride (24 mL, 257.7 mmol) was added slowly
dropwise to a 0.degree. C. suspension of
7-bromo-3-nitro[1,5]naphthyridin-4-ol (60.00 g, 222.2 mmol) in
N,N-dimethylformamide (DMF; 410 mL), maintaining the temperature
below 10.degree. C. After addition was completed, the reaction was
allowed to warm to ambient temperature over a 3 hour period. The
reaction mixture was then added to ice water (1700 mL) with
stirring. A solid precipitate formed, which was isolated by vacuum
filtration and rinsed with water. The material was partitioned
between chloroform (3 Liters) and saturated aqueous sodium
bicarbonate (300 mL). The organic phase was isolated, dried over
anhydrous sodium sulfate, then concentrated under reduced pressure
to yield 54.42 g of 7-bromo-4-chloro-3-nitro[1,5]naphthyridine as
short, off-white needles.
.sup.1H NMR (300 MHz, CDCl.sub.3) .delta. 9.32 (s, 1H), 9.21 (d,
J=2.5 Hz, 1H), 8.71(d, J=2.5 Hz, 1H).
Part E
1-[(4-Amino-7-bromo-2-ethoxymethyl-1H-imidazo[4,5-c][1,5]napthyridin-1-yl-
)methyl]cyclopentanol was prepared according to the general methods
of Example 3 using 7-bromo-4-chloro-3-nitro[1,5]naphthyridine in
lieu of 4-chloro-3-nitroquinoline in Part C. The crude product was
triturated with hot acetonitrile. The acetonitrile phase was
concentrated under reduced pressure. The residue was dissolved in
chloroform, washed with 1% aqueous sodium bicarbonate, dried over
sodium sulfate, and concentrated under reduced pressure. The
residue was purified by column chromatography eluting with 1.5%
methanol in chloroform. The resulting material was triturated with
hot acetonitrile. The mixture was cooled to ambient temperature and
a solid was isolated by filtration and dried in a vacuum oven at
110.degree. C. to provide
1-[(4-amino-7-bromo-2-ethoxymethyl-1H-imidazo[4,5-c][1,5]napthyridin-1-yl-
)methyl]cyclopentanol as a white solid, mp 166-167.5.degree. C.
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 8.53 (s, 1H), 8.10 (s,
1H), 7.15 (br s, 2H), 5.05 (br s, 2H), 4.95 (s, 2H), 4.82 (s, 1H),
3.52 (q, J=6.9 Hz, 2H), 4.64 (m, 6H), 1.39 (s, 2H), 1.14 (t, J=6.9
Hz, 3H); MS (APCI) m/z 421 (M+H).sup.+; Anal. calcd for
C.sub.18H.sub.22BrN.sub.5O.sub.2: C, 51.44; H, 5.28; N, 16.66.
Found: C, 51.32; H, 5.24; N, 16.63.
Example 156
4-[(4-Amino-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]-1-methylpiperi-
din-4-ol
##STR00219## Part A
Nitromethane (6.6 mL, 122.0 mmol) and sodium methoxide (0.94 mL of
25 wt % in methanol, 4.1 mmol) were added to a solution of
1-methyl-4-piperidone (10 mL, 81.3 mmol) in ethanol (10 mL). After
30 minutes more ethanol (15 mL) was added to facilitate stirring.
The reaction mixture was stirred at ambient temperature for 2 days
and then filtered. The isolated solid was rinsed with ether to
provide 10.39 g of 1-methyl-4-nitromethylpiperidin-4-ol as a white
powder. An additional 1.18 g was isolated from the filtrate.
Part B
Palladium hydroxide (2.3 g of 20% on carbon) was added to a
solution of 1-methyl-4-nitromethylpiperidin-4-ol (11.57 g) in
ethanol (120 mL). The mixture was placed under hydrogen pressure
(50 psi, 3.4.times.10.sup.5 Pa) on a Parr apparatus for 55 hours.
The reaction mixture was filtered through a layer of CELITE filter
aid and the filter cake was rinsed with methanol (100 mL). The
filtrate was concentrated under reduced pressure to provide 10.18 g
of 4-aminomethyl-1-methylpiperidin-4-ol as a thick oil.
Part C
Triethylamine (10.9 mL, 78.5 mmol) was added to a suspension of
2,4-dichloro-3-nitroquinoline (14.7 g, 60.4 mmol) in
dichloromethane (180 mL). The mixture was cooled to 5.degree. C.
and a solution of the material from Part B (66.4 mmol) in
dichloromethane (70 mL) was added over a period of 15 minutes. The
reaction mixture was stirred at 5.degree. C. for 1 hour and then at
ambient temperature overnight. The reaction mixture was
concentrated under reduced pressure. The residue was combined with
water (500 mL), stirred for 1 hour, and then filtered. The isolated
solid was triturated with acetonitrile to provide 13.25 g of
4-{[(2-chloro-3-nitroquinolin-4-yl)amino]methyl}-1-methylpiperidin-4-ol
as a bright yellow solid.
Part D
A mixture of
4-{[(2-chloro-3-nitroquinolin-4-yl)amino]methyl}-1-methylpiperidin-4-ol
(14.05 g), 5% platinum on carbon (1.1 g), acetonitrile (280 mL),
and isopropanol (84 mL) was placed under hydrogen pressure on a
Parr apparatus overnight. The reaction mixture was filtered through
a layer of CELITE filter aid. The filtrate was concentrated under
reduced pressure to provide crude
4-{[(3-amino-2-chloroquinolin-4-yl)amino]methyl}-1-methylpiperidin-4-ol.
This material was dissolved in 240 mL of acetonitrile.
Part E
Butyryl chloride (1.19 mL, 1.15 eq) was added to a 60 mL portion of
the solution from Part D. An hour later more butyryl chloride (0.1
eq) was added. The reaction mixture was concentrated under reduced
pressure. The residue was triturated with diethyl ether, isolated
by filtration, and dried to provide crude
N-(2-chloro-4-{[(4-hydroxy-1-methylpiperidin-4-yl)methyl]amino}quinolin-3-
-yl)butanamide.
Part F
A solution of 50% aqueous sodium hydroxide (2.39 g) in water (10.2
mL) was added to a solution of the material from Part E in ethanol
(30 mL). The reaction mixture was refluxed for 1 hour and then
concentrated under reduced pressure. The residue was partitioned
between chloroform and water. The organic layer was dried over
sodium sulfate and then concentrated under reduced pressure. The
residue was purified by HPFC eluting with a gradient of 20-50% CMA
in chloroform. The residue was recrystallized from acetonitrile and
the mixture was filtered. The filtrate was concentrated under
reduced pressure to provide
4-[(4-chloro-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]-1-methylpipe-
ridin-4-ol.
Part G
The material from Part F was combined with a solution of 7N ammonia
in methanol (16 mL) in a pressure vessel. The vessel was sealed and
then heated at 150.degree. C. for 18 hours. The reaction mixture
was concentrated under reduced pressure. The residue was purified
by HPFC eluting with a gradient of 25-100% solution over 6 L of 30%
methanol in chloroform, triturated with acetonitrile, and dried.
The resulting material was dissolved in water. The pH of the
solution was adjusted to pH 2 with 1N hydrochloric acid and then to
pH 14 with 50% aqueous sodium hydroxide and then chloroform was
added. The organic phase was separated and concentrated under
reduced pressure. The residue was triturated with hot chloroform
and the filtered while still hot. The isolated solid was combined
with chloroform (400 mL), washed with aqueous sodium bicarbonate
(2.times.60 mL), dried over sodium sulfate, and concentrated under
reduced pressure. The residue was dried under vacuum at 110.degree.
C. to provide 0.33 g of
4-[(4-amino-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]-1-methylpiper-
idin-4-ol as an off-white solid, mp 241-242.degree. C. .sup.1H NMR
(300 MHz, DMSO-d.sub.6) .delta. 8.28 (d, J=8.1 Hz, 1H), 7.57 (d,
J=8.1 Hz, 1H), 7.36 (t, J=8.1 Hz, 1H), 7.19 (t, J=8.1 Hz, 1H),
6.37, (br s, 2H), 4.60 (s, 1H), 4.54 (br s, 1H), 3.00 (t, J=7.5 Hz,
2H), 2.40 (s, 2H), 2.08 (s, 3H), 2.08 (m, 2H), 1.83 (hex, J=7.5 Hz,
2H), 1.72 (m, 4H), 1.31 (br s, 1H), 1.00 (t, J=7.5 Hz, 3H); MS
(APCI) m/z 354 (M+H).sup.+; Anal. calcd for
C.sub.20H.sub.27N.sub.5O: C, 67.96; H, 7.70; N, 19.81. Found: C,
67.86; H, 7.67; N, 19.85.
Example 157
4-[(4-Amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]-1-methylpiperid-
in-4-ol
##STR00220##
4-[(4-Amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]-1-methylpiperi-
din-4-ol was prepared according to the general method of Example
156 using propionyl chloride in lieu of butyryl chloride in Part E.
The crude product was triturated with chloroform. The resulting
material was dissolved in water. The pH of the solution was
adjusted to pH 2 with 1N hydrochloric acid and then to pH 14 with
50% aqueous sodium hydroxide and then chloroform was added. The
mixture was filtered to provide a gray solid. The organic phase
from the filtrate was concentrated under reduced pressure. The
residue was triturated with chloroform. The resulting solid was
combined with the gray solid, triturated with chloroform, and dried
to provide pure product as a gray solid, mp 233-234.degree. C.
.sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta. 8.29 (d, J=8.1 Hz, 1H),
7.58 (d, J=8.1 Hz, 1H), 7.37 (t, J=8.1 Hz, 1H), 7.19 (t, J=8.1 Hz,
1H), 6.38, (br s, 2H), 4.61 (s, 1H), 4.55 (br s, 1H), 3.05 (q,
J=7.5 Hz, 2H), 2.40 (s, 2H), 2.08 (s, 3H), 2.08 (m, 2H), 1.73 (m,
4H), 1.32 (br s, 1H), 1.35 (t, J=7.5 Hz, 3H); MS (APCI) m/z 340
(M+H).sup.+; Anal. calcd for C.sub.19H.sub.25N.sub.5O: C, 67.23; H,
7.42; N, 20.63. Found: C, 66.91; H, 7.70; N, 20.66.
Example 158
4-[(4-Amino-2-ethoxymethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]-1-methyl-
piperidin-4-ol
##STR00221##
4-[(4-Amino-2-ethoxymethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]-1-methy-
lpiperidin-4-ol was prepared according to the general method of
Example 156 using ethoxyacetyl chloride in lieu of butyryl chloride
in Part E. The crude product was triturated with hot acetonitrile;
the mixture was allowed to cool and a solid was isolated by
filtration. The solid was dissolved in water. The pH of the
solution was adjusted to pH 2 with 1N hydrochloric acid and then to
pH 14 with 50% aqueous sodium hydroxide and then chloroform was
added. The organic phase was separated and concentrated under
reduced pressure to provide a yellow solid. This material was
recrystallized from acetonitrile and then dried under vacuum at
105.degree. C. to provide pure product as a light brown solid, mp
197.5-198.5.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6) .delta.
8.30 (d, J=8.1 Hz, 1H), 7.59 (d, J=8.1 Hz, 1H), 7.40 (t, J=6.9 Hz,
1H), 7.21 (t, J=6.9 Hz, 1H), 6.54, (br s, 2H), 4.88 (br s, 2H),
4.71 (s, 2H), 4.67 (br s, 1H), 3.51 (q, J=6.9 Hz, 2H), 2.40 (m,
2H), 2.08 (s, 3H), 2.08 (m, 2H), 1.76 (m, 2H), 1.30 (br s, 2H),
1.13 (t, J=6.9 Hz, 3H); MS (APCI) m/z 370 (M+H).sup.+; Anal. calcd
for C.sub.20H.sub.27N.sub.5O.sub.2: C, 65.02; H, 7.37; N, 18.96.
Found: C, 64.75; H, 7.45; N, 19.15.
Example 159
2-Ethoxymethyl-1-({4-[2-(methylsulfonyl)ethoxy]tetrahydro-2H-pyran-4-yl}me-
thyl)-1H-imidazo[4,5-c]quinolin-4-amine
##STR00222##
4-[(2-Ethoxymethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetrahydro-2H-py-
ran-4-ol (4.05 g, Example 10 Parts A through E) was converted to
2-ethoxymethyl-1-({4-[2-(methylsulfonyl)ethoxy]tetrahydro-2H-pyran-4-yl}m-
ethyl)-1H-imidazo[4,5-c]quinolin-4-amine according to the general
methods of Example 13 using
4-[(2-ethoxymethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetrahydro-2H-py-
ran-4-ol in lieu of
tert-butyl[(2-ethoxymethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]-4-hydro-
xyypiperidine-1-carboxylate in Part A. The crude product was
purified by column chromatography (silica gel eluting with 95/5
dichloromethane/methanol) to provide a white foam. This material
was recrystallized from acetonitrile, isolated by filtration,
washed with acetonitrile, and then dried under vacuum at 65.degree.
C. to provide 50 mg of pure product as a white powder. MS (APCI)
m/z 463 (M+H).sup.+; Anal. Cacld for
C.sub.22H.sub.30N.sub.4O.sub.5S: C, 57.12; H, 6.54: N, 12.11.
Found: C, 57.08; H, 6.75; N, 12.04.
Example 160
3-[(4-Amino-2-propyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]tetrah-
ydrofuran-3-ol
##STR00223## Part A
Pyridinium chlorochromate (85.8 g, 3.5 eq) was added in portions
over a period of 5 minutes to a solution of
3-hydroxytetrahydrofuran (10.02 g, 1.0 eq) in dichloromethane (115
mL). The reaction mixture was stirred at ambient temperature for
3.5 hours and then applied directly to a column of silica gel (325
g). The column was eluted with diethyl ether. The fractions
containing product were combined and the solvent was removed by
atmospheric distillation to provide 5.22 g of
tetrahydrofuran-3-one.
Part B
Potassium cyanide (50 mg, 0.02 eq.) and 18-crown-6 macrocyclic
polyether (203 mg, 0.02 eq) were dissolved in methanol (8 mL). The
solution was stirred for 5 minutes and then concentrated under
reduced pressure. The resulting white solid was dissolved in
trimethylsilyl cyanide (5.5 mL, 1.0 eq.) and the solution was added
dropwise over a period of 1 minute to the material from Part A (1.0
eq). The reaction was cooled with an ice bath during the addition.
The reaction mixture was stirred in the ice bath for 2 minutes,
allowed to warm to ambient temperature, and stirred for 15
minutes.
Part C
The reaction mixture from Part B (1.0 eq) was diluted with
tetrahydrofuran (THF) and cooled to 0.degree. C. Solid lithium
aluminum hydride (1.46 g, 1.0 eq) was added in portions over a
period of 5 minutes. After 1 hour water (1.5 mL) was added
dropwise; the ice bath was removed, and the reaction was stirred
for several minutes. Sodium hydroxide (1.5 mL of 10%) and water
(4.5 mL) were added and the reaction mixture was stirred for 30
minutes. Magnesium sulfate was added and the reaction mixture was
stirred for another 10 minutes. The reaction mixture was filtered
through a layer of CELITE filter aid. The filter cake was rinsed
with THF (2.times.100 mL). The filtrate was concentrated under
vacuum to provide a light yellow liquid. This material was
concentrated from acetonitrile (2.times.100 mL) to provide 5.19 g
of a mixture of 3-(aminomethyl)tetrahydrofuran-3-ol and
(3-trimethylsilyloxytetrahydrofuran-3-yl)methylamine.
Part D
4-Chloro-3-nitronaphthyridine (7.13 g, 1.1 eq) and triethylamine
(5.2 1 mL, 1.1 eq) were added sequentially to a solution of the
material from Part C (1.0 eq) in dichloromethane (113 mL). The
reaction mixture was cooled briefly with an ice bath to control an
exotherm and then stirred at ambient temperature overnight. The
reaction mixture was diluted with water (200 mL) and
dichloromethane (350 mL). The aqueous layer was extracted with
dichloromethane (400 mL). The combined organics were dried over
magnesium sulfate and then concentrated under reduced pressure to
provide 10.96 g of a yellow solid. This material was dissolved in
methanol (350 mL). Potassium carbonate (5.0 g) was added; the
resulting suspension was stirred for 20 minutes and then
concentrated under reduced pressure. The residue was slurried with
water (130 mL) overnight and then filtered. The isolated solid was
rinsed with water (2.times.70 mL) and dried under vacuum to provide
8.27 g of
3-[3-nitro[1,5]napthyridin-4-yl)methyl]tetrahydrofuran-3-ol as a
yellow solid.
Part E
A suspension of
3-[3-nitro[1,5]napthyridin-4-yl)methyl]tetrahydrofuran-3-ol (2.00
g) and 10% palladium on carbon (200 mg) in ethanol (68 mL) was
placed under hydrogen pressure (50 psi, 3.4.times.10.sup.5 Pa) on a
Parr apparatus for 4 hours. The reaction mixture was sparged with
nitrogen for 15 minutes and then filtered through a layer of CELITE
filter aid. The filtrate was concentrated under reduced pressure.
The residue was reconcentrated from acetonitrile (2.times.75 mL)
and dichloromethane (2.times.50 mL) and then dried under high
vacuum to provide 1.79 g of
3-[3-amino[1,5]napthyridin-4-yl)methyl]tetrahydrofuran-3-ol as a
yellow foam.
Part F
Toluene (29 mL), trimethyl orthobutyrate (0.56 mL, 1.1 eq), and
pyridine hydrochloride (37 mg, 0.1 eq) were added to a suspension
of 3-[3-amino[1,5]napthyridin-4-yl)methyl]tetrahydrofuran-3-ol
(0.83 g, 1.0 eq) in chloroform (3 mL). The reaction mixture was
heated at reflux with stirring for 16 hours, allowed to cool to
ambient temperature, and then concentrated under reduced pressure.
The residue was triturated with acetonitrile (about 6 mL) and
filtered. The isolated solid was rinsed with acetonitrile
(3.times.4 mL) to provide 0.80 g of a tan solid. A portion (112 mg)
was purified by HPFC (silica gel eluting with 20% CMA in
chloroform) to provide 88 mg of
3-[(2-propyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]tetrahydrofur-
an-3-ol as light tan needles, mp 151-152.degree. C. .sup.1H NMR
(300 MHz, DMSO-d.sub.6): .delta. 9.25 (s, 1H), 8.96 (dd, J=1.6, 4.3
Hz, 1H), 8.51 (dd, J=1.6, 8.5 Hz, 1H), 7.73 (dd, J=4.3, 8.5 Hz,
1H), 5.37 (s, 1H), 5.30 (m, 1H), 5.08 (m, 1H), 3.80 (m, 3H), 3.46
(d, J=8.9 Hz, 1H), 3.12 (t, J=7.5 Hz, 2H), 2.12 (m, 1H), 1.91 (m,
2H), 1.66 (m, 1H), 1.03 (t, J=7.4 Hz, 3H); MS (APCI) m/z 313
(M+H).sup.+; Anal. calcd for C.sub.17H.sub.20N.sub.4O.sub.2: C,
65.37; H, 6.45; N, 17.94. Found: C, 65.13; H, 6.18; N, 17.88.
Part G
3-Chloroperbenzoic acid (0.60 g of 77%, 1.1 eq) was added to a
solution of
3-[(2-propyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]tetrahydro-
furan-3-ol (0.68 g, 1.0 eq) in chloroform. The reaction mixture was
stirred at ambient temperature for 3.5 hours. Ammonium hydroxide
(22 mL) and p-toluenesulfonyl chloride (0.50 g, 1.2 eq) were added
sequentially and the reaction mixture was stirred at ambient
temperature for 2 hours. The reaction mixture was diluted with
water (20 mL) and chloroform (30 mL). The aqueous layer was
extracted with chloroform (30 mL). The combined organics were dried
over magnesium sulfate and then concentrated under reduced pressure
to provide a brown foam. This material was triturated with ethyl
acetate (about 12 mL). A solid was isolated by filtration, rinsed
with ethyl acetate (4.times.5 mL), and then dried under vacuum to
provide 383 mg of a yellow solid. This material was triturated with
warm ethyl acetate (about 15 mL). A solid was isolated by
filtration, rinsed with ethyl acetate (3.times.5 mL), and then
dried under vacuum to provide 260 mg of
3-[(4-amino-2-propyl-1H-imidazo[4,5-c][1,5]-naphthyridin-1-yl)methyl]tetr-
ahydrofuran-3-ol as a tan powder, mp 171-173.degree. C. .sup.1H NMR
(300 MHz, DMSO-d.sub.6): .delta. 8.47 (dd, J=1.5, 4.3 Hz, 1H), 7.91
(dd, J=1.5, 8.4 Hz, 1H), 7.43 (dd, 1H), 6.75 (s, 2H), 5.46 (s, 1H),
5.22 (m, 1H), 4.98 (m, 1H), 3.80 (m, 3H), 3.45 (d, J=8.9 Hz, 1H),
3.04 (t, J=7.6 Hz, 2H), 2.09 (m, 1H), 1.85 (sextet, J=7.5 Hz, 2H),
1.66 (m, 1H), 1.01 (t, J=7.4 Hz, 3H); MS (APCI) m/z 328
(M+H).sup.+; Anal. calcd for C.sub.17H.sub.21N.sub.5O.sub.2: C,
62.37; H, 6.47; N, 21.39. Found: C, 62.14; H, 6.33; N, 21.31.
Example 161
3-[(4-Amino-2-ethyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]tetrahy-
drofuran-3-ol
##STR00224## Part A
3-[(2-ethyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]tetrahydro
furan-3-ol was prepared according to the methods of Parts A through
F in Example 160 using triethyl orthoformate in lieu of trimethyl
orthobutyrate in Part F. The crude product was triturated with
ethyl acetate (about 6 mL). A solid was isolated by filtration,
rinsed with ethyl acetate (4.times.5 mL), and then dried under
vacuum to provide 839 mg of a tan powder.
Part B
The material from Part A was oxidized and then aminated according
to the methods of Part G of Example 160. The crude product was
triturated with ethyl acetate (about 15 mL). A solid was isolated
by filtration, rinsed with ethyl acetate, and then dried under
vacuum to provide 610 mg of a light orange solid. This material was
recrystallized from acetonitrile (about 60 mL), isolated by
filtration, rinsed with acetonitrile (3.times.10 mL), and then
dried under high vacuum to provide 462 mg of
3-[(4-amino-2-ethyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]tetrah-
ydrofuran-3-ol as off white needles, mp 234-236.degree. C. .sup.1H
NMR (300 MHz, DMSO-d.sub.6): .delta. 8.47 (dd, J=1.6, 4.3 Hz, 1H),
7.92 (dd, J=1.6, 8.4 Hz, 1H), 7.43 (dd, J=4.3, 8.4 Hz, 1H), 6.76
(s, 2H), 5.47 (s, 1H), 5.21 (m, 1H), 4.97 (m, 1H), 3.79 (m, 3H),
3.45 (d, J=8.9 Hz, 1H), 3.08 (q, J=7.5 Hz, 2H), 2.11 (m, 1H), 1.66
(m, 1H), 1.37 (t, J=7.5 Hz, 3H); MS (APCI) m/z 314 (M+H).sup.+;
Anal. calcd for C.sub.16H.sub.19N.sub.5O.sub.2: C, 61.33; H, 6.11;
N, 22.35. Found: C, 61.27; H, 6.02; N, 22.58.
Example 162
3-{[4-Amino-2-(fluoromethyl)-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl]methy-
l}tetrahydrofuran-3-ol
##STR00225## Part A
Fluoroacetyl chloride (0.36 mL, 1.1 eq) was added dropwise over a
period of 2 minutes to a chilled (0.degree. C. suspension of
3-[3-amino[1,5]napthyridin-4-yl)methyl]tetrahydrofuran-3-ol (1.14
g, 1.0 eq) in dichloromethane (44 mL). After 30 minutes the
reaction mixture was allowed to warm to ambient temperature. The
reaction mixture was stirred for an additional 30 minutes and was
then concentrated under reduced pressure to provide
2-fluoro-N-(4-{[(3-hydroxytetrahydrofuran-3-yl)methyl]amino}[1,5]naphthyr-
idin-3-yl)acetamide hydrochloride as a yellow foam.
Part B
Triethylamine (1.83 mL, 3.0 eq) was added to a suspension of the
material from Part A (1.0 eq) in ethanol (30 mL). The reaction
mixture was heated at 70.degree. C. for 2.5 hours and then at
reflux for another hour. The reaction mixture was allowed to cool
to ambient temperature and then concentrated under reduced
pressure. The residue was suspended in 10% CMA in chloroform,
filtered through a cotton plug to remove solids, and then purified
by chromatography eluting with 10% CMA in chloroform for 2 column
volumes, with a gradient of 10-25% CMA for 8 column volumes, and
finally with 25% CMA in chloroform for 4 column volumes to provide
0.69 g of
3-{[2-(fluoromethyl)-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl]methyl}te-
trahydrofuran-3-ol.
Part C
The material from Part B was oxidized and then aminated according
to the methods of Part G of Example 160. The crude product was
triturated with ethyl acetate (about 8 mL). A solid was isolated by
filtration, rinsed with ethyl acetate (4.times.56 mL), and then
dried under vacuum to provide 345 mg of an orange foam. This
material was dissolved in hot 20% CMA in chloroform (10 mL) and
then purified by chromatography eluting with 20% CMA in chloroform
for 8 column volumes to provide 270 mg of an off white solid. This
material was triturated with ethyl acetate (about 8 mL). A solid
was isolated by filtration, rinsed with ethyl acetate (2.times.2
mL), and then dried under vacuum to provide 196 mg of
3-{[4-amino-2-(fluoromethyl)-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl]meth-
yl}tetrahydrofuran-3-ol as an off white powder, mp 209-210.degree.
C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): .delta. 8.51 (dd, J=1.5,
4.3 Hz, 1H), 7.94 (dd, J=1.5, 8.4 Hz, 1H), 7.49 (dd, J=4.3, 8.4 Hz,
1H), 7.00 (br s, 2H), 5.86 (m, 2H), 5.54 (s, 1H), 5.36 (d, J=14.3
Hz, 1H), 5.10 (d, J=14.3 Hz, 1H), 3.82 (m, 3H), 3.43 (d, J=9.0 Hz,
1H), 2.14 (ddd, J=8.5, 8.5, 12.6 Hz, 1H), 1.62 (m, 1H); MS (APCI)
m/z 318 (M+H).sup.+; Anal. calcd for
C.sub.15H.sub.16FN.sub.5O.sub.2.0.38H.sub.2O: C, 55.58; H, 5.21; N,
21.60. Found: C, 55.96; H, 4.89; N, 21.72.
Example 163
3-{[4-Amino-2-(fluoromethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}tetrahy-
drofuran-3-ol
##STR00226## Part A
A mixture of 3-[3-nitroquinolin-4-yl)methyl]tetrahydrofuran-3-ol
(2.5 g, Parts A through D of Example 160 using
4-chloro-3-nitroquinoline in lieu of
4-chloro-3-nitro[1,5]naphthyridine in Part D), 5% platinum on
carbon (0.25 g), and ethyl acetate (150 mL) was placed under
hydrogen pressure (40 psi, 2.8.times.10.sup.5 Pa) on a Parr
apparatus for 4 hours. The reaction mixture was filtered through a
layer of CELITE filter aid. The filtrate was concentrated under
reduced pressure and then dried under high vacuum to provide 2.20 g
of 3-[3-aminoquinolin-4-yl)methyl]tetrahydrofuran-3-ol as a brown
foam.
Part B
Fluoroacetyl chloride (0.578 g, 1.2 eq) was added dropwise over a
period of 3 minutes to a chilled (0.degree. C. suspension of
3-[3-aminoquinolin-4-yl)methyl]tetrahydrofuran-3-ol (1.3 g, 1.0 eq)
in dichloromethane (50 mL). After 30 minutes the reaction mixture
was allowed to warm to ambient temperature. The reaction mixture
was stirred overnight at ambient temperature and then concentrated
under reduced pressure to provide
2-fluoro-N-(4-{[(3-hydroxytetrahydrofuran-3-yl)methyl]amino}quinolin-3-yl-
)acetamide hydrochloride as a brown solid.
Part C
Triethylamine (2.1 mL, 3.0 eq) was added to a mixture of the
material from Part B (1.0 eq) and methanol (50 mL). The reaction
mixture was heated at 80.degree. C. for 2 hours, allowed to cool to
ambient temperature, and then concentrated under reduced pressure
to provide a brown solid. This material was combined with the
product from another run, dissolved in chloroform, and purified by
HPFC eluting with a gradient of 0-50% CMA in chloroform for 600 mL
and then with 50% CMA in chloroform for 1200 mL to provide 800 mg
of
3-{[2-(fluoromethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}tetrahydrofura-
n-3-ol as an orange solid.
Part D
The material from Part D was oxidized and then aminated according
to the methods of Part G of Example 160. The crude product was
triturated with chloroform and then filtered. The filtrate was
concentrated under reduced pressure. The residue was purified by
HPFC eluting sequentially with chloroform for 4 column volumes, a
gradient of 0-50% CMA in chloroform for 6 column volumes, and 50%
CMA in chloroform for 6 column volumes to provide a yellow solid.
This material was triturated with methanol. A solid was isolated by
filtration and dried under high vacuum to provide 148 mg of
3-{[4-amino-2-(fluoromethyl)-1H-imidazo[4,5-c]quinolin-1-yl]met-
hyl}tetrahydrofuran-3-ol as a light orange solid, mp
169-171.degree. C. .sup.1H NMR (300 MHz, DMSO-d.sub.6): 8.30 (d,
J=7.9 Hz, 1H), 7.61 (dd, J=8.3, 1.1 Hz, 1H), 7.45 (dt, J=7.5, 0.8
Hz, 1H), 7.23 (t, J=7.6, 1.1 Hz, 1H), 6.67 (s, 2H), 5.83 (d, J=48.0
Hz, 2H), 5.48 (s, 1H), 4.89 (s, 2H), 3.83 (m, 2H), 3.59 (dd,
J=103.8, 9.1 Hz, 2H), 1.91 (m, 2H); MS (EI) m/z 316 (M+H).sup.+;
Anal. calcd for C.sub.16H.sub.17FN.sub.4O.sub.2.0.58H.sub.2O: C,
58.81; H, 5.60; N, 17.14. Found: C, 58.92; H, 5.72; N, 17.01
Example 164
3-[(4-Amino-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetrahydrofuran-
-3-ol
##STR00227## Part A
3-[(2-Propyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetrahydrofuran-3-ol
was prepared using the method of Part F of Example 160 using
3-[3-aminoquinolin-4-yl)methyl]tetrahydrofuran-3-ol in lieu of
3-[3-amino[1,5]napthyridin-4-yl)methyl]tetrahydrofuran-3-ol. The
crude product was triturated with acetonitrile (about 10 mL) to
provide 500 mg of pure product. An additional 190 mg was isolated
from the filtrate.
Part B
The material from Part A was oxidized and then aminated according
to the methods of Part G of Example 160. The crude product was
triturated with chloroform and then filtered. The filtrate was
concentrated under reduced pressure. The residue was purified by
HPFC eluting sequentially with chloroform for 3 column volumes and
a gradient of 0-50% CMA in chloroform for 10 column volumes to
provide a yellow-orange solid. This material was triturated with
methanol. A solid was isolated by filtration. This material was
triturated with 10% aqueous sodium hydroxide (10 mL) to provide an
orange solid. This material was combined with acetonitrile, heated
to reflux, and then allowed to cool to ambient temperature. A solid
was isolated by filtration and dried under high vacuum to provide
3-[(4-amino-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetrahydrofura-
n-3-ol as a tan solid, mp 201-203.degree. C. .sup.1H NMR (300 MHz,
DMSO-d.sub.6): 8.25 (d, J=7.4 Hz, 1H), 7.59 (dd, J=8.3, 1.1 Hz,
1H), 7.38 (t, J=7.7 Hz, 1H), 7.19 (td, J=7.6, 1.2 Hz, 1H), 6.41 (s,
2H), 5.33 (s, 1H), 4.75 (s, 2H), 3.80 (m, 2H), 3.58 (dd, J=73.4,
9.0 Hz, 2H), 2.98 (t, J=7.4 Hz, 2H), 1.94 (m, 2H), 1.83 (m, J=7.5
Hz, 2H), 1.01 (t, J=7.4 Hz, 3H); MS (EI) m/z 327 (M+H).sup.+; Anal.
calcd for C.sub.18H.sub.22N.sub.4O.sub.2: C, 66.24; H, 6.79; N,
17.17. Found: C, 65.86; H, 6.82; N, 17.25.
Example 165
3-[(4-Amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetrahydro
furan-3-ol
##STR00228## Part A
3-[(2-Ethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetrahydrofuran-3-ol
was prepared using the method of Part F of Example 160 using
3-[3-aminoquinolin-4-yl)methyl]tetrahydrofuran-3-ol in lieu of
3-[3-amino[1,5]napthyridin-4-yl)methyl]tetrahydrofuran-3-ol and
trimethyl orthopropionate in lieu of trimethyl orthobutyrate. The
crude product was triturated with acetonitrile (about 10 mL) to
provide 737 mg of pure product. An additional 210 mg was isolated
from the filtrate.
Part B
The material from Part A was oxidized and then aminated according
to the methods of Part G of Example 160. The crude product was
triturated with acetonitrile (about 2 mL) to provide a tan solid.
This material was combined with the material from another run and
dissolved in refluxing acetonitrile (50 mL). The solution was
filtered and then cooled to -20.degree. C. A solid was isolated by
filtration and then dried under high vacuum to provide
3-[(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetrahydrofuran-
-3-ol as a light tan solid, mp 245-247.degree. C. .sup.1H NMR (300
MHz, DMSO-d.sub.6): 8.25 (d, J=7.6 Hz, 1H), 7.59 (dd, J=8.3, 1.2
Hz, 1H), 7.38 (t, J=7.6, 1.0 Hz, 1H), 7.19 (t, J=7.6, 1.2 Hz, 1H),
6.41 (s, 2H), 5.33 (s, 1H), 4.75 (s, 2H), 3.81 (m, 2H), 3.58 (dd,
J=75.4, 9.0 Hz, 2H), 3.02 (q, J=7.4 Hz, 2H), 1.89 (m, 2H), 1.36 (t,
J=7.4 Hz, 3H); MS (EI) m/z 312 (M+H).sup.+; Anal. calcd for
C.sub.17H.sub.20N.sub.4O.sub.2: C, 65.37; H, 6.45; N, 17.94. Found:
C, 65.30; H, 6.29; N, 18.00.
Example 166
3-[(4-Amino-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetrahydrofuran-
-3-ol
##STR00229## Part A
3-[(2-Methyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetrahydrofuran-3-ol
was prepared using the method of Part F of Example 160 using
3-[3-aminoquinolin-4-yl)methyl]tetrahydrofuran-3-ol in lieu of
3-[3-amino[1,5]napthyridin-4-yl)methyl]tetrahydrofuran-3-ol and
trimethyl orthoacetate in lieu of trimethyl orthobutyrate. The
crude product was dissolved in chloroform and purified by HPFC
eluting with chloroform for 3 column volumes and then with a
gradient of 0-50% CMA in chloroform for 8 column volumes to provide
0.87 g of product as an off white foam.
Part B
The material from Part A was oxidized and then aminated according
to the methods of Part G of Example 160. The crude product was
isolated by filtration and triturated with 10% sodium hydroxide.
The resulting solid was isolated by filtration, rinsed with water,
and then refluxed with acetonitrile. The purification procedure was
repeated and the resulting solid was isolated by filtration and
then dried under high vacuum to provide
3-[(4-amino-2-methyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]tetrah-
ydrofuran-3-ol as a light tan solid, mp 278.degree. C. (dec).
.sup.1H NMR (300 MHz, DMSO-d.sub.6): 8.24 (d, J=8.0 Hz, 1H), 7.59
(d, J=8.7 Hz, 1H), 7.38 (t, J=7.4 Hz, 1H), 7.19 (t, J=7.2 Hz, 1H),
6.45 (s, 2H), 5.36 (s, 1H), 4.74 (s, 2H), 3.82 (m, 2H), 3.50 (dd,
J=77.6, 9.0 Hz, 2H), 2.65 (s, 3H), 1.92 (m, 2H); MS (EI) m/z 298
(M+H).sup.+; Anal. calcd for
C.sub.16H.sub.18N.sub.4O.sub.2.0.52H.sub.2O: C, 62.45; H, 6.24; N,
18.21. Found: C, 62.39; H, 5.95; N, 17.81.
Examples 167-190
Part A
A suspension of 1-aminomethyl-1-cyclohexanol hydrochloride (20.0 g,
121 mmol) and 4-chloro-3-nitroquinoline (24.0 g, 115 mmol) in
dichloromethane (550 mL) was cooled to 0.degree. C., and
triethylamine (40 mL, 290 mmol) was added dropwise over a period of
30 minutes. The reaction was allowed to warm to room temperature
over two hours. An analysis by HPLC indicated that the
4-chloro-3-nitroquinoline starting material actually contained some
3-nitroquinolin-4-ol, and additional pure 4-chloro-3-nitroquinoline
(12.0 g, 57.5 mmol) was added. The reaction was stirred for four
hours, and additional 1-aminomethyl-1-cyclohexanol hydrochloride
(2.0 g, 12 mmol) was added, and the resulting suspension was
stirred for three days. The solvent was removed under reduced
pressure, and the residue was triturated in water for one hour and
isolated by filtration. The resulting solid was triturated with hot
dichloromethane and isolated by filtration from the hot mixture to
provide 36.5 g of
1-{[(3-nitroquinolin-4-yl)amino]methyl}cyclohexanol as a bright
yellow powder.
Part B
A suspension of 1-{[(3-nitroquinolin-4-yl)amino]methyl}cyclohexanol
(15.0 g, 49.8 mmol) in ethyl acetate (225 mL) in a Parr vessel was
purged with nitrogen; 5% platinum on carbon (1.5 g) was added. The
reaction was placed under hydrogen pressure (35 psi,
2.4.times.10.sup.5 Pa) for 3.5 hours and then filtered through a
layer of CELITE filter agent. The filter cake was washed with ethyl
acetate (100 mL), and the filtrate was concentrated under reduced
pressure to provide
1-{[(3-aminoquinolin-4-yl)amino]methyl}cyclohexanol as a yellow
solid.
Part C
A solution of the material from Part B in dichloromethane (200 mL)
was cooled to 0.degree. C., and chloroacetyl chloride (4.4 mL, 55
mmol) was added over a period of ten minutes. The reaction was
stirred for one hour at 0.degree. C. and then concentrated under
reduced pressure to provide
2-chloro-N-(4-{[(1-hydroxycyclohexyl)methyl]amino}quinolin-3-yl)acetamide
hydrochloride as a yellow solid.
Part D
Triethylamine (21 mL, 150 mmol) was added to a solution of the
material from Part C in ethanol (200 mL), and the reaction was
heated at 60.degree. C. for four hours. The solvent was removed
under reduced pressure, and the residue was partitioned between
dichloromethane (150 mL) and saturated aqueous sodium bicarbonate
(125 mL). The aqueous layer was separated and extracted with
dichloromethane (2.times.50 mL), and the combined organic fractions
were dried over magnesium sulfate, filtered, and concentrated under
reduced pressure to provide 14.2 g of an orange solid. The solid
was triturated with acetonitrile and isolated by filtration to
provide 10.74 g of
1-{[2-(chloromethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cyclohexanol
as a pale yellow solid.
Part E
3-Chloroperoxybenzoic acid (8.37 g of 70% pure material, 34 mmol)
was added to a suspension of
1-{[2-(chloromethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cyclohexanol
(8.0 g, 24 mmol) in chloroform (100 mL), and the reaction was
stirred at room temperature for four hours. Saturated aqueous
sodium bicarbonate (100 mL) was added, and the mixture was stirred
for 15 minutes. A precipitate formed and was isolated by filtration
to provide
1-{[2-(chloromethyl)-5-oxido-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cycloh-
exanol as a white solid.
Part F
Ammonium hydroxide (8 mL of 15 M) was added to a suspension of the
material from Part E in methanol (100 mL). The mixture was cooled
to 0.degree. C., and benzenesulfonyl chloride (6.5 mL, 51 mmol) was
added dropwise over a period of eight minutes. The reaction was
stirred at 0.degree. C. for one hour, and an analysis by HPLC
indicated the presence of starting material. Additional
benzenesulfonyl chloride (6.5 mL, 51 mmol) was added in two
portions over two hours. The reaction was allowed to warm to room
temperature slowly and stirred overnight. A precipitate was present
and was isolated by filtration, stirred with saturated aqueous
sodium bicarbonate (100 mL), isolated by filtration, washed with
water (50 mL), and dried to provide 6.14 g of
1-{[4-amino-2-(chloromethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cycloh-
exanol.
Part G
Potassium phthalimide (2.59 g, 14.0 mmol) was added to a solution
of
1-{[4-amino-2-(chloromethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cycloh-
exanol (5.07 g, 13.3 mmol) in DMF (50 mL), and the reaction mixture
was stirred at room temperature overnight. An analysis by HPLC
indicated the presence of starting material, and additional
potassium phthalimide (1 g) was added. The reaction was stirred for
an additional five hours, and then concentrated under reduced
pressure. The residue was triturated with methanol, and the
resulting white solid was isolated by filtration. The filtrate was
concentrated under reduced pressure, and the residue was triturated
with methanol to afford additional white solid, which was isolated
by filtration. The two solids were combined to provide
2-({4-amino-1-[(1-hydroxycyclohexyl)methyl]-1H-imidazo[4,5-c]quinolin-2-y-
l}methyl)-1H-isoindole-1,3(2H)-dione.
Part H
Hydrazine (2.1 mL, 66 mmol) was added to a suspension of the
material from Part G in ethanol (50 mL), and the reaction was
stirred for 24 hours at room temperature. The ethanol was removed
under reduced pressure, and the resulting white solid was sonicated
with hydrochloric acid (50 mL of 1M). The resulting suspension was
filtered to remove a solid, and the filtrate was adjusted to pH 8
with the addition of solid sodium bicarbonate. A precipitate formed
and was isolated by filtration and dried at 50.degree. C. overnight
in a vacuum oven to provide 2.99 g of
1-{[4-amino-2-(aminomethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cyclohe-
xanol as a white powder.
Part I
A reagent (0.11 mmol, 1.1 equivalents) from the table below was
added to a test tube containing
1-{[4-amino-2-(aminomethyl)-1H-imidazo[4,5-c]quinoline-1-yl]methyl}cycloh-
exanol (33 mg, 0.10 mmol) and N, N-diisopropylethylamine (0.035 mL,
0.20 mmol) in N,N-dimethylacetamide (DMA) (1 mL). The test tube was
capped and shaken overnight at ambient temperature. The solvent was
then removed by vacuum centrifugation.
The compounds were purified by prep HPLC according to the method
described in Examples 16-53. The table below shows the reagent
added to each test tube, the structure of the resulting compound,
and the observed accurate mass for the isolated trifluoroacetate
salt.
TABLE-US-00002 ##STR00230## Measured Mass Example Reagent R (M + H)
167 Propionyl chloride ##STR00231## 382.2239 168 Methyl
chloroformate ##STR00232## 384.2025 169 Cyclopropanecarbonyl
chloride ##STR00233## 394.2232 170 Butyryl chloride ##STR00234##
396.2399 171 Isobutyryl chloride ##STR00235## 396.2392 172
Cyclobutanecarbonyl chloride ##STR00236## 408.2421 173 Benzoyl
chloride ##STR00237## 430.2243 174 2-Chlorobenzoyl chloride
##STR00238## 464.1848 175 3-Chlorobenzoyl chloride ##STR00239##
464.1852 176 Isonicotinoyl chloride hydrochloride ##STR00240##
431.2201 177 Nicotinoyl chloride hydrochloride ##STR00241##
431.2199 178 Picolinoyl chloride hydrochloride ##STR00242##
431.2203 179 trans-2-Phenyl-1- Cyclopropanecarbonyl chloride
##STR00243## 470.2561 180 3,4-Dichlorobenzoyl chloride ##STR00244##
498.1449 181 Methanesulfonyl chloride ##STR00245## 404.1746 182
Ethanesulfonyl chloride ##STR00246## 418.1910 183 1-Propanesulfonyl
chloride ##STR00247## 432.2058 184 Isopropylsulfonyl chloride
##STR00248## 432.2075 185 Dimethylsulfamoyl chloride ##STR00249##
433.2028 186 Benzenesulfonyl chloride ##STR00250## 466.1906 187
1-Methylimidazole-4- sulfonyl chloride ##STR00251## 470.1980 188
alpha- Toluenesulfonyl chloride ##STR00252## 480.2076 189 3-
Chlorobenzenesulfonyl chloride ##STR00253## 500.1518 190 4-
Chlorobenzenesulfonyl chloride ##STR00254## 500.1518
Examples 191-205
Part A
Under a nitrogen atmosphere, nitromethane (116 mL, 2.14 mol) and
sodium ethoxide (2.6 g of 96% pure material, 36 mmol) were
sequentially added to a solution of cyclobutanone (50.0 g, 713
mmol) in ethanol (71 mL), and the resulting solution was stirred at
room temperature for 4 days. Some of the ethanol was removed under
reduced pressure, and water (100 mL) was added. The resulting
mixture was extracted with ethyl acetate (3.times.150 mL). The
combined extracts were washed sequentially with water (2.times.80
mL) and brine (40 mL), dried over sodium sulfate, filtered, and
concentrated under reduced pressure. The residue was purified by
vacuum distillation under high vacuum at 70.degree. C. to provide
46.1 g of 1-(nitromethyl)cyclobutanol as an orange liquid.
Part B
A mixture of 1-(nitromethyl)cyclobutanol (46.0 g, 351 mmol), 20%
palladium hydroxide on carbon (6.9 g) and ethanol (1 L) was placed
under hydrogen pressure (30 psi, 2.1.times.10.sup.5 Pa) on a Parr
apparatus for two days. An analysis by nuclear magnetic resonance
spectroscopy indicated the reaction was incomplete, and additional
20% palladium hydroxide on carbon (5 g) was added. The reaction was
placed under hydrogen pressure (30 psi, 2.1.times.10.sup.5 Pa) for
four days. The reaction mixture was filtered through a layer of
CELITE filter agent, and the filter cake was washed with methanol.
The filtrate was concentrated under reduced pressure to provide
34.8 g of 1-(aminomethyl)cyclobutanol as a white solid.
Part C
A solution of 4-chloro-3-nitroquinoline (30.0 g, 144 mmol) in
dichloromethane (350 mL) was cooled to 0.degree. C. under a
nitrogen atmosphere, and triethylamine (22.1 mL, 158 mmol) was
added. A solution of 1-(aminomethyl)cyclobutanol (16.0 g, 158 mmol)
in dichloromethane (130 mL) was then added over a period of one
hour, followed by a rinse of dichloromethane (100 mL). The reaction
was stirred at room temperature overnight. The solvent was removed
under reduced pressure, and the residue was triturated in water
(500 mL) and saturated aqueous sodium bicarbonate (200 mL) for two
hours. A solid was present and was isolated by filtration, washed
with a large amount of water, and dried in a vacuum oven at
55.degree. C. to provide 38.7 g of
1-{[(3-nitroquinolin-4-yl)amino]methyl}cyclobutanol as a yellow
solid.
Part D
1-{[(3-Nitroquinolin-4-yl)amino]methyl}cyclobutanol (14.0 g, 51.2
mmol) was hydrogenated (50 psi, 3.5.times.10.sup.5 Pa) according to
the method described in Part B of Examples 167-190 to provide
1-{[(3-aminoquinolin-4-yl)amino]methyl}cyclobutanol as a yellow
solid.
Part E
A solution of the material from Part D in dichloromethane (250 mL)
was cooled to 0.degree. C., and chloroacetyl chloride (4.50 mL,
56.4 mmol) was added over a period of 15 minutes. The reaction was
allowed to warm to room temperature and stirred for four hours. An
analysis by LC/MS indicated the presence of starting material, and
additional chloroacetyl chloride (1 mL) was added. The reaction was
stirred overnight at room temperature and then concentrated under
reduced pressure to provide
2-chloro-N-(4-{[(1-hydroxycyclobutyl)methyl]amino}quinolin-3-yl)acetamide
hydrochloride.
Part F
The method described in Part D of Examples 167-190 was used to
treat the material from Part E with triethylamine (21.4 mL, 154
mmol) with the modifications that the reaction was heated at
50.degree. C. for four hours, chloroform was used in the work-up
procedure, and following the work-up procedure, the product was not
purified by trituration.
1-{[2-(Chloromethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cyclobutanol
(16.5 g) was obtained as a yellow solid containing small amounts of
chloroform and triethylamine.
Part G
3-Chloroperoxybenzoic acid (9.15 g of 70% pure material, 37.1 mmol)
was added to a suspension of
1-{[2-(chloromethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cyclobutanol
(8.00 g, 26.5 mmol) in chloroform (100 mL) under a nitrogen
atmosphere, and the reaction was stirred at room temperature
overnight. Additional chloroform (200 mL) was added, and the
solution was washed sequentially with saturated aqueous sodium
bicarbonate (2.times.80 mL) and brine (20 mL), dried over magnesium
sulfate, filtered, and concentrated under reduced pressure to
provide
1-{[2-(chloromethyl)-5-oxido-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cyclob-
utanol as a yellow solid.
Part H
Ammonium hydroxide (8.83 mL of 15 M) was added to a solution of the
material from Part G in methanol (100 mL). The mixture was cooled
to 0.degree. C. under a nitrogen atmosphere, and benzenesulfonyl
chloride (7.10 mL, 55.7 mmol) was added dropwise over a period of
eight minutes. The reaction was stirred at 0.degree. C. for two
hours, combined with material from another run, and concentrated
under reduced pressure. The residue was dissolved in chloroform
(300 mL), and the resulting solution was washed sequentially with
saturated aqueous sodium carbonate (2.times.80 mL) and brine (40
mL), dried over sodium sulfate, filtered, and concentrated under
reduced pressure. The crude product was purified by prep HPLC using
a HORIZON HPFC system (silica cartridge, eluting with
chloroform:CMA in a gradient from 100:0 to 70:30) to provide 4.00 g
of
1-{[4-amino-2-(chloromethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cyclob-
utanol as a yellow solid.
Part I
Under a nitrogen atmosphere, potassium phthalimide (1.21 g, 6.52
mmol) was added to a solution of
1-{[4-amino-2-(chloromethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cyclob-
utanol (1.88 g, 5.93 mmol) in DMF (30 mL), and the reaction mixture
was stirred at room temperature overnight and then concentrated
under reduced pressure. The residue was partitioned between
chloroform (200 mL) and water (25 mL)/saturated aqueous sodium
bicarbonate (2.times.40 mL). The organic layer was washed with
brine (2.times.40 mL), dried over sodium sulfate, filtered, and
concentrated under reduced pressure to provide 2.42 g of
2-({4-amino-1-[(1-hydroxycyclobutyl)methyl]-1H-imidazo[4,5-c]qu-
inolin-2-yl}methyl)-1H-isoindole-1,3(2H)-dione.
Part J
Under a nitrogen atmosphere, hydrazine (0.89 mL, 28 mmol) was added
to a suspension of
2-({4-amino-1-[(1-hydroxycyclobutyl)methyl]-1H-imidazo[4,5-c]quinolin-2-y-
l}methyl)-1H-isoindole-1,3(2H)-dione (2.42 g, 5.66 mmol) in ethanol
(57 mL), and the reaction was stirred for two hours at room
temperature. The ethanol was removed under reduced pressure, and
the resulting white solid was triturated with 2 N hydrochloric
acid. The resulting suspension was filtered to remove a solid, and
the filter cake was washed with water. The filtrate was made basic
with the addition of solid sodium bicarbonate. A precipitate formed
and was isolated by filtration, washed with water, and dried at
50.degree. C. for three days in a vacuum oven to provide 0.994 g of
1-{[4-amino-2-(aminomethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cyclobu-
tanol as a yellow solid.
Part K
A reagent (0.11 mmol, 1.1 equivalents) from the table below was
added to a test tube containing
1-{[4-amino-2-(aminomethyl)-1H-imidazo[4,5-c]quinolin-1-yl]methyl}cyclobu-
tanol (30 mg, 0.10 mmol) and N,N-diisopropylethylamine (0.036 mL,
0.20 mmol) in DMA (1 mL). The test tube was capped and vortexed
overnight at ambient temperature. Two drops of water were added to
each reaction, and the solvent was then removed by vacuum
centrifugation.
The compounds were purified by prep HPLC according to the method
described in Examples 16-53. The table below shows the reagent
added to each test tube, the structure of the resulting compound,
and the observed accurate mass for the isolated trifluoroacetate
salt.
TABLE-US-00003 ##STR00255## Ex- Measured am- Mass ple Reagent R (M
+ H) 191 Propionyl chloride ##STR00256## 354.1905 192
Cyclopropanecarbonyl chloride ##STR00257## 366.1926 193 Isobutyryl
chloride ##STR00258## 368.2078 194 Benzoyl chloride ##STR00259##
402.1927 195 4-Methoxybenzoyl chloride ##STR00260## 432.2044 196
4-Chlorobenzoyl chloride ##STR00261## 436.1553 197 Nicotinoyl
chloride hydrochloride ##STR00262## 403.1879 198
3,4-Dichlorobenzoyl chloride ##STR00263## 470.1158 199
Methanesulfonyl chloride ##STR00264## 376.1445 200 Ethanesulfonyl
chloride ##STR00265## 390.1597 201 Isopropylsulfonyl chloride
##STR00266## 404.1769 202 Dimethylsulfamoyl chloride ##STR00267##
405.1712 203 Benzenesulfonyl chloride ##STR00268## 438.1631 204
1-Methylimidazole-4- sulfonyl chloride ##STR00269## 442.1665 205
2,2,2- Trifluoroethanesulfonyl chloride ##STR00270## 444.1327
Examples 206-248
A reagent (0.11 mmol, 1.1 eq) from the table below was added to a
test tube. A solution of
4-[4-amino-2-methyl-1H-imidazo[4,5-c][1,5]napthyridin-1-yl)methyl]piperid-
ine-4-ol dihydrochloride (38 mg, 0.10 mmol, 1.0 eq. Example 125
Part A) and N,N-diisopropylethylamine (0.086 mL, 5 eq)) in DMA (1
mL) and chloroform (1 mL) was added. The test tube was capped and
shaken overnight at ambient temperature. The reaction was quenched
with water (2 drops). The solvent was then removed by vacuum
centrifugation.
The compounds were purified by prep HPLC according to the method
described in Examples 16-53. The table below shows the reagent
added to each test tube, the structure of the resulting compound,
and the observed accurate mass for the isolated trifluoroacetate
salt.
TABLE-US-00004 ##STR00271## Measured Example Reagent R Mass (M + H)
206 Cyclopropanecarbonyl chloride ##STR00272## 381.2019 207 Butyryl
chloride ##STR00273## 383.2228 208 Isobutyryl chloride ##STR00274##
383.2212 209 Cyclobutanecarbonyl chloride ##STR00275## 395.2163 210
Cyclopentanecarbonyl chloride ##STR00276## 409.2366 211 Benzoyl
chloride ##STR00277## 417.2057 212 Cyclohexanecarbonyl chloride
##STR00278## 423.2545 213 3-Cyanobenzoyl chloride ##STR00279##
442.1995 214 3-Methoxybenzoyl chloride ##STR00280## 447.2169 215
4-Methoxybenzoyl chloride ##STR00281## 447.2149 216 3-Chlorobenzoyl
chloride ##STR00282## 451.1666 217 4-Chlorobenzoyl chloride
##STR00283## 451.1650 218 Isonicotinoyl chloride hydrochloride
##STR00284## 418.1962 219 Nicotinoyl chloride hydrochloride
##STR00285## 418.2012 220 Methanesulfonyl chloride ##STR00286##
391.1589 221 Ethanesulfonyl chloride ##STR00287## 405.1729 222
1-Propanesulfonyl chloride ##STR00288## 419.1881 223
Isopropylsulfonyl chloride ##STR00289## 419.1894 224
Dimethylsulfamoyl chloride ##STR00290## 420.1837 225
Benzenesulfonyl chloride ##STR00291## 453.1713 226 1
-Methylimidazole-4- sulfonyl chloride ##STR00292## 457.1778 227
3-Cyanobenzenesulfonyl chloride ##STR00293## 478.1635 228
4-Cyanobenzenesulfonyl chloride ##STR00294## 478.1655 229
3-Methoxybenzenesulfonyl chloride ##STR00295## 483.1805 230
4-Methoxybenzenesulfonyl chloride ##STR00296## 483.1801 231
3-Chlorobenzenesulfonyl chloride ##STR00297## 487.1300 232
4-Chlorobenzenesulfonyl chloride ##STR00298## 487.1334 233 Ethyl
isocyanate ##STR00299## 384.2174 234 Isopropyl isocyanate
##STR00300## 398.2327 235 n-Propyl isocyanate ##STR00301## 398.2311
236 Cyclopentyl isocyanate ##STR00302## 424.2468 237 Phenyl
isocyanate ##STR00303## 432.2142 238 Cyclohexyl isocyanate
##STR00304## 438.2636 239 4-Cyanophenyl isocyanate ##STR00305##
457.2062 240 2-Methoxyphenyl isocyanate ##STR00306## 462.2251 241
3-Methoxyphenyl isocyanate ##STR00307## 462.2230 242
4-Methoxyphenyl isocyanate ##STR00308## 462.2254 243 2-Chlorophenyl
isocyanate ##STR00309## 466.1767 244 3-Chlorophenyl isocyanate
##STR00310## 466.1758 245 4-Chlorophenyl isocyanate ##STR00311##
466.1754 246 1-Pyrrolidinecarbonyl chloride ##STR00312## 410.2304
247 1-Piperidinecarbonyl chloride ##STR00313## 424.2472 248
4-Morpholinylcarbonyl chloride ##STR00314## 426.2259
Examples 249-285
A reagent (0.11 mmol, 1.1 eq) from the table below was added to a
test tube. A solution of
4-[4-amino-2-ethyl-1H-imidazo[4,5-c][1,5]napthyridin-1-yl)methyl]piperidi-
ne-4-ol dihydrochloride (40 mg, 0.10 mmol, 1.0 eq. Example 121 Part
A) and N,N-diisopropylethylamine (0.086 mL, 5 eq)) in DMA (1 mL)
and chloroform (1 mL) was added. The test tube was capped and
shaken overnight at ambient temperature. Ammonium hydroxide (100
.mu.L) was added to the tube and the tube was vortexed for 4 hours.
The solvent was then removed by vacuum centrifugation.
The compounds were purified by prep HPLC according to the method
described in Examples 16-53. The table below shows the reagent
added to each test tube, the structure of the resulting compound,
and the observed accurate mass for the isolated trifluoroacetate
salt.
TABLE-US-00005 ##STR00315## Measured Example Reagent R Mass (M + H)
249 Cyclopropanecarbonyl chloride ##STR00316## 395.2208 250 Butyryl
chloride ##STR00317## 397.2383 251 Isobutyryl chloride ##STR00318##
397.2387 252 Cyclopentanecarbonyl chloride ##STR00319## 423.2492
253 Benzoyl chloride ##STR00320## 431.2166 254 3-Methoxybenzoyl
chloride ##STR00321## 461.2286 255 p-Anisoyl chloride ##STR00322##
461.2288 256 2-Chlorobenzoyl chloride ##STR00323## 465.1803 257
3-Chlorobenzoyl chloride ##STR00324## 465.1821 258 4-Chlorobenzoyl
chloride ##STR00325## 465.1801 259 Isonicotinoyl chloride
hydrochloride ##STR00326## 432.2170 260 Nicotinoyl chloride
hydrochloride ##STR00327## 432.2142 261 Methanesulfonyl chloride
##STR00328## 405.1687 262 Ethanesulfonyl chloride ##STR00329##
419.1889 263 1-Propanesulfonyl chloride ##STR00330## 433.2048 264
Isoproplsulfonyl chloride ##STR00331## 433.2039 265
Dimethylsulfamoyl chloride ##STR00332## 434.1998 266
1-Butanesulfonyl chloride ##STR00333## 447.2179 267 Benzenesulfonyl
chloride ##STR00334## 467.1826 268 1-Methylimidazole-4- sulfonyl
chloride ##STR00335## 471.1924 269 3-Methoxybenzenesulfonyl
chloride ##STR00336## 497.1972 270 4-Methoxybenzenesulfonyl
chloride ##STR00337## 497.1990 271 2-Chlorobenzenesulfonyl chloride
##STR00338## 501.1467 272 3-Chlorobenzenesulfonyl chloride
##STR00339## 501.1501 273 4-Chlorobenzenesulfonyl chloride
##STR00340## 501.1434 274 Methyl isocyanate ##STR00341## 384.2187
275 Isopropyl isocyanate ##STR00342## 412.2495 276 N-Propyl
isocyanate ##STR00343## 412.2497 277 Cyclopentyl isocyanate
##STR00344## 438.2639 278 Cyclohexyl isocyanate ##STR00345##
452.2793 279 3-Methoxyphenyl isocyanate ##STR00346## 476.2431 280
4-Methoxyphenyl isocyanate ##STR00347## 476.2431 281 4-Chlorophenyl
isocyanate ##STR00348## 480.1892 282 1-Pyrrolidinecarbonyl chloride
##STR00349## 424.2480 283 1-Piperidinecarbonyl chloride
##STR00350## 438.2584 284 4-Morpholinylcarbonyl chloride
##STR00351## 440.2442 285 4-Methyl-1- piperazinecarbonyl chloride
##STR00352## 453.2715
Examples 286-330
Part A
Tert-Butyl
{1-[(2-ethoxymethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclopropyl}car-
bamate (3.40 g, Parts A through H of Example 92) was oxidized and
then aminated according to the general method of Part I of Example
12. The crude product was purified by HPFC eluting with a gradient
of 0-30% CMA in chloroform to provide a yellow solid. This material
was recrystallized from dichloromethane/hexanes to provide 2.60 g
of tert-butyl
{1-[(4-amino-2-ethoxymethyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclopr-
opyl}carbamate as a pale yellow solid.
Part B
Aqueous hydrochloric acid (6 mL of 6M) was added to a solution of
the material from Part A in ethanol (12 mL). The reaction mixture
was heated at 50.degree. C. for 4 hours and then concentrated under
reduced pressure. The residue was concentrated from methanol 3
times and then triturated with acetonitrile to provide 2.43 g of
1-[(1-aminocyclopropyl)methyl]-2-ethoxymethyl-1H-imidazo[4,5-c]quinolin-4-
-amine hydrochloride.
Part C
A reagent (1.1 eq) from the table below was added to a test tube
containing a solution of
1-[(1-aminocyclopropyl)methyl]-2-ethoxymethyl-1H-imidazo[4,5-c]quinolin-4-
-amine hydrochloride (33 mg, 0.010 mmol, 1 eq) and
N,N-diisopropylethylamine (0.083 mL, 5 eq) in N,N-dimethylacetamide
(1 mL). The test tube was capped and shaken overnight at ambient
temperature. The reaction was quenched with water (2 drops). The
solvent was then removed by vacuum centrifugation.
The compounds were purified by prep HPLC according to the method
described in Examples 16-53. The table below shows the reagent
added to each test tube, the structure of the resulting compound,
and the observed accurate mass for the isolated trifluoroacetate
salt.
TABLE-US-00006 ##STR00353## Measured Ex Reagent R Mass (M + H) 286
Cyclopropanecarbonyl chloride ##STR00354## 380.2065 287 Butyryl
chloride ##STR00355## 382.2237 288 Isobutyryl chloride ##STR00356##
382.2235 289 Cyclobutanecarbonyl chloride ##STR00357## 394.2235 290
Cyclopentanecarbonyl chloride ##STR00358## 408.2385 291 Benzoyl
chloride ##STR00359## 416.2090 292 Cyclohexanecarbonyl chloride
##STR00360## 422.2563 293 Hydrocinnamoyl chloride ##STR00361##
444.2401 294 3-Methoxybenzoyl chloride ##STR00362## 446.2193 295
4-Methoxybenzoyl chloride ##STR00363## 446.2207 296 3-Chlorobenzoyl
chloride ##STR00364## 450.1702 297 4-Chlorobenzoyl chloride
##STR00365## 450.1710 298 Isonicotinoyl chloride hydrochloride
##STR00366## 417.2043 299 Nicotinoyl chloride hydrochloride
##STR00367## 417.2057 300 Picolinoyl chloride hydrochloride
##STR00368## 417.2023 301 trans-2-Phenyl-1- cyclopropanecarbonyl
chloride ##STR00369## 456.2364 302 3,4-Dichlorobenzoyl chloride
##STR00370## 484.1310 303 Methanesulfonyl chloride ##STR00371##
390.1560 304 Ethanesulfonyl chloride ##STR00372## 404.1773 305
1-Propanesulfonyl chloride ##STR00373## 418.1898 306
1-Butanesulfonyl chloride ##STR00374## 432.2047 307 Benzenesulfonyl
chloride ##STR00375## 452.1747 308 1-Methylimidazole-4- sulfonyl
chloride ##STR00376## 456.1817 309 alpha-Toluenesulfonyl chloride
##STR00377## 466.1900 310 3-Cyanobenzenesulfonyl chloride
##STR00378## 477.1770 311 3-Methoxybenzenesulfonyl chloride
##STR00379## 482.1856 312 4-Methoxybenzenesulfonyl chloride
##STR00380## 482.1843 313 3-Chlorobenzenesulfonyl chloride
##STR00381## 486.1353 314 4-Chlorobenzenesulfonyl chloride
##STR00382## 486.1349 315 Methyl isocyanate ##STR00383## 369.2036
316 Ethyl isocyanate ##STR00384## 383.2194 317 Isopropyl isocyanate
##STR00385## 397.2347 318 N-Propyl isocyanate ##STR00386## 397.2359
319 Cyclopentyl isocyanate ##STR00387## 423.2502 320 Phenyl
isocyanate ##STR00388## 431.2188 321 Cyclohexyl isocyanate
##STR00389## 437.2674 322 (R)-(+)-alpha-Methylbenzyl isocyanate
##STR00390## 459.2507 323 (S)-(-)-alpha-Methylbenzyl isocyanate
##STR00391## 459.2516 324 3-Methoxyphenyl isocyanate ##STR00392##
461.2294 325 4-Methoxyphenyl isocyanate ##STR00393## 461.2318 326
3-Chlorophenyl isocyanate ##STR00394## 465.1809 327 4-Chlorophenyl
isocyanate ##STR00395## 465.1796 328 N,N-Dimethylcarbamoyl chloride
##STR00396## 383.2202 329 1-Piperidinecarbonyl chloride
##STR00397## 423.2494 330 4-Morpholinylcarbonyl chloride
##STR00398## 425.2287
Examples 331-338
Part A
A reagent (1.1 eq) from the table below was added to a test tube
containing a solution of
1-[(1-aminocyclopropyl)methyl]-2-ethoxymethyl-1H-imidazo[4,5-c]quinolin-4-
-amine hydrochloride (3.6 mg, 0.1 mmol, 1 eq) and
N,N-diisopropylethylamine (0.083 mL, 5 eq) in N,N-dimethylacetamide
(1 mL). The test tube was capped and shaken for 4 hours at ambient
temperature. The solvent was then removed by vacuum centrifugation.
The residue was purified by solid-supported liquid-liquid
extraction according to the following procedure. The residue was
dissolved in chloroform (1 mL) and then loaded onto diatomaceous
earth that had been equilibrated with water (1 mL) for 20 minutes.
After 10 minutes chloroform (5 mL) was added to elute the product
from the diatomaceous earth into a test tube. The solvent was then
removed by vacuum centrifugation.
Part B
Dichloromethane (1 mL) was added to the test tube and the test tube
was shaken to bring all material into solution. The solution was
cooled to 0.degree. C. Boron tribromide (400 .mu.L of 1M in
dichloromethane) was added to the test tube. The test tube was
shaken and then placed into an ice bath for 30 minutes. The
reaction mixture was stirred at ambient temperature overnight.
Methanol (1 mL) and hydrochloric acid (500 .mu.L of 6N) were added
to the test tube and the test tube was shaken. The solvents were
removed by vacuum centrifugation.
The compounds were purified by prep HPLC according to the method
described in Examples 16-53. The table below shows the reagent
added to each test tube, the structure of the resulting compound,
and the observed accurate mass for the isolated trifluoroacetate
salt.
TABLE-US-00007 ##STR00399## Measured Mass Example Reagent R (M + H)
331 Cyclopropanecarbonyl chloride ##STR00400## 352.1752 332 Benzoyl
chloride ##STR00401## 388.1777 333 Methanesulfonyl chloride
##STR00402## 362.1293 334 Benzenesulfonyl chloride ##STR00403##
424.1436 335 Phenyl isocyanate ##STR00404## 403.1885 336
4-Morpholinylcarbonyl chloride ##STR00405## 397.1995 337 Methyl
isocyanate ##STR00406## 341.1703 338 Isopropyl isocyanate
##STR00407## 369.2047
Examples 339-378
Part A
Trimethyl orthobutyrate (5.0 mL, 1.3 eq) and pyridine hydrochloride
(0.14 g, 0.05 eq) were added to a suspension of ethyl
1-[(3-aminoquinolin-4-ylamino)methyl]cyclobutyrate (24.3 mmol, 1.0
eq, prepared according to the general methods of Parts A through D
of Example 92 using 1,3-dibromopropane in lieu of 1,2-dibromoethane
in Part A) in toluene (100 mL). The mixture was heated at reflux
for 2 hours, allowed to cool to ambient temperature, and then
concentrated under reduced pressure. The residue was triturated
with acetonitrile. A solid was isolated by filtration to provide
7.55 g of ethyl
1-[(2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclobutyrate as
a white solid.
Part B
The material from Part A was converted to tert-butyl
{1-[(2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclobutyl}carbamate
according to the general methods of Parts G and H of Example 92.
The crude product was triturated with acetonitrile to provide 4.36
g of tert-butyl
{1-[(2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclobutyl}carbamate
as a white solid.
Part C
The material from Part B was oxidized and then aminated according
to the general methods of Part I of Example 12. The crude product
was triturated with acetonitrile to provide 2.91 g of tert-butyl
{1-[(4-amino-2-propyl-1H-imidazo[4,5-c]quinolin-1-yl)methyl]cyclobutyl}ca-
rbamate as a tan powder.
Part D
Aqueous hydrochloric acid (6 mL of 6M) was added to a solution of
the material from Part C in ethanol (12 mL). The reaction mixture
was heated at 60.degree. C. for 8 hours and then concentrated under
reduced pressure. The residue was concentrated from methanol 3
times and then triturated with acetonitrile to provide 2.99 g of
1-[(1-aminocyclobutyl)methyl]-2-propyl-1H-imidazo[4,5-c]quinolin-4-amine
hydrochloride.
Part E
A reagent (1.1 eq) from the table below was added to a test tube
containing a solution of
1-[(1-aminocyclobutyl)methyl]-2-propyl-1H-imidazo[4,5-c]quinolin-4-amine
hydrochloride (42 mg, 0.010 mmol, 1 eq) and
N,N-diisopropylethylamine (0.087 mL, 5 eq) in N,N-dimethylacetamide
(1 mL). The test tube was capped and shaken overnight at ambient
temperature. The reaction was quenched with water (2 drops). The
solvent was then removed by vacuum centrifugation.
The compounds were purified by prep HPLC according to the method
described in Examples 16-53. The table below shows the reagent
added to each test tube, the structure of the resulting compound,
and the observed accurate mass for the isolated trifluoroacetate
salt.
TABLE-US-00008 ##STR00408## Measured Example Reagent R Mass (M + H)
339 Propionyl chloride ##STR00409## 366.2293 340
Cyclopropanecarbonyl chloride ##STR00410## 378.2281 341
Cyclobutanecarbonyl chloride ##STR00411## 392.2454 342
Cyclopentanecarbonyl chloride ##STR00412## 406.2603 343
Phenylacetyl chloride ##STR00413## 428.2433 344 2-Methoxybenzoyl
chloride ##STR00414## 444.2429 345 3-Chlorobenzoyl chloride
##STR00415## 448.1901 346 4-Chlorobenzoyl chloride ##STR00416##
448.1914 347 Picolinoyl chloride hydrochloride ##STR00417##
415.2257 348 3,4-Dimethoxybenzoyl chloride ##STR00418## 474.2503
349 3,4-Dichlorobenzoyl chloride ##STR00419## 482.1516 350
Methanesulfonyl chloride ##STR00420## 388.1819 351
Dimethylsulfamoyl chloride ##STR00421## 417.2081 352
1-Methylimidazole-4- sulfonyl chloride ##STR00422## 454.2015 353
2,2,2- Trifluoroethanesulfonyl chloride ##STR00423## 456.1696 354
3-Fluorobenzenesulfonyl chloride ##STR00424## 468.1885 355
4-Fluorobenzenesulfonyl chloride ##STR00425## 468.1908 356
3-Cyanobenzenesulfonyl chloride ##STR00426## 475.1916 357
4-Cyanobenzenesulfonyl chloride ##STR00427## 475.1931 358 4-
Methoxybenzenesulfonyl chloride ##STR00428## 480.2073 359
3-Chlorobenzenesulfonyl chloride ##STR00429## 484.1579 360 3,4-
Dimethoxybenzenesulfonyl chloride ##STR00430## 510.2143 361 3,4-
Dichlorobenzenesulfonyl chloride ##STR00431## 518.1169 362 Ethyl
isocyanate ##STR00432## 381.2421 363 Isopropyl isocyanate
##STR00433## 395.2561 364 n-Propyl isocyanate ##STR00434## 395.2554
365 n-Butyl isocyanate ##STR00435## 409.2722 366 Cyclopentyl
isocyanate ##STR00436## 421.2711 367 Phenyl isocyanate ##STR00437##
429.2395 368 Cyclohexyl isocyanate ##STR00438## 435.2869 369
3-Pyridyl isothiocyanate ##STR00439## 446.2140 370 (R)-(+)-alpha-
Methylbenzyl isocyanate ##STR00440## 457.2723 371 (S)-(-)-alpha-
Methylbenzyl isocyanate ##STR00441## 457.2736 372 3-Methoxyphenyl
isocyanate ##STR00442## 459.2513 373 4-Methoxyphenyl isocyanate
##STR00443## 459.2504 374 4-Chlorophenyl isocyanate ##STR00444##
463.2012 375 N,N-Dimethylcarbamoyl chloride ##STR00445## 381.2413
376 1-Piperidinecarbonyl chloride ##STR00446## 421.2741 377
2-Oxo-1- imidazolidinecarbonyl chloride ##STR00447## 422.2295 378
4-Morpholinylcarbonyl chloride ##STR00448## 423.2523
Example 379
Tert-butyl
3-[(4-amino-2-propyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)me-
thyl]-3-hydroxyazetidine-1-carboxylate
##STR00449## Part A
A mixture of 1-benzhydrylazetidin-3-ol (5.00 g, 20.9 mmol, prepared
according to A. G. Anderson, Jr. and R. Lok, J. Org. Chem., 37,
3953 (1972)), ammonium formate (6.59 g, 104.5 mmol), and 10%
palladium on carbon (1.00 g) in ethanol (100 mL) was heated at
70.degree. C. overnight. The reaction mixture was filtered through
CELITE filter agent, which was rinsed with methanol and the
filtrate was concentrated in vacuo to give crude azetidin-3-ol.
Part B
Under a nitrogen atmosphere a mixture of the material from Part A,
di(tert-butyl) dicarbonate (11.4 g, 52.2 mmol),
N,N-dimethylpyridin-4-amine (255 mg, 2.09 mmol) and
N,N-dimethylformamide (75 mL) was stirred at room temperature for 3
hours. The reaction mixture was concentrated under reduced pressure
and the residue dissolved in ethyl acetate (100 mL), washed with
water (2.times.50 mL) and saturated aqueous sodium chloride (30
mL), dried over sodium sulfate, filtered and concentrated under
reduced pressure. The material was purified by HPFC eluting with a
gradient of 0-20% ethyl acetate in hexanes to give 3.70 g of a
clear oil. The oil was dissolved in methanol (200 mL), aqueous
sodium hydroxide (12.6 mL of 2N) was added and the solution was
stirred at room temperature for 3 hours. The solvent was partially
removed under reduced pressure, water (20 mL) was added and the
solution was extracted with chloroform (3.times.100 mL). The
combined organics were washed with saturated aqueous sodium
chloride (30 mL), dried over sodium sulfate, filtered and
concentrated under reduced pressure to provide 2.30 g of tert-butyl
3-hydroxyazetidine-1-carboxylate as a clear oil.
Part C
Under a nitrogen atmosphere sulfur trioxide pyridine complex (6.34
g, 39.8 mmol) was added portionwise to a chilled (0.degree. C.)
solution of tert-butyl 3-hydroxyazetidine-1-carboxylate (2.30 g)
and triethylamine (5.55 mL, 39.8 mmol) in dimethyl sulfoxide (11.5
mL) and dichloromethane (23 mL). The solution was stirred at
0.degree. C. for another hour, poured into 70 mL of saturated
aqueous ammonium chloride and then extracted with diethyl ether
(3.times.100 mL). The combined organics were washed with water
(2.times.30 mL) and brine (20 mL), dried over sodium sulfate,
filtered and concentrated under reduced pressure to give tert-butyl
3-oxoazetidine-1-carboxylate as a clear oil.
Part D
The material from part C was converted to tert-butyl
3-(aminomethyl)-3-hydroxyazetidine-1-carboxylate according to the
general methods of Parts A and B of Example 4. The product was
isolated as 1.48 g of a white solid.
Part E
Tert-butyl
3-[(4-amino-2-propyl-1H-imidazo[4,5-c][1,5]naphthyridin-1-yl)methyl]-3-hy-
droxyazetidine-1-carboxylate was prepared according to the methods
of Parts A through D of Example 120 using tert-butyl
3-(aminomethyl)-3-hydroxyazetidine-1-carboxylate in lieu of
tert-butyl 4-(aminomethyl)-4-hydroxypiperidine-1-carboxylate in
part A and using trimethylorthobutyrate in lieu of
triethylorthopropionate in Part C. The crude product was purified
by HPFC eluting with a gradient of 0-25% CMA in chloroform.
Trituration with acetonitrile provided 620 mg of the pure product
as an off-white powder, mp 134.0-135.0.degree. C. HRMS (EI) calcd
for C.sub.21H.sub.28N.sub.6O.sub.3+H 413.2301, found 413.2319.
Exemplary Compounds Table 1
Ceartain exemplary compounds, including some of those described
above in the Examples, have the following Formulas(II-1, III-1,
IV-1, and V-1)wherin R.sub.2, Z, R', and m are defined immediately
below in the table. In this table, for each ring system, each row
represents one specific compound.
TABLE-US-00009 II-1 ##STR00450## III-1 ##STR00451## IV-1
##STR00452## V-1 ##STR00453## R.sub.2 Z R' m H Bond --OH 1 H Bond
--OH 2 H Bond --OH 3 H Bond --OCH.sub.3 1 H Bond --OCH.sub.3 2 H
Bond --OCH.sub.3 3 H Bond --NH.sub.2 1 H Bond --NH.sub.2 2 H Bond
--NH.sub.2 3 H --CH.sub.2-- --OH 1 H --CH.sub.2-- --OH 2 H
--CH.sub.2-- --OH 3 H --CH.sub.2-- --OCH.sub.3 1 H --CH.sub.2--
--OCH.sub.3 2 H --CH.sub.2-- --OCH.sub.3 3 H --CH.sub.2--
--NH.sub.2 1 H --CH.sub.2-- --NH.sub.2 2 H --CH.sub.2-- --NH.sub.2
3 H --CH.sub.2CH.sub.2-- --OH 1 H --CH.sub.2CH.sub.2-- --OH 2 H
--CH.sub.2CH.sub.2-- --OH 3 H --CH.sub.2CH.sub.2-- --OCH.sub.3 1 H
--CH.sub.2CH.sub.2-- --OCH.sub.3 2 H --CH.sub.2CH.sub.2--
--OCH.sub.3 3 H --CH.sub.2CH.sub.2-- --NH.sub.2 1 H
--CH.sub.2CH.sub.2-- --NH.sub.2 2 H --CH.sub.2CH.sub.2-- --NH.sub.2
3 H --CH.sub.2CH.sub.2CH.sub.2-- --OH 1 H
--CH.sub.2CH.sub.2CH.sub.2-- --OH 2 H --CH.sub.2CH.sub.2CH.sub.2--
--OH 3 H --CH.sub.2CH.sub.2CH.sub.2-- --OCH.sub.3 1 H
--CH.sub.2CH.sub.2CH.sub.2-- --OCH.sub.3 2 H
--CH.sub.2CH.sub.2CH.sub.2-- --OCH.sub.3 3 H
--CH.sub.2CH.sub.2CH.sub.2-- --NH.sub.2 1 H
--CH.sub.2CH.sub.2CH.sub.2-- --NH.sub.2 2 H
--CH.sub.2CH.sub.2CH.sub.2-- --NH.sub.2 3 H
--CH.sub.2--O--CH.sub.2-- --OH 1 H --CH.sub.2--O--CH.sub.2-- --OH 2
H --CH.sub.2--O--CH.sub.2-- --OH 3 H --CH.sub.2--O--CH.sub.2--
--OCH.sub.3 1 H --CH.sub.2--O--CH.sub.2-- --OCH.sub.3 2 H
--CH.sub.2--O--CH.sub.2-- --OCH.sub.3 3 H --CH.sub.2--O--CH.sub.2--
--NH.sub.2 1 H --CH.sub.2--O--CH.sub.2-- --NH.sub.2 2 H
--CH.sub.2--O--CH.sub.2-- --NH.sub.2 3 methyl Bond --OH 1 methyl
Bond --OH 2 methyl Bond --OH 3 methyl Bond --OCH.sub.3 1 methyl
Bond --OCH.sub.3 2 methyl Bond --OCH.sub.3 3 methyl Bond --NH.sub.2
1 methyl Bond --NH.sub.2 2 methyl Bond --NH.sub.2 3 methyl
--CH.sub.2-- --OH 1 methyl --CH.sub.2-- --OH 2 methyl --CH.sub.2--
--OH 3 methyl --CH.sub.2-- --OCH.sub.3 1 methyl --CH.sub.2--
--OCH.sub.3 2 methyl --CH.sub.2-- --OCH.sub.3 3 methyl --CH.sub.2--
--NH.sub.2 1 methyl --CH.sub.2-- --NH.sub.2 2 methyl --CH.sub.2--
--NH.sub.2 3 methyl --CH.sub.2CH.sub.2-- --OH 1 methyl
--CH.sub.2CH.sub.2-- --OH 2 methyl --CH.sub.2CH.sub.2-- --OH 3
methyl --CH.sub.2CH.sub.2-- --OCH.sub.3 1 methyl
--CH.sub.2CH.sub.2-- --OCH.sub.3 2 methyl --CH.sub.2CH.sub.2--
--OCH.sub.3 3 methyl --CH.sub.2CH.sub.2-- --NH.sub.2 1 methyl
--CH.sub.2CH.sub.2-- --NH.sub.2 2 methyl --CH.sub.2CH.sub.2--
--NH.sub.2 3 methyl --CH.sub.2CH.sub.2CH.sub.2-- --OH 1 methyl
--CH.sub.2CH.sub.2CH.sub.2-- --OH 2 methyl
--CH.sub.2CH.sub.2CH.sub.2-- --OH 3 methyl
--CH.sub.2CH.sub.2CH.sub.2-- --OCH.sub.3 1 methyl
--CH.sub.2CH.sub.2CH.sub.2-- --OCH.sub.3 2 methyl
--CH.sub.2CH.sub.2CH.sub.2-- --OCH.sub.3 3 methyl
--CH.sub.2CH.sub.2CH.sub.2-- --NH.sub.2 1 methyl
--CH.sub.2CH.sub.2CH.sub.2-- --NH.sub.2 2 methyl
--CH.sub.2CH.sub.2CH.sub.2-- --NH.sub.2 3 methyl
--CH.sub.2--O--CH.sub.2-- --OH 1 methyl --CH.sub.2--O--CH.sub.2--
--OH 2 methyl --CH.sub.2--O--CH.sub.2-- --OH 3 methyl
--CH.sub.2--O--CH.sub.2-- --OCH.sub.3 1 methyl
--CH.sub.2--O--CH.sub.2-- --OCH.sub.3 2 methyl
--CH.sub.2--O--CH.sub.2-- --OCH.sub.3 3 methyl
--CH.sub.2--O--CH.sub.2-- --NH.sub.2 1 methyl
--CH.sub.2--O--CH.sub.2-- --NH.sub.2 2 methyl
--CH.sub.2--O--CH.sub.2-- --NH.sub.2 3 ethyl Bond --OH 1 ethyl Bond
--OH 2 ethyl Bond --OH 3 ethyl Bond --OCH.sub.3 1 ethyl Bond
--OCH.sub.3 2 ethyl Bond --OCH.sub.3 3 ethyl Bond --NH.sub.2 1
ethyl Bond --NH.sub.2 2 ethyl Bond --NH.sub.2 3 ethyl --CH.sub.2--
--OH 1 ethyl --CH.sub.2-- --OH 2 ethyl --CH.sub.2-- --OH 3 ethyl
--CH.sub.2-- --OCH.sub.3 1 ethyl --CH.sub.2-- --OCH.sub.3 2 ethyl
--CH.sub.2-- --OCH.sub.3 3 ethyl --CH.sub.2-- --NH.sub.2 1 ethyl
--CH.sub.2-- --NH.sub.2 2 ethyl --CH.sub.2-- --NH.sub.2 3 ethyl
--CH.sub.2CH.sub.2-- --OH 1 ethyl --CH.sub.2CH.sub.2-- --OH 2 ethyl
--CH.sub.2CH.sub.2-- --OH 3 ethyl --CH.sub.2CH.sub.2-- --OCH.sub.3
1 ethyl --CH.sub.2CH.sub.2-- --OCH.sub.3 2 ethyl
--CH.sub.2CH.sub.2-- --OCH.sub.3 3 ethyl --CH.sub.2CH.sub.2--
--NH.sub.2 1 ethyl --CH.sub.2CH.sub.2-- --NH.sub.2 2 ethyl
--CH.sub.2CH.sub.2-- --NH.sub.2 3 ethyl
--CH.sub.2CH.sub.2CH.sub.2-- --OH 1 ethyl
--CH.sub.2CH.sub.2CH.sub.2-- --OH 2 ethyl
--CH.sub.2CH.sub.2CH.sub.2-- --OH 3 ethyl
--CH.sub.2CH.sub.2CH.sub.2-- --OCH.sub.3 1 ethyl
--CH.sub.2CH.sub.2CH.sub.2-- --OCH.sub.3 2 ethyl
--CH.sub.2CH.sub.2CH.sub.2-- --OCH.sub.3 3 ethyl
--CH.sub.2CH.sub.2CH.sub.2-- --NH.sub.2 1 ethyl
--CH.sub.2CH.sub.2CH.sub.2-- --NH.sub.2 2 ethyl
--CH.sub.2CH.sub.2CH.sub.2-- --NH.sub.2 3 ethyl
--CH.sub.2--O--CH.sub.2-- --OH 1 ethyl --CH.sub.2--O--CH.sub.2--
--OH 2 ethyl --CH.sub.2--O--CH.sub.2-- --OH 3 ethyl
--CH.sub.2--O--CH.sub.2-- --OCH.sub.3 1 ethyl
--CH.sub.2--O--CH.sub.2-- --OCH.sub.3 2 ethyl
--CH.sub.2--O--CH.sub.2-- --OCH.sub.3 3 ethyl
--CH.sub.2--O--CH.sub.2-- --NH.sub.2 1 ethyl
--CH.sub.2--O--CH.sub.2-- --NH.sub.2 2 ethyl
--CH.sub.2--O--CH.sub.2-- --NH.sub.2 3 n-propyl Bond --OH 1
n-propyl Bond --OH 2 n-propyl Bond --OH 3 n-propyl Bond --OCH.sub.3
1 n-propyl Bond --OCH.sub.3 2 n-propyl Bond --OCH.sub.3 3 n-propyl
Bond --NH.sub.2 1 n-propyl Bond --NH.sub.2 2 n-propyl Bond
--NH.sub.2 3 n-propyl --CH.sub.2-- --OH 1 n-propyl --CH.sub.2--
--OH 2 n-propyl --CH.sub.2-- --OH 3 n-propyl --CH.sub.2--
--OCH.sub.3 1 n-propyl --CH.sub.2-- --OCH.sub.3 2 n-propyl
--CH.sub.2-- --OCH.sub.3 3 n-propyl --CH.sub.2-- --NH.sub.2 1
n-propyl --CH.sub.2-- --NH.sub.2 2 n-propyl --CH.sub.2-- --NH.sub.2
3 n-propyl --CH.sub.2CH.sub.2-- --OH 1 n-propyl
--CH.sub.2CH.sub.2-- --OH 2 n-propyl --CH.sub.2CH.sub.2-- --OH 3
n-propyl --CH.sub.2CH.sub.2-- --OCH.sub.3 1 n-propyl
--CH.sub.2CH.sub.2-- --OCH.sub.3 2 n-propyl --CH.sub.2CH.sub.2--
--OCH.sub.3 3 n-propyl --CH.sub.2CH.sub.2-- --NH.sub.2 1 n-propyl
--CH.sub.2CH.sub.2-- --NH.sub.2 2 n-propyl --CH.sub.2CH.sub.2--
--NH.sub.2 3 n-propyl --CH.sub.2CH.sub.2CH.sub.2-- --OH 1 n-propyl
--CH.sub.2CH.sub.2CH.sub.2-- --OH 2 n-propyl
--CH.sub.2CH.sub.2CH.sub.2-- --OH 3 n-propyl
--CH.sub.2CH.sub.2CH.sub.2-- --OCH.sub.3 1 n-propyl
--CH.sub.2CH.sub.2CH.sub.2-- --OCH.sub.3 2 n-propyl
--CH.sub.2CH.sub.2CH.sub.2-- --OCH.sub.3 3 n-propyl
--CH.sub.2CH.sub.2CH.sub.2-- --NH.sub.2 1 n-propyl
--CH.sub.2CH.sub.2CH.sub.2-- --NH.sub.2 2 n-propyl
--CH.sub.2CH.sub.2CH.sub.2-- --NH.sub.2 3 n-propyl
--CH.sub.2--O--CH.sub.2-- --OH 1 n-propyl --CH.sub.2--O--CH.sub.2--
--OH 2 n-propyl --CH.sub.2--O--CH.sub.2-- --OH 3 n-propyl
--CH.sub.2--O--CH.sub.2-- --OCH.sub.3 1 n-propyl
--CH.sub.2--O--CH.sub.2-- --OCH.sub.3 2 n-propyl
--CH.sub.2--O--CH.sub.2-- --OCH.sub.3 3 n-propyl
--CH.sub.2--O--CH.sub.2-- --NH.sub.2 1 n-propyl
--CH.sub.2--O--CH.sub.2-- --NH.sub.2 2 n-propyl
--CH.sub.2--O--CH.sub.2-- --NH.sub.2 3 n-butyl Bond --OH 1 n-butyl
Bond --OH 2 n-butyl Bond --OH 3 n-butyl Bond --OCH.sub.3 1 n-butyl
Bond --OCH.sub.3 2 n-butyl Bond --OCH.sub.3 3 n-butyl Bond
--NH.sub.2 1 n-butyl Bond --NH.sub.2 2 n-butyl Bond --NH.sub.2 3
n-butyl --CH.sub.2-- --OH 1 n-butyl --CH.sub.2-- --OH 2 n-butyl
--CH.sub.2-- --OH 3 n-butyl --CH.sub.2-- --OCH.sub.3 1 n-butyl
--CH.sub.2-- --OCH.sub.3 2 n-butyl --CH.sub.2-- --OCH.sub.3 3
n-butyl --CH.sub.2-- --NH.sub.2 1 n-butyl --CH.sub.2-- --NH.sub.2 2
n-butyl --CH.sub.2-- --NH.sub.2 3 n-butyl --CH.sub.2CH.sub.2-- --OH
1 n-butyl --CH.sub.2CH.sub.2-- --OH 2 n-butyl --CH.sub.2CH.sub.2--
--OH 3 n-butyl --CH.sub.2CH.sub.2-- --OCH.sub.3 1 n-butyl
--CH.sub.2CH.sub.2-- --OCH.sub.3 2 n-butyl --CH.sub.2CH.sub.2--
--OCH.sub.3 3 n-butyl --CH.sub.2CH.sub.2-- --NH.sub.2 1 n-butyl
--CH.sub.2CH.sub.2-- --NH.sub.2 2 n-butyl --CH.sub.2CH.sub.2--
--NH.sub.2 3 n-butyl --CH.sub.2CH.sub.2CH.sub.2-- --OH 1 n-butyl
--CH.sub.2CH.sub.2CH.sub.2-- --OH 2 n-butyl
--CH.sub.2CH.sub.2CH.sub.2-- --OH 3 n-butyl
--CH.sub.2CH.sub.2CH.sub.2-- --OCH.sub.3 1 n-butyl
--CH.sub.2CH.sub.2CH.sub.2-- --OCH.sub.3 2 n-butyl
--CH.sub.2CH.sub.2CH.sub.2-- --OCH.sub.3 3 n-butyl
--CH.sub.2CH.sub.2CH.sub.2-- --NH.sub.2 1 n-butyl
--CH.sub.2CH.sub.2CH.sub.2-- --NH.sub.2 2 n-butyl
--CH.sub.2CH.sub.2CH.sub.2-- --NH.sub.2 3 n-butyl
--CH.sub.2--O--CH.sub.2-- --OH 1 n-butyl --CH.sub.2--O--CH.sub.2--
--OH 2 n-butyl --CH.sub.2--O--CH.sub.2-- --OH 3 n-butyl
--CH.sub.2--O--CH.sub.2-- --OCH.sub.3 1 n-butyl
--CH.sub.2--O--CH.sub.2-- --OCH.sub.3 2 n-butyl
--CH.sub.2--O--CH.sub.2-- --OCH.sub.3 3 n-butyl
--CH.sub.2--O--CH.sub.2-- --NH.sub.2 1 n-butyl
--CH.sub.2--O--CH.sub.2-- --NH.sub.2 2 n-butyl
--CH.sub.2--O--CH.sub.2-- --NH.sub.2 3 ethoxymethyl Bond --OH 1
ethoxymethyl Bond --OH 2 ethoxymethyl Bond --OH 3 ethoxymethyl Bond
--OCH.sub.3 1 ethoxymethyl Bond --OCH.sub.3 2 ethoxymethyl Bond
--OCH.sub.3 3 ethoxymethyl Bond --NH.sub.2 1 ethoxymethyl Bond
--NH.sub.2 2 ethoxymethyl Bond --NH.sub.2 3 ethoxymethyl
--CH.sub.2-- --OH 1 ethoxymethyl --CH.sub.2-- --OH 2 ethoxymethyl
--CH.sub.2-- --OH 3 ethoxymethyl --CH.sub.2-- --OCH.sub.3 1
ethoxymethyl --CH.sub.2-- --OCH.sub.3 2 ethoxymethyl --CH.sub.2--
--OCH.sub.3 3 ethoxymethyl --CH.sub.2-- --NH.sub.2 1 ethoxymethyl
--CH.sub.2-- --NH.sub.2 2 ethoxymethyl --CH.sub.2-- --NH.sub.2 3
ethoxymethyl --CH.sub.2CH.sub.2-- --OH 1 ethoxymethyl
--CH.sub.2CH.sub.2-- --OH 2 ethoxymethyl --CH.sub.2CH.sub.2-- --OH
3 ethoxymethyl --CH.sub.2CH.sub.2-- --OCH.sub.3 1 ethoxymethyl
--CH.sub.2CH.sub.2-- --OCH.sub.3 2 ethoxymethyl
--CH.sub.2CH.sub.2-- --OCH.sub.3 3 ethoxymethyl
--CH.sub.2CH.sub.2-- --NH.sub.2 1 ethoxymethyl --CH.sub.2CH.sub.2--
--NH.sub.2 2 ethoxymethyl --CH.sub.2CH.sub.2-- --NH.sub.2 3
ethoxymethyl --CH.sub.2CH.sub.2CH.sub.2-- --OH 1 ethoxymethyl
--CH.sub.2CH.sub.2CH.sub.2-- --OH 2 ethoxymethyl
--CH.sub.2CH.sub.2CH.sub.2-- --OH 3 ethoxymethyl
--CH.sub.2CH.sub.2CH.sub.2-- --OCH.sub.3 1 ethoxymethyl
--CH.sub.2CH.sub.2CH.sub.2-- --OCH.sub.3 2 ethoxymethyl
--CH.sub.2CH.sub.2CH.sub.2-- --OCH.sub.3 3 ethoxymethyl
--CH.sub.2CH.sub.2CH.sub.2-- --NH.sub.2 1 ethoxymethyl
--CH.sub.2CH.sub.2CH.sub.2-- --NH.sub.2 2 ethoxymethyl
--CH.sub.2CH.sub.2CH.sub.2-- --NH.sub.2 3 ethoxymethyl
--CH.sub.2--O--CH.sub.2-- --OH 1 ethoxymethyl
--CH.sub.2--O--CH.sub.2-- --OH 2 ethoxymethyl
--CH.sub.2--O--CH.sub.2-- --OH 3 ethoxymethyl
--CH.sub.2--O--CH.sub.2-- --OCH.sub.3 1 ethoxymethyl
--CH.sub.2--O--CH.sub.2-- --OCH.sub.3 2 ethoxymethyl
--CH.sub.2--O--CH.sub.2-- --OCH.sub.3 3 ethoxymethyl
--CH.sub.2--O--CH.sub.2-- --NH.sub.2 1 ethoxymethyl
--CH.sub.2--O--CH.sub.2-- --NH.sub.2 2 ethoxymethyl
--CH.sub.2--O--CH.sub.2-- --NH.sub.2 3 2-methoxyethyl Bond --OH 1
2-methoxyethyl Bond --OH 2 2-methoxyethyl Bond --OH 3
2-methoxyethyl Bond --OCH.sub.3 1 2-methoxyethyl Bond --OCH.sub.3 2
2-methoxyethyl Bond --OCH.sub.3 3 2-methoxyethyl Bond --NH.sub.2 1
2-methoxyethyl Bond --NH.sub.2 2 2-methoxyethyl Bond --NH.sub.2 3
2-methoxyethyl --CH.sub.2-- --OH 1 2-methoxyethyl --CH.sub.2-- --OH
2 2-methoxyethyl --CH.sub.2-- --OH 3 2-methoxyethyl --CH.sub.2--
--OCH.sub.3 1 2-methoxyethyl --CH.sub.2-- --OCH.sub.3 2
2-methoxyethyl --CH.sub.2-- --OCH.sub.3 3 2-methoxyethyl
--CH.sub.2-- --NH.sub.2 1 2-methoxyethyl --CH.sub.2-- --NH.sub.2 2
2-methoxyethyl --CH.sub.2-- --NH.sub.2 3 2-methoxyethyl
--CH.sub.2CH.sub.2-- --OH 1 2-methoxyethyl --CH.sub.2CH.sub.2--
--OH 2 2-methoxyethyl --CH.sub.2CH.sub.2-- --OH 3 2-methoxyethyl
--CH.sub.2CH.sub.2-- --OCH.sub.3 1 2-methoxyethyl
--CH.sub.2CH.sub.2-- --OCH.sub.3 2 2-methoxyethyl
--CH.sub.2CH.sub.2-- --OCH.sub.3 3 2-methoxyethyl
--CH.sub.2CH.sub.2-- --NH.sub.2 1 2-methoxyethyl
--CH.sub.2CH.sub.2-- --NH.sub.2 2 2-methoxyethyl
--CH.sub.2CH.sub.2-- --NH.sub.2 3 2-methoxyethyl
--CH.sub.2CH.sub.2CH.sub.2-- --OH 1 2-methoxyethyl
--CH.sub.2CH.sub.2CH.sub.2-- --OH 2 2-methoxyethyl
--CH.sub.2CH.sub.2CH.sub.2-- --OH 3 2-methoxyethyl
--CH.sub.2CH.sub.2CH.sub.2-- --OCH.sub.3 1 2-methoxyethyl
--CH.sub.2CH.sub.2CH.sub.2-- --OCH.sub.3 2 2-methoxyethyl
--CH.sub.2CH.sub.2CH.sub.2-- --OCH.sub.3 3 2-methoxyethyl
--CH.sub.2CH.sub.2CH.sub.2-- --NH.sub.2 1 2-methoxyethyl
--CH.sub.2CH.sub.2CH.sub.2-- --NH.sub.2 2 2-methoxyethyl
--CH.sub.2CH.sub.2CH.sub.2-- --NH.sub.2 3 2-methoxyethyl
--CH.sub.2--O--CH.sub.2-- --OH 1 2-methoxyethyl
--CH.sub.2--O--CH.sub.2-- --OH 2 2-methoxyethyl
--CH.sub.2--O--CH.sub.2-- --OH 3 2-methoxyethyl
--CH.sub.2--O--CH.sub.2-- --OCH.sub.3 1 2-methoxyethyl
--CH.sub.2--O--CH.sub.2-- --OCH.sub.3 2 2-methoxyethyl
--CH.sub.2--O--CH.sub.2-- --OCH.sub.3 3 2-methoxyethyl
--CH.sub.2--O--CH.sub.2-- --NH.sub.2 1 2-methoxyethyl
--CH.sub.2--O--CH.sub.2-- --NH.sub.2 2 2-methoxyethyl
--CH.sub.2--O--CH.sub.2-- --NH.sub.2 3
Exemplary Compounds Table 2
Ceartain exemplary compounds, including some of those described
above in the Examples, have the following Formulas(II-2, III-2,
IV-2, and V-2)wherin R.sub.2, Q, R', R.sub.4, and m are defined
immediately below in the table. In this table, for each ring
system, each row represents one specific compound.
TABLE-US-00010 III-2 ##STR00454## III-2 ##STR00455## IV-2
##STR00456## V-2 ##STR00457## R.sub.2 Q R.sub.4 R' m H Bond Methyl
--OH 1 H Bond Methyl --OH 2 H Bond Methyl --OH 3 H Bond Methyl
--OCH.sub.3 1 H Bond methyl --OCH.sub.3 2 H Bond methyl --OCH.sub.3
3 H Bond ethyl --OH 1 H Bond ethyl --OH 2 H Bond ethyl --OH 3 H
Bond ethyl --OCH.sub.3 1 H Bond ethyl --OCH.sub.3 2 H Bond ethyl
--OCH.sub.3 3 H Bond isopropyl --OH 1 H Bond isopropyl --OH 2 H
Bond isopropyl --OH 3 H Bond isopropyl --OCH.sub.3 1 H Bond
isopropyl --OCH.sub.3 2 H Bond isopropyl --OCH.sub.3 3 H Bond
phenyl --OH 1 H Bond phenyl --OH 2 H Bond phenyl --OH 3 H Bond
phenyl --OCH.sub.3 1 H Bond phenyl --OCH.sub.3 2 H Bond phenyl
--OCH.sub.3 3 H --C(O)-- methyl --OH 1 H --C(O)-- methyl --OH 2 H
--C(O)-- methyl --OH 3 H --C(O)-- methyl --OCH.sub.3 1 H --C(O)--
methyl --OCH.sub.3 2 H --C(O)-- methyl --OCH.sub.3 3 H --C(O)--
ethyl --OH 1 H --C(O)-- ethyl --OH 2 H --C(O)-- ethyl --OH 3 H
--C(O)-- ethyl --OCH.sub.3 1 H --C(O)-- ethyl --OCH.sub.3 2 H
--C(O)-- ethyl --OCH.sub.3 3 H --C(O)-- isopropyl --OH 1 H --C(O)--
isopropyl --OH 2 H --C(O)-- isopropyl --OH 3 H --C(O)-- isopropyl
--OCH.sub.3 1 H --C(O)-- isopropyl --OCH.sub.3 2 H --C(O)--
isopropyl --OCH.sub.3 3 H --C(O)-- phenyl --OH 1 H --C(O)-- phenyl
--OH 2 H --C(O)-- phenyl --OH 3 H --C(O)-- phenyl --OCH.sub.3 1 H
--C(O)-- phenyl --OCH.sub.3 2 H --C(O)-- phenyl --OCH.sub.3 3 H
--S(O).sub.2-- methyl --OH 1 H --S(O).sub.2-- methyl --OH 2 H
--S(O).sub.2-- methyl --OH 3 H --S(O).sub.2-- methyl --OCH.sub.3 1
H --S(O).sub.2-- methyl --OCH.sub.3 2 H --S(O).sub.2-- methyl
--OCH.sub.3 3 H --S(O).sub.2-- ethyl --OH 1 H --S(O).sub.2-- ethyl
--OH 2 H --S(O).sub.2-- ethyl --OH 3 H --S(O).sub.2-- ethyl
--OCH.sub.3 1 H --S(O).sub.2-- ethyl --OCH.sub.3 2 H --S(O).sub.2--
ethyl --OCH.sub.3 3 H --S(O).sub.2-- isopropyl --OH 1 H
--S(O).sub.2-- isopropyl --OH 2 H --S(O).sub.2-- isopropyl --OH 3 H
--S(O).sub.2-- isopropyl --OCH.sub.3 1 H --S(O).sub.2-- isopropyl
--OCH.sub.3 2 H --S(O).sub.2-- isopropyl --OCH.sub.3 3 H
--S(O).sub.2-- phenyl --OH 1 H --S(O).sub.2-- phenyl --OH 2 H
--S(O).sub.2-- phenyl --OH 3 H --S(O).sub.2-- phenyl --OCH.sub.3 1
H --S(O).sub.2-- phenyl --OCH.sub.3 2 H --S(O).sub.2-- phenyl
--OCH.sub.3 3 H --C(O)--NH-- methyl --OH 1 H --C(O)--NH-- methyl
--OH 2 H --C(O)--NH-- methyl --OH 3 H --C(O)--NH-- methyl
--OCH.sub.3 1 H --C(O)--NH-- methyl --OCH.sub.3 2 H --C(O)--NH--
methyl --OCH.sub.3 3 H --C(O)--NH-- ethyl --OH 1 H --C(O)--NH--
ethyl --OH 2 H --C(O)--NH-- ethyl --OH 3 H --C(O)--NH-- ethyl
--OCH.sub.3 1 H --C(O)--NH-- ethyl --OCH.sub.3 2 H --C(O)--NH--
ethyl --OCH.sub.3 3 H --C(O)--NH-- isopropyl --OH 1 H --C(O)--NH--
isopropyl --OH 2 H --C(O)--NH-- isopropyl --OH 3 H --C(O)--NH--
isopropyl --OCH.sub.3 1 H --C(O)--NH-- isopropyl --OCH.sub.3 2 H
--C(O)--NH-- isopropyl --OCH.sub.3 3 H --C(O)--NH-- phenyl --OH 1 H
--C(O)--NH-- phenyl --OH 2 H --C(O)--NH-- phenyl --OH 3 H
--C(O)--NH-- phenyl --OCH.sub.3 1 H --C(O)--NH-- phenyl --OCH.sub.3
2 H --C(O)--NH-- phenyl --OCH.sub.3 3 methyl Bond methyl --OH 1
methyl Bond methyl --OH 2 methyl Bond methyl --OH 3 methyl Bond
methyl --OCH.sub.3 1 methyl Bond methyl --OCH.sub.3 2 methyl Bond
methyl --OCH.sub.3 3 methyl Bond ethyl --OH 1 methyl Bond ethyl
--OH 2 methyl Bond ethyl --OH 3 methyl Bond ethyl --OCH.sub.3 1
methyl Bond ethyl --OCH.sub.3 2 methyl Bond ethyl --OCH.sub.3 3
methyl Bond isopropyl --OH 1 methyl Bond isopropyl --OH 2 methyl
Bond isopropyl --OH 3 methyl Bond isopropyl --OCH.sub.3 1 methyl
Bond isopropyl --OCH.sub.3 2 methyl Bond isopropyl --OCH.sub.3 3
methyl Bond phenyl --OH 1 methyl Bond phenyl --OH 2 methyl Bond
phenyl --OH 3 methyl Bond phenyl --OCH.sub.3 1 methyl Bond phenyl
--OCH.sub.3 2 methyl Bond phenyl --OCH.sub.3 3 methyl --C(O)--
methyl --OH 1 methyl --C(O)-- methyl --OH 2 methyl --C(O)-- methyl
--OH 3 methyl --C(O)-- methyl --OCH.sub.3 1 methyl --C(O)-- methyl
--OCH.sub.3 2 methyl --C(O)-- methyl --OCH.sub.3 3 methyl --C(O)--
ethyl --OH 1 methyl --C(O)-- ethyl --OH 2 methyl --C(O)-- ethyl
--OH 3 methyl --C(O)-- ethyl --OCH.sub.3 1 methyl --C(O)-- ethyl
--OCH.sub.3 2 methyl --C(O)-- ethyl --OCH.sub.3 3 methyl --C(O)--
isopropyl --OH 1 methyl --C(O)-- isopropyl --OH 2 methyl --C(O)--
isopropyl --OH 3 methyl --C(O)-- isopropyl --OCH.sub.3 1 methyl
--C(O)-- isopropyl --OCH.sub.3 2 methyl --C(O)-- isopropyl
--OCH.sub.3 3 methyl --C(O)-- phenyl --OH 1 methyl --C(O)-- phenyl
--OH 2 methyl --C(O)-- phenyl --OH 3 methyl --C(O)-- phenyl
--OCH.sub.3 1 methyl --C(O)-- phenyl --OCH.sub.3 2 methyl --C(O)--
phenyl --OCH.sub.3 3 methyl --S(O).sub.2-- methyl --OH 1 methyl
--S(O).sub.2-- methyl --OH 2 methyl --S(O).sub.2-- methyl --OH 3
methyl --S(O).sub.2-- methyl --OCH.sub.3 1 methyl --S(O).sub.2--
methyl --OCH.sub.3 2 methyl --S(O).sub.2-- methyl --OCH.sub.3 3
methyl --S(O).sub.2-- ethyl --OH 1 methyl --S(O).sub.2-- ethyl --OH
2 methyl --S(O).sub.2-- ethyl --OH 3 methyl --S(O).sub.2-- ethyl
--OCH.sub.3 1 methyl --S(O).sub.2-- ethyl --OCH.sub.3 2 methyl
--S(O).sub.2-- ethyl --OCH.sub.3 3 methyl --S(O).sub.2-- isopropyl
--OH 1 methyl --S(O).sub.2-- isopropyl --OH 2 methyl --S(O).sub.3--
isopropyl --OH 3 methyl --S(O).sub.2-- isopropyl --OCH.sub.3 1
methyl --S(O).sub.2-- isopropyl --OCH.sub.3 2 methyl --S(O).sub.2--
isopropyl --OCH.sub.3 3 methyl --S(O).sub.2-- phenyl --OH 1 methyl
--S(O).sub.2-- phenyl --OH 2 methyl --S(O).sub.2-- phenyl --OH 3
methyl --S(O).sub.2-- phenyl --OCH.sub.3 1 methyl --S(O).sub.2--
phenyl --OCH.sub.3 2 methyl --S(O).sub.2-- phenyl --OCH.sub.3 3
methyl --C(O)--NH-- methyl --OH 1 methyl --C(O)--NH-- methyl --OH 2
methyl --C(O)--NH-- methyl --OH 3 methyl --C(O)--NH-- methyl
--OCH.sub.3 1 methyl --C(O)--NH-- methyl --OCH.sub.3 2 methyl
--C(O)--NH-- methyl --OCH.sub.3 3 methyl --C(O)--NH-- ethyl --OH 1
methyl --C(O)--NH-- ethyl --OH 2 methyl --C(O)--NH-- ethyl --OH 3
methyl --C(O)--NH-- ethyl --OCH.sub.3 1 methyl --C(O)--NH-- ethyl
--OCH.sub.3 2 methyl --C(O)--NH-- ethyl --OCH.sub.3 3 methyl
--C(O)--NH-- isopropyl --OH 1 methyl --C(O)--NH-- isopropyl --OH 2
methyl --C(O)--NH-- isopropyl --OH 3 methyl --C(O)--NH-- isopropyl
--OCH.sub.3 1 methyl --C(O)--NH-- isopropyl --OCH.sub.3 2 methyl
--C(O)--NH-- isopropyl --OCH.sub.3 3 methyl --C(O)--NH-- phenyl
--OH 1 methyl --C(O)--NH-- phenyl --OH 2 methyl --C(O)--NH-- phenyl
--OH 3 methyl --C(O)--NH-- phenyl --OCH.sub.3 1 methyl --C(O)--NH--
phenyl --OCH.sub.3 2 methyl --C(O)--NH-- phenyl --OCH.sub.3 3 ethyl
Bond methyl --OH 1 ethyl Bond methyl --OH 2 ethyl Bond methyl --OH
3 ethyl Bond methyl --OCH.sub.3 1 ethyl Bond methyl --OCH.sub.3 2
ethyl Bond methyl --OCH.sub.3 3 ethyl Bond ethyl --OH 1 ethyl Bond
ethyl --OH 2 ethyl Bond ethyl --OH 3 ethyl Bond ethyl --OCH.sub.3 1
ethyl Bond ethyl --OCH.sub.3 2 ethyl Bond ethyl --OCH.sub.3 3 ethyl
Bond isopropyl --OH 1 ethyl Bond isopropyl --OH 2 ethyl Bond
isopropyl --OH 3 ethyl Bond isopropyl --OCH.sub.3 1 ethyl Bond
isopropyl --OCH.sub.3 2 ethyl Bond isopropyl --OCH.sub.3 3 ethyl
Bond phenyl --OH 1 ethyl Bond phenyl --OH 2 ethyl Bond phenyl --OH
3 ethyl Bond phenyl --OCH.sub.3 1 ethyl Bond phenyl --OCH.sub.3 2
ethyl Bond phenyl --OCH.sub.3 3 ethyl --C(O)-- methyl --OH 1 ethyl
--C(O)-- methyl --OH 2 ethyl --C(O)-- methyl --OH 3 ethyl --C(O)--
methyl --OCH.sub.3 1 ethyl --C(O)-- methyl --OCH.sub.3 2 ethyl
--C(O)-- methyl --OCH.sub.3 3 ethyl --C(O)-- ethyl --OH 1 ethyl
--C(O)-- ethyl --OH 2 ethyl --C(O)-- ethyl --OH 3 ethyl --C(O)--
ethyl --OCH.sub.3 1 ethyl --C(O)-- ethyl --OCH.sub.3 2 ethyl
--C(O)-- ethyl --OCH.sub.3 3 ethyl --C(O)-- isopropyl --OH 1 ethyl
--C(O)-- isopropyl --OH 2 ethyl --C(O)-- isopropyl --OH 3 ethyl
--C(O)-- isopropyl --OCH.sub.3 1 ethyl --C(O)-- isopropyl
--OCH.sub.3 2 ethyl --C(O)-- isopropyl --OCH.sub.3 3 ethyl --C(O)--
phenyl --OH 1 ethyl --C(O)-- phenyl --OH 2 ethyl --C(O)-- phenyl
--OH 3 ethyl --C(O)-- phenyl --OCH.sub.3 1
ethyl --C(O)-- phenyl --OCH.sub.3 2 ethyl --C(O)-- phenyl
--OCH.sub.3 3 ethyl --S(O).sub.2-- methyl --OH 1 ethyl
--S(O).sub.2-- methyl --OH 2 ethyl --S(O).sub.2-- methyl --OH 3
ethyl --S(O).sub.2-- methyl --OCH.sub.3 1 ethyl --S(O).sub.2--
methyl --OCH.sub.3 2 ethyl --S(O).sub.2-- methyl --OCH.sub.3 3
ethyl --S(O).sub.2-- ethyl --OH 1 ethyl --S(O).sub.2-- ethyl --OH 2
ethyl --S(O).sub.2-- ethyl --OH 3 ethyl --S(O).sub.2-- ethyl
--OCH.sub.3 1 ethyl --S(O).sub.2-- ethyl --OCH.sub.3 2 ethyl
--S(O).sub.2-- ethyl --OCH.sub.3 3 ethyl --S(O).sub.2-- isopropyl
--OH 1 ethyl --S(O).sub.2-- isopropyl --OH 2 ethyl --S(O).sub.2--
isopropyl --OH 3 ethyl --S(O).sub.2-- isopropyl --OCH.sub.3 1 ethyl
--S(O).sub.2-- isopropyl --OCH.sub.3 2 ethyl --S(O).sub.2--
isopropyl --OCH.sub.3 3 ethyl --S(O).sub.2-- phenyl --OH 1 ethyl
--S(O).sub.2-- phenyl --OH 2 ethyl --S(O).sub.2-- phenyl --OH 3
ethyl --S(O).sub.2-- phenyl --OCH.sub.3 1 ethyl --S(O).sub.2--
phenyl --OCH.sub.3 2 ethyl --S(O).sub.2-- phenyl --OCH.sub.3 3
ethyl --C(O)--NH-- methyl --OH 1 ethyl --C(O)--NH-- methyl --OH 2
ethyl --C(O)--NH-- methyl --OH 3 ethyl --C(O)--NH-- methyl
--OCH.sub.3 1 ethyl --C(O)--NH-- methyl --OCH.sub.3 2 ethyl
--C(O)--NH-- methyl --OCH.sub.3 3 ethyl --C(O)--NH-- ethyl --OH 1
ethyl --C(O)--NH-- ethyl --OH 2 ethyl --C(O)--NH-- ethyl --OH 3
ethyl --C(O)--NH-- ethyl --OCH.sub.3 1 ethyl --C(O)--NH-- ethyl
--OCH.sub.3 2 ethyl --C(O)--NH-- ethyl --OCH.sub.3 3 ethyl
--C(O)--NH-- isopropyl --OH 1 ethyl --C(O)--NH-- isopropyl --OH 2
ethyl --C(O)--NH-- isopropyl --OH 3 ethyl --C(O)--NH-- isopropyl
--OCH.sub.3 1 ethyl --C(O)--NH-- isopropyl --OCH.sub.3 2 ethyl
--C(O)--NH-- isopropyl --OCH.sub.3 3 ethyl --C(O)--NH-- phenyl --OH
1 ethyl --C(O)--NH-- phenyl --OH 2 ethyl --C(O)--NH-- phenyl --OH 3
ethyl --C(O)--NH-- phenyl --OCH.sub.3 1 ethyl --C(O)--NH-- phenyl
--OCH.sub.3 2 ethyl --C(O)--NH-- phenyl --OCH.sub.3 3 n-propyl Bond
methyl --OH 1 n-propyl Bond methyl --OH 2 n-propyl Bond methyl --OH
3 n-propyl Bond methyl --OCH.sub.3 1 n-propyl Bond methyl
--OCH.sub.3 2 n-propyl Bond methyl --OCH.sub.3 3 n-propyl Bond
ethyl --OH 1 n-propyl Bond ethyl --OH 2 n-propyl Bond ethyl --OH 3
n-propyl Bond ethyl --OCH.sub.3 1 n-propyl Bond ethyl --OCH.sub.3 2
n-propyl Bond ethyl --OCH.sub.3 3 n-propyl Bond isopropyl --OH 1
n-propyl Bond isopropyl --OH 2 n-propyl Bond isopropyl --OH 3
n-propyl Bond isopropyl --OCH.sub.3 1 n-propyl Bond isopropyl
--OCH.sub.3 2 n-propyl Bond isopropyl --OCH.sub.3 3 n-propyl Bond
phenyl --OH 1 n-propyl Bond phenyl --OH 2 n-propyl Bond phenyl --OH
3 n-propyl Bond phenyl --OCH.sub.3 1 n-propyl Bond phenyl
--OCH.sub.3 2 n-propyl Bond phenyl --OCH.sub.3 3 n-propyl --C(O)--
methyl --OH 1 n-propyl --C(O)-- methyl --OH 2 n-propyl --C(O)--
methyl --OH 3 n-propyl --C(O)-- methyl --OCH.sub.3 1 n-propyl
--C(O)-- methyl --OCH.sub.3 2 n-propyl --C(O)-- methyl --OCH.sub.3
3 n-propyl --C(O)-- ethyl --OH 1 n-propyl --C(O)-- ethyl --OH 2
n-propyl --C(O)-- ethyl --OH 3 n-propyl --C(O)-- ethyl --OCH.sub.3
1 n-propyl --C(O)-- ethyl --OCH.sub.3 2 n-propyl --C(O)-- ethyl
--OCH.sub.3 3 n-propyl --C(O)-- isopropyl --OH 1 n-propyl --C(O)--
isopropyl --OH 2 n-propyl --C(O)-- isopropyl --OH 3 n-propyl
--C(O)-- isopropyl --OCH.sub.3 1 n-propyl --C(O)-- isopropyl
--OCH.sub.3 2 n-propyl --C(O)-- isopropyl --OCH.sub.3 3 n-propyl
--C(O)-- phenyl --OH 1 n-propyl --C(O)-- phenyl --OH 2 n-propyl
--C(O)-- phenyl --OH 3 n-propyl --C(O)-- phenyl --OCH.sub.3 1
n-propyl --C(O)-- phenyl --OCH.sub.3 2 n-propyl --C(O)-- phenyl
--OCH.sub.3 3 n-propyl --S(O).sub.2-- methyl --OH 1 n-propyl
--S(O).sub.2-- methyl --OH 2 n-propyl --S(O).sub.2-- methyl --OH 3
n-propyl --S(O).sub.2-- methyl --OCH.sub.3 1 n-propyl
--S(O).sub.2-- methyl --OCH.sub.3 2 n-propyl --S(O).sub.2-- methyl
--OCH.sub.3 3 n-propyl --S(O).sub.2-- ethyl --OH 1 n-propyl
--S(O).sub.2-- ethyl --OH 2 n-propyl --S(O).sub.2-- ethyl --OH 3
n-propyl --S(O).sub.2-- ethyl --OCH.sub.3 1 n-propyl --S(O).sub.2--
ethyl --OCH.sub.3 2 n-propyl --S(O).sub.2-- ethyl --OCH.sub.3 3
n-propyl --S(O).sub.2-- isopropyl --OH 1 n-propyl --S(O).sub.2--
isopropyl --OH 2 n-propyl --S(O).sub.2-- isopropyl --OH 3 n-propyl
--S(O).sub.2-- isopropyl --OCH.sub.3 1 n-propyl --S(O).sub.2--
isopropyl --OCH.sub.3 2 n-propyl --S(O).sub.2-- isopropyl
--OCH.sub.3 3 n-propyl --S(O).sub.2-- phenyl --OH 1 n-propyl
--S(O).sub.2-- phenyl --OH 2 n-propyl --S(O).sub.2-- phenyl --OH 3
n-propyl --S(O).sub.2-- phenyl --OCH.sub.3 1 n-propyl
--S(O).sub.2-- phenyl --OCH.sub.3 2 n-propyl --S(O).sub.2-- phenyl
--OCH.sub.3 3 n-propyl --C(O)--NH-- methyl --OH 1 n-propyl
--C(O)--NH-- methyl --OH 2 n-propyl --C(O)--NH-- methyl --OH 3
n-propyl --C(O)--NH-- methyl --OCH.sub.3 1 n-propyl --C(O)--NH--
methyl --OCH.sub.3 2 n-propyl --C(O)--NH-- methyl --OCH.sub.3 3
n-propyl --C(O)--NH-- ethyl --OH 1 n-propyl --C(O)--NH-- ethyl --OH
2 n-propyl --C(O)--NH-- ethyl --OH 3 n-propyl --C(O)--NH-- ethyl
--OCH.sub.3 1 n-propyl --C(O)--NH-- ethyl --OCH.sub.3 2 n-propyl
--C(O)--NH-- ethyl --OCH.sub.3 3 n-propyl --C(O)--NH-- isopropyl
--OH 1 n-propyl --C(O)--NH-- isopropyl --OH 2 n-propyl --C(O)--NH--
isopropyl --OH 3 n-propyl --C(O)--NH-- isopropyl --OCH.sub.3 1
n-propyl --C(O)--NH-- isopropyl --OCH.sub.3 2 n-propyl --C(O)--NH--
isopropyl --OCH.sub.3 3 n-propyl --C(O)--NH-- phenyl --OH 1
n-propyl --C(O)--NH-- phenyl --OH 2 n-propyl --C(O)--NH-- phenyl
--OH 3 n-propyl --C(O)--NH-- phenyl --OCH.sub.3 1 n-propyl
--C(O)--NH-- phenyl --OCH.sub.3 2 n-propyl --C(O)--NH-- phenyl
--OCH.sub.3 3 n-butyl Bond methyl --OH 1 n-butyl Bond methyl --OH 2
n-butyl Bond methyl --OH 3 n-butyl Bond methyl --OCH.sub.3 1
n-butyl Bond methyl --OCH.sub.3 2 n-butyl Bond methyl --OCH.sub.3 3
n-butyl Bond ethyl --OH 1 n-butyl Bond ethyl --OH 2 n-butyl Bond
ethyl --OH 3 n-butyl Bond ethyl --OCH.sub.3 1 n-butyl Bond ethyl
--OCH.sub.3 2 n-butyl Bond ethyl --OCH.sub.3 3 n-butyl Bond
isopropyl --OH 1 n-butyl Bond isopropyl --OH 2 n-butyl Bond
isopropyl --OH 3 n-butyl Bond isopropyl --OCH.sub.3 1 n-butyl Bond
isopropyl --OCH.sub.3 2 n-butyl Bond isopropyl --OCH.sub.3 3
n-butyl Bond phenyl --OH 1 n-butyl Bond phenyl --OH 2 n-butyl Bond
phenyl --OH 3 n-butyl Bond phenyl --OCH.sub.3 1 n-butyl Bond phenyl
--OCH.sub.3 2 n-butyl Bond phenyl --OCH.sub.3 3 n-butyl --C(O)--
methyl --OH 1 n-butyl --C(O)-- methyl --OH 2 n-butyl --C(O)--
methyl --OH 3 n-butyl --C(O)-- methyl --OCH.sub.3 1 n-butyl
--C(O)-- methyl --OCH.sub.3 2 n-butyl --C(O)-- methyl --OCH.sub.3 3
n-butyl --C(O)-- ethyl --OH 1 n-butyl --C(O)-- ethyl --OH 2 n-butyl
--C(O)-- ethyl --OH 3 n-butyl --C(O)-- ethyl --OCH.sub.3 1 n-butyl
--C(O)-- ethyl --OCH.sub.3 2 n-butyl --C(O)-- ethyl --OCH.sub.3 3
n-butyl --C(O)-- isopropyl --OH 1 n-butyl --C(O)-- isopropyl --OH 2
n-butyl --C(O)-- isopropyl --OH 3 n-butyl --C(O)-- isopropyl
--OCH.sub.3 1 n-butyl --C(O)-- isopropyl --OCH.sub.3 2 n-butyl
--C(O)-- isopropyl --OCH.sub.3 3 n-butyl --C(O)-- phenyl --OH 1
n-butyl --C(O)-- phenyl --OH 2 n-butyl --C(O)-- phenyl --OH 3
n-butyl --C(O)-- phenyl --OCH.sub.3 1 n-butyl --C(O)-- phenyl
--OCH.sub.3 2 n-butyl --C(O)-- phenyl --OCH.sub.3 3 n-butyl
--S(O).sub.2-- methyl --OH 1 n-butyl --S(O).sub.2-- methyl --OH 2
n-butyl --S(O).sub.2-- methyl --OH 3 n-butyl --S(O).sub.2-- methyl
--OCH.sub.3 1 n-butyl --S(O).sub.2-- methyl --OCH.sub.3 2 n-butyl
--S(O).sub.2-- methyl --OCH.sub.3 3 n-butyl --S(O).sub.2-- ethyl
--OH 1 n-butyl --S(O).sub.2-- ethyl --OH 2 n-butyl --S(O).sub.2--
ethyl --OH 3 n-butyl --S(O).sub.2-- ethyl --OCH.sub.3 1 n-butyl
--S(O).sub.2-- ethyl --OCH.sub.3 2 n-butyl --S(O).sub.2-- ethyl
--OCH.sub.3 3 n-butyl --S(O).sub.2-- isopropyl --OH 1 n-butyl
--S(O).sub.2-- isopropyl --OH 2 n-butyl --S(O).sub.2-- isopropyl
--OH 3 n-butyl --S(O).sub.2-- isopropyl --OCH.sub.3 1 n-butyl
--S(O).sub.2-- isopropyl --OCH.sub.3 2 n-butyl --S(O).sub.2--
isopropyl --OCH.sub.3 3 n-butyl --S(O).sub.2-- phenyl --OH 1
n-butyl --S(O).sub.2-- phenyl --OH 2 n-butyl --S(O).sub.2-- phenyl
--OH 3 n-butyl --S(O).sub.2-- phenyl --OCH.sub.3 1 n-butyl
--S(O).sub.2-- phenyl --OCH.sub.3 2 n-butyl --S(O).sub.2-- phenyl
--OCH.sub.3 3 n-buivl --C(O)--NH-- methyl --OH 1 n-butyl
--C(O)--NH-- methyl --OH 2 n-butyl --C(O)--NH-- methyl OH 3 n-butyl
--C(O)--NH-- methyl --OCH.sub.3 1 n-butyl --C(O)--NH-- methyl
--OCH.sub.3 2 n-butyl --C(O)--NH-- methyl --OCH.sub.3 3 n-butyl
--C(O)--NH-- ethyl --OH 1 n-butyl --C(O)--NH-- ethyl --OH 2 n-butyl
--C(O)--NH-- ethyl --OH 3 n-butyl --C(O)--NH-- ethyl --OCH.sub.3 1
n-butyl --C(O)--NH-- ethyl --OCH.sub.3 2 n-butyl --C(O)--NH-- ethyl
--OCH.sub.3 3 n-butyl --C(O)--NH-- isopropyl --OH 1 n-butyl
--C(O)--NH-- isopropyl --OH 2 n-butyl --C(O)--NH-- isopropyl --OH 3
n-butyl --C(O)--NH-- isopropyl --OCH.sub.3 1 n-butyl --C(O)--NH--
isopropyl --OCH.sub.3 2 n-butyl --C(O)--NH-- isopropyl --OCH.sub.3
3 n-butyl --C(O)--NH-- phenyl --OH 1 n-butyl --C(O)--NH-- phenyl
--OH 2 n-butyl --C(O)--NH-- phenyl --OH 3 n-butyl --C(O)--NH--
phenyl --OCH.sub.3 1 n-butyl --C(O)--NH-- phenyl --OCH.sub.3 2
n-butyl --C(O)--NH-- phenyl --OCH.sub.3 3 ethoxymethyl Bond methyl
--OH 1 ethoxymethyl Bond methyl --OH 2 ethoxymethyl Bond methyl
--OH 3 ethoxymethyl Bond methyl --OCH.sub.3 1 ethoxymethyl Bond
methyl --OCH.sub.3 2 ethoxymethyl Bond methyl --OCH.sub.3 3
ethoxymethyl Bond ethyl --OH 1 ethoxymethyl Bond ethyl --OH 2
ethoxymethyl Bond ethyl --OH 3
ethoxymethyl Bond ethyl --OCH.sub.3 1 ethoxymethyl Bond ethyl
--OCH.sub.3 2 ethoxymethyl Bond ethyl --OCH.sub.3 3 ethoxymethyl
Bond isopropyl --OH 1 ethoxymethyl Bond isopropyl --OH 2
ethoxymethyl Bond isopropyl --OH 3 ethoxymethyl Bond isopropyl
--OCH.sub.3 1 ethoxymethyl Bond isopropyl --OCH.sub.3 2
ethoxymethyl Bond isopropyl --OCH.sub.3 3 ethoxymethyl Bond phenyl
--OH 1 ethoxymethyl Bond phenyl --OH 2 ethoxymethyl Bond phenyl
--OH 3 ethoxymethyl Bond phenyl --OCH.sub.3 1 ethoxymethyl Bond
phenyl --OCH.sub.3 2 ethoxymethyl Bond phenyl --OCH.sub.3 3
ethoxymethyl --C(O)-- methyl --OH 1 ethoxymethyl --C(O)-- methyl
--OH 2 ethoxymethyl --C(O)-- methyl --OH 3 ethoxymethyl --C(O)--
methyl --OCH.sub.3 1 ethoxymethyl --C(O)-- methyl --OCH.sub.3 2
ethoxymethyl --C(O)-- methyl --OCH.sub.3 3 ethoxymethyl --C(O)--
ethyl --OH 1 ethoxymethyl --C(O)-- ethyl --OH 2 ethoxymethyl
--C(O)-- ethyl --OH 3 ethoxymethyl --C(O)-- ethyl --OCH.sub.3 1
ethoxymethyl --C(O)-- ethyl --OCH.sub.3 2 ethoxymethyl --C(O)--
ethyl --OCH.sub.3 3 ethoxymethyl --C(O)-- isopropyl --OH 1
ethoxymethyl --C(O)-- isopropyl --OH 2 ethoxymethyl --C(O)--
isopropyl --OH 3 ethoxymethyl --C(O)-- isopropyl --OCH.sub.3 1
ethoxymethyl --C(O)-- isopropyl --OCH.sub.3 2 ethoxymethyl --C(O)--
isopropyl --OCH.sub.3 3 ethoxymethyl --C(O)-- phenyl --OH 1
ethoxymethyl --C(O)-- phenyl --OH 2 ethoxymethyl --C(O)-- phenyl
--OH 3 ethoxymethyl --C(O)-- phenyl --OCH.sub.3 1 ethoxymethyl
--C(O)-- phenyl --OCH.sub.3 2 ethoxymethyl --C(O)-- phenyl
--OCH.sub.3 3 ethoxymethyl --S(O).sub.2-- methyl --OH 1
ethoxymethyl --S(O).sub.2-- methyl --OH 2 ethoxymethyl
--S(O).sub.2-- methyl --OH 3 ethoxymethyl --S(O).sub.2-- methyl
--OCH.sub.3 1 ethoxymethyl --S(O).sub.2-- methyl --OCH.sub.3 2
ethoxymethyl --S(O).sub.2-- methyl --OCH.sub.3 3 ethoxymethyl
--S(O).sub.2-- ethyl --OH 1 ethoxymethyl --S(O).sub.2-- ethyl --OH
2 ethoxymethyl --S(O).sub.2-- ethyl --OH 3 ethoxymethyl
--S(O).sub.2-- ethyl --OCH.sub.3 1 ethoxymethyl --S(O).sub.2--
ethyl --OCH.sub.3 2 ethoxymethyl --S(O).sub.2-- ethyl --OCH.sub.3 3
ethoxymethyl --S(O).sub.2-- isopropyl --OH 1 ethoxymethyl
--S(O).sub.2-- isopropyl --OH 2 ethoxymethyl --S(O).sub.2--
isopropyl --OH 3 ethoxymethyl --S(O).sub.2-- isopropyl --OCH.sub.3
1 ethoxymethyl --S(O).sub.2-- isopropyl --OCH.sub.3 2 ethoxymethyl
--S(O).sub.2-- isopropyl --OCH.sub.3 3 ethoxymethyl --S(O).sub.2--
phenyl --OH 1 ethoxymethyl --S(O).sub.2-- phenyl --OH 2
ethoxymethyl --S(O).sub.2-- phenyl --OH 3 ethoxymethyl
--S(O).sub.2-- phenyl --OCH.sub.3 1 ethoxymethyl --S(O).sub.2--
phenyl --OCH.sub.3 2 ethoxymethyl --S(O).sub.2-- phenyl --OCH.sub.3
3 ethoxymethyl --C(O)--NH-- methyl --OH 1 ethoxymethyl --C(O)--NH--
methyl --OH 2 ethoxymethyl --C(O)--NH-- methyl --OH 3 ethoxymethyl
--C(O)--NH-- methyl --OCH.sub.3 1 ethoxymethyl --C(O)--NH-- methyl
--OCH.sub.3 2 ethoxymethyl --C(O)--NH-- methyl --OCH.sub.3 3
ethoxymethyl --C(O)--NH-- ethyl --OH 1 ethoxymethyl --C(O)--NH--
ethyl --OH 2 ethoxymethyl --C(O)--NH-- ethyl --OH 3 ethoxymethyl
--C(O)--NH-- ethyl --OCH.sub.3 1 ethoxymethyl --C(O)--NH-- ethyl
--OCH.sub.3 2 ethoxymethyl --C(O)--NH-- ethyl --OCH.sub.3 3
ethoxymethyl --C(O)--NH-- isopropyl --OH 1 ethoxymethyl
--C(O)--NH-- isopropyl --OH 2 ethoxymethyl --C(O)--NH-- isopropyl
--OH 3 ethoxymethyl --C(O)--NH-- isopropyl --OCH.sub.3 1
ethoxymethyl --C(O)--NH-- isopropyl --OCH.sub.3 2 ethoxymethyl
--C(O)--NH-- isopropyl --OCH.sub.3 3 ethoxymethyl --C(O)--NH--
phenyl --OH 1 ethoxymethyl --C(O)--NH-- phenyl --OH 2 ethoxymethyl
--C(O)--NH-- phenyl --OH 3 ethoxymethyl --C(O)--NH-- phenyl
--OCH.sub.3 1 ethoxymethyl --C(O)--NH-- phenyl --OCH.sub.3 2
ethoxymethyl --C(O)--NH-- phenyl --OCH.sub.3 3 2-methoxyethyl Bond
methyl --OH 1 2-methoxyethyl Bond methyl --OH 2 2-methoxyethyl Bond
methyl --OH 3 2-methoxyethyl Bond methyl --OCH.sub.3 1
2-methoxyethyl Bond methyl --OCH.sub.3 2 2-methoxyethyl Bond methyl
--OCH.sub.3 3 2-methoxyethyl Bond ethyl --OH 1 2-methoxyethyl Bond
ethyl --OH 2 2-methoxyethyl Bond ethyl --OH 3 2-methoxyethyl Bond
ethyl --OCH.sub.3 1 2-methoxyethyl Bond ethyl --OCH.sub.3 2
2-methoxyethyl Bond ethyl --OCH.sub.3 3 2-methoxyethyl Bond
isopropyl --OH 1 2-methoxyethyl Bond isopropyl --OH 2
2-methoxyethyl Bond isopropyl --OH 3 2-methoxyethyl Bond isopropyl
--OCH.sub.3 1 2-methoxyethyl Bond isopropyl --OCH.sub.3 2
2-methoxyethyl Bond isopropyl --OCH.sub.3 3 2-methoxyethyl Bond
phenyl --OH 1 2-methoxyethyl Bond phenyl --OH 2 2-methoxyethyl Bond
phenyl --OH 3 2-methoxyethyl Bond phenyl --OCH.sub.3 1
2-methoxyethyl Bond phenyl --OCH.sub.3 2 2-methoxyethyl Bond phenyl
--OCH.sub.3 3 2-methoxyethyl --C(O)-- methyl --OH 1 2-methoxyethyl
--C(O)-- methyl --OH 2 2-methoxyethyl --C(O)-- methyl --OH 3
2-methoxyethyl --C(O)-- methyl --OCH.sub.3 1 2-methoxyethyl
--C(O)-- methyl --OCH.sub.3 2 2-methoxyethyl --C(O)-- methyl
--OCH.sub.3 3 2-methoxyethyl --C(O)-- ethyl --OH 1 2-methoxyethyl
--C(O)-- ethyl --OH 2 2-methoxyethyl --C(O)-- ethyl --OH 3
2-methoxyethyl --C(O)-- ethyl --OCH.sub.3 1 2-methoxyethyl --C(O)--
ethyl --OCH.sub.3 2 2-methoxyethyl --C(O)-- ethyl --OCH.sub.3 3
2-methoxyethyl --C(O)-- isopropyl --OH 1 2-methoxyethyl --C(O)--
isopropyl --OH 2 2-methoxyethyl --C(O)-- isopropyl --OH 3
2-methoxyethyl --C(O)-- isopropyl --OCH.sub.3 1 2-methoxyethyl
--C(O)-- isopropyl --OCH.sub.3 2 2-methoxyethyl --C(O)-- isopropyl
--OCH.sub.3 3 2-methoxyethyl --C(O)-- phenyl --OH 1 2-methoxyethyl
--C(O)-- phenyl --OH 2 2-methoxyethyl --C(O)-- phenyl --OH 3
2-methoxyethyl --C(O)-- phenyl --OCH.sub.3 1 2-methoxyethyl
--C(O)-- phenyl --OCH.sub.3 2 2-methoxyethyl --C(O)-- phenyl
--OCH.sub.3 3 2-methoxyethyl --S(O).sub.2-- methyl --OH 1
2-methoxyethyl --S(O).sub.2-- methyl --OH 2 2-methoxyethyl
--S(O).sub.2-- methyl --OH 3 2-methoxyethyl --S(O).sub.2-- methyl
--OCH.sub.3 1 2-methoxyethyl --S(O).sub.2-- methyl --OCH.sub.3 2
2-methoxyethyl --S(O).sub.2-- methyl --OCH.sub.3 3 2-methoxyethyl
--S(O).sub.2-- ethyl --OH 1 2-methoxyethyl --S(O).sub.2-- ethyl
--OH 2 2-methoxyethyl --S(O).sub.2-- ethyl --OH 3 2-methoxyethyl
--S(O).sub.2-- ethyl --OCH.sub.3 1 2-methoxyethyl --S(O).sub.2--
ethyl --OCH.sub.3 2 2-methoxyethyl --S(O).sub.2-- ethyl --OCH.sub.3
3 2-methoxyethyl --S(O).sub.2-- isopropyl --OH 1 2-methoxyethyl
--S(O).sub.2-- isopropyl --OH 2 2-methoxyethyl --S(O).sub.2--
isopropyl --OH 3 2-methoxyethyl --S(O).sub.2-- isopropyl
--OCH.sub.3 1 2-methoxyethyl --S(O).sub.2-- isopropyl --OCH.sub.3 2
2-methoxyethyl --S(O).sub.2-- isopropyl --OCH.sub.3 3
2-methoxyethyl --S(O).sub.2-- phenyl --OH 1 2-methoxyethyl
--S(O).sub.2-- phenyl --OH 2 2-methoxyethyl --S(O).sub.2-- phenyl
--OH 3 2-methoxyethyl --S(O).sub.2-- phenyl --OCH.sub.3 1
2-methoxyethyl --S(O).sub.2-- phenyl --OCH.sub.3 2 2-methoxyethyl
--S(O).sub.2-- phenyl --OCH.sub.3 3 2-methoxyethyl --C(O)--NH--
methyl --OH 1 2-methoxyethyl --C(O)--NH-- methyl --OH 2
2-methoxyethyl --C(O)--NH-- methyl --OH 3 2-methoxyethyl
--C(O)--NH-- methyl --OCH.sub.3 1 2-methoxyethyl --C(O)--NH--
methyl --OCH.sub.3 2 2-methoxyethyl --C(O)--NH-- methyl --OCH.sub.3
3 2-methoxyethyl --C(O)--NH-- ethyl --OH 1 2-methoxyethyl
--C(O)--NH-- ethyl --OH 2 2-methoxyethyl --C(O)--NH-- ethyl --OH 3
2-methoxyethyl --C(O)--NH-- ethyl --OCH.sub.3 1 2-methoxyethyl
--C(O)--NH-- ethyl --OCH.sub.3 2 2-methoxyethyl --C(O)--NH-- ethyl
--OCH.sub.3 3 2-methoxyethyl --C(O)--NH-- isopropyl --OH 1
2-methoxyethyl --C(O)--NH-- isopropyl --OH 2 2-methoxyethyl
--C(O)--NH-- isopropyl --OH 3 2-methoxyethyl --C(O)--NH-- isopropyl
--OCH.sub.3 1 2-methoxyethyl --C(O)--NH-- isopropyl --OCH.sub.3 2
2-methoxyethyl --C(O)--NH-- isopropyl --OCH.sub.3 3 2-methoxyethyl
--C(O)--NH-- phenyl --OH 1 2-methoxyethyl --C(O)--NH-- phenyl --OH
2 2-methoxyethyl --C(O)--NH-- phenyl --OH 3 2-methoxyethyl
--C(O)--NH-- phenyl --OCH.sub.3 1 2-methoxyethyl --C(O)--NH--
phenyl --OCH.sub.3 2 2-methoxyethyl --C(O)--NH-- phenyl --OCH.sub.3
3
Exemplary Compounds Table 3
Ceartain exemplary compounds, including some of those described
above in the Examples, have the following Formulas(II-3, III-3,
IV-3, and V-3)wherin R.sub.2, Z, R.sub.4, and m are defined
immediately below in the table. In this table, for each ring
system, each row represents one specific compound.
TABLE-US-00011 II-3 ##STR00458## III-3 ##STR00459## IV-3
##STR00460## V-3 ##STR00461## R.sub.2 Q Z R.sub.4 m H Bond
--CH.sub.2CH.sub.2CH.sub.2-- methyl 1 H Bond
--CH.sub.2CH.sub.2CH.sub.2-- methyl 2 H Bond
--CH.sub.2CH.sub.2CH.sub.2-- methyl 3 H Bond
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 1 H Bond
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 2 H Bond
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 3 H Bond
--CH.sub.2--O--CH.sub.2-- methyl 1 H Bond --CH.sub.2--O--CH.sub.2--
methyl 2 H Bond --CH.sub.2--O--CH.sub.2-- methyl 3 H Bond
--CH.sub.2--O--CH.sub.2-- ethyl 1 H Bond --CH.sub.2--O--CH.sub.2--
ethyl 2 H Bond --CH.sub.2--O--CH.sub.2-- ethyl 3 H --C(O)--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 1 H --C(O)--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 2 H --C(O)--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 3 H --C(O)--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 1 H --C(O)--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 2 H --C(O)--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 3 H --C(O)--
--CH.sub.2--O--CH.sub.2-- methyl 1 H --C(O)--
--CH.sub.2--O--CH.sub.2-- methyl 2 H --C(O)--
--CH.sub.2--O--CH.sub.2-- methyl 3 H --C(O)--
--CH.sub.2--O--CH.sub.2-- ethyl 1 H --C(O)--
--CH.sub.2--O--CH.sub.2-- ethyl 2 H --C(O)--
--CH.sub.2--O--CH.sub.2-- ethyl 3 H --S(O).sub.2--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 1 H --S(O).sub.2--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 2 H --S(O).sub.2--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 3 H --S(O).sub.2--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 1 H --S(O).sub.2--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 2 H --S(O).sub.2--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 3 H --S(O).sub.2--
--CH.sub.2--O--CH.sub.2-- methyl 1 H --S(O).sub.2--
--CH.sub.2--O--CH.sub.2-- methyl 2 H --S(O).sub.2--
--CH.sub.2--O--CH.sub.2-- methyl 3 H --S(O).sub.2--
--CH.sub.2--O--CH.sub.2-- ethyl 1 H --S(O).sub.2--
--CH.sub.2--O--CH.sub.2-- ethyl 2 H --S(O).sub.2--
--CH.sub.2--O--CH.sub.2-- ethyl 3 H --C(O)--NH--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 1 H --C(O)--NH--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 2 H --C(O)--NH--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 3 H --C(O)--NH--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 1 H --C(O)--NH--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 2 H --C(O)--NH--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 3 H --C(O)--NH--
--CH.sub.2--O--CH.sub.2-- methyl 1 H --C(O)--NH--
--CH.sub.2--O--CH.sub.2-- methyl 2 H --C(O)--NH--
--CH.sub.2--O--CH.sub.2-- methyl 3 H --C(O)--NH--
--CH.sub.2--O--CH.sub.2-- ethyl 1 H --C(O)--NH--
--CH.sub.2--O--CH.sub.2-- ethyl 2 H --C(O)--NH--
--CH.sub.2--O--CH.sub.2-- ethyl 3 methyl Bond
--CH.sub.2CH.sub.2CH.sub.2-- methyl 1 methyl Bond
--CH.sub.2CH.sub.2CH.sub.2-- methyl 2 methyl Bond
--CH.sub.2CH.sub.2CH.sub.2-- methyl 3 methyl Bond
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 1 methyl Bond
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 2 methyl Bond
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 3 methyl Bond
--CH.sub.2--O--CH.sub.2-- methyl 1 methyl Bond
--CH.sub.2--O--CH.sub.2-- methyl 2 methyl Bond
--CH.sub.2--O--CH.sub.2-- methyl 3 methyl Bond
--CH.sub.2--O--CH.sub.2-- ethyl 1 methyl Bond
--CH.sub.2--O--CH.sub.2-- ethyl 2 methyl Bond
--CH.sub.2--O--CH.sub.2-- ethyl 3 methyl --C(O)--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 1 methyl --C(O)--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 2 methyl --C(O)--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 3 methyl --C(O)--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 1 methyl --C(O)--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 2 methyl --C(O)--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 3 methyl --C(O)--
--CH.sub.2--O--CH.sub.2-- methyl 1 methyl --C(O)--
--CH.sub.2--O--CH.sub.2-- methyl 2 methyl --C(O)--
--CH.sub.2--O--CH.sub.2-- methyl 3 methyl --C(O)--
--CH.sub.2--O--CH.sub.2-- ethyl 1 methyl --C(O)--
--CH.sub.2--O--CH.sub.2-- ethyl 2 methyl --C(O)--
--CH.sub.2--O--CH.sub.2-- ethyl 3 methyl --S(O).sub.2--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 1 methyl --S(O).sub.2--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 2 methyl --S(O).sub.2--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 3 methyl --S(O).sub.2--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 1 methyl --S(O).sub.2--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 2 methyl --S(O).sub.2--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 3 methyl --S(O).sub.2--
--CH.sub.2--O--CH.sub.2-- methyl 1 methyl --S(O).sub.2--
--CH.sub.2--O--CH.sub.2-- methyl 2 methyl --S(O).sub.2--
--CH.sub.2--O--CH.sub.2-- methyl 3 methyl --S(O).sub.2--
--CH.sub.2--O--CH.sub.2-- ethyl 1 methyl --S(O).sub.2--
--CH.sub.2--O--CH.sub.2-- ethyl 2 methyl --S(O).sub.2--
--CH.sub.2--O--CH.sub.2-- ethyl 3 methyl --C(O)--NH--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 1 methyl --C(O)--NH--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 2 methyl --C(O)--NH--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 3 methyl --C(O)--NH--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 1 methyl --C(O)--NH--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 2 methyl --C(O)--NH--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 3 methyl --C(O)--NH--
--CH.sub.2--O--CH.sub.2-- methyl 1 methyl --C(O)--NH--
--CH.sub.2--O--CH.sub.2-- methyl 2 methyl --C(O)--NH--
--CH.sub.2--O--CH.sub.2-- methyl 3 methyl --C(O)--NH--
--CH.sub.2--O--CH.sub.2-- ethyl 1 methyl --C(O)--NH--
--CH.sub.2--O--CH.sub.2-- ethyl 2 methyl --C(O)--NH--
--CH.sub.2--O--CH.sub.2-- ethyl 3 ethyl Bond
--CH.sub.2CH.sub.2CH.sub.2-- methyl 1 ethyl Bond
--CH.sub.2CH.sub.2CH.sub.2-- methyl 2 ethyl Bond
--CH.sub.2CH.sub.2CH.sub.2-- methyl 3 ethyl Bond
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 1 ethyl Bond
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 2 ethyl Bond
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 3 ethyl Bond
--CH.sub.2--O--CH.sub.2-- methyl 1 ethyl Bond
--CH.sub.2--O--CH.sub.2-- methyl 2 ethyl Bond
--CH.sub.2--O--CH.sub.2-- methyl 3 ethyl Bond
--CH.sub.2--O--CH.sub.2-- ethyl 1 ethyl Bond
--CH.sub.2--O--CH.sub.2-- ethyl 2 ethyl Bond
--CH.sub.2--O--CH.sub.2-- ethyl 3 ethyl --C(O)--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 1 ethyl --C(O)--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 2 ethyl --C(O)--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 3 ethyl --C(O)--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 1 ethyl --C(O)--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 2 ethyl --C(O)--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 3 ethyl --C(O)--
--CH.sub.2--O--CH.sub.2-- methyl 1 ethyl --C(O)--
--CH.sub.2--O--CH.sub.2-- methyl 2 ethyl --C(O)--
--CH.sub.2--O--CH.sub.2-- methyl 3 ethyl --C(O)--
--CH.sub.2--O--CH.sub.2-- ethyl 1 ethyl --C(O)--
--CH.sub.2--O--CH.sub.2-- ethyl 2 ethyl --C(O)--
--CH.sub.2--O--CH.sub.2-- ethyl 3 ethyl --S(O).sub.2--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 1 ethyl --S(O).sub.2--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 2 ethyl --S(O).sub.2--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 3 ethyl --S(O).sub.2--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 1 ethyl --S(O).sub.2--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 2 ethyl --S(O).sub.2--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 3 ethyl --S(O).sub.2--
--CH.sub.2--O--CH.sub.2-- methyl 1 ethyl --S(O).sub.2--
--CH.sub.2--O--CH.sub.2-- methyl 2 ethyl --S(O).sub.2--
--CH.sub.2--O--CH.sub.2-- methyl 3 ethyl --S(O).sub.2--
--CH.sub.2--O--CH.sub.2-- ethyl 1 ethyl --S(O).sub.2--
--CH.sub.2--O--CH.sub.2-- ethyl 2 ethyl --S(O).sub.2--
--CH.sub.2--O--CH.sub.2-- ethyl 3 ethyl --C(O)--NH--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 1 ethyl --C(O)--NH--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 2 ethyl --C(O)--NH--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 3 ethyl --C(O)--NH--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 1 ethyl --C(O)--NH--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 2 ethyl --C(O)--NH--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 3 ethyl --C(O)--NH--
--CH.sub.2--O--CH.sub.2-- methyl 1 ethyl --C(O)--NH--
--CH.sub.2--O--CH.sub.2-- methyl 2 ethyl --C(O)--NH--
--CH.sub.2--O--CH.sub.2-- methyl 3 ethyl --C(O)--NH--
--CH.sub.2--O--CH.sub.2-- ethyl 1 ethyl --C(O)--NH--
--CH.sub.2--O--CH.sub.2-- ethyl 2 ethyl --C(O)--NH--
--CH.sub.2--O--CH.sub.2-- ethyl 3 n-propyl Bond
--CH.sub.2CH.sub.2CH.sub.2-- methyl 1 n-propyl Bond
--CH.sub.2CH.sub.2CH.sub.2-- methyl 2 n-propyl Bond
--CH.sub.2CH.sub.2CH.sub.2-- methyl 3 n-propyl Bond
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 1 n-propyl Bond
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 2 n-propyl Bond
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 3 n-propyl Bond
--CH.sub.2--O--CH.sub.2-- methyl 1 n-propyl Bond
--CH.sub.2--O--CH.sub.2-- methyl 2 n-propyl Bond
--CH.sub.2--O--CH.sub.2-- methyl 3 n-propyl Bond
--CH.sub.2--O--CH.sub.2-- ethyl 1 n-propyl Bond
--CH.sub.2--O--CH.sub.2-- ethyl 2 n-propyl Bond
--CH.sub.2--O--CH.sub.2-- ethyl 3 n-propyl --C(O)--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 1 n-propyl --C(O)--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 2 n-propyl --C(O)--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 3 n-propyl --C(O)--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 1 n-propyl --C(O)--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 2 n-propyl --C(O)--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 3 n-propyl --C(O)--
--CH.sub.2--O--CH.sub.2-- methyl 1 n-propyl --C(O)--
--CH.sub.2--O--CH.sub.2-- methyl 2 n-propyl --C(O)--
--CH.sub.2--O--CH.sub.2-- methyl 3 n-propyl --C(O)--
--CH.sub.2--O--CH.sub.2-- ethyl 1 n-propyl --C(O)--
--CH.sub.2--O--CH.sub.2-- ethyl 2 n-propyl --C(O)--
--CH.sub.2--O--CH.sub.2-- ethyl 3 n-propyl --S(O).sub.2--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 1 n-propyl --S(O).sub.2--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 2 n-propyl --S(O).sub.2--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 3 n-propyl --S(O).sub.2--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 1 n-propyl --S(O).sub.2--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 2 n-propyl --S(O).sub.2--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 3 n-propyl --S(O).sub.2--
--CH.sub.2--O--CH.sub.2-- methyl 1 n-propyl --S(O).sub.2--
--CH.sub.2--O--CH.sub.2-- methyl 2 n-propyl --S(O).sub.2--
--CH.sub.2--O--CH.sub.2-- methyl 3 n-propyl --S(O).sub.2--
--CH.sub.2--O--CH.sub.2-- ethyl 1 n-propyl --S(O).sub.2--
--CH.sub.2--O--CH.sub.2-- ethyl 2 n-propyl --S(O).sub.2--
--CH.sub.2--O--CH.sub.2-- ethyl 3 n-propyl --C(O)--NH--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 1 n-propyl --C(O)--NH--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 2 n-propyl --C(O)--NH--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 3 n-propyl --C(O)--NH--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 1 n-propyl --C(O)--NH--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 2 n-propyl --C(O)--NH--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 3 n-propyl --C(O)--NH--
--CH.sub.2--O--CH.sub.2-- methyl 1 n-propyl --C(O)--NH--
--CH.sub.2--O--CH.sub.2-- methyl 2 n-propyl --C(O)--NH--
--CH.sub.2--O--CH.sub.2-- methyl 3 n-propyl --C(O)--NH--
--CH.sub.2--O--CH.sub.2-- ethyl 1 n-propyl --C(O)--NH--
--CH.sub.2--O--CH.sub.2-- ethyl 2 n-propyl --C(O)--NH--
--CH.sub.2--O--CH.sub.2-- ethyl 3 n-butyl Bond
--CH.sub.2CH.sub.2CH.sub.2-- methyl 1 n-butyl Bond
--CH.sub.2CH.sub.2CH.sub.2-- methyl 2 n-butyl Bond
--CH.sub.2CH.sub.2CH.sub.2-- methyl 3 n-butyl Bond
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 1 n-butyl Bond
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 2 n-butyl Bond
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 3 n-butyl Bond
--CH.sub.2--O--CH.sub.2-- methyl 1 n-butyl Bond
--CH.sub.2--O--CH.sub.2-- methyl 2 n-butyl Bond
--CH.sub.2--O--CH.sub.2-- methyl 3 n-butyl Bond
--CH.sub.2--O--CH.sub.2-- ethyl 1 n-butyl Bond
--CH.sub.2--O--CH.sub.2-- ethyl 2 n-butyl Bond
--CH.sub.2--O--CH.sub.2-- ethyl 3 n-butyl --C(O)--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 1 n-butyl --C(O)--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 2 n-butyl --C(O)--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 3 n-butyl --C(O)--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 1 n-butyl --C(O)--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 2 n-butyl --C(O)--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 3 n-butyl --C(O)--
--CH.sub.2--O--CH.sub.2-- methyl 1 n-butyl --C(O)--
--CH.sub.2--O--CH.sub.2-- methyl 2 n-butyl --C(O)--
--CH.sub.2--O--CH.sub.2-- methyl 3 n-butyl --C(O)--
--CH.sub.2--O--CH.sub.2-- ethyl 1 n-butyl --C(O)--
--CH.sub.2--O--CH.sub.2-- ethyl 2 n-butyl --C(O)--
--CH.sub.2--O--CH.sub.2-- ethyl 3 n-butyl --S(O).sub.2--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 1 n-butyl --S(O).sub.2--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 2 n-butyl --S(O).sub.2--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 3 n-butyl --S(O).sub.2--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 1 n-butyl --S(O).sub.2--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 2 n-butyl --S(O).sub.2--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 3 n-butyl --S(O).sub.2--
--CH.sub.2--O--CH.sub.2-- methyl 1 n-butyl --S(O).sub.2--
--CH.sub.2--O--CH.sub.2-- methyl 2 n-butyl --S(O).sub.2--
--CH.sub.2--O--CH.sub.2-- methyl 3 n-butyl --S(O).sub.2--
--CH.sub.2--O--CH.sub.2-- ethyl 1 n-butyl --S(O).sub.2--
--CH.sub.2--O--CH.sub.2-- ethyl 2 n-butyl --S(O).sub.2--
--CH.sub.2--O--CH.sub.2-- ethyl 3 n-butyl --C(O)--NH--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 1 n-butyl --C(O)--NH--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 2 n-butyl --C(O)--NH--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 3 n-butyl --C(O)--NH--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 1 n-butyl --C(O)--NH--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 2 n-butyl --C(O)--NH--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 3 n-butyl --C(O)--NH--
--CH.sub.2--O--CH.sub.2-- methyl 1 n-butyl --C(O)--NH--
--CH.sub.2--O--CH.sub.2-- methyl 2 n-butyl --C(O)--NH--
--CH.sub.2--O--CH.sub.2-- methyl 3 n-butyl --C(O)--NH--
--CH.sub.2--O--CH.sub.2-- ethyl 1
n-butyl --C(O)--NH-- --CH.sub.2--O--CH.sub.2-- ethyl 2 n-butyl
--C(O)--NH-- --CH.sub.2--O--CH.sub.2-- ethyl 3 ethoxymethyl Bond
--CH.sub.2CH.sub.2CH.sub.2-- methyl 1 ethoxymethyl Bond
--CH.sub.2CH.sub.2CH.sub.2-- methyl 2 ethoxymethyl Bond
--CH.sub.2CH.sub.2CH.sub.2-- methyl 3 ethoxymethyl Bond
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 1 ethoxymethyl Bond
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 2 ethoxymethyl Bond
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 3 ethoxymethyl Bond
--CH.sub.2--O--CH.sub.2-- methyl 1 ethoxymethyl Bond
--CH.sub.2--O--CH.sub.2-- methyl 2 ethoxymethyl Bond
--CH.sub.2--O--CH.sub.2-- methyl 3 ethoxymethyl Bond
--CH.sub.2--O--CH.sub.2-- ethyl 1 ethoxymethyl Bond
--CH.sub.2--O--CH.sub.2-- ethyl 2 ethoxymethyl Bond
--CH.sub.2--O--CH.sub.2-- ethyl 3 ethoxymethyl --C(O)--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 1 ethoxymethyl --C(O)--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 2 ethoxymethyl --C(O)--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 3 ethoxymethyl --C(O)--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 1 ethoxymethyl --C(O)--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 2 ethoxymethyl --C(O)--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 3 ethoxymethyl --C(O)--
--CH.sub.2--O--CH.sub.2-- methyl 1 ethoxymethyl --C(O)--
--CH.sub.2--O--CH.sub.2-- methyl 2 ethoxymethyl --C(O)--
--CH.sub.2--O--CH.sub.2-- methyl 3 ethoxymethyl --C(O)--
--CH.sub.2--O--CH.sub.2-- ethyl 1 ethoxymethyl --C(O)--
--CH.sub.2--O--CH.sub.2-- ethyl 2 ethoxymethyl --C(O)--
--CH.sub.2--O--CH.sub.2-- ethyl 3 ethoxymethyl --S(O).sub.2--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 1 ethoxymethyl --S(O).sub.2--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 2 ethoxymethyl --S(O).sub.2--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 3 ethoxymethyl --S(O).sub.2--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 1 ethoxymethyl --S(O).sub.2--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 2 ethoxymethyl --S(O).sub.2--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 3 ethoxymethyl --S(O).sub.2--
--CH.sub.2--O--CH.sub.2-- methyl 1 ethoxymethyl --S(O).sub.2--
--CH.sub.2--O--CH.sub.2-- methyl 2 ethoxymethyl --S(O).sub.2--
--CH.sub.2--O--CH.sub.2-- methyl 3 ethoxymethyl --S(O).sub.2--
--CH.sub.2--O--CH.sub.2-- ethyl 1 ethoxymethyl --S(O).sub.2--
--CH.sub.2--O--CH.sub.2-- ethyl 2 ethoxymethyl --S(O).sub.2--
--CH.sub.2--O--CH.sub.2-- ethyl 3 ethoxymethyl --C(O)--NH--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 1 ethoxymethyl --C(O)--NH--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 2 ethoxymethyl --C(O)--NH--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 3 ethoxymethyl --C(O)--NH--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 1 ethoxymethyl --C(O)--NH--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 2 ethoxymethyl --C(O)--NH--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 3 ethoxymethyl --C(O)--NH--
--CH.sub.2--O--CH.sub.2-- methyl 1 ethoxymethyl --C(O)--NH--
--CH.sub.2--O--CH.sub.2-- methyl 2 ethoxymethyl --C(O)--NH--
--CH.sub.2--O--CH.sub.2-- methyl 3 ethoxymethyl --C(O)--NH--
--CH.sub.2--O--CH.sub.2-- ethyl 1 ethoxymethyl --C(O)--NH--
--CH.sub.2--O--CH.sub.2-- ethyl 2 ethoxymethyl --C(O)--NH--
--CH.sub.2--O--CH.sub.2-- ethyl 3 2-methoxyethyl Bond
--CH.sub.2CH.sub.2CH.sub.2-- methyl 1 2-methoxyethyl Bond
--CH.sub.2CH.sub.2CH.sub.2-- methyl 2 2-methoxyethyl Bond
--CH.sub.2CH.sub.2CH.sub.2-- methyl 3 2-methoxyethyl Bond
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 1 2-methoxyethyl Bond
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 2 2-methoxyethyl Bond
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 3 2-methoxyethyl Bond
--CH.sub.2--O--CH.sub.2-- methyl 1 2-methoxyethyl Bond
--CH.sub.2--O--CH.sub.2-- methyl 2 2-methoxyethyl Bond
--CH.sub.2--O--CH.sub.2-- methyl 3 2-methoxyethyl Bond
--CH.sub.2--O--CH.sub.2-- ethyl 1 2-methoxyethyl Bond
--CH.sub.2--O--CH.sub.2-- ethyl 2 2-methoxyethyl Bond
--CH.sub.2--O--CH.sub.2-- ethyl 3 2-methoxyethyl --C(O)--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 1 2-methoxyethyl --C(O)--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 2 2-methoxyethyl --C(O)--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 3 2-methoxyethyl --C(O)--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 1 2-methoxyethyl --C(O)--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 2 2-methoxyethyl --C(O)--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 3 2-methoxyethyl --C(O)--
--CH.sub.2--O--CH.sub.2-- methyl 1 2-methoxyethyl --C(O)--
--CH.sub.2--O--CH.sub.2-- methyl 2 2-methoxyethyl --C(O)--
--CH.sub.2--O--CH.sub.2-- methyl 3 2-methoxyethyl --C(O)--
--CH.sub.2--O--CH.sub.2-- ethyl 1 2-methoxyethyl --C(O)--
--CH.sub.2--O--CH.sub.2-- ethyl 2 2-methoxyethyl --C(O)--
--CH.sub.2--O--CH.sub.2-- ethyl 3 2-methoxyethyl --S(O).sub.2--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 1 2-methoxyethyl --S(O).sub.2--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 2 2-methoxyethyl --S(O).sub.2--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 3 2-methoxyethyl --S(O).sub.2--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 1 2-methoxyethyl --S(O).sub.2--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 2 2-methoxyethyl --S(O).sub.2--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 3 2-methoxyethyl --S(O).sub.2--
--CH.sub.2--O--CH.sub.2-- methyl 1 2-methoxyethyl --S(O).sub.2--
--CH.sub.2--O--CH.sub.2-- methyl 2 2-methoxyethyl --S(O).sub.2--
--CH.sub.2--O--CH.sub.2-- methyl 3 2-methoxyethyl --S(O).sub.2--
--CH.sub.2--O--CH.sub.2-- ethyl 1 2-methoxyethyl --S(O).sub.2--
--CH.sub.2--O--CH.sub.2-- ethyl 2 2-methoxyethyl --S(O).sub.2--
--CH.sub.2--O--CH.sub.2-- ethyl 3 2-methoxyethyl --C(O)--NH--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 1 2-methoxyethyl --C(O)--NH--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 2 2-methoxyethyl --C(O)--NH--
--CH.sub.2CH.sub.2CH.sub.2-- methyl 3 2-methoxyethyl --C(O)--NH--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 1 2-methoxyethyl --C(O)--NH--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 2 2-methoxyethyl --C(O)--NH--
--CH.sub.2CH.sub.2CH.sub.2-- ethyl 3 2-methoxyethyl --C(O)--NH--
--CH.sub.2--O--CH.sub.2-- methyl 1 2-methoxyethyl --C(O)--NH--
--CH.sub.2--O--CH.sub.2-- methyl 2 2-methoxyethyl --C(O)--NH--
--CH.sub.2--O--CH.sub.2-- methyl 3 2-methoxyethyl --C(O)--NH--
--CH.sub.2--O--CH.sub.2-- ethyl 1 2-methoxyethyl --C(O)--NH--
--CH.sub.2--O--CH.sub.2-- ethyl 2 2-methoxyethyl --C(O)--NH--
--CH.sub.2--O--CH.sub.2-- ethyl 3
Exemplary Compounds Table 4
Certain exemplary compounds, including some of those described
above in the Examples, have the following Formulas (II-4, III-4,
IV-4, and V-4) wherein R.sub.2, Z, and m are defined immediately
below in the table. In this table, for each ring system, each row
represents one specific compound.
TABLE-US-00012 II-4 ##STR00462## III-4 ##STR00463## IV-4
##STR00464## V-4 ##STR00465## R.sub.2 Z m hydroxymethyl Bond 1
hydroxymethyl Bond 2 2-hydroxyethyl Bond 1 2-hydroxyethyl Bond 2
hydroxymethyl --CH.sub.2-- 1 hydroxymethyl --CH.sub.2-- 2
2-hydroxyethyl --CH.sub.2-- 1 2-hydroxyethyl --CH.sub.2-- 2
hydroxymethyl --CH.sub.2CH.sub.2-- 1 hydroxymethyl
--CH.sub.2CH.sub.2-- 2 2-hydroxyethyl --CH.sub.2CH.sub.2-- 1
2-hydroxyethyl --CH.sub.2CH.sub.2-- 2 hydroxymethyl
--CH.sub.2CH.sub.2CH.sub.2-- 1 hydroxymethyl
--CH.sub.2CH.sub.2CH.sub.2-- 2 2-hydroxyethyl
--CH.sub.2CH.sub.2CH.sub.2-- 1 2-hydroxyethyl
--CH.sub.2CH.sub.2CH.sub.2-- 2 hydroxymethyl
--CH.sub.2--O--CH.sub.2-- 1 hydroxymethyl --CH.sub.2--O--CH.sub.2--
2 2-hydroxyethyl --CH.sub.2--O--CH.sub.2-- 1 2-hydroxyethyl
--CH.sub.2--O--CH.sub.2-- 2 H --CH.sub.2--O-- 1 H --CH.sub.2--O-- 2
methyl --CH.sub.2--O-- 1 methyl --CH.sub.2--O-- 2 ethyl
--CH.sub.2--O-- 1 ethyl --CH.sub.2--O-- 2 n-propyl --CH.sub.2--O--
1 n-propyl --CH.sub.2--O-- 2 n-butyl --CH.sub.2--O-- 1 n-butyl
--CH.sub.2--O-- 2 ethoxymethyl --CH.sub.2--O-- 1 ethoxymethyl
--CH.sub.2--O-- 2 hydroxymethyl --CH.sub.2--O-- 1 hydroxymethyl
--CH.sub.2--O-- 2 2-hydroxyethyl --CH.sub.2--O-- 1 2-hydroxyethyl
--CH.sub.2--O-- 2 H --O-- 1 H --O-- 2 methyl --O-- 1 methyl --O-- 2
ethyl --O-- 1 ethyl --O-- 2 n-propyl --O-- 1 n-propyl --O-- 2
n-butyl --O-- 1 n-butyl --O-- 2 ethoxymethyl --O-- 1 ethoxymethyl
--O-- 2 hydroxymethyl --O-- 1 hydroxymethyl --O-- 2 2-hydroxyethyl
--O-- 1 2-hydroxyethyl --O-- 2
Exemplary Compounds Table 5
Certain exemplary compounds, including some of those described
above in the Examples, have the following Formulas (II-5, III-5,
IV-5, and V-5) wherein R.sub.2, and m are defined immediately below
in the table. In this table, for each ring system, each row
represents one specific compound.
TABLE-US-00013 II-5 ##STR00466## III-5 ##STR00467## IV-5
##STR00468## V-5 ##STR00469## R.sub.2 m hydroxymethyl 1
hydroxymethyl 2 2-hydroxyethyl 1 2-hydroxyethyl 2
Compounds of the invention have been found to induce biosynthesis
when tested using the method described below.
CYTOKINE INDUCTION IN HUMAN CELLS
An in vitro human blood cell system is used to assess cytokine
induction. Activity is based on the measurement of interferon
(.alpha.) and tumor necrosis factor (.alpha.) (IFN-.alpha. and
TNF-.alpha., respectively) secreted into culture media as described
by Testerman et. al. in "Cytokine Induction by the Immunomodulators
Imiquimod and S-27609", Journal of Leukocyte Biology, 58, 365-372
(September, 1995).
Blood Cell Preparation for Culture
Whole blood from healthy human donors is collected by venipuncture
into vacutainer tubes or syringes containing EDTA. Peripheral blood
mononuclear cells (PBMC) are separated from whole blood by density
gradient centrifugation using HISTOPAQUE-1077 (Sigma, St. Louis,
Mo.) or Ficoll-Paque Plus (Amersham Biosciences Piscataway, N.J.).
Blood is diluted 1:1 with Dulbecco's Phosphate Buffered Saline
(DPBS) or Hank's Balanced Salts Solution (HBSS). Alternately, whole
blood is placed in Accuspin (Sigma) or LeucoSep (Greiner Bio-One,
Inc., Longwood, Fla.) centrifuge frit tubes containing density
gradient medium. The PBMC layer is collected and washed twice with
DPBS or HBSS and re-suspended at 4.times.10.sup.6 cells/mL in RPMI
complete. The PBMC suspension is added to 96 well flat bottom
sterile tissue culture plates containing an equal volume of RPMI
complete media containing test compound.
Compound Preparation
The compounds are solubilized in dimethyl sulfoxide (DMSO). The
DMSO concentration should not exceed a final concentration of 1%
for addition to the culture wells. The compounds are generally
tested at concentrations ranging from 30-0.014 .mu.M. Controls
include cell samples with media only, cell samples with DMSO only
(no compound), and cell samples with reference compound.
Incubation
The solution of test compound is added at 60 .mu.M to the first
well containing RPMI complete and serial 3 fold dilutions are made
in the wells. The PBMC suspension is then added to the wells in an
equal volume, bringing the test compound concentrations to the
desired range (usually 30-0.014 .mu.M). The final concentration of
PBMC suspension is 2.times.10.sup.6 cells/mL. The plates are
covered with sterile plastic lids, mixed gently and then incubated
for 18 to 24 hours at 37.degree. C. in a 5% carbon dioxide
atmosphere.
Separation
Following incubation the plates are centrifuged for 10 minutes at
1000 rpm (approximately 200.times.g) at 4.degree. C. The cell-free
culture supernatant is removed and transferred to sterile
polypropylene tubes. Samples are maintained at -30 to -70.degree.
C. until analysis. The samples are analyzed for IFN-.alpha. by
ELISA and for TNF-.alpha. by IGEN/BioVeris Assay.
Interferon (.alpha.) and Tumor Necrosis Factor (.alpha.)
Analysis
IFN-.alpha. concentration is determined with a human multi-subtype
colorimetric sandwich ELISA (Catalog Number 41105) from PBL
Biomedical Laboratories, Piscataway, N.J. Results are expressed in
pg/mL.
The TNF-.alpha.concentration is determined by ORIGEN M-Series
Immunoassay and read on an IGEN M-8 analyzer from BioVeris
Corporation, formerly known as IGEN International, Gaithersburg,
Md. The immunoassay uses a human TNF-.alpha. capture and detection
antibody pair (Catalog Numbers AHC3419 and AHC3712) from Biosource
International, Camarillo, Calif. Results are expressed in
pg/mL.
Assay Data and Analysis
In total, the data output of the assay consists of concentration
values of TNF-.alpha. and IFN-.alpha. (y-axis) as a function of
compound concentration (x-axis).
Analysis of the data has two steps. First, the greater of the mean
DMSO (DMSO control wells) or the experimental background (usually
20 pg/mL for IFN-.alpha. and 40 pg/mL for TNF-.alpha.) is
subtracted from each reading. If any negative values result from
background subtraction, the reading is reported as "*", and is
noted as not reliably detectable. In subsequent calculations and
statistics, "*", is treated as a zero. Second, all background
subtracted values are multiplied by a single adjustment ratio to
decrease experiment to experiment variability. The adjustment ratio
is the area of the reference compound in the new experiment divided
by the expected area of the reference compound based on the past 61
experiments (unadjusted readings). This results in the scaling of
the reading (y-axis) for the new data without changing the shape of
the dose-response curve. The reference compound used is
2-[4-amino-2-ethoxymethyl-6,7,8,9-tetrahydro-.alpha.,.alpha.-dimethyl-1H--
imidazo[4,5-c]quinolin-1-yl]ethanol hydrate (U.S. Pat. No.
5,352,784; Example 91) and the expected area is the sum of the
median dose values from the past 61 experiments.
The minimum effective concentration is calculated based on the
background-subtracted, reference-adjusted results for a given
experiment and compound. The minimum effective concentration
(molar) is the lowest of the tested compound concentrations that
induces a response over a fixed cytokine concentration for the
tested cytokine (usually 20 pg/mL for IFN-.alpha. and 40 pg/mL for
TNF-.alpha.). The maximal response is the maximal amount of
cytokine (pg/ml) produced in the dose-response.
CYTOKINE INDUCTION IN HUMAN CELLS
High Throughput Screen
The CYTOKINE INDUCTION IN HUMAN CELLS test method described above
was modified as follows for high throughput screening.
Blood Cell Preparation for Culture
Whole blood from healthy human donors is collected by venipuncture
into vacutainer tubes or syringes containing EDTA. Peripheral blood
mononuclear cells (PBMC) are separated from whole blood by density
gradient centrifugation using HISTOPAQUE-1077 (Sigma, St. Louis,
Mo.) or Ficoll-Paque Plus (Amersham Biosciences Piscataway, N.J.).
Whole blood is placed in Accuspin (Sigma) or LeucoSep (Greiner
Bio-One, Inc., Longwood, Fla.) centrifuge frit tubes containing
density gradient medium. The PBMC layer is collected and washed
twice with DPBS or HBSS and re-suspended at 4.times.10.sup.6
cells/mL in RPMI complete (2-fold the final cell density). The PBMC
suspension is added to 96-well flat bottom sterile tissue culture
plates.
Compound Preparation
The compounds are solubilized in dimethyl sulfoxide (DMSO). The
compounds are generally tested at concentrations ranging from
30-0.014 .mu.M. Controls include cell samples with media only, cell
samples with DMSO only (no compound), and cell samples with a
reference compound
2-[4-amino-2-ethoxymethyl-6,7,8,9-tetrahydro-.alpha.,.alpha.-dimethyl-1H--
imidazo[4,5-c]quinolin-1-yl]ethanol hydrate (U.S. Pat. No.
5,352,784; Example 91) on each plate. The solution of test compound
is added at 7.5 mM to the first well of a dosing plate and serial 3
fold dilutions are made for the 7 subsequent concentrations in
DMSO. RPMI Complete media is then added to the test compound
dilutions in order to reach a final compound concentration of
2-fold higher (60-0.028 .mu.M) than the final tested concentration
range.
Incubation
Compound solution is then added to the wells containing the PBMC
suspension bringing the test compound concentrations to the desired
range (usually 30-0.014 .mu.M) and the DMSO concentration to 0.4%.
The final concentration of PBMC suspension is 2.times.10.sup.6
cells/mL. The plates are covered with sterile plastic lids, mixed
gently and then incubated for 18 to 24 hours at 37.degree. C. in a
5% carbon dioxide atmosphere.
Separation
Following incubation the plates are centrifuged for 10 minutes at
1000 rpm (approximately 200 g) at 4.degree. C. 4-plex Human Panel
MSD MULTI-SPOT 96-well plates are pre-coated with the appropriate
capture antibodies by MesoScale Discovery, Inc. (MSD, Gaithersburg,
Md.). The cell-free culture supernatants are removed and
transferred to the MSD plates. Fresh samples are typically tested,
although they may be maintained at -30 to -70.degree. C. until
analysis.
Interferon-.alpha. and Tumor Necrosis Factor-.alpha. Analysis
MSD MULTI-SPOT plates contain within each well capture antibodies
for human TNF-.alpha. and human IFN-.alpha. that have been
pre-coated on specific spots. Each well contains four spots: one
human TNF-.alpha. capture antibody (MSD) spot, one human
IFN-.alpha. capture antibody (PBL Biomedical Laboratories,
Piscataway, N.J.) spot, and two inactive bovine serum albumin
spots. The human TNF-.alpha. capture and detection antibody pair is
from MesoScale Discovery. The human IFN-.alpha. multi-subtype
antibody (PBL Biomedical Laboratories) captures all IFN-.alpha.
subtypes except IFN-.alpha. F (IFNA21). Standards consist of
recombinant human TNF-.alpha. (R&D Systems, Minneapolis, Minn.)
and IFN-.alpha. (PBL Biomedical Laboratories). Samples and separate
standards are added at the time of analysis to each MSD plate. Two
human IFN-.alpha. detection antibodies (Cat. Nos. 21112 &
21100, PBL) are used in a two to one ratio (weight:weight) to each
other to determine the IFN-.alpha. concentrations. The
cytokine-specific detection antibodies are labeled with the
SULFO-TAG reagent (MSD). After adding the SULFO-TAG labeled
detection antibodies to the wells, each well's
electrochemoluminescent levels are read using MSD's Sector HTS
READER. Results are expressed in pg/mL upon calculation with known
cytokine standards.
Assay Data and Analysis
In total, the data output of the assay consists of concentration
values of TNF-.alpha. or IFN-.alpha. (y-axis) as a function of
compound concentration (x-axis).
A plate-wise scaling is performed within a given experiment aimed
at reducing plate-to-plate variability associated within the same
experiment. First, the greater of the median DMSO (DMSO control
wells) or the experimental background (usually 20 pg/mL for
IFN-.alpha. and 40 pg/mL for TNF-.alpha.) is subtracted from each
reading. Negative values that may result from background
subtraction are set to zero. Each plate within a given experiment
has a reference compound that serves as a control. This control is
used to calculate a median expected area under the curve across all
plates in the assay. A plate-wise scaling factor is calculated for
each plate as a ratio of the area of the reference compound on the
particular plate to the median expected area for the entire
experiment. The data from each plate are then multiplied by the
plate-wise scaling factor for all plates. Only data from plates
bearing a scaling factor of between 0.5 and 2.0 (for both cytokines
IFN-.alpha., TNF-.alpha.) are reported. Data from plates with
scaling factors outside the above mentioned interval are retested
until they bear scaling factors inside the above mentioned
interval. The above method produces a scaling of the y-values
without altering the shape of the curve. The reference compound
used is
2-[4-amino-2-ethoxymethyl-6,7,8,9-tetrahydro-.alpha.,.alpha.-dimethyl-1H--
imidazo[4,5-c]quinolin-1-yl]ethanol hydrate (U.S. Pat. No.
5,352,784; Example 91). The median expected area is the median area
across all plates that are part of a given experiment.
A second scaling may also be performed to reduce inter-experiment
variability (across multiple experiments). All
background-subtracted values are multiplied by a single adjustment
ratio to decrease experiment-to-experiment variability. The
adjustment ratio is the area of the reference compound in the new
experiment divided by the expected area of the reference compound
based on an average of previous experiments (unadjusted readings).
This results in the scaling of the reading (y-axis) for the new
data without changing the shape of the dose-response curve. The
reference compound used is
2-[4-amino-2-ethoxymethyl-6,7,8,9-tetrahydro-.alpha.,.alpha.-dimethyl-1H--
imidazo[4,5-c]quinolin-1-yl]ethanol hydrate (U.S. Pat. No.
5,352,784; Example 91) and the expected area is the sum of the
median dose values from an average of previous experiments.
The minimum effective concentration is calculated based on the
background-subtracted, reference-adjusted results for a given
experiment and compound. The minimum effective concentration
(molar) is the lowest of the tested compound concentrations that
induces a response over a fixed cytokine concentration for the
tested cytokine (usually 20 pg/mL for IFN-.alpha. and 40 pg/mL for
TNF-.alpha.). The maximal response is the maximal amount of
cytokine (pg/ml) produced in the dose-response.
The complete disclosures of the patents, patent documents, and
publications cited herein are incorporated by reference in their
entirety as if each were individually incorporated. Various
modifications and alterations to this invention will become
apparent to those skilled in the art without departing from the
scope and spirit of this invention. It should be understood that
this invention is not intended to be unduly limited by the
illustrative embodiments and examples set forth herein and that
such examples and embodiments are presented by way of example only
with the scope of the invention intended to be limited only by the
claims set forth herein as follows.
* * * * *